{"page": 1, "allrow": 0, "type": "text", "inside": ""}
{"page": 1, "allrow": 1, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 1, "allrow": 2, "type": "text", "inside": "普洛药业股份有限公司"}
{"page": 1, "allrow": 3, "type": "text", "inside": "2019年年度报告"}
{"page": 1, "allrow": 4, "type": "text", "inside": "2020年03月"}
{"page": 1, "allrow": 5, "type": "页脚", "inside": "1"}
{"page": 2, "allrow": 6, "type": "text", "inside": ""}
{"page": 2, "allrow": 7, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 2, "allrow": 8, "type": "text", "inside": "第一节重要提示、目录和释义"}
{"page": 2, "allrow": 9, "type": "text", "inside": "公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。"}
{"page": 2, "allrow": 10, "type": "text", "inside": "公司负责人祝方猛、主管会计工作负责人张进辉及会计机构负责人(会计主管人员)张进辉声明：保证年度报告中财务报告的真实、准确、完整。"}
{"page": 2, "allrow": 11, "type": "text", "inside": "所有董事均已出席了审议本报告的董事会会议。"}
{"page": 2, "allrow": 12, "type": "text", "inside": "本报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺，请投资者注意投资风险。"}
{"page": 2, "allrow": 13, "type": "text", "inside": "公司经本次董事会审议通过的利润分配预案为：以1，178，523，492股为基数，向全体股东每10股派发现金红利1.65元（含税），送红股0股（含税），不以公积金转增股本。"}
{"page": 2, "allrow": 14, "type": "页脚", "inside": "2"}
{"page": 3, "allrow": 15, "type": "text", "inside": ""}
{"page": 3, "allrow": 16, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 3, "allrow": 17, "type": "text", "inside": "目录"}
{"page": 3, "allrow": 18, "type": "text", "inside": "第一节重要提示、目录和释义..............................................................2"}
{"page": 3, "allrow": 19, "type": "text", "inside": "第二节公司简介和主要财务指标..........................................................5"}
{"page": 3, "allrow": 20, "type": "text", "inside": "第三节公司业务概要............................................................................11"}
{"page": 3, "allrow": 21, "type": "text", "inside": "第四节经营情况讨论与分析................................................................13"}
{"page": 3, "allrow": 22, "type": "text", "inside": "第五节重要事项....................................................................................23"}
{"page": 3, "allrow": 23, "type": "text", "inside": "第六节股份变动及股东情况................................................................38"}
{"page": 3, "allrow": 24, "type": "text", "inside": "第七节优先股相关情况........................................................................44"}
{"page": 3, "allrow": 25, "type": "text", "inside": "第八节可转换公司债券相关情况........................................................45"}
{"page": 3, "allrow": 26, "type": "text", "inside": "第九节董事、监事、高级管理人员和员工情况...............................46"}
{"page": 3, "allrow": 27, "type": "text", "inside": "第十节公司治理....................................................................................53"}
{"page": 3, "allrow": 28, "type": "text", "inside": "第十一节公司债券相关情况................................................................58"}
{"page": 3, "allrow": 29, "type": "text", "inside": "第十二节财务报告..................................................................................59"}
{"page": 3, "allrow": 30, "type": "text", "inside": "第十三节备查文件目录........................................................................203"}
{"page": 3, "allrow": 31, "type": "页脚", "inside": "3"}
{"page": 4, "allrow": 32, "type": "text", "inside": ""}
{"page": 4, "allrow": 33, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 4, "allrow": 34, "type": "text", "inside": "释义"}
{"page": 4, "allrow": 35, "type": "excel", "inside": "['释义项', '指', '释义内容']"}
{"page": 4, "allrow": 36, "type": "excel", "inside": "['中国证监会', '指', '中国证券监督管理委员会']"}
{"page": 4, "allrow": 37, "type": "excel", "inside": "['深交所', '指', '深圳证券交易所']"}
{"page": 4, "allrow": 38, "type": "excel", "inside": "['《公司法》', '指', '《中华人民共和国公司法》']"}
{"page": 4, "allrow": 39, "type": "excel", "inside": "['《证券法》', '指', '《中华人民共和国证券法》']"}
{"page": 4, "allrow": 40, "type": "excel", "inside": "['《股票上市规则》', '指', '《深圳证券交易所股票上市规则（2018年修订）》']"}
{"page": 4, "allrow": 41, "type": "excel", "inside": "['本公司、公司或普洛药业', '指', '普洛药业股份有限公司']"}
{"page": 4, "allrow": 42, "type": "excel", "inside": "['实际控制人', '指', '横店社团经济企业联合会']"}
{"page": 4, "allrow": 43, "type": "excel", "inside": "['控股股东', '指', '横店集团控股有限公司']"}
{"page": 4, "allrow": 44, "type": "excel", "inside": "['浙江普洛生物', '指', '浙江普洛生物科技有限公司']"}
{"page": 4, "allrow": 45, "type": "excel", "inside": "['山东汉兴', '指', '山东汉兴医药科技有限公司']"}
{"page": 4, "allrow": 46, "type": "excel", "inside": "['普洛得邦制药', '指', '浙江普洛得邦制药有限公司']"}
{"page": 4, "allrow": 47, "type": "excel", "inside": "['山东普洛得邦', '指', '山东普洛得邦医药有限公司']"}
{"page": 4, "allrow": 48, "type": "excel", "inside": "['普洛家园药业', '指', '浙江普洛家园药业有限公司']"}
{"page": 4, "allrow": 49, "type": "excel", "inside": "['普洛康裕制药', '指', '浙江普洛康裕制药有限公司']"}
{"page": 4, "allrow": 50, "type": "excel", "inside": "['安徽普洛生物', '指', '安徽普洛生物科技有限公司']"}
{"page": 4, "allrow": 51, "type": "excel", "inside": "['普洛进出口', '指', '浙江横店普洛进出口有限公司']"}
{"page": 4, "allrow": 52, "type": "excel", "inside": "['宁波普洛进出口', '指', '宁波普洛进出口有限公司']"}
{"page": 4, "allrow": 53, "type": "excel", "inside": "['巨泰药业', '指', '浙江巨泰药业有限公司']"}
{"page": 4, "allrow": 54, "type": "text", "inside": ""}
{"page": 4, "allrow": 55, "type": "页脚", "inside": "4"}
{"page": 5, "allrow": 56, "type": "text", "inside": ""}
{"page": 5, "allrow": 57, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 5, "allrow": 58, "type": "text", "inside": "第二节公司简介和主要财务指标"}
{"page": 5, "allrow": 59, "type": "text", "inside": "一、公司信息"}
{"page": 5, "allrow": 60, "type": "excel", "inside": "['股票简称', '', '普洛药业', '股票代码', '000739']"}
{"page": 5, "allrow": 61, "type": "excel", "inside": "['股票上市证券交易所', '', '深圳证券交易所', '', '']"}
{"page": 5, "allrow": 62, "type": "excel", "inside": "['公司的中文名称', '普洛药业股份有限公司', '', '', '']"}
{"page": 5, "allrow": 63, "type": "excel", "inside": "['公司的中文简称', '', '普洛药业', '', '']"}
{"page": 5, "allrow": 64, "type": "excel", "inside": "['公司的外文名称（如有）', '', 'Apeloa Pharmaceutical Co.,Ltd', '', '']"}
{"page": 5, "allrow": 65, "type": "excel", "inside": "['公司的外文名称缩写（如有）', '', 'APELOA', '', '']"}
{"page": 5, "allrow": 66, "type": "excel", "inside": "['公司的法定代表人', '祝方猛', '', '', '']"}
{"page": 5, "allrow": 67, "type": "excel", "inside": "['注册地址', '', '浙江省东阳市横店江南路399号', '', '']"}
{"page": 5, "allrow": 68, "type": "excel", "inside": "['注册地址的邮政编码', '', '322118', '', '']"}
{"page": 5, "allrow": 69, "type": "excel", "inside": "['办公地址', '', '浙江省东阳市横店江南路399号', '', '']"}
{"page": 5, "allrow": 70, "type": "excel", "inside": "['办公地址的邮政编码', '', '322118', '', '']"}
{"page": 5, "allrow": 71, "type": "excel", "inside": "['公司网址', '', 'www.apeloa.com', '', '']"}
{"page": 5, "allrow": 72, "type": "excel", "inside": "['电子信箱', '', '000739@apeloa.com', '', '']"}
{"page": 5, "allrow": 73, "type": "text", "inside": ""}
{"page": 5, "allrow": 74, "type": "text", "inside": "二、联系人和联系方式"}
{"page": 5, "allrow": 75, "type": "excel", "inside": "['', '董事会秘书', '证券事务代表']"}
{"page": 5, "allrow": 76, "type": "excel", "inside": "['姓名', '周玉旺', '楼云娜']"}
{"page": 5, "allrow": 77, "type": "excel", "inside": "['联系地址', '浙江省东阳市横店江南路399号', '浙江省东阳市横店江南路399号']"}
{"page": 5, "allrow": 78, "type": "excel", "inside": "['电话', '0579-86557527', '0579-86557527']"}
{"page": 5, "allrow": 79, "type": "excel", "inside": "['传真', '0579-86558122', '0579-86558122']"}
{"page": 5, "allrow": 80, "type": "excel", "inside": "['电子信箱', '000739@apeloa.com', '000739@apeloa.com']"}
{"page": 5, "allrow": 81, "type": "text", "inside": ""}
{"page": 5, "allrow": 82, "type": "text", "inside": "三、信息披露及备置地点"}
{"page": 5, "allrow": 83, "type": "excel", "inside": "['公司选定的信息披露媒体的名称', '证券时报、上海证券报']"}
{"page": 5, "allrow": 84, "type": "excel", "inside": "['登载年度报告的中国证监会指定网站的网址', 'http://www.cninfo.com.cn']"}
{"page": 5, "allrow": 85, "type": "excel", "inside": "['公司年度报告备置地点', '浙江省东阳市横店江南路399号']"}
{"page": 5, "allrow": 86, "type": "text", "inside": ""}
{"page": 5, "allrow": 87, "type": "页脚", "inside": "5"}
{"page": 6, "allrow": 88, "type": "text", "inside": ""}
{"page": 6, "allrow": 89, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 6, "allrow": 90, "type": "text", "inside": "四、注册变更情况"}
{"page": 6, "allrow": 91, "type": "excel", "inside": "['组织机构代码', '913300002646284831']"}
{"page": 6, "allrow": 92, "type": "excel", "inside": "['公司上市以来主营业务的变化情况（如有）', '2001年12月，公司进行了资产重组，主营业务由商业零售向医药化工转变。']"}
{"page": 6, "allrow": 93, "type": "excel", "inside": "['', '2001年12月，公司进行了资产重组，重组完成以后，横店集团控股有限公司']"}
{"page": 6, "allrow": 94, "type": "excel", "inside": "['历次控股股东的变更情况（如有）', '成为本公司控股股东。']"}
{"page": 6, "allrow": 95, "type": "text", "inside": ""}
{"page": 6, "allrow": 96, "type": "text", "inside": "五、其他有关资料"}
{"page": 6, "allrow": 97, "type": "text", "inside": "公司聘请的会计师事务所"}
{"page": 6, "allrow": 98, "type": "excel", "inside": "['会计师事务所名称', '和信会计师事务所（特殊普通合伙）']"}
{"page": 6, "allrow": 99, "type": "excel", "inside": "['会计师事务所办公地址', '山东省济南市历下区文化东路59号山东盐业大厦7层']"}
{"page": 6, "allrow": 100, "type": "excel", "inside": "['签字会计师姓名', '左伟、陈征']"}
{"page": 6, "allrow": 101, "type": "text", "inside": ""}
{"page": 6, "allrow": 102, "type": "text", "inside": "公司聘请的报告期内履行持续督导职责的保荐机构"}
{"page": 6, "allrow": 103, "type": "text", "inside": "□适用√不适用"}
{"page": 6, "allrow": 104, "type": "text", "inside": "公司聘请的报告期内履行持续督导职责的财务顾问"}
{"page": 6, "allrow": 105, "type": "text", "inside": "□适用√不适用"}
{"page": 6, "allrow": 106, "type": "text", "inside": "六、主要会计数据和财务指标"}
{"page": 6, "allrow": 107, "type": "text", "inside": "公司是否需追溯调整或重述以前年度会计数据"}
{"page": 6, "allrow": 108, "type": "text", "inside": "√是□否"}
{"page": 6, "allrow": 109, "type": "excel", "inside": "['', '', '2019年', '2018年', '本年比上年增减', '2017年']"}
{"page": 6, "allrow": 110, "type": "excel", "inside": "['营业收入（元）', '', '7,210,711,386.14', '6,375,980,498.49', '13.09%', '5,551,763,065.13']"}
{"page": 6, "allrow": 111, "type": "excel", "inside": "['归属于上市公司股东的净利润（元）', '553,400,761.42', '553,400,761.42', '370,561,028.28', '49.34%', '256,635,750.61']"}
{"page": 6, "allrow": 112, "type": "excel", "inside": "['归属于上市公司股东的扣除非经常性损益的净利润（元）', '529,730,823.18', '529,730,823.18', '341,962,401.90', '54.91%', '209,219,175.06']"}
{"page": 6, "allrow": 113, "type": "excel", "inside": "['经营活动产生的现金流量净额（元）', '1,360,066,190.36', '1,360,066,190.36', '832,821,083.96', '63.31%', '209,799,349.56']"}
{"page": 6, "allrow": 114, "type": "excel", "inside": "['基本每股收益（元/股）', '', '0.4696', '0.3144', '49.36%', '0.2232']"}
{"page": 6, "allrow": 115, "type": "excel", "inside": "['稀释每股收益（元/股）', '', '0.4696', '0.3144', '49.36%', '0.2232']"}
{"page": 6, "allrow": 116, "type": "excel", "inside": "['加权平均净资产收益率', '', '15.66%', '11.63%', '4.03%', '9.38%']"}
{"page": 6, "allrow": 117, "type": "excel", "inside": "['', '', '', '', '本年末比上年末增', '']"}
{"page": 6, "allrow": 118, "type": "excel", "inside": "['', '', '2019年末', '2018年末', '减', '2017年末']"}
{"page": 6, "allrow": 119, "type": "excel", "inside": "['总资产（元）', '', '6,522,585,923.42', '5,751,761,393.99', '13.40%', '5,696,995,625.18']"}
{"page": 6, "allrow": 120, "type": "excel", "inside": "['归属于上市公司股东的净资产（元）', '3,767,986,787.28', '3,767,986,787.28', '3,345,260,092.73', '12.64%', '3,050,974,977.55']"}
{"page": 6, "allrow": 121, "type": "text", "inside": ""}
{"page": 6, "allrow": 122, "type": "页脚", "inside": "6"}
{"page": 7, "allrow": 123, "type": "text", "inside": ""}
{"page": 7, "allrow": 124, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 7, "allrow": 125, "type": "text", "inside": "追溯调整或重述原因"}
{"page": 7, "allrow": 126, "type": "text", "inside": "同一控制下企业合并"}
{"page": 7, "allrow": 127, "type": "excel", "inside": "['', '', '2018年', '', '本年比上年', '2017年', '']"}
{"page": 7, "allrow": 128, "type": "excel", "inside": "['', '2019年', '', '', '增减', '', '']"}
{"page": 7, "allrow": 129, "type": "excel", "inside": "['', '', '调整前', '调整后', '调整后', '调整前', '调整后']"}
{"page": 7, "allrow": 130, "type": "excel", "inside": "['', '7,210,711,38', '6,376,400,63', '6,375,980,49', '', '5,551,763,06', '5,551,763,06']"}
{"page": 7, "allrow": 131, "type": "excel", "inside": "['营业收入（元）', '6.14', '8.55', '8.49', '13.09%', '5.13', '5.13']"}
{"page": 7, "allrow": 132, "type": "excel", "inside": "['归属于上市公司股东的净利润（元）', '553,400,761.42', '370,566,842.35', '370,561,028.28', '49.34%', '256,592,089.41', '256,635,750.61']"}
{"page": 7, "allrow": 133, "type": "excel", "inside": "['归属于上市公司股东的扣除非经常性损益的净利润（元）', '529,730,823.18', '341,962,401.90', '341,962,401.90', '54.91%', '209,219,175.06', '209,219,175.06']"}
{"page": 7, "allrow": 134, "type": "excel", "inside": "['经营活动产生的现金流量净额（元）', '1,360,066,190.36', '832,692,274.38', '832,821,083.96', '63.31%', '209,799,349.56', '209,799,349.56']"}
{"page": 7, "allrow": 135, "type": "excel", "inside": "['基本每股收益（元/股）', '0.4696', '0.3144', '0.3144', '49.36%', '0.2232', '0.2232']"}
{"page": 7, "allrow": 136, "type": "excel", "inside": "['稀释每股收益（元/股）', '0.4696', '0.3144', '0.3144', '49.36%', '0.2232', '0.2232']"}
{"page": 7, "allrow": 137, "type": "excel", "inside": "['加权平均净资产收益率', '15.66%', '11.64%', '11.63%', '4.03%', '9.38%', '9.38%']"}
{"page": 7, "allrow": 138, "type": "excel", "inside": "['', '', '2018年末', '', '本年末比上', '2017年末', '']"}
{"page": 7, "allrow": 139, "type": "excel", "inside": "['', '2019年末', '', '', '年末增减', '', '']"}
{"page": 7, "allrow": 140, "type": "excel", "inside": "['', '', '调整前', '调整后', '调整后', '调整前', '调整后']"}
{"page": 7, "allrow": 141, "type": "excel", "inside": "['', '6,522,585,92', '5,750,766,27', '5,751,761,39', '', '5,691,123,92', '5,696,995,62']"}
{"page": 7, "allrow": 142, "type": "excel", "inside": "['总资产（元）', '3.42', '9.01', '3.99', '13.40%', '8.46', '5.18']"}
{"page": 7, "allrow": 143, "type": "excel", "inside": "['归属于上市公司股东的净资产（元）', '3,767,986,787.28', '3,344,285,537.75', '3,345,260,092.73', '12.64%', '3,049,994,608.50', '3,050,974,977.55']"}
{"page": 7, "allrow": 144, "type": "text", "inside": "会计政策变更的原因及会计差错更正的情况"}
{"page": 7, "allrow": 145, "type": "text", "inside": "注：1、在报告期内公司因派发股票股利、公积金转增股本、拆股而增加或并股而减少公司总股本，但不影响股东权益金额的，应当根据相关会计准则的规定按最新股本调整并列报最近3年的基本每股收益和稀释每股收益。"}
{"page": 7, "allrow": 146, "type": "text", "inside": "2、如果报告期末至年度报告披露日，公司股本因送红股、资本公积转增股本的原因发生变化且不影响股东权益金额的，应当根据相关会计准则的规定按最新股本调整并列报最近3年的基本每股收益和稀释每股收益。"}
{"page": 7, "allrow": 147, "type": "text", "inside": "3、报告期内公司股本总额因IPO、增发、配股、股权激励行权、股份回购等影响所有者权益金额的事项发生变动的，在计算每股收益时应根据股份变动的时间对股本总额进行加权平均。公司在计算基本每股收益时，作为同一控制下企业合并的合并方，应将作为对价而发行的全部新股数计入合并当年和对比年度的发行在外的普通股加权平均数（即权重为1）；在存在稀释性潜在普通股的条件下，公司应采用同样的原则计算稀释每股收益。"}
{"page": 7, "allrow": 148, "type": "text", "inside": "4、在报告期末至年度报告披露日，公司股本总额因IPO、增发、配股、股权激励行权、股份回购等影响所有者权益金额的事项发生变动的，当期和比较期间每股收益无需因此调整，各报告期的每股收益仍按相关期间股本总额的加权平均数计算；"}
{"page": 7, "allrow": 149, "type": "text", "inside": "但是，公司应当填报“按最新股本总额计算的每股收益”，按最新股本总额计算的每股收益＝归属于上市公司股东的净利润/最新股本总额。"}
{"page": 7, "allrow": 150, "type": "text", "inside": "5、发行优先股并分类为权益工具的公司，在计算每股收益和普通股股东的净资产收益率（以下简称“净资产收益率”）时应"}
{"page": 7, "allrow": 151, "type": "text", "inside": "考虑优先股的影响。计算基本每股收益和净资产收益率时，归属于普通股股东的净利润不应包含优先股股利，其中对于不可"}
{"page": 7, "allrow": 152, "type": "text", "inside": "累计优先股，应扣除当年经审议批准宣告发放的股利；对于累计优先股，无论当期是否宣告发放，均应扣除相关股利。对于"}
{"page": 7, "allrow": 153, "type": "页脚", "inside": "7"}
{"page": 8, "allrow": 154, "type": "text", "inside": ""}
{"page": 8, "allrow": 155, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 8, "allrow": 156, "type": "text", "inside": "存在具有潜在稀释性的优先股，应考虑其假定转换对计算基本每股收益的分子、分母进行调整后计算确定稀释每股收益。计算净资产收益率时，归属于普通股股东的加权平均净资产不应包括优先股股东享有的净资产，其中对于累积优先股，应扣除已累计但尚未宣告发放的股利。发行永续债等并分类为权益工具的公司，在计算每股收益和净资产收益率时参照上述优先股的计算方法。"}
{"page": 8, "allrow": 157, "type": "text", "inside": "6、本报告期对上年度财务数据进行了追溯调整或重述的，应当披露会计政策变更的原因及会计差错更正的情况，上年度期末和上年度同期应当同时列示追溯调整或重述前后的数据。"}
{"page": 8, "allrow": 158, "type": "text", "inside": "7、对非经常性损益、净资产收益率和每股收益的确定和计算，中国证监会另有规定的，应当遵照执行。"}
{"page": 8, "allrow": 159, "type": "text", "inside": "8、编制合并财务报表的公司应当以合并财务报表数据填列或计算以上数据和指标。"}
{"page": 8, "allrow": 160, "type": "text", "inside": "9、如公司成立未满3年，应当披露公司成立后完整会计年度的上述会计数据和财务指标。"}
{"page": 8, "allrow": 161, "type": "text", "inside": "10、根据《企业会计准则第34号—每股收益》及《公开发行证券的公司信息披露编报规则第9号—净资产收益率和每股收益的计算及披露》（2010年修订）的规定计算每股收益及净资产收益率。"}
{"page": 8, "allrow": 162, "type": "text", "inside": "截止披露前一交易日的公司总股本："}
{"page": 8, "allrow": 163, "type": "excel", "inside": "['截止披露前一交易日的公司总股本（股）', '1,178,523,492']"}
{"page": 8, "allrow": 164, "type": "text", "inside": "用最新股本计算的全面摊薄每股收益"}
{"page": 8, "allrow": 165, "type": "excel", "inside": "['支付的优先股股利', '0.00']"}
{"page": 8, "allrow": 166, "type": "excel", "inside": "['用最新股本计算的全面摊薄每股收益（元/股）', '0.4696']"}
{"page": 8, "allrow": 167, "type": "text", "inside": "注：“用最新股本计算的全面摊薄每股收益（元/股）”主要用于计算市盈率等指标，应根据证监会《证券期货统计指标（2016"}
{"page": 8, "allrow": 168, "type": "text", "inside": "年修订）》规定口径计算，请以“截止披露前一交易日的公司总股本（股）”为基数（包括回购股份）进行计算，与利润表中每股收益计算口径可能存在不一致的情形。"}
{"page": 8, "allrow": 169, "type": "text", "inside": "是否存在公司债"}
{"page": 8, "allrow": 170, "type": "text", "inside": "□是√否"}
{"page": 8, "allrow": 171, "type": "text", "inside": "公司是否存在最近两年连续亏损的情形"}
{"page": 8, "allrow": 172, "type": "text", "inside": "□是√否□不适用"}
{"page": 8, "allrow": 173, "type": "text", "inside": "须办理公司债券停牌及暂停上市交易相关事项，并于年报披露时停牌！"}
{"page": 8, "allrow": 174, "type": "text", "inside": "七、境内外会计准则下会计数据差异"}
{"page": 8, "allrow": 175, "type": "text", "inside": "1、同时按照国际会计准则与按照中国会计准则披露的财务报告中净利润和净资产差异情况"}
{"page": 8, "allrow": 176, "type": "text", "inside": "□适用√不适用"}
{"page": 8, "allrow": 177, "type": "text", "inside": "公司报告期不存在按照国际会计准则与按照中国会计准则披露的财务报告中净利润和净资产差异情况。"}
{"page": 8, "allrow": 178, "type": "text", "inside": "2、同时按照境外会计准则与按照中国会计准则披露的财务报告中净利润和净资产差异情况"}
{"page": 8, "allrow": 179, "type": "text", "inside": "□适用√不适用"}
{"page": 8, "allrow": 180, "type": "text", "inside": "公司报告期不存在按照境外会计准则与按照中国会计准则披露的财务报告中净利润和净资产差异情况。"}
{"page": 8, "allrow": 181, "type": "text", "inside": "八、分季度主要财务指标"}
{"page": 8, "allrow": 182, "type": "text", "inside": "单位：元"}
{"page": 8, "allrow": 183, "type": "excel", "inside": "['第一季度', '第二季度', '第三季度', '第四季度']"}
{"page": 8, "allrow": 184, "type": "text", "inside": ""}
{"page": 8, "allrow": 185, "type": "页脚", "inside": "8"}
{"page": 9, "allrow": 186, "type": "text", "inside": ""}
{"page": 9, "allrow": 187, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 9, "allrow": 188, "type": "excel", "inside": "['营业收入', '1,675,316,248.13', '1,874,057,579.89', '1,865,842,652.34', '1,795,494,905.78']"}
{"page": 9, "allrow": 189, "type": "excel", "inside": "['归属于上市公司股东的净利润', '110,560,349.54', '170,276,773.46', '150,776,960.38', '121,786,678.04']"}
{"page": 9, "allrow": 190, "type": "excel", "inside": "['归属于上市公司股东的扣除非经常性损益的净利润', '108,298,282.32', '183,304,186.25', '135,673,407.06', '102,454,947.55']"}
{"page": 9, "allrow": 191, "type": "excel", "inside": "['经营活动产生的现金流量净额', '180,356,281.54', '353,726,788.25', '549,238,395.18', '276,744,725.39']"}
{"page": 9, "allrow": 192, "type": "text", "inside": "上述财务指标或其加总数是否与公司已披露季度报告、半年度报告相关财务指标存在重大差异"}
{"page": 9, "allrow": 193, "type": "text", "inside": "□是√否"}
{"page": 9, "allrow": 194, "type": "text", "inside": "九、非经常性损益项目及金额"}
{"page": 9, "allrow": 195, "type": "text", "inside": "√适用□不适用"}
{"page": 9, "allrow": 196, "type": "text", "inside": "单位：元"}
{"page": 9, "allrow": 197, "type": "excel", "inside": "['项目', '', '2019年金额', '2018年金额', '2017年金额', '', '说明']"}
{"page": 9, "allrow": 198, "type": "excel", "inside": "['非流动资产处置损益（包括已计提资产减值准备的冲销部分）', '-5,938,126.90', '', '-25,311,797.32', '-605,195.58', '', '']"}
{"page": 9, "allrow": 199, "type": "excel", "inside": "['越权审批或无正式批准文件的税收返还、减免', '', '', '7,593,697.87', '13,830,327.92', '', '']"}
{"page": 9, "allrow": 200, "type": "excel", "inside": "['计入当期损益的政府补助（与企业业务密切相关，按照国家统一标准定额或定量享受的政府补助除外）', '89,808,796.26', '', '62,627,005.16', '39,993,278.85', '本期收到的政府补助同比增加', '']"}
{"page": 9, "allrow": 201, "type": "excel", "inside": "['计入当期损益的对非金融企业收取的资金占用费', '', '', '', '', '', '']"}
{"page": 9, "allrow": 202, "type": "excel", "inside": "['企业取得子公司、联营企业及合营企业的投资成本小于取得投资时应享有被投资单位可辨认净资产公允价值产生的收益', '', '', '', '', '', '']"}
{"page": 9, "allrow": 203, "type": "excel", "inside": "['非货币性资产交换损益', '', '', '', '', '', '']"}
{"page": 9, "allrow": 204, "type": "excel", "inside": "['委托他人投资或管理资产的损益', '', '', '', '', '', '']"}
{"page": 9, "allrow": 205, "type": "excel", "inside": "['因不可抗力因素，如遭受自然灾害而计提的各项资产减值准备', '', '', '', '', '', '']"}
{"page": 9, "allrow": 206, "type": "excel", "inside": "['债务重组损益', '', '', '', '', '', '']"}
{"page": 9, "allrow": 207, "type": "excel", "inside": "['企业重组费用，如安置职工的支出、整合费用等', '', '', '', '', '', '']"}
{"page": 9, "allrow": 208, "type": "excel", "inside": "['交易价格显失公允的交易产生的超过公允价值部分的损益', '', '', '', '', '', '']"}
{"page": 9, "allrow": 209, "type": "excel", "inside": "['同一控制下企业合并产生的子公司期初至合并日的当期净损益', '', '', '-5,814.07', '43,661.20', '', '']"}
{"page": 9, "allrow": 210, "type": "excel", "inside": "['与公司正常经营业务无关的或有事项产生的损益', '', '', '', '', '', '']"}
{"page": 9, "allrow": 211, "type": "text", "inside": ""}
{"page": 9, "allrow": 212, "type": "页脚", "inside": "9"}
{"page": 10, "allrow": 213, "type": "text", "inside": ""}
{"page": 10, "allrow": 214, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 10, "allrow": 215, "type": "excel", "inside": "['除同公司正常经营业务相关的有效套期保值业务外，持有交易性金融资产、衍生金融资产、交易性金融负债、衍生金融负债产生的公允价值变动损益，以及处置交易性金融资产、衍生金融资产、交易性金融负债、衍生金融负债和其他债权投资取得的投资收益', '-61,762,572.48', '-11,851,809.20', '78,145.83', '']"}
{"page": 10, "allrow": 216, "type": "excel", "inside": "['单独进行减值测试的应收款项、合同资产减值准备转回', '', '', '', '']"}
{"page": 10, "allrow": 217, "type": "excel", "inside": "['对外委托贷款取得的损益', '', '', '', '']"}
{"page": 10, "allrow": 218, "type": "excel", "inside": "['采用公允价值模式进行后续计量的投资性房地产公允价值变动产生的损益', '', '', '', '']"}
{"page": 10, "allrow": 219, "type": "excel", "inside": "['根据税收、会计等法律、法规的要求对当期损益进行一次性调整对当期损益的影响', '', '', '', '']"}
{"page": 10, "allrow": 220, "type": "excel", "inside": "['受托经营取得的托管费收入', '', '', '', '']"}
{"page": 10, "allrow": 221, "type": "excel", "inside": "['除上述各项之外的其他营业外收入和支出', '-655,153.67', '591,977.33', '3,650,639.69', '']"}
{"page": 10, "allrow": 222, "type": "excel", "inside": "['其他符合非经常性损益定义的损益项目', '', '1,981,245.07', '748,034.28', '']"}
{"page": 10, "allrow": 223, "type": "excel", "inside": "['减：所得税影响额', '-2,216,995.03', '7,025,878.46', '10,322,316.64', '']"}
{"page": 10, "allrow": 224, "type": "excel", "inside": "['少数股东权益影响额（税后）', '', '', '', '']"}
{"page": 10, "allrow": 225, "type": "excel", "inside": "['合计', '23,669,938.24', '28,598,626.38', '47,416,575.55', '--']"}
{"page": 10, "allrow": 226, "type": "text", "inside": ""}
{"page": 10, "allrow": 227, "type": "text", "inside": "对公司根据《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》定义界定的非经常性损益项目，以及把《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因"}
{"page": 10, "allrow": 228, "type": "text", "inside": "□适用√不适用"}
{"page": 10, "allrow": 229, "type": "text", "inside": "公司报告期不存在将根据《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》定义、列举的非经常性损益项目界定为经常性损益的项目的情形。"}
{"page": 10, "allrow": 230, "type": "页脚", "inside": "10"}
{"page": 11, "allrow": 231, "type": "text", "inside": ""}
{"page": 11, "allrow": 232, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 11, "allrow": 233, "type": "text", "inside": "第三节公司业务概要"}
{"page": 11, "allrow": 234, "type": "text", "inside": "一、报告期内公司从事的主要业务"}
{"page": 11, "allrow": 235, "type": "text", "inside": "公司所属医药制造行业，主营业务涵盖原料药中间体、合同研发生产服务（CDMO）、制剂业务和进出口贸易业务等。"}
{"page": 11, "allrow": 236, "type": "text", "inside": "（一）主要涵盖品种如下："}
{"page": 11, "allrow": 237, "type": "text", "inside": "（1）原料药中间体"}
{"page": 11, "allrow": 238, "type": "text", "inside": "包括口服头孢系列、口服青霉素系列、精神类系列、心脑血管类系列和兽药原料药中间体系列。"}
{"page": 11, "allrow": 239, "type": "text", "inside": "（2）合同研发生产服务"}
{"page": 11, "allrow": 240, "type": "text", "inside": "包括研发服务、专利期内的商业化产品、专利过期的商业化产品。"}
{"page": 11, "allrow": 241, "type": "text", "inside": "（3）制剂"}
{"page": 11, "allrow": 242, "type": "text", "inside": "制剂产品包括抗感染类、心脑血管类、精神类和抗肿瘤类等。"}
{"page": 11, "allrow": 243, "type": "text", "inside": "公司在三大业务领域形成了独特的市场优势："}
{"page": 11, "allrow": 244, "type": "text", "inside": "（1）原料药中间体：近年来，随着公司安全环保、质量管理、技术支持的不断投入，公司产品已逐步在成本、质量、技术方面形成了较强的市场竞争优势。"}
{"page": 11, "allrow": 245, "type": "text", "inside": "（2）CDMO（合同研发生产服务）：公司CDMO业务具备“化学合成+生物发酵”双轮驱动的技术能力和“多客户、多产品”的竞争优势，主要工厂都获得美国FDA、日本PMDA、欧盟认证通过，具备国际大药企合格供应商的资质。公司不断地在加大CDMO研发上的投入，CDMO业务也实现了从原来的起始原料药加注册中间体为主的产业模式向以注册中间体加原料药为主的产业模式转变。"}
{"page": 11, "allrow": 246, "type": "text", "inside": "（3）制剂：公司一直坚持“仿创结合”，仿制药寻求差异化，创新药寻求做临床价值，目标在抗感染、心脑血管、抗肿瘤和精神类药物领域逐步发展优势品种，建立公司有中间体原料药、制剂一体化优势的品种，甚至包括一些技术难度较大的复方制剂和缓控释制剂等。"}
{"page": 11, "allrow": 247, "type": "text", "inside": "二、主要资产重大变化情况"}
{"page": 11, "allrow": 248, "type": "text", "inside": "1、主要资产重大变化情况"}
{"page": 11, "allrow": 249, "type": "excel", "inside": "['主要资产', '重大变化说明']"}
{"page": 11, "allrow": 250, "type": "excel", "inside": "['股权资产', '无重大变化']"}
{"page": 11, "allrow": 251, "type": "excel", "inside": "['固定资产', '无重大变化']"}
{"page": 11, "allrow": 252, "type": "excel", "inside": "['无形资产', '无重大变化']"}
{"page": 11, "allrow": 253, "type": "excel", "inside": "['在建工程', '无重大变化']"}
{"page": 11, "allrow": 254, "type": "text", "inside": ""}
{"page": 11, "allrow": 255, "type": "text", "inside": "2、主要境外资产情况"}
{"page": 11, "allrow": 256, "type": "text", "inside": "□适用√不适用"}
{"page": 11, "allrow": 257, "type": "页脚", "inside": "11"}
{"page": 12, "allrow": 258, "type": "text", "inside": ""}
{"page": 12, "allrow": 259, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 12, "allrow": 260, "type": "text", "inside": "三、核心竞争力分析"}
{"page": 12, "allrow": 261, "type": "text", "inside": "1、较强的研发实力"}
{"page": 12, "allrow": 262, "type": "text", "inside": "公司历来坚持自主开发与产学研相结合的发展模式，逐步建立以企业为主体的技术创新体系，现拥有两家省级院士工作站、两家国家级博士后科研工作站，一家手性药物及中间体技术国家工程研究中心。公司原料药事业部下设化学、生物和工程三个技术中心；CDMO事业部在上海和横店分别设有研发中心；制剂的开发和研究主要在杭州药物研究院。公司拥有全职博士34名，浙江省“千人计划”专家4人及专职研发人员400余人。"}
{"page": 12, "allrow": 263, "type": "text", "inside": "2、丰富的产品线和专利技术"}
{"page": 12, "allrow": 264, "type": "text", "inside": "公司主要产品涉及抗感染类、抗肿瘤类、心血脑管类、精神类以及兽药类等多个领域，拥有独特的市场竞争优势，其中头孢克肟、金刚烷胺、（伪）麻黄碱等原料药占有重要市场地位，美托洛尔、安非他酮、阿莫西林侧链系列、氟苯尼考母核、沙坦联苯母核等具有市场领导地位；抗肿瘤类药物乌苯美司胶囊、口服抗感染药物头孢克肟系列产品、阿莫西林克拉维酸钾等制剂产品占较大市场份额。截止报告期末，公司拥有发明专利128项，实用新型专利58项。"}
{"page": 12, "allrow": 265, "type": "text", "inside": "3、覆盖全球的营销网络"}
{"page": 12, "allrow": 266, "type": "text", "inside": "公司建立了全球性的销售网络，覆盖北美洲、欧洲、亚洲、南美洲、非洲以及国内各大中型城市，产品远销70余个国家和地区。"}
{"page": 12, "allrow": 267, "type": "text", "inside": "4、领先的质量及EHS管理体系"}
{"page": 12, "allrow": 268, "type": "text", "inside": "公司具备国际化的制造能力，建立了规范的质量管理体系和EHS体系。已有数条生产线分别通过WHO、OPCW、美国FDA、欧盟COS、德国GMP和日本PMDA等官方核查与认证。公司先后于2016和2017年在四家子公司共投资5套RTO尾气处理系统，2018"}
{"page": 12, "allrow": 269, "type": "text", "inside": "年在另外两家子公司又投2套RTO尾气处理系统。各子公司固废均能做到有序合规处理，真正做到绿色环保生产，为企业的安全生产和未来可持续发展保驾护航。"}
{"page": 12, "allrow": 270, "type": "text", "inside": "5、员工持股计划增强员工积极性"}
{"page": 12, "allrow": 271, "type": "text", "inside": "公司在报告期内实施了第一期员工持股计划，对包括公司主要管理层在内的252名员工进行了激励。有效地在公司和员工之间建立了利益共享机制，以实现激励员工，增强员工工作的积极性和创造性，有利于驱动公司的经营业绩，实现公司效益最大化的目标。"}
{"page": 12, "allrow": 272, "type": "页脚", "inside": "12"}
{"page": 13, "allrow": 273, "type": "text", "inside": ""}
{"page": 13, "allrow": 274, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 13, "allrow": 275, "type": "text", "inside": "第四节经营情况讨论与分析"}
{"page": 13, "allrow": 276, "type": "text", "inside": "一、概述"}
{"page": 13, "allrow": 277, "type": "text", "inside": "2019年，在国家医保控费、三医联动、药品相关政策频出的大背景下，整个医药行业都产生了巨大的影响和变化，资本市场对医药企业的态度也在发生改变。中国医药行业的全行业逻辑由原来的准入(政府准入和医院准入)转变为成本和规模(包括质量管理和供货能力),行业竞争从销售端转移至研发生产端，成本、质量和技术能力成为未来竞争的重点。但从另一个角度出发，也为原料药制剂一体化企业提供了新的发展机遇，相关产品可以享受政策红利，在短期内快速形成销售，以成本优势快速占据大部分市场份额。另外，政府也陆续出台了鼓励医药企业创新发展的一系列政策，推动医药企业积极布局创新药，希望未来能够在良性竞争的环境下推动整个行业的优化发展。"}
{"page": 13, "allrow": 278, "type": "text", "inside": "过去的一年，公司在严峻的外部背景下，积极适应国家政策变化，各事业部及各子公司团结一致，紧紧围绕公司发展战略，紧抓安全环保、质量不放松，不遗余力地推动全年生产保障工作，积极完成了全年预算目标，营业收入和净利润双双创下了历史新高。2019年公司实现营业收入721,071.14万元，同比增长13.09%，实现净利润55,340.08万元，同比增长49.34%。"}
{"page": 13, "allrow": 279, "type": "text", "inside": "一、生产管理情况"}
{"page": 13, "allrow": 280, "type": "text", "inside": "公司各事业部和各子公司持续推进生产管理工作，为企业业绩提升添砖加瓦。原料药业务方面，公司努力做强战略品种，培育重点品种，开发新产品，提升产品竞争力，有序推进产业转型升级。CDMO业务方面，公司获得了省第一批现代服务业与先进制造业深度融合试点单位，与全球几家动保公司的业务合作进一步向纵深发展，实现从原来的起始原料药加注册中间体为主的产业模式向以注册中间体加原料药为主的产业模式转型升级。制剂业务方面，公司积极拓展从原料药到制剂的上下游一体化业务，对国内外制剂业务进行了合理的战略布局，同时，全力推进新项目的品种申报工作。"}
{"page": 13, "allrow": 281, "type": "text", "inside": "二、研发和项目情况"}
{"page": 13, "allrow": 282, "type": "text", "inside": "公司结合战略的调整对研发体系进行了优化，加强研发梯队建设，新设立了原料药技术中心生物研发部和CDMO上海研发中心，研发梯队初步形成，新引进了包括7名博士在内的200余人来支持公司未来的可持续发展。"}
{"page": 13, "allrow": 283, "type": "text", "inside": "项目研究和申报方面，2019年9月份，公司第一个ANDA项目-盐酸安非他酮缓释片通过美国FDA批准上市；左乙拉西坦片以新四类获批并在国内上市（视同通过一致性评价），并成功入围国家“4+7”集采扩围，实现快速放量销售。截止报告期末，公司已进入注册程序的项目品种中，已向NMPA提交注册申请的项目共9个，多个项目已进入审评审批阶段。目前正在进行一致性评价研究的项目有16个，其中已申报品种3个。另外，中药经典名方工作有序推进，正在进行研究的项目有6个，均已完成申报资料的准备工作。公司治疗脑中风的一类新药索法地尔Ⅱ期临床实验部分已完成，目前正在进行Ⅱ期临床数据统计工作。"}
{"page": 13, "allrow": 284, "type": "text", "inside": "2019年全年，公司共获发明专利授权5件。截至目前，公司拥有各项有效专利195项，其中发明专利137件，实用新型专利58件。"}
{"page": 13, "allrow": 285, "type": "text", "inside": "三、质量和EHS体系建设情况"}
{"page": 13, "allrow": 286, "type": "text", "inside": "公司全年持续加强质量和EHS体系建设，努力提高产品市场竞争能力。质量体系按照新的药品管理法，全面推进各项工作。全年接受了各类质量审计181次，其中国外官方5次，国内官方28次，国外重要客户审计71次，国内客户审计77次，为公司整个药品的生产经营环节提供了强大质量保证。"}
{"page": 13, "allrow": 287, "type": "text", "inside": "2019年，公司环保投入超1.2亿。环保工作始终贯彻环保优先、绿色发展理念，优化工程技术创新，强化源头减排。EHS体系持续完善安全生产、环保责任体系，强化过程管控、监管服务并重，不断提升危机管理能力，持续细化风险分析和管控，着力构建隐患排查机制。"}
{"page": 13, "allrow": 288, "type": "text", "inside": "四、人才培养和储备"}
{"page": 13, "allrow": 289, "type": "text", "inside": "公司根据战略发展需求，加强员工的招聘与培训，注重员工职业发展、薪酬绩效管理，主导推动员工的结构性调整，以班组建设活动为载体，积极开展员工能力建设，努力打造高素质人才队伍。"}
{"page": 13, "allrow": 290, "type": "text", "inside": "报告期内，公司为建立长效激励机制，吸引和保留人才，充分调动核心骨干及高级管理者的积极性，提升公司市场竞争力，实施了第一期员工持股计划，激励对象包括公司主要管理层在内的252名员工。该方案的实施可以有效地在公司和员"}
{"page": 13, "allrow": 291, "type": "页脚", "inside": "13"}
{"page": 14, "allrow": 292, "type": "text", "inside": ""}
{"page": 14, "allrow": 293, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 14, "allrow": 294, "type": "text", "inside": "工之间建立利益共享机制，有利于驱动公司的经营业绩，以实现激励员工、增强员工工作的积极性和创造性，实现公司效益和股东利益最大化的目标。"}
{"page": 14, "allrow": 295, "type": "text", "inside": "二、主营业务分析"}
{"page": 14, "allrow": 296, "type": "text", "inside": "1、概述"}
{"page": 14, "allrow": 297, "type": "text", "inside": "参见“经营情况讨论与分析”中的“一、概述”相关内容。"}
{"page": 14, "allrow": 298, "type": "text", "inside": "2、收入与成本"}
{"page": 14, "allrow": 299, "type": "text", "inside": "（1）营业收入构成"}
{"page": 14, "allrow": 300, "type": "text", "inside": "单位：元"}
{"page": 14, "allrow": 301, "type": "excel", "inside": "['', '2019年', '', '2018年', '', '']"}
{"page": 14, "allrow": 302, "type": "excel", "inside": "['', '金额', '占营业收入比重', '金额', '占营业收入比重', '同比增减']"}
{"page": 14, "allrow": 303, "type": "excel", "inside": "['营业收入合计', '7,210,711,386.14', '100%', '6,375,980,498.49', '100%', '13.09%']"}
{"page": 14, "allrow": 304, "type": "excel", "inside": "['分行业', '', '', '', '', '']"}
{"page": 14, "allrow": 305, "type": "excel", "inside": "['医药主营业务', '7,198,139,226.36', '99.83%', '6,364,715,162.14', '99.82%', '13.09%']"}
{"page": 14, "allrow": 306, "type": "excel", "inside": "['其他业务', '12,572,159.78', '0.17%', '11,265,336.35', '0.18%', '11.60%']"}
{"page": 14, "allrow": 307, "type": "excel", "inside": "['分产品', '', '', '', '', '']"}
{"page": 14, "allrow": 308, "type": "excel", "inside": "['中间体及原料药', '5,294,203,691.58', '73.42%', '4,537,017,617.83', '71.16%', '16.69%']"}
{"page": 14, "allrow": 309, "type": "excel", "inside": "['制剂', '1,124,824,014.45', '15.60%', '1,152,454,464.16', '18.07%', '-2.40%']"}
{"page": 14, "allrow": 310, "type": "excel", "inside": "['CDMO', '722,082,650.07', '10.01%', '663,633,620.25', '10.41%', '8.81%']"}
{"page": 14, "allrow": 311, "type": "excel", "inside": "['其他', '57,028,870.26', '0.79%', '11,609,459.90', '0.18%', '391.23%']"}
{"page": 14, "allrow": 312, "type": "excel", "inside": "['其他业务', '12,572,159.78', '0.17%', '11,265,336.35', '0.18%', '11.60%']"}
{"page": 14, "allrow": 313, "type": "excel", "inside": "['分地区', '', '', '', '', '']"}
{"page": 14, "allrow": 314, "type": "excel", "inside": "['国内地区', '4,181,382,144.32', '57.99%', '3,804,256,674.73', '59.67%', '9.91%']"}
{"page": 14, "allrow": 315, "type": "excel", "inside": "['国外地区', '3,029,329,241.82', '42.01%', '2,571,723,823.76', '40.33%', '17.79%']"}
{"page": 14, "allrow": 316, "type": "text", "inside": "（2）占公司营业收入或营业利润10%以上的行业、产品或地区情况"}
{"page": 14, "allrow": 317, "type": "text", "inside": "√适用□不适用"}
{"page": 14, "allrow": 318, "type": "text", "inside": "单位：元"}
{"page": 14, "allrow": 319, "type": "excel", "inside": "['', '', '', '', '营业收入比上', '营业成本比上', '毛利率比上年']"}
{"page": 14, "allrow": 320, "type": "excel", "inside": "['', '营业收入', '营业成本', '毛利率', '年同期增减', '年同期增减', '同期增减']"}
{"page": 14, "allrow": 321, "type": "excel", "inside": "['分行业', '', '', '', '', '', '']"}
{"page": 14, "allrow": 322, "type": "text", "inside": ""}
{"page": 14, "allrow": 323, "type": "页脚", "inside": "14"}
{"page": 15, "allrow": 324, "type": "text", "inside": ""}
{"page": 15, "allrow": 325, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 15, "allrow": 326, "type": "excel", "inside": "['', '7,198,139,226.', '4,863,626,240.', '', '', '', '']"}
{"page": 15, "allrow": 327, "type": "excel", "inside": "['主营业务医药', '36', '99', '32.43%', '13.09%', '12.29%', '0.48%']"}
{"page": 15, "allrow": 328, "type": "excel", "inside": "['分产品', '', '', '', '', '', '']"}
{"page": 15, "allrow": 329, "type": "excel", "inside": "['中间体及原料药', '5,294,203,691.58', '4,069,388,124.24', '23.14%', '16.69%', '14.35%', '1.58%']"}
{"page": 15, "allrow": 330, "type": "excel", "inside": "['', '1,124,824,014.', '', '', '', '', '']"}
{"page": 15, "allrow": 331, "type": "excel", "inside": "['制剂', '45', '286,552,239.53', '74.52%', '-2.40%', '-11.01%', '2.46%']"}
{"page": 15, "allrow": 332, "type": "excel", "inside": "['CDMO', '722,082,650.07', '452,835,110.31', '37.29%', '8.81%', '2.51%', '3.85%']"}
{"page": 15, "allrow": 333, "type": "excel", "inside": "['分地区', '', '', '', '', '', '']"}
{"page": 15, "allrow": 334, "type": "excel", "inside": "['', '4,168,809,984.', '2,476,757,612.', '', '', '', '']"}
{"page": 15, "allrow": 335, "type": "excel", "inside": "['国内地区', '54', '55', '40.59%', '9.91%', '20.63%', '-5.28%']"}
{"page": 15, "allrow": 336, "type": "excel", "inside": "['', '3,029,329,241.', '2,386,868,628.', '', '', '', '']"}
{"page": 15, "allrow": 337, "type": "excel", "inside": "['国外地区', '82', '44', '21.21%', '17.79%', '4.77%', '9.79%']"}
{"page": 15, "allrow": 338, "type": "text", "inside": ""}
{"page": 15, "allrow": 339, "type": "text", "inside": "公司主营业务数据统计口径在报告期发生调整的情况下，公司最近1年按报告期末口径调整后的主营业务数据"}
{"page": 15, "allrow": 340, "type": "text", "inside": "□适用√不适用"}
{"page": 15, "allrow": 341, "type": "text", "inside": "（3）公司实物销售收入是否大于劳务收入"}
{"page": 15, "allrow": 342, "type": "text", "inside": "√是□否"}
{"page": 15, "allrow": 343, "type": "excel", "inside": "['行业分类', '项目', '单位', '2019年', '2018年', '同比增减']"}
{"page": 15, "allrow": 344, "type": "excel", "inside": "['', '销售量', 'kg', '54,891,444.56', '42,986,771.22', '27.69%']"}
{"page": 15, "allrow": 345, "type": "excel", "inside": "['中间体及原料药', '生产量', 'kg', '54,771,411.15', '43,844,226.53', '24.92%']"}
{"page": 15, "allrow": 346, "type": "excel", "inside": "['', '库存量', 'kg', '2,426,776.85', '2,546,810.26', '-4.71%']"}
{"page": 15, "allrow": 347, "type": "excel", "inside": "['', '销售量', '盒、瓶、支', '73,828,701', '77,731,080', '-5.02%']"}
{"page": 15, "allrow": 348, "type": "excel", "inside": "['制剂', '生产量', '盒、瓶、支', '67,057,119', '77,899,935', '-13.92%']"}
{"page": 15, "allrow": 349, "type": "excel", "inside": "['', '库存量', '盒、瓶、支', '5,946,706', '12,718,288', '-53.24%']"}
{"page": 15, "allrow": 350, "type": "excel", "inside": "['', '销售量', 'kg', '740,802.34', '655,961.35', '12.93%']"}
{"page": 15, "allrow": 351, "type": "excel", "inside": "['CDMO', '生产量', 'kg', '773,661.8', '696,295.62', '11.11%']"}
{"page": 15, "allrow": 352, "type": "excel", "inside": "['', '库存量', 'kg', '167,156.11', '134,296.65', '24.47%']"}
{"page": 15, "allrow": 353, "type": "text", "inside": "相关数据同比发生变动30%以上的原因说明"}
{"page": 15, "allrow": 354, "type": "text", "inside": "□适用√不适用"}
{"page": 15, "allrow": 355, "type": "text", "inside": "（4）公司已签订的重大销售合同截至本报告期的履行情况"}
{"page": 15, "allrow": 356, "type": "text", "inside": "□适用√不适用"}
{"page": 15, "allrow": 357, "type": "text", "inside": "（5）营业成本构成"}
{"page": 15, "allrow": 358, "type": "text", "inside": "行业分类"}
{"page": 15, "allrow": 359, "type": "页脚", "inside": "15"}
{"page": 16, "allrow": 360, "type": "text", "inside": ""}
{"page": 16, "allrow": 361, "type": "text", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 16, "allrow": 362, "type": "text", "inside": "行业分类"}
{"page": 16, "allrow": 363, "type": "text", "inside": "单位：元"}
{"page": 16, "allrow": 364, "type": "excel", "inside": "['', '', '2019年', '', '2018年', '', '']"}
{"page": 16, "allrow": 365, "type": "excel", "inside": "['行业分类', '项目', '金额', '占营业成本比重', '金额', '占营业成本比重', '同比增减']"}
{"page": 16, "allrow": 366, "type": "excel", "inside": "['医药主营业务', '原材料', '3,897,835,999.72', '79.93%', '3,467,826,354.69', '80.06%', '-0.13%']"}
{"page": 16, "allrow": 367, "type": "excel", "inside": "['医药主营业务', '人工', '159,825,498.07', '3.28%', '142,391,732.73', '3.29%', '-0.01%']"}
{"page": 16, "allrow": 368, "type": "excel", "inside": "['医药主营业务', '制造费用', '818,916,996.50', '16.79%', '721,136,371.88', '16.65%', '0.14%']"}
{"page": 16, "allrow": 369, "type": "text", "inside": "说明"}
{"page": 16, "allrow": 370, "type": "text", "inside": "（6）报告期内合并范围是否发生变动"}
{"page": 16, "allrow": 371, "type": "text", "inside": "□是√否"}
{"page": 16, "allrow": 372, "type": "text", "inside": "（7）公司报告期内业务、产品或服务发生重大变化或调整有关情况"}
{"page": 16, "allrow": 373, "type": "text", "inside": "□适用√不适用"}
{"page": 16, "allrow": 374, "type": "text", "inside": "（8）主要销售客户和主要供应商情况"}
{"page": 16, "allrow": 375, "type": "text", "inside": "公司主要销售客户情况"}
{"page": 16, "allrow": 376, "type": "excel", "inside": "['前五名客户合计销售金额（元）', '', '792,527,075.98']"}
{"page": 16, "allrow": 377, "type": "excel", "inside": "['前五名客户合计销售金额占年度销售总额比例', '', '10.99%']"}
{"page": 16, "allrow": 378, "type": "excel", "inside": "['前五名客户销售额中关联方销售额占年度销售总额比例', '0.00%', '']"}
{"page": 16, "allrow": 379, "type": "text", "inside": ""}
{"page": 16, "allrow": 380, "type": "text", "inside": "公司前5大客户资料"}
{"page": 16, "allrow": 381, "type": "excel", "inside": "['序号', '客户名称', '销售额（元）', '占年度销售总额比例']"}
{"page": 16, "allrow": 382, "type": "excel", "inside": "['1', 'A', '188,304,210.55', '2.61%']"}
{"page": 16, "allrow": 383, "type": "excel", "inside": "['2', 'B', '169,831,469.14', '2.36%']"}
{"page": 16, "allrow": 384, "type": "excel", "inside": "['3', 'C', '162,890,427.86', '2.26%']"}
{"page": 16, "allrow": 385, "type": "excel", "inside": "['4', 'D', '136,636,102.63', '1.89%']"}
{"page": 16, "allrow": 386, "type": "excel", "inside": "['5', 'E', '134,864,865.80', '1.87%']"}
{"page": 16, "allrow": 387, "type": "excel", "inside": "['合计', '--', '792,527,075.98', '10.99%']"}
{"page": 16, "allrow": 388, "type": "text", "inside": "主要客户其他情况说明"}
{"page": 16, "allrow": 389, "type": "text", "inside": "□适用√不适用"}
{"page": 16, "allrow": 390, "type": "text", "inside": "公司主要供应商情况"}
{"page": 16, "allrow": 391, "type": "excel", "inside": "['前五名供应商合计采购金额（元）', '628,358,041.73']"}
{"page": 16, "allrow": 392, "type": "excel", "inside": "['前五名供应商合计采购金额占年度采购总额比例', '11.35%']"}
{"page": 17, "allrow": 393, "type": "text", "inside": ""}
{"page": 17, "allrow": 394, "type": "text", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 17, "allrow": 395, "type": "excel", "inside": "['前五名供应商采购额中关联方采购额占年度采购总额比例', '4.65%']"}
{"page": 17, "allrow": 396, "type": "text", "inside": ""}
{"page": 17, "allrow": 397, "type": "text", "inside": "公司前5名供应商资料"}
{"page": 17, "allrow": 398, "type": "excel", "inside": "['序号', '供应商名称', '采购额（元）', '占年度采购总额比例']"}
{"page": 17, "allrow": 399, "type": "excel", "inside": "['1', 'A', '153,984,566.19', '2.78%']"}
{"page": 17, "allrow": 400, "type": "excel", "inside": "['2', 'B', '141,106,887.15', '2.55%']"}
{"page": 17, "allrow": 401, "type": "excel", "inside": "['3', 'C', '123,442,821.20', '2.23%']"}
{"page": 17, "allrow": 402, "type": "excel", "inside": "['4', 'D', '106,107,819.16', '1.92%']"}
{"page": 17, "allrow": 403, "type": "excel", "inside": "['5', 'E', '103,715,948.03', '1.87%']"}
{"page": 17, "allrow": 404, "type": "excel", "inside": "['合计', '--', '628,358,041.73', '11.35%']"}
{"page": 17, "allrow": 405, "type": "text", "inside": "主要供应商其他情况说明"}
{"page": 17, "allrow": 406, "type": "text", "inside": "□适用√不适用"}
{"page": 17, "allrow": 407, "type": "text", "inside": "3、费用"}
{"page": 17, "allrow": 408, "type": "text", "inside": "单位：元"}
{"page": 17, "allrow": 409, "type": "excel", "inside": "['', '', '2019年', '', '2018年', '同比增减', '重大变动说明']"}
{"page": 17, "allrow": 410, "type": "excel", "inside": "['销售费用', '835,337,733.34', '', '808,934,578.51', '', '3.26%', '']"}
{"page": 17, "allrow": 411, "type": "excel", "inside": "['管理费用', '458,116,308.60', '', '461,126,486.80', '', '-0.65%', '']"}
{"page": 17, "allrow": 412, "type": "excel", "inside": "['财务费用', '12,859,175.74', '', '2,438,465.26', '', '427.35%', '主要是本期汇兑收益同比减少']"}
{"page": 17, "allrow": 413, "type": "excel", "inside": "['研发费用', '359,893,448.82', '', '269,650,776.53', '', '33.47%', '']"}
{"page": 17, "allrow": 414, "type": "text", "inside": ""}
{"page": 17, "allrow": 415, "type": "text", "inside": "4、研发投入"}
{"page": 17, "allrow": 416, "type": "text", "inside": "√适用□不适用"}
{"page": 17, "allrow": 417, "type": "text", "inside": "我公司一直坚持创研结合的原则，报告期内进一步加大了创新药开发和投入力度，推进技术创新，推动产业结构调整和升级。"}
{"page": 17, "allrow": 418, "type": "text", "inside": "公司研发投入情况"}
{"page": 17, "allrow": 419, "type": "excel", "inside": "['', '2019年', '2018年', '变动比例']"}
{"page": 17, "allrow": 420, "type": "excel", "inside": "['研发人员数量（人）', '491', '447', '9.84%']"}
{"page": 17, "allrow": 421, "type": "excel", "inside": "['研发人员数量占比', '8.59%', '7.76%', '0.83%']"}
{"page": 17, "allrow": 422, "type": "excel", "inside": "['研发投入金额（元）', '339,827,028.46', '291,705,721.39', '16.50%']"}
{"page": 17, "allrow": 423, "type": "excel", "inside": "['研发投入占营业收入比例', '4.71%', '4.58%', '0.13%']"}
{"page": 17, "allrow": 424, "type": "excel", "inside": "['研发投入资本化的金额（元）', '0.00', '0.00', '0.00%']"}
{"page": 17, "allrow": 425, "type": "excel", "inside": "['资本化研发投入占研发投入的比例', '0.00%', '0.00%', '0.00%']"}
{"page": 18, "allrow": 426, "type": "text", "inside": ""}
{"page": 18, "allrow": 427, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 18, "allrow": 428, "type": "text", "inside": "□适用√不适用"}
{"page": 18, "allrow": 429, "type": "text", "inside": "研发投入资本化率大幅变动的原因及其合理性说明"}
{"page": 18, "allrow": 430, "type": "text", "inside": "□适用√不适用"}
{"page": 18, "allrow": 431, "type": "text", "inside": "5、现金流"}
{"page": 18, "allrow": 432, "type": "text", "inside": "单位：元"}
{"page": 18, "allrow": 433, "type": "excel", "inside": "['项目', '', '2019年', '', '2018年', '同比增减']"}
{"page": 18, "allrow": 434, "type": "excel", "inside": "['经营活动现金流入小计', '5,396,148,977.13', '', '4,977,361,017.68', '', '8.41%']"}
{"page": 18, "allrow": 435, "type": "excel", "inside": "['经营活动现金流出小计', '4,036,082,786.77', '', '4,144,539,933.72', '', '-2.62%']"}
{"page": 18, "allrow": 436, "type": "excel", "inside": "['经营活动产生的现金流量净额', '', '1,360,066,190.36', '', '832,821,083.96', '63.31%']"}
{"page": 18, "allrow": 437, "type": "excel", "inside": "['投资活动现金流入小计', '523,449,685.81', '', '275,038,010.76', '', '90.32%']"}
{"page": 18, "allrow": 438, "type": "excel", "inside": "['投资活动现金流出小计', '964,284,823.73', '', '454,017,417.41', '', '112.39%']"}
{"page": 18, "allrow": 439, "type": "excel", "inside": "['投资活动产生的现金流量净额', '-440,835,137.92', '', '-178,979,406.65', '', '-146.30%']"}
{"page": 18, "allrow": 440, "type": "excel", "inside": "['筹资活动现金流入小计', '380,000,000.00', '', '1,165,087,344.47', '', '-67.38%']"}
{"page": 18, "allrow": 441, "type": "excel", "inside": "['筹资活动现金流出小计', '1,086,152,369.56', '', '1,758,831,854.49', '', '-38.25%']"}
{"page": 18, "allrow": 442, "type": "excel", "inside": "['筹资活动产生的现金流量净额', '-706,152,369.56', '', '-593,744,510.02', '', '18.93%']"}
{"page": 18, "allrow": 443, "type": "excel", "inside": "['现金及现金等价物净增加额', '216,352,891.90', '', '67,347,667.46', '', '221.25%']"}
{"page": 18, "allrow": 444, "type": "text", "inside": "相关数据同比发生重大变动的主要影响因素说明"}
{"page": 18, "allrow": 445, "type": "text", "inside": "□适用√不适用"}
{"page": 18, "allrow": 446, "type": "text", "inside": "报告期内公司经营活动产生的现金净流量与本年度净利润存在重大差异的原因说明"}
{"page": 18, "allrow": 447, "type": "text", "inside": "□适用√不适用"}
{"page": 18, "allrow": 448, "type": "text", "inside": "三、非主营业务分析"}
{"page": 18, "allrow": 449, "type": "text", "inside": "□适用√不适用"}
{"page": 18, "allrow": 450, "type": "text", "inside": "四、资产及负债状况"}
{"page": 18, "allrow": 451, "type": "text", "inside": "1、资产构成重大变动情况"}
{"page": 18, "allrow": 452, "type": "text", "inside": "单位：元"}
{"page": 18, "allrow": 453, "type": "excel", "inside": "['', '', '2019年末', '', '2019年初金额 占总资产比例', '', '', '']"}
{"page": 18, "allrow": 454, "type": "excel", "inside": "['', '', '金额', '占总资产比例', '金额', '', '比重增减', '重大变动说明']"}
{"page": 18, "allrow": 455, "type": "excel", "inside": "['货币资金', '1,035,809,494.05', '', '15.88%', '644,375,303.19', '11.20%', '4.68%', '']"}
{"page": 18, "allrow": 456, "type": "excel", "inside": "['应收账款', '1,025,138,596.19', '', '15.72%', '1,024,424,679.11', '17.81%', '-2.09%', '']"}
{"page": 18, "allrow": 457, "type": "excel", "inside": "['存货', '', '993,043,012.37', '15.22%', '901,643,879.75', '15.68%', '-0.46%', '']"}
{"page": 18, "allrow": 458, "type": "excel", "inside": "['长期股权投资', '122,214,608.04', '', '1.87%', '100,871,723.22', '1.75%', '0.12%', '']"}
{"page": 18, "allrow": 459, "type": "text", "inside": ""}
{"page": 18, "allrow": 460, "type": "页脚", "inside": "18"}
{"page": 19, "allrow": 461, "type": "text", "inside": ""}
{"page": 19, "allrow": 462, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 19, "allrow": 463, "type": "excel", "inside": "['固定资产', '1,898,972,408.21', '29.11%', '1,971,680,172.58', '34.28%', '-5.17%', '']"}
{"page": 19, "allrow": 464, "type": "excel", "inside": "['在建工程', '118,847,992.45', '1.82%', '151,569,855.81', '2.64%', '-0.82%', '']"}
{"page": 19, "allrow": 465, "type": "excel", "inside": "['短期借款', '50,000,000.00', '0.77%', '614,100,000.00', '10.68%', '-9.91%', '本期归还借款']"}
{"page": 19, "allrow": 466, "type": "text", "inside": "2、以公允价值计量的资产和负债"}
{"page": 19, "allrow": 467, "type": "text", "inside": "□适用√不适用"}
{"page": 19, "allrow": 468, "type": "text", "inside": "3、截至报告期末的资产权利受限情况"}
{"page": 19, "allrow": 469, "type": "excel", "inside": "['项目', '期末账面价值', '期初账面价值', '期末受限原因']"}
{"page": 19, "allrow": 470, "type": "excel", "inside": "['货币资金', '317,736,154.02', '142,654,855.06', '保证金']"}
{"page": 19, "allrow": 471, "type": "excel", "inside": "['交易性金融资产', '310,000,000.00', '', '质押']"}
{"page": 19, "allrow": 472, "type": "excel", "inside": "['应收款项融资', '28,130,841.00', '27,361,189.10', '质押']"}
{"page": 19, "allrow": 473, "type": "excel", "inside": "['固定资产', '62,782,453.27', '78,244,378.68', '抵押']"}
{"page": 19, "allrow": 474, "type": "excel", "inside": "['无形资产', '85,846,372.32', '118,499,686.50', '抵押']"}
{"page": 19, "allrow": 475, "type": "text", "inside": ""}
{"page": 19, "allrow": 476, "type": "text", "inside": "五、投资状况"}
{"page": 19, "allrow": 477, "type": "text", "inside": "1、总体情况"}
{"page": 19, "allrow": 478, "type": "text", "inside": "√适用□不适用"}
{"page": 19, "allrow": 479, "type": "excel", "inside": "['报告期投资额（元）', '上年同期投资额（元）', '变动幅度']"}
{"page": 19, "allrow": 480, "type": "excel", "inside": "['248,698,751.67', '180,059,130.86', '38.12%']"}
{"page": 19, "allrow": 481, "type": "text", "inside": "2、报告期内获取的重大的股权投资情况"}
{"page": 19, "allrow": 482, "type": "text", "inside": "□适用√不适用"}
{"page": 19, "allrow": 483, "type": "text", "inside": "3、报告期内正在进行的重大的非股权投资情况"}
{"page": 19, "allrow": 484, "type": "text", "inside": "□适用√不适用"}
{"page": 19, "allrow": 485, "type": "text", "inside": "4、金融资产投资"}
{"page": 19, "allrow": 486, "type": "text", "inside": "（1）证券投资情况"}
{"page": 19, "allrow": 487, "type": "text", "inside": "□适用√不适用"}
{"page": 19, "allrow": 488, "type": "text", "inside": "公司报告期不存在证券投资。"}
{"page": 19, "allrow": 489, "type": "页脚", "inside": "19"}
{"page": 20, "allrow": 490, "type": "text", "inside": ""}
{"page": 20, "allrow": 491, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 20, "allrow": 492, "type": "text", "inside": "（2）衍生品投资情况"}
{"page": 20, "allrow": 493, "type": "text", "inside": "□适用√不适用"}
{"page": 20, "allrow": 494, "type": "text", "inside": "公司报告期不存在衍生品投资。"}
{"page": 20, "allrow": 495, "type": "text", "inside": "5、募集资金使用情况"}
{"page": 20, "allrow": 496, "type": "text", "inside": "□适用√不适用"}
{"page": 20, "allrow": 497, "type": "text", "inside": "公司报告期无募集资金使用情况。"}
{"page": 20, "allrow": 498, "type": "text", "inside": "六、重大资产和股权出售"}
{"page": 20, "allrow": 499, "type": "text", "inside": "1、出售重大资产情况"}
{"page": 20, "allrow": 500, "type": "text", "inside": "□适用√不适用"}
{"page": 20, "allrow": 501, "type": "text", "inside": "公司报告期未出售重大资产。"}
{"page": 20, "allrow": 502, "type": "text", "inside": "2、出售重大股权情况"}
{"page": 20, "allrow": 503, "type": "text", "inside": "□适用√不适用"}
{"page": 20, "allrow": 504, "type": "text", "inside": "七、主要控股参股公司分析"}
{"page": 20, "allrow": 505, "type": "text", "inside": "√适用□不适用"}
{"page": 20, "allrow": 506, "type": "text", "inside": "主要子公司及对公司净利润影响达10%以上的参股公司情况"}
{"page": 20, "allrow": 507, "type": "text", "inside": "单位：元"}
{"page": 20, "allrow": 508, "type": "excel", "inside": "['公司名称', '公司类型', '主要业务', '注册资本', '总资产', '净资产', '营业收入', '营业利润', '净利润']"}
{"page": 20, "allrow": 509, "type": "excel", "inside": "['', '', '化学原料', '83,750,000', '1,474,008,', '1,051,882,', '1,013,238,', '84,473,745', '80,536,000']"}
{"page": 20, "allrow": 510, "type": "excel", "inside": "['康裕制药', '子公司', '药及制剂', '.00', '511.11', '825.48', '855.11', '.83', '.40']"}
{"page": 20, "allrow": 511, "type": "excel", "inside": "['', '', '制造等', '', '', '', '', '', '']"}
{"page": 20, "allrow": 512, "type": "excel", "inside": "['', '', '化学原料', '126,500,00', '1,284,096,', '573,058,76', '2,043,328,', '214,105,74', '195,699,87']"}
{"page": 20, "allrow": 513, "type": "excel", "inside": "['家园药业', '子公司', '药及中间', '0.00', '076.23', '6.05', '799.24', '5.41', '3.25']"}
{"page": 20, "allrow": 514, "type": "excel", "inside": "['', '', '体制造等', '', '', '', '', '', '']"}
{"page": 20, "allrow": 515, "type": "excel", "inside": "['', '', '化学原料', '130,000,00', '974,209,56', '432,349,75', '944,246,20', '76,821,451', '70,425,632']"}
{"page": 20, "allrow": 516, "type": "excel", "inside": "['得邦制药', '子公司', '药及中间', '0.00', '0.49', '9.85', '7.41', '.12', '.69']"}
{"page": 20, "allrow": 517, "type": "excel", "inside": "['', '', '体制造等', '', '', '', '', '', '']"}
{"page": 20, "allrow": 518, "type": "excel", "inside": "['', '', '自营和代', '', '', '', '', '', '']"}
{"page": 20, "allrow": 519, "type": "excel", "inside": "['普洛进出口', '子公司', '理各类商品及技术', '50,000,000.00', '1,491,886,327.11', '675,622,485.39', '3,331,387,042.19', '134,270,496.45', '98,406,339.33']"}
{"page": 20, "allrow": 520, "type": "excel", "inside": "['', '', '进出口等', '', '', '', '', '', '']"}
{"page": 20, "allrow": 521, "type": "text", "inside": ""}
{"page": 20, "allrow": 522, "type": "text", "inside": "报告期内取得和处置子公司的情况"}
{"page": 20, "allrow": 523, "type": "text", "inside": "√适用□不适用"}
{"page": 20, "allrow": 524, "type": "页脚", "inside": "20"}
{"page": 21, "allrow": 525, "type": "text", "inside": ""}
{"page": 21, "allrow": 526, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 21, "allrow": 527, "type": "excel", "inside": "['公司名称', '报告期内取得和处置子公司方式', '对整体生产经营和业绩的影响']"}
{"page": 21, "allrow": 528, "type": "excel", "inside": "['东阳普洛康裕保健食品有限公司', '购买股权', '无重大影响']"}
{"page": 21, "allrow": 529, "type": "text", "inside": ""}
{"page": 21, "allrow": 530, "type": "text", "inside": "主要控股参股公司情况说明"}
{"page": 21, "allrow": 531, "type": "text", "inside": "八、公司控制的结构化主体情况"}
{"page": 21, "allrow": 532, "type": "text", "inside": "□适用√不适用"}
{"page": 21, "allrow": 533, "type": "text", "inside": "九、公司未来发展的展望"}
{"page": 21, "allrow": 534, "type": "text", "inside": "2020年，公司将以绿色发展为基础，科技创新为动力，持续推进“做精原料药、做强CDMO、做优制剂”的发展战略。"}
{"page": 21, "allrow": 535, "type": "text", "inside": "继续秉承“共创、共有、共富、共享”的核心价值观和“仁爱、中庸、团队、执行”的核心文化理念，持续打造“快乐学习、快乐运动、快乐工作”的三个快乐企业文化，团结一致、不忘初心、齐心耕耘，向着实现公司、员工和股东共同利益最大化的目标不断奋进。"}
{"page": 21, "allrow": 536, "type": "text", "inside": "十、接待调研、沟通、采访等活动情况"}
{"page": 21, "allrow": 537, "type": "text", "inside": "1、报告期内接待调研、沟通、采访等活动登记表"}
{"page": 21, "allrow": 538, "type": "text", "inside": "√适用□不适用"}
{"page": 21, "allrow": 539, "type": "excel", "inside": "['接待时间', '接待方式', '接待对象类型', '调研的基本情况索引']"}
{"page": 21, "allrow": 540, "type": "excel", "inside": "['', '', '', 'https://view.officeapps.live.com/op/view.aspx?src=http%3A%2F%2Fst']"}
{"page": 21, "allrow": 541, "type": "excel", "inside": "['2019年12月25日', '实地调研', '机构', 'atic.cninfo.com.cn%2Ffinalpage%2F2019-12-26%2F1207196921.doc']"}
{"page": 21, "allrow": 542, "type": "excel", "inside": "['', '', '', 'x']"}
{"page": 21, "allrow": 543, "type": "excel", "inside": "['', '', '', 'https://view.officeapps.live.com/op/view.aspx?src=http%3A%2F%2Fst']"}
{"page": 21, "allrow": 544, "type": "excel", "inside": "['2019年12月02日', '实地调研', '机构', 'atic.cninfo.com.cn%2Ffinalpage%2F2019-12-03%2F1207133838.doc']"}
{"page": 21, "allrow": 545, "type": "excel", "inside": "['', '', '', 'x']"}
{"page": 21, "allrow": 546, "type": "excel", "inside": "['', '', '', 'https://view.officeapps.live.com/op/view.aspx?src=http%3A%2F%2Fst']"}
{"page": 21, "allrow": 547, "type": "excel", "inside": "['2019年11月27日', '实地调研', '机构', 'atic.cninfo.com.cn%2Ffinalpage%2F2019-11-28%2F1207121921.doc']"}
{"page": 21, "allrow": 548, "type": "excel", "inside": "['', '', '', 'x']"}
{"page": 21, "allrow": 549, "type": "excel", "inside": "['', '', '', 'https://view.officeapps.live.com/op/view.aspx?src=http%3A%2F%2Fst']"}
{"page": 21, "allrow": 550, "type": "excel", "inside": "['2019年08月15日', '电话沟通', '机构', 'atic.cninfo.com.cn%2Ffinalpage%2F2019-08-16%2F1206537921.doc']"}
{"page": 21, "allrow": 551, "type": "excel", "inside": "['', '', '', 'x']"}
{"page": 21, "allrow": 552, "type": "excel", "inside": "['', '', '', 'https://view.officeapps.live.com/op/view.aspx?src=http%3A%2F%2Fst']"}
{"page": 21, "allrow": 553, "type": "excel", "inside": "['2019年08月01日', '实地调研', '机构', 'atic.cninfo.com.cn%2Ffinalpage%2F2019-08-02%2F1206493321.doc']"}
{"page": 21, "allrow": 554, "type": "excel", "inside": "['', '', '', 'x']"}
{"page": 21, "allrow": 555, "type": "excel", "inside": "['', '', '', 'https://view.officeapps.live.com/op/view.aspx?src=http%3A%2F%2Fst']"}
{"page": 21, "allrow": 556, "type": "excel", "inside": "['2019年04月24日', '实地调研', '机构', 'atic.cninfo.com.cn%2Ffinalpage%2F2019-04-25%2F1206101087.doc']"}
{"page": 21, "allrow": 557, "type": "excel", "inside": "['', '', '', 'x']"}
{"page": 21, "allrow": 558, "type": "text", "inside": ""}
{"page": 21, "allrow": 559, "type": "页脚", "inside": "21"}
{"page": 22, "allrow": 560, "type": "text", "inside": ""}
{"page": 22, "allrow": 561, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 22, "allrow": 562, "type": "excel", "inside": "['', '', '', '', 'https://view.officeapps.live.com/op/view.aspx?src=http%3A%2F%2Fst']"}
{"page": 22, "allrow": 563, "type": "excel", "inside": "['2019年03月10日', '电话沟通', '机构', '', 'atic.cninfo.com.cn%2Ffinalpage%2F2019-03-11%2F1205893283.doc']"}
{"page": 22, "allrow": 564, "type": "excel", "inside": "['', '', '', '', 'x']"}
{"page": 22, "allrow": 565, "type": "excel", "inside": "['接待次数', '', '', '7', '']"}
{"page": 22, "allrow": 566, "type": "excel", "inside": "['接待机构数量', '', '', '128', '']"}
{"page": 22, "allrow": 567, "type": "excel", "inside": "['接待个人数量', '', '', '45', '']"}
{"page": 22, "allrow": 568, "type": "excel", "inside": "['接待其他对象数量', '', '', '0', '']"}
{"page": 22, "allrow": 569, "type": "excel", "inside": "['是否披露、透露或泄露未公开重大信息', '', '', '否', '']"}
{"page": 22, "allrow": 570, "type": "text", "inside": ""}
{"page": 22, "allrow": 571, "type": "页脚", "inside": "22"}
{"page": 23, "allrow": 572, "type": "text", "inside": ""}
{"page": 23, "allrow": 573, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 23, "allrow": 574, "type": "text", "inside": "第五节重要事项"}
{"page": 23, "allrow": 575, "type": "text", "inside": "一、公司普通股利润分配及资本公积金转增股本情况"}
{"page": 23, "allrow": 576, "type": "text", "inside": "报告期内普通股利润分配政策，特别是现金分红政策的制定、执行或调整情况"}
{"page": 23, "allrow": 577, "type": "text", "inside": "□适用√不适用"}
{"page": 23, "allrow": 578, "type": "text", "inside": "公司近3年（包括本报告期）的普通股股利分配方案（预案）、资本公积金转增股本方案（预案）情况"}
{"page": 23, "allrow": 579, "type": "text", "inside": "（1）2017年度，以公司2017年末总股本1,178,523,492股为基数，每10股派发现金股利0.65元（含税）。该方案经2017年年度股东大会审议通过并已实施完毕。"}
{"page": 23, "allrow": 580, "type": "text", "inside": "（2）2018年度，以公司2018年末总股本1,178,523,492股为基数，每10股派发现金股利1.10元（含税）。该方案经2018年年度股东大会审议通过并已实施完毕。"}
{"page": 23, "allrow": 581, "type": "text", "inside": "（3）2019年度，以公司2019年末总股本1,178,523,492股为基数，每10股派发现金股利1.65元（含税）。该方案尚需经2019"}
{"page": 23, "allrow": 582, "type": "text", "inside": "年年度股东大会审议通过。"}
{"page": 23, "allrow": 583, "type": "text", "inside": "公司近三年（包括本报告期）普通股现金分红情况表"}
{"page": 23, "allrow": 584, "type": "text", "inside": "单位：元"}
{"page": 23, "allrow": 585, "type": "excel", "inside": "['', '现金分红金', '分红年度合并报表中归', '现金分红金额占合并报表中归属于', '以其他方式（如回购股', '以其他方式现金分红金额占合并报表中归属于', '现金分红总', '现金分红总额（含其他方式）占合并报表中归']"}
{"page": 23, "allrow": 586, "type": "excel", "inside": "['分红年度', '额（含税）', '属于上市公', '上市公司普', '份）现金分', '上市公司普', '额（含其他', '属于上市公']"}
{"page": 23, "allrow": 587, "type": "excel", "inside": "['', '', '司普通股股东的净利润', '通股股东的净利润的比率', '红的金额', '通股股东的净利润的比例', '方式）', '司普通股股东的净利润的比率']"}
{"page": 23, "allrow": 588, "type": "excel", "inside": "['', '194,456,376.', '553,400,761.', '', '', '', '194,456,376.', '']"}
{"page": 23, "allrow": 589, "type": "excel", "inside": "['2019年', '80', '42', '35.14%', '', '', '18', '35.14%']"}
{"page": 23, "allrow": 590, "type": "excel", "inside": "['', '129,637,584.', '370,561,028.', '', '', '', '129,637,584.', '']"}
{"page": 23, "allrow": 591, "type": "excel", "inside": "['2018年', '12', '28', '34.98%', '', '', '12', '34.98%']"}
{"page": 23, "allrow": 592, "type": "excel", "inside": "['', '76,604,026.9', '256,592,089.', '', '', '', '76,604,026.9', '']"}
{"page": 23, "allrow": 593, "type": "excel", "inside": "['2017年', '8', '41', '29.85%', '', '', '8', '29.85%']"}
{"page": 23, "allrow": 594, "type": "text", "inside": ""}
{"page": 23, "allrow": 595, "type": "text", "inside": "公司报告期内盈利且母公司可供普通股股东分配利润为正但未提出普通股现金红利分配预案"}
{"page": 23, "allrow": 596, "type": "text", "inside": "□适用√不适用"}
{"page": 23, "allrow": 597, "type": "text", "inside": "二、本报告期利润分配及资本公积金转增股本情况"}
{"page": 23, "allrow": 598, "type": "text", "inside": "√适用□不适用"}
{"page": 23, "allrow": 599, "type": "excel", "inside": "['每10股送红股数（股）', '0']"}
{"page": 23, "allrow": 600, "type": "excel", "inside": "['每10股派息数（元）（含税）', '1.65']"}
{"page": 23, "allrow": 601, "type": "excel", "inside": "['每10股转增数（股）', '0']"}
{"page": 23, "allrow": 602, "type": "text", "inside": ""}
{"page": 23, "allrow": 603, "type": "页脚", "inside": "23"}
{"page": 24, "allrow": 604, "type": "text", "inside": ""}
{"page": 24, "allrow": 605, "type": "text", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 24, "allrow": 606, "type": "excel", "inside": "['分配预案的股本基数（股）', '1,178,523,492']"}
{"page": 24, "allrow": 607, "type": "excel", "inside": "['现金分红金额（元）（含税）', '194,456,376.18']"}
{"page": 24, "allrow": 608, "type": "excel", "inside": "['以其他方式（如回购股份）现金分红金额（元）', '0.00']"}
{"page": 24, "allrow": 609, "type": "excel", "inside": "['现金分红总额（含其他方式）（元）', '194,456,376.18']"}
{"page": 24, "allrow": 610, "type": "excel", "inside": "['可分配利润（元）', '203,923,772.67']"}
{"page": 24, "allrow": 611, "type": "excel", "inside": "['现金分红总额（含其他方式）占利润分配总额的比例', '100%']"}
{"page": 24, "allrow": 612, "type": "excel", "inside": "['本次现金分红情况', '']"}
{"page": 24, "allrow": 613, "type": "excel", "inside": "['公司发展阶段属成长期且有重大资金支出安排的，进行利润分配时，现金分红在本次利润分配中所占比例最低应达到20％', '']"}
{"page": 24, "allrow": 614, "type": "excel", "inside": "['利润分配或资本公积金转增预案的详细情况说明', '']"}
{"page": 24, "allrow": 615, "type": "excel", "inside": "['根据《公司法》和《公司章程》的规定并结合公司实际生产经营情况，公司2019年度利润分配预案为：以公司2019年12月31日总股本1,178,523,492股为基数，拟向全体股东每10股派发现金股利1.65元（含税），剩余未分配利润留转以后年度分配，不送红股，也不以资本公积金转增股本。', '']"}
{"page": 24, "allrow": 616, "type": "text", "inside": ""}
{"page": 24, "allrow": 617, "type": "text", "inside": "三、承诺事项履行情况"}
{"page": 24, "allrow": 618, "type": "text", "inside": "1、公司实际控制人、股东、关联方、收购人以及公司等承诺相关方在报告期内履行完毕及截至报告期末尚未履行完毕的承诺事项"}
{"page": 24, "allrow": 619, "type": "text", "inside": "√适用□不适用"}
{"page": 24, "allrow": 620, "type": "excel", "inside": "['承诺事由', '承诺方', '', '承诺类型', '承诺内容', '承诺时间', '承诺期限', '履行情况']"}
{"page": 24, "allrow": 621, "type": "excel", "inside": "['股改承诺', '', '', '', '', '', '', '']"}
{"page": 24, "allrow": 622, "type": "excel", "inside": "['收购报告书或权益变动报告书中所作承诺', '', '', '', '', '', '', '']"}
{"page": 24, "allrow": 623, "type": "excel", "inside": "['', '横店集团控股有限公司；横店社团经济企业联合会', '其他承诺', '关于同业竞争、关联交易、资金占用方面的承诺', '保持上市公司独立性、避免同业竞争、规范关联交易的承诺关于交易标', '2012年06月19日', '长期有效', '持续承诺，履行正常']"}
{"page": 24, "allrow": 624, "type": "excel", "inside": "['资产重组时所作承诺', '', '', '', '的部分资产', '', '', '']"}
{"page": 24, "allrow": 625, "type": "excel", "inside": "['', '横店集团控股有限公司', '', '', '瑕疵的补偿承诺、对上市公司进行进一步规范化管理的承诺', '2012年08月01日', '长期有效', '持续承诺，履行正常']"}
{"page": 25, "allrow": 626, "type": "text", "inside": ""}
{"page": 25, "allrow": 627, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 25, "allrow": 628, "type": "excel", "inside": "['', '', '', '此次认购的普洛药业股票自此次非', '', '', '']"}
{"page": 25, "allrow": 629, "type": "excel", "inside": "['首次公开发行或再融资时所作承诺', '横店集团控股有限公司', '股份限售承诺', '公开发行结束之日起', '2017年11月28日', '3年', '持续承诺，履行正常']"}
{"page": 25, "allrow": 630, "type": "excel", "inside": "['', '', '', '36个月内不得转让。', '', '', '']"}
{"page": 25, "allrow": 631, "type": "excel", "inside": "['股权激励承诺', '', '', '', '', '', '']"}
{"page": 25, "allrow": 632, "type": "excel", "inside": "['其他对公司中小股东所作承诺', '', '', '', '', '', '']"}
{"page": 25, "allrow": 633, "type": "excel", "inside": "['承诺是否按时履行', '是', '', '', '', '', '']"}
{"page": 25, "allrow": 634, "type": "text", "inside": ""}
{"page": 25, "allrow": 635, "type": "text", "inside": "2、公司资产或项目存在盈利预测，且报告期仍处在盈利预测期间，公司就资产或项目达到原盈利预测及其原因做出说明"}
{"page": 25, "allrow": 636, "type": "text", "inside": "□适用√不适用"}
{"page": 25, "allrow": 637, "type": "text", "inside": "四、控股股东及其关联方对上市公司的非经营性占用资金情况"}
{"page": 25, "allrow": 638, "type": "text", "inside": "□适用√不适用"}
{"page": 25, "allrow": 639, "type": "text", "inside": "公司报告期不存在控股股东及其关联方对上市公司的非经营性占用资金。"}
{"page": 25, "allrow": 640, "type": "text", "inside": "五、董事会、监事会、独立董事（如有）对会计师事务所本报告期“非标准审计报告”的说明"}
{"page": 25, "allrow": 641, "type": "text", "inside": "□适用√不适用"}
{"page": 25, "allrow": 642, "type": "text", "inside": "六、与上年度财务报告相比，会计政策、会计估计和核算方法发生变化的情况说明"}
{"page": 25, "allrow": 643, "type": "text", "inside": "□适用√不适用"}
{"page": 25, "allrow": 644, "type": "text", "inside": "公司报告期无会计政策、会计估计和核算方法发生变化的情况。"}
{"page": 25, "allrow": 645, "type": "text", "inside": "七、报告期内发生重大会计差错更正需追溯重述的情况说明"}
{"page": 25, "allrow": 646, "type": "text", "inside": "□适用√不适用"}
{"page": 25, "allrow": 647, "type": "text", "inside": "公司报告期无重大会计差错更正需追溯重述的情况。"}
{"page": 25, "allrow": 648, "type": "text", "inside": "八、与上年度财务报告相比，合并报表范围发生变化的情况说明"}
{"page": 25, "allrow": 649, "type": "text", "inside": "√适用□不适用"}
{"page": 25, "allrow": 650, "type": "text", "inside": "报告期内增加合并单位：本期公司购买了东阳普洛康裕保健食品有限公司100%股权。"}
{"page": 25, "allrow": 651, "type": "页脚", "inside": "25"}
{"page": 26, "allrow": 652, "type": "text", "inside": ""}
{"page": 26, "allrow": 653, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 26, "allrow": 654, "type": "text", "inside": "九、聘任、解聘会计师事务所情况"}
{"page": 26, "allrow": 655, "type": "text", "inside": "现聘任的会计师事务所"}
{"page": 26, "allrow": 656, "type": "excel", "inside": "['境内会计师事务所名称', '和信会计师事务所（特殊普通合伙）', '']"}
{"page": 26, "allrow": 657, "type": "excel", "inside": "['境内会计师事务所报酬（万元）', '', '120']"}
{"page": 26, "allrow": 658, "type": "excel", "inside": "['境内会计师事务所审计服务的连续年限', '', '7']"}
{"page": 26, "allrow": 659, "type": "excel", "inside": "['境内会计师事务所注册会计师姓名', '', '左伟、陈征']"}
{"page": 26, "allrow": 660, "type": "excel", "inside": "['境内会计师事务所注册会计师审计服务的连续年限', '', '1年、1年']"}
{"page": 26, "allrow": 661, "type": "text", "inside": "当期是否改聘会计师事务所"}
{"page": 26, "allrow": 662, "type": "text", "inside": "□是√否"}
{"page": 26, "allrow": 663, "type": "text", "inside": "聘请内部控制审计会计师事务所、财务顾问或保荐人情况"}
{"page": 26, "allrow": 664, "type": "text", "inside": "√适用□不适用"}
{"page": 26, "allrow": 665, "type": "text", "inside": "本年度公司聘请和信会计师事务所有限公司（特殊普通合伙）为公司内部控制审计会计师事务所，期间共支付内部控制审计费60万元。"}
{"page": 26, "allrow": 666, "type": "text", "inside": "十、年度报告披露后面临暂停上市和终止上市情况"}
{"page": 26, "allrow": 667, "type": "text", "inside": "□适用√不适用"}
{"page": 26, "allrow": 668, "type": "text", "inside": "十一、破产重整相关事项"}
{"page": 26, "allrow": 669, "type": "text", "inside": "□适用√不适用"}
{"page": 26, "allrow": 670, "type": "text", "inside": "公司报告期未发生破产重整相关事项。"}
{"page": 26, "allrow": 671, "type": "text", "inside": "十二、重大诉讼、仲裁事项"}
{"page": 26, "allrow": 672, "type": "text", "inside": "□适用√不适用"}
{"page": 26, "allrow": 673, "type": "text", "inside": "本报告期公司无重大诉讼、仲裁事项。"}
{"page": 26, "allrow": 674, "type": "text", "inside": "十三、处罚及整改情况"}
{"page": 26, "allrow": 675, "type": "text", "inside": "□适用√不适用"}
{"page": 26, "allrow": 676, "type": "text", "inside": "公司报告期不存在处罚及整改情况。"}
{"page": 26, "allrow": 677, "type": "text", "inside": "十四、公司及其控股股东、实际控制人的诚信状况"}
{"page": 26, "allrow": 678, "type": "text", "inside": "□适用√不适用"}
{"page": 26, "allrow": 679, "type": "text", "inside": "十五、公司股权激励计划、员工持股计划或其他员工激励措施的实施情况"}
{"page": 26, "allrow": 680, "type": "text", "inside": "√适用□不适用"}
{"page": 26, "allrow": 681, "type": "text", "inside": "报告期内，公司实施了第一期员工持股计划，2019年5月10日、2019年5月28日分别召开公司第七届董事会第十五次会"}
{"page": 26, "allrow": 682, "type": "页脚", "inside": "26"}
{"page": 27, "allrow": 683, "type": "text", "inside": ""}
{"page": 27, "allrow": 684, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 27, "allrow": 685, "type": "text", "inside": "议和2019年第一次临时股东大会，会议审议通过了《关于<普洛药业股份有限公司第一期员工持股计划（草案）>及摘要的议案》，2019年6月11日，公司第一期员工持股计划通过大宗交易方式完成了股票购买，受让了东阳市勤胜投资合伙企业（有限合伙）、东阳市合商投资合伙企业（有限合伙）以及东阳市恒前投资合伙企业（有限合伙）持有的公司全部股权，合计32,664,016股，占公司总股本的2.77%，成交金额为260,658,847.68元（不含交易费用），成交均价7.98元/股。该计划所购买的股票锁定期为12个月。本次员工持股计划具体内容请参见公司刊登在《上海证券报》、《证券时报》和巨潮资讯网上的相关公告。"}
{"page": 27, "allrow": 686, "type": "text", "inside": "十六、重大关联交易"}
{"page": 27, "allrow": 687, "type": "text", "inside": "1、与日常经营相关的关联交易"}
{"page": 27, "allrow": 688, "type": "text", "inside": "√适用□不适用"}
{"page": 27, "allrow": 689, "type": "excel", "inside": "['', '', '关联', '关联', '关联', '关联', '关联交易', '占同类交', '获批的交', '是否', '关联', '可获得的', '', '']"}
{"page": 27, "allrow": 690, "type": "excel", "inside": "['关联交易方', '关联关系', '交易类型', '交易内容', '交易定价', '交易价格', '金额（万', '易金额的', '易额度（万', '超过获批', '交易结算', '同类交易', '披露日期', '披露索引']"}
{"page": 27, "allrow": 691, "type": "excel", "inside": "['', '', '', '', '原则', '', '元）', '比例', '元）', '额度', '方式', '市价', '', '']"}
{"page": 27, "allrow": 692, "type": "excel", "inside": "['', '同受', '', '', '', '', '', '', '', '', '', '', '', 'http:/']"}
{"page": 27, "allrow": 693, "type": "excel", "inside": "['浙江横店热电有限公司', '本公司最终控制人', '采购', '蒸汽、电', '市价', '市价', '10,371', '1.87%', '13,572', '否', '承兑、电汇等', '无', '2019年03月08日', '/www.cninfo.com']"}
{"page": 27, "allrow": 694, "type": "excel", "inside": "['', '控制', '', '', '', '', '', '', '', '', '', '', '', '']"}
{"page": 27, "allrow": 695, "type": "excel", "inside": "['', '', '', '', '', '', '10,37', '', '13,57', '', '', '', '', '']"}
{"page": 27, "allrow": 696, "type": "excel", "inside": "['合计', '', '', '', '--', '--', '1', '', '2', '--', '--', '--', '--', '--']"}
{"page": 27, "allrow": 697, "type": "excel", "inside": "['大额销货退回的详细情况', '', '', '', '无', '', '', '', '', '', '', '', '', '']"}
{"page": 27, "allrow": 698, "type": "excel", "inside": "['按类别对本期将发生的日常关联交易进行总金额预计的，在报告期内的实际履行情况（如有）', '', '', '', '按正常市场活动进行交易，没有超过预计金额。', '', '', '', '', '', '', '', '', '']"}
{"page": 27, "allrow": 699, "type": "excel", "inside": "['交易价格与市场参考价格差异较大的原因（如适用）', '', '', '', '不适用', '', '', '', '', '', '', '', '', '']"}
{"page": 27, "allrow": 700, "type": "text", "inside": ""}
{"page": 27, "allrow": 701, "type": "text", "inside": "2、资产或股权收购、出售发生的关联交易"}
{"page": 27, "allrow": 702, "type": "text", "inside": "□适用√不适用"}
{"page": 27, "allrow": 703, "type": "text", "inside": "公司报告期未发生资产或股权收购、出售的关联交易。"}
{"page": 27, "allrow": 704, "type": "text", "inside": "3、共同对外投资的关联交易"}
{"page": 27, "allrow": 705, "type": "text", "inside": "□适用√不适用"}
{"page": 27, "allrow": 706, "type": "text", "inside": "公司报告期未发生共同对外投资的关联交易。"}
{"page": 27, "allrow": 707, "type": "页脚", "inside": "27"}
{"page": 28, "allrow": 708, "type": "text", "inside": ""}
{"page": 28, "allrow": 709, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 28, "allrow": 710, "type": "text", "inside": "4、关联债权债务往来"}
{"page": 28, "allrow": 711, "type": "text", "inside": "□适用√不适用"}
{"page": 28, "allrow": 712, "type": "text", "inside": "公司报告期不存在关联债权债务往来。"}
{"page": 28, "allrow": 713, "type": "text", "inside": "5、其他重大关联交易"}
{"page": 28, "allrow": 714, "type": "text", "inside": "□适用√不适用"}
{"page": 28, "allrow": 715, "type": "text", "inside": "公司报告期无其他重大关联交易。"}
{"page": 28, "allrow": 716, "type": "text", "inside": "十七、重大合同及其履行情况"}
{"page": 28, "allrow": 717, "type": "text", "inside": "1、托管、承包、租赁事项情况"}
{"page": 28, "allrow": 718, "type": "text", "inside": "（1）托管情况"}
{"page": 28, "allrow": 719, "type": "text", "inside": "□适用√不适用"}
{"page": 28, "allrow": 720, "type": "text", "inside": "公司报告期不存在托管情况。"}
{"page": 28, "allrow": 721, "type": "text", "inside": "（2）承包情况"}
{"page": 28, "allrow": 722, "type": "text", "inside": "□适用√不适用"}
{"page": 28, "allrow": 723, "type": "text", "inside": "公司报告期不存在承包情况。"}
{"page": 28, "allrow": 724, "type": "text", "inside": "（3）租赁情况"}
{"page": 28, "allrow": 725, "type": "text", "inside": "□适用√不适用"}
{"page": 28, "allrow": 726, "type": "text", "inside": "公司报告期不存在租赁情况。"}
{"page": 28, "allrow": 727, "type": "text", "inside": "2、重大担保"}
{"page": 28, "allrow": 728, "type": "text", "inside": "√适用□不适用"}
{"page": 28, "allrow": 729, "type": "text", "inside": "（1）担保情况"}
{"page": 28, "allrow": 730, "type": "text", "inside": "单位：万元"}
{"page": 28, "allrow": 731, "type": "excel", "inside": "['公司及其子公司对外担保情况（不包括对子公司的担保）', '', '', '', '', '', '', '', '']"}
{"page": 28, "allrow": 732, "type": "excel", "inside": "['', '担保额度相关', '担保额', '', '实际担保', '', '', '是否履', '是否为']"}
{"page": 28, "allrow": 733, "type": "excel", "inside": "['担保对象名称', '公告披', '度', '实际发生日期', '金额', '担保类型', '担保期', '行完毕', '关联方']"}
{"page": 28, "allrow": 734, "type": "excel", "inside": "['', '露日期', '', '', '', '', '', '', '担保']"}
{"page": 28, "allrow": 735, "type": "excel", "inside": "['公司对子公司的担保情况', '', '', '', '', '', '', '', '']"}
{"page": 28, "allrow": 736, "type": "text", "inside": ""}
{"page": 28, "allrow": 737, "type": "页脚", "inside": "28"}
{"page": 29, "allrow": 738, "type": "text", "inside": ""}
{"page": 29, "allrow": 739, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 29, "allrow": 740, "type": "excel", "inside": "['', '担保额度相关', '担保额', '', '实际担保', '', '', '是否履', '是否为']"}
{"page": 29, "allrow": 741, "type": "excel", "inside": "['担保对象名称', '公告披', '度', '实际发生日期', '金额', '担保类型', '担保期', '行完毕', '关联方']"}
{"page": 29, "allrow": 742, "type": "excel", "inside": "['', '露日期', '', '', '', '', '', '', '担保']"}
{"page": 29, "allrow": 743, "type": "excel", "inside": "['', '2019年', '', '2019年09月', '', '连带责任', '20190919-', '', '']"}
{"page": 29, "allrow": 744, "type": "excel", "inside": "['普洛得邦制药', '03月08', '10,000', '19日', '9,990', '保证', '20200919', '否', '否']"}
{"page": 29, "allrow": 745, "type": "excel", "inside": "['', '日', '', '', '', '', '', '', '']"}
{"page": 29, "allrow": 746, "type": "excel", "inside": "['', '2018年', '', '2019年02月', '', '连带责任', '20190212-', '', '']"}
{"page": 29, "allrow": 747, "type": "excel", "inside": "['普洛得邦制药', '03月10', '8,000', '12日', '8,000', '保证', '2020211', '否', '否']"}
{"page": 29, "allrow": 748, "type": "excel", "inside": "['', '日', '', '', '', '', '', '', '']"}
{"page": 29, "allrow": 749, "type": "excel", "inside": "['', '2018年', '', '2018年09月', '', '连带责任', '20180904-', '', '']"}
{"page": 29, "allrow": 750, "type": "excel", "inside": "['普洛得邦制药', '03月10', '5,000', '04日', '5,000', '保证', '20200403', '是', '否']"}
{"page": 29, "allrow": 751, "type": "excel", "inside": "['', '日', '', '', '', '', '', '', '']"}
{"page": 29, "allrow": 752, "type": "excel", "inside": "['', '2018年', '', '2018年03月', '', '连带责任', '20180314-', '', '']"}
{"page": 29, "allrow": 753, "type": "excel", "inside": "['山东汉兴', '03月10', '10,000', '14日', '10,000', '保证', '20190313', '是', '否']"}
{"page": 29, "allrow": 754, "type": "excel", "inside": "['', '日', '', '', '', '', '', '', '']"}
{"page": 29, "allrow": 755, "type": "excel", "inside": "['', '2018年', '', '2019年03月', '', '连带责任', '20190312-', '', '']"}
{"page": 29, "allrow": 756, "type": "excel", "inside": "['山东汉兴', '03月10', '10,000', '12日', '5,000', '保证', '20200312', '是', '否']"}
{"page": 29, "allrow": 757, "type": "excel", "inside": "['', '日', '', '', '', '', '', '', '']"}
{"page": 29, "allrow": 758, "type": "excel", "inside": "['', '2018年', '', '2018年03月', '', '连带责任', '20180306-', '', '']"}
{"page": 29, "allrow": 759, "type": "excel", "inside": "['山东普洛得邦', '03月10', '8,000', '06日', '8,000', '保证', '20190305', '是', '否']"}
{"page": 29, "allrow": 760, "type": "excel", "inside": "['', '日', '', '', '', '', '', '', '']"}
{"page": 29, "allrow": 761, "type": "excel", "inside": "['', '2018年', '', '2019年03月', '', '连带责任', '20190306-', '', '']"}
{"page": 29, "allrow": 762, "type": "excel", "inside": "['山东普洛得邦', '03月10', '8,000', '06日', '8,000', '保证', '20200306', '是', '否']"}
{"page": 29, "allrow": 763, "type": "excel", "inside": "['', '日', '', '', '', '', '', '', '']"}
{"page": 29, "allrow": 764, "type": "excel", "inside": "['', '2018年', '', '2018年09月', '', '连带责任', '20180904-', '', '']"}
{"page": 29, "allrow": 765, "type": "excel", "inside": "['普洛家园药业', '03月10', '5,000', '04日', '5,000', '保证', '20200403', '是', '否']"}
{"page": 29, "allrow": 766, "type": "excel", "inside": "['', '日', '', '', '', '', '', '', '']"}
{"page": 29, "allrow": 767, "type": "excel", "inside": "['', '2017年', '', '2018年02月', '', '连带责任', '20180201-', '', '']"}
{"page": 29, "allrow": 768, "type": "excel", "inside": "['普洛家园药业', '03月15', '10,000', '01日', '5,000', '保证', '20190131', '是', '否']"}
{"page": 29, "allrow": 769, "type": "excel", "inside": "['', '日', '', '', '', '', '', '', '']"}
{"page": 29, "allrow": 770, "type": "excel", "inside": "['', '2017年', '', '2018年01月', '', '连带责任', '20180131-', '', '']"}
{"page": 29, "allrow": 771, "type": "excel", "inside": "['普洛康裕制药', '03月15', '19,000', '31日', '11,400', '保证', '20190130', '是', '否']"}
{"page": 29, "allrow": 772, "type": "excel", "inside": "['', '日', '', '', '', '', '', '', '']"}
{"page": 29, "allrow": 773, "type": "excel", "inside": "['', '2018年', '', '2018年05月', '', '连带责任', '20180514-', '', '']"}
{"page": 29, "allrow": 774, "type": "excel", "inside": "['普洛康裕制药', '03月10', '5,000', '14日', '5,000', '保证', '20190426', '是', '否']"}
{"page": 29, "allrow": 775, "type": "excel", "inside": "['', '日', '', '', '', '', '', '', '']"}
{"page": 29, "allrow": 776, "type": "excel", "inside": "['', '2018年', '', '2019年02月', '', '连带责任', '20190225-', '', '']"}
{"page": 29, "allrow": 777, "type": "excel", "inside": "['普洛康裕制药', '03月10', '5,000', '25日', '5,000', '保证', '20200119', '是', '否']"}
{"page": 29, "allrow": 778, "type": "excel", "inside": "['', '日', '', '', '', '', '', '', '']"}
{"page": 29, "allrow": 779, "type": "text", "inside": ""}
{"page": 29, "allrow": 780, "type": "页脚", "inside": "29"}
{"page": 30, "allrow": 781, "type": "text", "inside": ""}
{"page": 30, "allrow": 782, "type": "text", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 30, "allrow": 783, "type": "excel", "inside": "['', '2018年', '', '2018年04月', '', '', '连带责任', '20180423-', '', '']"}
{"page": 30, "allrow": 784, "type": "excel", "inside": "['巨泰药业', '03月10', '2,000', '23日', '', '10', '保证', '20210423', '是', '否']"}
{"page": 30, "allrow": 785, "type": "excel", "inside": "['', '日', '', '', '', '', '', '', '', '']"}
{"page": 30, "allrow": 786, "type": "excel", "inside": "['', '2018年', '', '2018年10月', '', '', '连带责任', '20181030-', '', '']"}
{"page": 30, "allrow": 787, "type": "excel", "inside": "['安微普洛生物', '03月10', '5,000', '30日', '', '1,500', '保证', '20190404', '是', '否']"}
{"page": 30, "allrow": 788, "type": "excel", "inside": "['', '日', '', '', '', '', '', '', '', '']"}
{"page": 30, "allrow": 789, "type": "excel", "inside": "['', '2018年', '', '2018年09月', '', '', '连带责任', '20180925-', '', '']"}
{"page": 30, "allrow": 790, "type": "excel", "inside": "['普洛进出口', '03月10', '36,000', '25日', '', '36,000', '保证', '20200925', '是', '否']"}
{"page": 30, "allrow": 791, "type": "excel", "inside": "['', '日', '', '', '', '', '', '', '', '']"}
{"page": 30, "allrow": 792, "type": "excel", "inside": "['', '2019年', '', '2019年06月', '', '', '连带责任', '20190628-', '', '']"}
{"page": 30, "allrow": 793, "type": "excel", "inside": "['普洛进出口', '03月08', '13,000', '28日', '', '13,000', '保证', '20200627', '否', '否']"}
{"page": 30, "allrow": 794, "type": "excel", "inside": "['', '日', '', '', '', '', '', '', '', '']"}
{"page": 30, "allrow": 795, "type": "excel", "inside": "['', '2019年', '', '2019年10月', '', '', '连带责任', '20191031-', '', '']"}
{"page": 30, "allrow": 796, "type": "excel", "inside": "['普洛进出口', '03月08', '15,000', '31日', '', '15,000', '保证', '202020103', '否', '否']"}
{"page": 30, "allrow": 797, "type": "excel", "inside": "['', '日', '', '', '', '', '', '0', '', '']"}
{"page": 30, "allrow": 798, "type": "excel", "inside": "['', '2019年', '', '2019年10月', '', '', '连带责任', '20191031-', '', '']"}
{"page": 30, "allrow": 799, "type": "excel", "inside": "['宁波普洛进出口', '10月18', '5,000', '31日', '', '5,000', '保证', '20201030', '否', '否']"}
{"page": 30, "allrow": 800, "type": "excel", "inside": "['', '日', '', '', '', '', '', '', '', '']"}
{"page": 30, "allrow": 801, "type": "excel", "inside": "['报告期内审批对子公司担保额度合计（B1）', '', '237,000', '', '', '报告期内对子公司担保实际发生额合计（B2）', '', '155,900', '', '']"}
{"page": 30, "allrow": 802, "type": "excel", "inside": "['报告期末已审批的对子公司担保额度合计（B3）', '', '237,000', '', '', '报告期末对子公司实际担保余额合计（B4）', '', '50,990', '', '']"}
{"page": 30, "allrow": 803, "type": "excel", "inside": "['子公司对子公司的担保情况', '', '', '', '', '', '', '', '', '']"}
{"page": 30, "allrow": 804, "type": "excel", "inside": "['', '担保额度相关', '担保额', '', '实际担保金额', '', '', '', '是否履', '是否为']"}
{"page": 30, "allrow": 805, "type": "excel", "inside": "['担保对象名称', '公告披', '度', '实际发生日期', '', '', '担保类型', '担保期', '行完毕', '关联方']"}
{"page": 30, "allrow": 806, "type": "excel", "inside": "['', '露日期', '', '', '', '', '', '', '', '担保']"}
{"page": 30, "allrow": 807, "type": "excel", "inside": "['公司担保总额（即前三大项的合计）', '', '', '', '', '', '', '', '', '']"}
{"page": 30, "allrow": 808, "type": "excel", "inside": "['报告期内审批担保额度合计（A1+B1+C1）', '', '237,000', '', '', '报告期内担保实际发生额合计（A2+B2+C2）', '', '155,900', '', '']"}
{"page": 30, "allrow": 809, "type": "excel", "inside": "['报告期末已审批的担保额度合计（A3+B3+C3）', '', '237,000', '', '', '报告期末实际担保余额合计（A4+B4+C4）', '', '50,990', '', '']"}
{"page": 30, "allrow": 810, "type": "excel", "inside": "['实际担保总额（即A4+B4+C4）占公司净资产的比例', '', '', '', '', '13.53%', '', '', '', '']"}
{"page": 30, "allrow": 811, "type": "excel", "inside": "['其中：', '', '', '', '', '', '', '', '', '']"}
{"page": 30, "allrow": 812, "type": "excel", "inside": "['为股东、实际控制人及其关联方提供担保的余额（D）', '', '', '', '', '0', '', '', '', '']"}
{"page": 30, "allrow": 813, "type": "excel", "inside": "['直接或间接为资产负债率超过70%的被担保对象提供的债务担保余额（E）', '', '', '', '', '0', '', '', '', '']"}
{"page": 30, "allrow": 814, "type": "excel", "inside": "['担保总额超过净资产50%部分的金额（F）', '', '', '', '', '0', '', '', '', '']"}
{"page": 30, "allrow": 815, "type": "excel", "inside": "['上述三项担保金额合计（D+E+F）', '', '', '', '', '0', '', '', '', '']"}
{"page": 31, "allrow": 816, "type": "text", "inside": ""}
{"page": 31, "allrow": 817, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 31, "allrow": 818, "type": "excel", "inside": "['对未到期担保，报告期内已发生担保责任或可能承担连带清偿责任的情况说明（如有）', '不适用']"}
{"page": 31, "allrow": 819, "type": "excel", "inside": "['违反规定程序对外提供担保的说明（如有）', '不适用']"}
{"page": 31, "allrow": 820, "type": "text", "inside": ""}
{"page": 31, "allrow": 821, "type": "text", "inside": "采用复合方式担保的具体情况说明"}
{"page": 31, "allrow": 822, "type": "text", "inside": "（2）违规对外担保情况"}
{"page": 31, "allrow": 823, "type": "text", "inside": "□适用√不适用"}
{"page": 31, "allrow": 824, "type": "text", "inside": "公司报告期无违规对外担保情况。"}
{"page": 31, "allrow": 825, "type": "text", "inside": "3、委托他人进行现金资产管理情况"}
{"page": 31, "allrow": 826, "type": "text", "inside": "（1）委托理财情况"}
{"page": 31, "allrow": 827, "type": "text", "inside": "√适用□不适用"}
{"page": 31, "allrow": 828, "type": "text", "inside": "报告期内委托理财概况"}
{"page": 31, "allrow": 829, "type": "text", "inside": "单位：万元"}
{"page": 31, "allrow": 830, "type": "excel", "inside": "['具体类型', '委托理财的资金来源', '委托理财发生额', '未到期余额', '逾期未收回的金额']"}
{"page": 31, "allrow": 831, "type": "excel", "inside": "['银行理财产品', '自有闲置资金', '10,000', '10,000', '0']"}
{"page": 31, "allrow": 832, "type": "excel", "inside": "['银行理财产品', '自有闲置资金', '1,000', '1,000', '0']"}
{"page": 31, "allrow": 833, "type": "excel", "inside": "['银行理财产品', '自有闲置资金', '10,000', '10,000', '0']"}
{"page": 31, "allrow": 834, "type": "excel", "inside": "['银行理财产品', '自有闲置资金', '10,000', '10,000', '0']"}
{"page": 31, "allrow": 835, "type": "excel", "inside": "['银行理财产品', '自有闲置资金', '5,000', '5,000', '0']"}
{"page": 31, "allrow": 836, "type": "excel", "inside": "['其他类', '自有闲置资金', '5,000', '5,000', '0']"}
{"page": 31, "allrow": 837, "type": "excel", "inside": "['其他类', '自有闲置资金', '5,000', '5,000', '0']"}
{"page": 31, "allrow": 838, "type": "excel", "inside": "['合计', '', '46,000', '46,000', '0']"}
{"page": 31, "allrow": 839, "type": "text", "inside": "单项金额重大或安全性较低、流动性较差、不保本的高风险委托理财具体情况"}
{"page": 31, "allrow": 840, "type": "text", "inside": "□适用√不适用"}
{"page": 31, "allrow": 841, "type": "text", "inside": "委托理财出现预期无法收回本金或存在其他可能导致减值的情形"}
{"page": 31, "allrow": 842, "type": "text", "inside": "□适用√不适用"}
{"page": 31, "allrow": 843, "type": "text", "inside": "（2）委托贷款情况"}
{"page": 31, "allrow": 844, "type": "text", "inside": "□适用√不适用"}
{"page": 31, "allrow": 845, "type": "text", "inside": "公司报告期不存在委托贷款。"}
{"page": 31, "allrow": 846, "type": "text", "inside": "4、其他重大合同"}
{"page": 31, "allrow": 847, "type": "text", "inside": "□适用√不适用"}
{"page": 31, "allrow": 848, "type": "text", "inside": "公司报告期不存在其他重大合同。"}
{"page": 31, "allrow": 849, "type": "页脚", "inside": "31"}
{"page": 32, "allrow": 850, "type": "text", "inside": ""}
{"page": 32, "allrow": 851, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 32, "allrow": 852, "type": "text", "inside": "十八、社会责任情况"}
{"page": 32, "allrow": 853, "type": "text", "inside": "1、履行社会责任情况"}
{"page": 32, "allrow": 854, "type": "text", "inside": "公司积极推进EHS体系建设，规范EHS组织和职责，开展EHS科学管理。公司形成了ISO14001环境管理体系全覆盖，全面运行OHSAS18001体系和安全标准化。2019年所有子公司都通过EHS体系监督审核。"}
{"page": 32, "allrow": 855, "type": "text", "inside": "2、履行精准扶贫社会责任情况"}
{"page": 32, "allrow": 856, "type": "text", "inside": "（1）精准扶贫规划"}
{"page": 32, "allrow": 857, "type": "text", "inside": "公司报告年度暂未开展精准扶贫工作，也暂无后续精准扶贫计划。"}
{"page": 32, "allrow": 858, "type": "text", "inside": "（2）年度精准扶贫概要"}
{"page": 32, "allrow": 859, "type": "text", "inside": "（3）精准扶贫成效"}
{"page": 32, "allrow": 860, "type": "excel", "inside": "['指标', '计量单位', '数量/开展情况']"}
{"page": 32, "allrow": 861, "type": "excel", "inside": "['一、总体情况', '——', '——']"}
{"page": 32, "allrow": 862, "type": "excel", "inside": "['二、分项投入', '——', '——']"}
{"page": 32, "allrow": 863, "type": "excel", "inside": "['1.产业发展脱贫', '——', '——']"}
{"page": 32, "allrow": 864, "type": "excel", "inside": "['2.转移就业脱贫', '——', '——']"}
{"page": 32, "allrow": 865, "type": "excel", "inside": "['3.易地搬迁脱贫', '——', '——']"}
{"page": 32, "allrow": 866, "type": "excel", "inside": "['4.教育扶贫', '——', '——']"}
{"page": 32, "allrow": 867, "type": "excel", "inside": "['5.健康扶贫', '——', '——']"}
{"page": 32, "allrow": 868, "type": "excel", "inside": "['6.生态保护扶贫', '——', '——']"}
{"page": 32, "allrow": 869, "type": "excel", "inside": "['7.兜底保障', '——', '——']"}
{"page": 32, "allrow": 870, "type": "excel", "inside": "['8.社会扶贫', '——', '——']"}
{"page": 32, "allrow": 871, "type": "excel", "inside": "['9.其他项目', '——', '——']"}
{"page": 32, "allrow": 872, "type": "excel", "inside": "['三、所获奖项（内容、级别）', '——', '——']"}
{"page": 32, "allrow": 873, "type": "text", "inside": ""}
{"page": 32, "allrow": 874, "type": "text", "inside": "（4）后续精准扶贫计划"}
{"page": 32, "allrow": 875, "type": "text", "inside": "3、环境保护相关的情况"}
{"page": 32, "allrow": 876, "type": "text", "inside": "上市公司及其子公司是否属于环境保护部门公布的重点排污单位"}
{"page": 32, "allrow": 877, "type": "text", "inside": "是"}
{"page": 32, "allrow": 878, "type": "excel", "inside": "['', '主要污染物', '', '排放口', '排放口', '排放浓', '执行的污染', '', '核定', '超标排']"}
{"page": 32, "allrow": 879, "type": "excel", "inside": "['公司名称', '及特征污染', '排放方式', '数量', '分布情', '度mg/l', '物排放标准', '排放总量t/a', '的排', '放情况']"}
{"page": 32, "allrow": 880, "type": "excel", "inside": "['', '物名称', '', '', '况', '', '', '', '放总', '']"}
{"page": 32, "allrow": 881, "type": "text", "inside": ""}
{"page": 32, "allrow": 882, "type": "页脚", "inside": "32"}
{"page": 33, "allrow": 883, "type": "text", "inside": ""}
{"page": 33, "allrow": 884, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 33, "allrow": 885, "type": "excel", "inside": "['', '', '', '', '', '', '', '', '', '量（t/a）', '']"}
{"page": 33, "allrow": 886, "type": "excel", "inside": "['', 'COD氨氮', '连续', '1个', '厂区北侧', '215.084.20', '东生态办【2017】12号纳管内控标准限值：500mg/L东生态办【2017】12号纳管内控标准限值：25mg/L焚烧炉执行GB18484-200', '', '112.7882.204', '（473.2）（31.55）', '无无']"}
{"page": 33, "allrow": 887, "type": "excel", "inside": "['普洛家园药业', '二氧化硫', '连续', '', '', '103.70', '1标准： SO2≤300 mg/m3', '', '11.2', '17.02', '无']"}
{"page": 33, "allrow": 888, "type": "excel", "inside": "['', '氮氧化物', '连续', '2个', '厂区北侧', '88.89', 'RTO执行GB16297-1996标准： SO2≤550mg/m3焚烧炉执行GB18484-2001标准： NOx≤500 mg/m3RTO执行GB16297-1996标准： NOx≤240mg/m3', '', '9.6', '23.17', '无']"}
{"page": 33, "allrow": 889, "type": "excel", "inside": "['', 'COD', '连续', '1个', '厂区北侧', '38.13', '长许可[2014]279号标准限值：60mg/L长许可[2014]279号', '18.30.84', '', '137.6', '无']"}
{"page": 33, "allrow": 890, "type": "excel", "inside": "['安徽普洛生物', '氨氮', '', '', '', '1.75', '标准限值：15mg/L', '', '', '20.6', '无']"}
{"page": 33, "allrow": 891, "type": "excel", "inside": "['', '二氧化硫氮氧化物', '间歇', '1个', '厂区北侧', '149.38240.74', 'GB13271-2014标准： SO2≤400mg/m3GB13271-2014标准： NOx', '12.119.5', '', '57.670.56', '无无']"}
{"page": 33, "allrow": 892, "type": "text", "inside": ""}
{"page": 33, "allrow": 893, "type": "页脚", "inside": "33"}
{"page": 34, "allrow": 894, "type": "text", "inside": ""}
{"page": 34, "allrow": 895, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 34, "allrow": 896, "type": "excel", "inside": "['', '', '', '', '', '', '≤400mg/m3', '', '', '']"}
{"page": 34, "allrow": 897, "type": "excel", "inside": "['', 'COD', '连续', '1个', '厂区西北侧', '199.33', '东生态办【2017】12号纳管内控标准限值：500mg/L东生态办【2017】12号', '17.94', '34.41', '无']"}
{"page": 34, "allrow": 898, "type": "excel", "inside": "['普洛得邦制药', '氨氮', '', '', '', '4.11', '纳管内控标准限值：25mg/L', '0.37', '6.45', '无']"}
{"page": 34, "allrow": 899, "type": "excel", "inside": "['', '二氧化硫氮氧化物', '连续', '1个', '厂区西侧', '19.7995.83', 'GB16297-1996标准： SO2≤550mg/m3GB16297-1996标准： NOx≤240mg/m3', '0.954.6', '1.53917.28', '无无']"}
{"page": 34, "allrow": 900, "type": "excel", "inside": "['', 'COD氨氮', '连续', '1个', '厂区南侧', '36.850.63', '东生态办【2011】4号纳管标准限值：100mg/L东生态办【2011】4号', '15.270.259', '44.994.5', '无无']"}
{"page": 34, "allrow": 901, "type": "excel", "inside": "['浙江普洛生物', '', '', '', '', '', '纳管标准限值：15mg/L', '', '', '']"}
{"page": 34, "allrow": 902, "type": "excel", "inside": "['', '二氧化硫氮氧化物', '间歇', '1个', '厂区中间', '78.06169.72', 'GB13271-2014标准： SO2≤400mg/m3GB13271-2014标准： NOx≤400mg/m3', '5.6212.22', '64.2499.89', '无无']"}
{"page": 34, "allrow": 903, "type": "excel", "inside": "['', 'COD', '连续', '1个', '厂区西侧', '528.93', '污水处理厂协议内控标准限值：2000mg/L', '128', '（485.27）', '无']"}
{"page": 34, "allrow": 904, "type": "excel", "inside": "['山东普洛得邦', '氨氮', '', '', '', '30.08', '污水处理厂协议内控标', '7.28', '（24.', '无']"}
{"page": 34, "allrow": 905, "type": "excel", "inside": "['', '二氧化硫', '连续', '3个', '老区西侧', '2.15', '准限值：100mg/LDB37/2376—2013标准：SO2', '0.142', '2635）33.6102', '无']"}
{"page": 34, "allrow": 906, "type": "text", "inside": ""}
{"page": 34, "allrow": 907, "type": "页脚", "inside": "34"}
{"page": 35, "allrow": 908, "type": "text", "inside": ""}
{"page": 35, "allrow": 909, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 35, "allrow": 910, "type": "excel", "inside": "['', '', '', '', '新区南侧', '', '≤50mg/m3', '', '', '']"}
{"page": 35, "allrow": 911, "type": "excel", "inside": "['', '氮氧化物', '', '', '', '37.22', 'DB37/2376—2013标准：NOx≤100mg/m3', '2.01', '51.81', '无']"}
{"page": 35, "allrow": 912, "type": "excel", "inside": "['', 'COD氨氮二氧化硫', '连续连续', '2个', '新区北侧、老区西北侧', '184.93.62117.5', '污水厂进管内控标准限值：500mg/L污水厂进管内控标准限值：25mg/L焚烧炉执行GB18484-2001标准： SO2≤300 mg/m3', '31.7151.3062.82', '42.2377.9248.64', '无无无']"}
{"page": 35, "allrow": 913, "type": "excel", "inside": "['普洛康裕制药', '', '', '', '', '', 'RTO执行GB16297-199', '', '', '']"}
{"page": 35, "allrow": 914, "type": "excel", "inside": "['', '氮氧化物', '连续', '2个', '老区北侧', '42.5', '6标准： SO2≤550mg/m3焚烧炉执行GB18484-2001标准： NOx≤500 mg/m3RTO执行GB16297-1996标准： NOx≤240mg/m3', '1.02', '18', '无']"}
{"page": 35, "allrow": 915, "type": "excel", "inside": "['', 'COD氨氮', '连续', '1个', '南区西北侧', '584.338.20', '污水厂协议标准限值：1500mg/L污水厂协议标准限值：100mg/L', '276.393.88', '（700.53）（46.7）', '无无']"}
{"page": 35, "allrow": 916, "type": "excel", "inside": "['山东汉兴', '', '', '', '', '', 'DB37/2376—', '', '', '']"}
{"page": 35, "allrow": 917, "type": "excel", "inside": "['', '二氧化硫氮氧化物', '连续连续', '3个', '南区西北侧、北区北侧', '15.341.5', '2013标准：SO2≤50mg/m3DB37/2376—2013标准：NOx≤100mg/m3', '1.012.74', '3.4710.49', '无无']"}
{"page": 35, "allrow": 918, "type": "text", "inside": ""}
{"page": 35, "allrow": 919, "type": "text", "inside": "防治污染设施的建设和运行情况"}
{"page": 35, "allrow": 920, "type": "页脚", "inside": "35"}
{"page": 36, "allrow": 921, "type": "text", "inside": ""}
{"page": 36, "allrow": 922, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 36, "allrow": 923, "type": "text", "inside": "1.防治废水污染设施："}
{"page": 36, "allrow": 924, "type": "text", "inside": "公司按环境保护法律法规要求，配置相应的废水预处理和末端治理设施，配备设备检修、维护人员，对操作人员进行全面的培训。所有废水总排口已全部安装了污染物在线监测设施。至今污染防治设施全部处于正常运行状态，连续稳定达标排放，无超标排放情况。"}
{"page": 36, "allrow": 925, "type": "text", "inside": "公司2019年共投入约5711万元，加强废水处理能力建设，进一步削减水污染物排放总量。投资了MVR、闪蒸、吹脱等废水处理设施，通过回收废水中的溴、氨、溶剂、产品等资源实施源头减排。另外对原有污水处理设施开展提标改造，稳定运行。"}
{"page": 36, "allrow": 926, "type": "text", "inside": "2.防治废气污染设施："}
{"page": 36, "allrow": 927, "type": "text", "inside": "公司目前为止共投资了8套RTO废气处理设施，总有机废气处理量达到20万m3/h。公司所有废气污染防治设施正常运行，废气监测各项指标符合国家和地方排放标准，无超标情况发生。"}
{"page": 36, "allrow": 928, "type": "text", "inside": "2019年公司投入约6500万元，加强废气污染源头减排和末端治理能力的建设。主要投资的项目包括密闭化改造、离心机升级改造、二氯甲烷废气回收系统、RTO设施、煤改气项目等，另外RTO排气全部安装了在线监测系统，有效监控废气的排放。"}
{"page": 36, "allrow": 929, "type": "text", "inside": "3.防治固废污染设施："}
{"page": 36, "allrow": 930, "type": "text", "inside": "公司按国家和地方规定强化危废管理，推行危废减量化、危废资源化利用。目前固废贮存库、自行焚烧处置设施等运行正常，焚烧炉排放的废气符合国家和地方规定的废气排放标准，无违法排放情况发生。"}
{"page": 36, "allrow": 931, "type": "text", "inside": "2019年公司投入1000多万元，实施包括焚烧炉尾气处理系统改造、余热锅炉利用、污泥干化、危废库提升改造、危废鉴定、锅炉煤改生物质等项目，减少固废产生量，提高焚烧废气污染物的排放指标。"}
{"page": 36, "allrow": 932, "type": "text", "inside": "建设项目环境影响评价及其他环境保护行政许可情况"}
{"page": 36, "allrow": 933, "type": "excel", "inside": "['子公司名称', '时间', '项目内容', '审批部门']"}
{"page": 36, "allrow": 934, "type": "excel", "inside": "['浙江普洛生物', '2019年4月', '年产500吨芬苯达唑粉技改项目环境影响报告表批复，金环建东〔2019〕19号', '金华市生态环境局（东阳分局）']"}
{"page": 36, "allrow": 935, "type": "excel", "inside": "['山东汉兴', '2019年5月', '年产 10000 吨氨基酸、3000 吨 D-乙酯、500 吨 羟基甲氧基乙苯及副产品 54963 吨项目环境影响报告书的批复，潍环审字（2019）8号', '潍坊市生态环境局']"}
{"page": 36, "allrow": 936, "type": "excel", "inside": "['得邦制药', '2019年11月', '金环建东（2017）4号批复的年产100吨TP091、20吨NF-ATMO、40吨头孢卡品酯中间体、20吨氟氧头孢中间体、2吨头孢维星钠项目环保验收', '金华市生态环境局（东阳分局）']"}
{"page": 36, "allrow": 937, "type": "text", "inside": ""}
{"page": 36, "allrow": 938, "type": "text", "inside": "突发环境事件应急预案"}
{"page": 36, "allrow": 939, "type": "text", "inside": "公司成立了安全环保管理委员会，策划和指导公司安全、环境事故应急管理体系建设。所有子公司均设立了EHS管理组织和应急救援队伍，均编制了安全、环境事故综合应急预案和专项预案，预案在相关政府部门备案，落实了安全、环境事故应急设施和措施，进行了定期培训和演练。"}
{"page": 36, "allrow": 940, "type": "text", "inside": "公司EHS监管部定期对各子公司安全、环境应急管理体系运行进行监督考核，指导各子公司双预防体系建设、隐患排查治理、安全环保标准化工作。坚持问题导向，突出整治重点，深入现场排查问题，确保了公司安全、环保风险得到有效控制。"}
{"page": 36, "allrow": 941, "type": "text", "inside": "环境自行监测方案"}
{"page": 36, "allrow": 942, "type": "text", "inside": "根据当地环保政府部门的要求，公司正不断完善排污许可证管理，编制废水、废气和噪声环境自行监测方案并在环保局"}
{"page": 36, "allrow": 943, "type": "text", "inside": "官网上进行了信息公开。所有子公司的标排口均安装了自动在线监测装置，实时将监测数据联网传输到环保局，另外根据当"}
{"page": 36, "allrow": 944, "type": "text", "inside": "地环保局要求，公司还编制手动监测方案，定期委托有资质的监测机构进行取样监测并报送环保局进行公开，所有监测数据"}
{"page": 36, "allrow": 945, "type": "text", "inside": "接受环保局和社会监督。"}
{"page": 36, "allrow": 946, "type": "页脚", "inside": "36"}
{"page": 37, "allrow": 947, "type": "text", "inside": ""}
{"page": 37, "allrow": 948, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 37, "allrow": 949, "type": "text", "inside": "自行监测方案均建立了质量保证措施。一是根据相关污染物排放标准严格核对监测数据，发现偏差及时采取纠正措施。"}
{"page": 37, "allrow": 950, "type": "text", "inside": "二是监测活动根据在线和固定源相关技术规定开展，确保监测数据100%上报。三是委托第三方开展在线设施的维护校准工作。"}
{"page": 37, "allrow": 951, "type": "text", "inside": "其他应当公开的环境信息"}
{"page": 37, "allrow": 952, "type": "text", "inside": "家园药业、得邦制药等子公司完成固废核查、温室气体排放核查、土壤污染筛查等工作。"}
{"page": 37, "allrow": 953, "type": "text", "inside": "其他环保相关信息"}
{"page": 37, "allrow": 954, "type": "text", "inside": "无"}
{"page": 37, "allrow": 955, "type": "text", "inside": "十九、其他重大事项的说明"}
{"page": 37, "allrow": 956, "type": "text", "inside": "□适用√不适用"}
{"page": 37, "allrow": 957, "type": "text", "inside": "公司报告期不存在需要说明的其他重大事项。"}
{"page": 37, "allrow": 958, "type": "text", "inside": "二十、公司子公司重大事项"}
{"page": 37, "allrow": 959, "type": "text", "inside": "□适用√不适用"}
{"page": 37, "allrow": 960, "type": "页脚", "inside": "37"}
{"page": 38, "allrow": 961, "type": "text", "inside": ""}
{"page": 38, "allrow": 962, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 38, "allrow": 963, "type": "text", "inside": "第六节股份变动及股东情况"}
{"page": 38, "allrow": 964, "type": "text", "inside": "一、股份变动情况"}
{"page": 38, "allrow": 965, "type": "text", "inside": "1、股份变动情况"}
{"page": 38, "allrow": 966, "type": "text", "inside": "单位：股"}
{"page": 38, "allrow": 967, "type": "excel", "inside": "['', '本次变动前', '', '本次变动增减（＋，－）', '', '', '', '', '本次变动后', '']"}
{"page": 38, "allrow": 968, "type": "excel", "inside": "['', '数量', '比例', '发行新', '送股', '公积金', '其他', '小计', '数量', '比例']"}
{"page": 38, "allrow": 969, "type": "excel", "inside": "['', '', '', '股', '', '转股', '', '', '', '']"}
{"page": 38, "allrow": 970, "type": "excel", "inside": "['', '31,699,', '', '', '', '', '', '', '31,699,', '']"}
{"page": 38, "allrow": 971, "type": "excel", "inside": "['一、有限售条件股份', '427', '2.69%', '', '', '', '', '', '427', '2.69%']"}
{"page": 38, "allrow": 972, "type": "excel", "inside": "['', '31,699,', '', '', '', '', '', '', '31,699,', '']"}
{"page": 38, "allrow": 973, "type": "excel", "inside": "['3、其他内资持股', '427', '2.69%', '', '', '', '', '', '427', '2.69%']"}
{"page": 38, "allrow": 974, "type": "excel", "inside": "['', '31,699,', '', '', '', '', '', '', '31,699,', '']"}
{"page": 38, "allrow": 975, "type": "excel", "inside": "['其中：境内法人持股', '427', '2.69%', '', '', '', '', '', '427', '2.69%']"}
{"page": 38, "allrow": 976, "type": "excel", "inside": "['', '1,146,8', '', '', '', '', '', '', '1,146,8', '']"}
{"page": 38, "allrow": 977, "type": "excel", "inside": "['二、无限售条件股份', '24,065', '97.31%', '', '', '', '', '', '24,065', '97.31%']"}
{"page": 38, "allrow": 978, "type": "excel", "inside": "['', '1,146,8', '', '', '', '', '', '', '1,146,8', '']"}
{"page": 38, "allrow": 979, "type": "excel", "inside": "['1、人民币普通股', '24,065', '97.31%', '', '', '', '', '', '24,065', '97.31%']"}
{"page": 38, "allrow": 980, "type": "excel", "inside": "['', '1,178,5', '100.00', '', '', '', '', '', '1,178,5', '100.00']"}
{"page": 38, "allrow": 981, "type": "excel", "inside": "['三、股份总数', '23,492', '%', '', '', '', '', '', '23,492', '%']"}
{"page": 38, "allrow": 982, "type": "text", "inside": "股份变动的原因"}
{"page": 38, "allrow": 983, "type": "text", "inside": "□适用√不适用"}
{"page": 38, "allrow": 984, "type": "text", "inside": "股份变动的批准情况"}
{"page": 38, "allrow": 985, "type": "text", "inside": "□适用√不适用"}
{"page": 38, "allrow": 986, "type": "text", "inside": "股份变动的过户情况"}
{"page": 38, "allrow": 987, "type": "text", "inside": "□适用√不适用"}
{"page": 38, "allrow": 988, "type": "text", "inside": "股份回购的实施进展情况"}
{"page": 38, "allrow": 989, "type": "text", "inside": "□适用√不适用"}
{"page": 38, "allrow": 990, "type": "text", "inside": "采用集中竞价方式减持回购股份的实施进展情况"}
{"page": 38, "allrow": 991, "type": "text", "inside": "□适用√不适用"}
{"page": 38, "allrow": 992, "type": "text", "inside": "股份变动对最近一年和最近一期基本每股收益和稀释每股收益、归属于公司普通股股东的每股净资产等财务指标的影响□适用√不适用"}
{"page": 38, "allrow": 993, "type": "text", "inside": "公司认为必要或证券监管机构要求披露的其他内容"}
{"page": 38, "allrow": 994, "type": "text", "inside": "□适用√不适用"}
{"page": 38, "allrow": 995, "type": "页脚", "inside": "38"}
{"page": 39, "allrow": 996, "type": "text", "inside": ""}
{"page": 39, "allrow": 997, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 39, "allrow": 998, "type": "text", "inside": "2、限售股份变动情况"}
{"page": 39, "allrow": 999, "type": "text", "inside": "□适用√不适用"}
{"page": 39, "allrow": 1000, "type": "text", "inside": "二、证券发行与上市情况"}
{"page": 39, "allrow": 1001, "type": "text", "inside": "1、报告期内证券发行（不含优先股）情况"}
{"page": 39, "allrow": 1002, "type": "text", "inside": "□适用√不适用"}
{"page": 39, "allrow": 1003, "type": "text", "inside": "2、公司股份总数及股东结构的变动、公司资产和负债结构的变动情况说明"}
{"page": 39, "allrow": 1004, "type": "text", "inside": "□适用√不适用"}
{"page": 39, "allrow": 1005, "type": "text", "inside": "3、现存的内部职工股情况"}
{"page": 39, "allrow": 1006, "type": "text", "inside": "□适用√不适用"}
{"page": 39, "allrow": 1007, "type": "text", "inside": "三、股东和实际控制人情况"}
{"page": 39, "allrow": 1008, "type": "text", "inside": "1、公司股东数量及持股情况"}
{"page": 39, "allrow": 1009, "type": "text", "inside": "单位：股"}
{"page": 39, "allrow": 1010, "type": "excel", "inside": "['', '', '', '', '', '年度报告披露日前上一月末普通股股东总数', '', '35,755', '', '报告期末表决', '', '', '', '', '', '', '年度报告披露日前上一月末', '', '']"}
{"page": 39, "allrow": 1011, "type": "excel", "inside": "['', '报告期末普通股股东总数', '36,126', '', '', '', '', '', '', '权恢复的优先股股东总数（如有）（参见注8）', '', '', '', '', '0', '', '表决权恢复的优先股股东总数（如有）（参', '', '0']"}
{"page": 39, "allrow": 1012, "type": "excel", "inside": "['', '', '', '', '', '', '', '', '', '', '', '', '', '', '', '', '见注8）', '', '']"}
{"page": 39, "allrow": 1013, "type": "excel", "inside": "['', '持股5%以上的股东或前10名股东持股情况', '', '', '', '', '', '', '', '', '', '', '', '', '', '', '', '', '']"}
{"page": 39, "allrow": 1014, "type": "excel", "inside": "['', '', '', '', '', '', '持股比例', '报告期末持股数量', '报告期内增减', '', '', '持有有限售条', '', '持有无限售条', '', '质押或冻结情况', '', '', '']"}
{"page": 39, "allrow": 1015, "type": "excel", "inside": "['', '股东名称', '', '', '股东性质', '', '', '', '变动情', '', '', '件的股', '', '件的股', '', '股份状态', '', '数量', '']"}
{"page": 39, "allrow": 1016, "type": "excel", "inside": "['', '', '', '', '', '', '', '', '况', '', '', '份数量', '', '份数量', '', '', '', '', '']"}
{"page": 39, "allrow": 1017, "type": "excel", "inside": "['横店集团控股有限公司', '', '', '境内非国有法人', '', '', '28.08%', '330,941,729', '', '', '31,654,182', '', '299,287,547', '', '', '质押', '', '156,000,000', '']"}
{"page": 39, "allrow": 1018, "type": "excel", "inside": "['浙江横店进出口有限公司', '', '', '境内非国有法人', '', '', '13.28%', '156,552,903', '', '', '', '', '156,552,903', '', '', '质押', '', '55,000,000', '']"}
{"page": 39, "allrow": 1019, "type": "excel", "inside": "['横店集团康裕药业有限公司', '', '', '境内非国有法人', '', '', '5.05%', '59,560,488', '', '', '', '', '59,560,488', '', '', '', '', '', '']"}
{"page": 39, "allrow": 1020, "type": "excel", "inside": "['横店集团家园化工有限公司', '', '', '境内非国有法人', '', '', '3.80%', '44,750,178', '', '', '', '', '44,750,178', '', '', '质押', '', '44,750,160', '']"}
{"page": 39, "allrow": 1021, "type": "text", "inside": ""}
{"page": 39, "allrow": 1022, "type": "页脚", "inside": "39"}
{"page": 40, "allrow": 1023, "type": "text", "inside": ""}
{"page": 40, "allrow": 1024, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 40, "allrow": 1025, "type": "excel", "inside": "['香港中央结算有限公司', '', '境外法人', '3.41%', '', '40,141,413', '+24,528,049', '40,141,413', '', '']"}
{"page": 40, "allrow": 1026, "type": "excel", "inside": "['普洛药业股份有限公司－第一期员工持股计划', '', '其他', '2.77%', '', '32,664,016', '+32,664,016', '32,664,016', '', '']"}
{"page": 40, "allrow": 1027, "type": "excel", "inside": "['招商银行股份有限公司－兴全合宜灵活配置混合型证券投资基金', '', '其他', '2.05%', '', '24,105,565', '+3,828,554', '24,105,565', '', '']"}
{"page": 40, "allrow": 1028, "type": "excel", "inside": "['中国工商银行股份有限公司－中欧时代先锋股票型发起式证券投资基金', '', '其他', '1.08%', '', '12,760,966', '+2,123,728', '12,760,966', '', '']"}
{"page": 40, "allrow": 1029, "type": "excel", "inside": "['青岛市供销社资产运营（集团）中心', '', '境内非国有法人', '0.98%', '', '11,560,000', '', '11,560,000', '', '']"}
{"page": 40, "allrow": 1030, "type": "excel", "inside": "['兴业全球基金－兴业银行－兴全－股票红利特定多客户资产管理计划', '', '境内非国有法人', '0.86%', '', '10,085,071', '+10,085,071', '10,085,071', '', '']"}
{"page": 40, "allrow": 1031, "type": "excel", "inside": "['', '上述股东关联关系或一致行动的说明', '', '', '浙江横店进出口有限公司、横店集团康裕药业有限公司、横店集团家园化工有限公司为关联企业，与横店集团控股有限公司构成为一致行动人关系。', '', '', '', '', '']"}
{"page": 40, "allrow": 1032, "type": "excel", "inside": "['', '前10名无限售条件股东持股情况', '', '', '', '', '', '', '', '']"}
{"page": 40, "allrow": 1033, "type": "excel", "inside": "['', '', '', '', '', '', '', '', '股份种类', '']"}
{"page": 40, "allrow": 1034, "type": "excel", "inside": "['', '股东名称', '', '', '报告期末持有无限售条件股份数量', '', '', '', '股份种类', '数量']"}
{"page": 40, "allrow": 1035, "type": "excel", "inside": "['横店集团控股有限公司', '', '', '299,287,547', '', '', '', '', '人民币普通股', '299,287,547']"}
{"page": 40, "allrow": 1036, "type": "excel", "inside": "['浙江横店进出口有限公司', '', '', '156,552,903', '', '', '', '', '人民币普通股', '156,552,903']"}
{"page": 40, "allrow": 1037, "type": "excel", "inside": "['横店集团康裕药业有限公司', '', '', '59,560,488', '', '', '', '', '人民币普通股', '59,560,488']"}
{"page": 40, "allrow": 1038, "type": "excel", "inside": "['横店集团家园化工有限公司', '', '', '44,750,178', '', '', '', '', '人民币普通股', '44,750,178']"}
{"page": 40, "allrow": 1039, "type": "excel", "inside": "['香港中央结算有限公司', '', '', '40,141,413', '', '', '', '', '人民币普通股', '40,141,413']"}
{"page": 40, "allrow": 1040, "type": "excel", "inside": "['普洛药业股份有限公司－第一期员工持股计划', '', '', '32,664,016', '', '', '', '', '人民币普通股', '32,664,016']"}
{"page": 40, "allrow": 1041, "type": "excel", "inside": "['招商银行股份有限公司－兴全合宜灵活配置混合型证券投资基金', '', '', '24,105,565', '', '', '', '', '人民币普通股', '24,105,565']"}
{"page": 40, "allrow": 1042, "type": "text", "inside": ""}
{"page": 40, "allrow": 1043, "type": "页脚", "inside": "40"}
{"page": 41, "allrow": 1044, "type": "text", "inside": ""}
{"page": 41, "allrow": 1045, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 41, "allrow": 1046, "type": "excel", "inside": "['中国工商银行股份有限公司－中欧时代先锋股票型发起式证券投资基金', '', '12,760,966', '', '人民币普通股', '12,760,966']"}
{"page": 41, "allrow": 1047, "type": "excel", "inside": "['青岛市供销社资产运营（集团）中心', '', '11,560,000', '', '人民币普通股', '11,560,000']"}
{"page": 41, "allrow": 1048, "type": "excel", "inside": "['兴业全球基金－兴业银行－兴全－股票红利特定多客户资产管理计划', '', '10,085,071', '', '人民币普通股', '10,085,071']"}
{"page": 41, "allrow": 1049, "type": "excel", "inside": "['', '前10名无限售流通股股东之间，以及前10名无限售流通股股东和前10名股东之间关联关系或一致行动的说明', '', '浙江横店进出口有限公司、横店集团康裕药业有限公司、横店集团家园化工有限公司为关联企业，与横店集团控股有限公司构成为一致行动人关系。', '', '']"}
{"page": 41, "allrow": 1050, "type": "text", "inside": ""}
{"page": 41, "allrow": 1051, "type": "text", "inside": "公司前10名普通股股东、前10名无限售条件普通股股东在报告期内是否进行约定购回交易"}
{"page": 41, "allrow": 1052, "type": "text", "inside": "□是√否"}
{"page": 41, "allrow": 1053, "type": "text", "inside": "公司前10名普通股股东、前10名无限售条件普通股股东在报告期内未进行约定购回交易。"}
{"page": 41, "allrow": 1054, "type": "text", "inside": "2、公司控股股东情况"}
{"page": 41, "allrow": 1055, "type": "text", "inside": "控股股东性质：社团集体控股"}
{"page": 41, "allrow": 1056, "type": "text", "inside": "控股股东类型：法人"}
{"page": 41, "allrow": 1057, "type": "excel", "inside": "['', '法定代表人/单位', '', '', '', '']"}
{"page": 41, "allrow": 1058, "type": "excel", "inside": "['控股股东名称', '负责人', '成立日期', '组织机构代码', '主要经营业务', '']"}
{"page": 41, "allrow": 1059, "type": "excel", "inside": "['', '', '', '', '投资管理和经营：电子电气、医药化工，影视娱乐、建筑建材、房产置业、轻纺针织、机械航空服务、旅游服务、', '、']"}
{"page": 41, "allrow": 1060, "type": "excel", "inside": "['横店集团控股有限公司', '徐永安', '1999年11月22日', '91330783717672584H', '商贸物流、信息网络、', '']"}
{"page": 41, "allrow": 1061, "type": "excel", "inside": "['', '', '', '', '金融投资、教育卫生体育、畜牧草业；货物进出口和技术进出口（法律禁止的除外，法律限制的凭有效证件经营）', '']"}
{"page": 41, "allrow": 1062, "type": "text", "inside": ""}
{"page": 41, "allrow": 1063, "type": "页脚", "inside": "41"}
{"page": 42, "allrow": 1064, "type": "text", "inside": ""}
{"page": 42, "allrow": 1065, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 42, "allrow": 1066, "type": "excel", "inside": "['', '直接持有浙商银行5.84%股权；直接持有横店集团东磁股份有限公司50.02%股权，通过东阳市博驰投资合伙企业（有限合伙）间接持有横店集团东磁股份有限公司0.05%股权；直接持有英洛华科技股份有限公司39.38%股权，通过横店集团东磁有限公司、浙江横店进出口有限公司、金华相家投资合伙企业（有限合伙）、东阳市恒益投资合伙企业（有限合伙）间']"}
{"page": 42, "allrow": 1067, "type": "excel", "inside": "['控股股东报告期内控股和参股的其他境内外上市公司的股权情况', '接持有英洛华科技股份有限公司10.06%股权；直接持有横店集团得邦照明股份有限公司48.19%股权，通过浙江横店进出口有限公司、金华德明投资合伙企业（有限合伙）间接持有横店集团得邦照明股份有限公司20.75%股权；直接持有横店影视股份有限公司80.35%股']"}
{"page": 42, "allrow": 1068, "type": "excel", "inside": "['', '权，通过金华恒影投资合伙企业（有限合伙）间接持有4.42%股权；直接持有南华期货股份有限公司73.3%股权，通过浙江横店进出口有限公司、横店集团东磁股份有限公司、东阳市横华投资合伙企业（有限合伙）间接持有南华期货股份有限公司3%股权。']"}
{"page": 42, "allrow": 1069, "type": "text", "inside": ""}
{"page": 42, "allrow": 1070, "type": "text", "inside": "控股股东报告期内变更"}
{"page": 42, "allrow": 1071, "type": "text", "inside": "□适用√不适用"}
{"page": 42, "allrow": 1072, "type": "text", "inside": "公司报告期控股股东未发生变更。"}
{"page": 42, "allrow": 1073, "type": "text", "inside": "3、公司实际控制人及其一致行动人"}
{"page": 42, "allrow": 1074, "type": "text", "inside": "实际控制人性质：境内其他机构"}
{"page": 42, "allrow": 1075, "type": "text", "inside": "实际控制人类型：法人"}
{"page": 42, "allrow": 1076, "type": "excel", "inside": "['', '法定代表人/单', '', '', '', '']"}
{"page": 42, "allrow": 1077, "type": "excel", "inside": "['实际控制人名称', '位负责人', '成立日期', '组织机构代码', '主要经营业务', '']"}
{"page": 42, "allrow": 1078, "type": "excel", "inside": "['', '', '2001年08月03', '51330783765209009', '1、对资本投入企业单位的资产实行管理；2、开展企业单位经营管理的理论研究；3、', '，']"}
{"page": 42, "allrow": 1079, "type": "excel", "inside": "['横店社团经济企业联合会', '徐永安', '日', 'G', '开展对社会责任共享的理论', '']"}
{"page": 42, "allrow": 1080, "type": "excel", "inside": "['', '', '', '', '研究与实践探索；4、兴办医药、学校，兴建道路、桥梁捐款等公益、慈善事业。', '']"}
{"page": 42, "allrow": 1081, "type": "excel", "inside": "['实际控制人报告期内控制的其他境内外上市公司的股权情况', '通过横店集团控股有限公司间接持有浙商银行4.09%股权，横店东磁35.05%股权，英洛华34.61%股权，得邦照明48.26%股权，横店影视59.34%股权，南华期货53.41%股权。', '', '', '', '']"}
{"page": 42, "allrow": 1082, "type": "text", "inside": ""}
{"page": 42, "allrow": 1083, "type": "text", "inside": "实际控制人报告期内变更"}
{"page": 42, "allrow": 1084, "type": "text", "inside": "□适用√不适用"}
{"page": 42, "allrow": 1085, "type": "text", "inside": "公司报告期实际控制人未发生变更。"}
{"page": 42, "allrow": 1086, "type": "text", "inside": "公司与实际控制人之间的产权及控制关系的方框图"}
{"page": 42, "allrow": 1087, "type": "页脚", "inside": "42"}
{"page": 43, "allrow": 1088, "type": "text", "inside": ""}
{"page": 43, "allrow": 1089, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 43, "allrow": 1090, "type": "text", "inside": "实际控制人通过信托或其他资产管理方式控制公司"}
{"page": 43, "allrow": 1091, "type": "text", "inside": "□适用√不适用"}
{"page": 43, "allrow": 1092, "type": "text", "inside": "4、其他持股在10%以上的法人股东"}
{"page": 43, "allrow": 1093, "type": "text", "inside": "□适用√不适用"}
{"page": 43, "allrow": 1094, "type": "text", "inside": "5、控股股东、实际控制人、重组方及其他承诺主体股份限制减持情况"}
{"page": 43, "allrow": 1095, "type": "text", "inside": "□适用√不适用"}
{"page": 43, "allrow": 1096, "type": "页脚", "inside": "43"}
{"page": 44, "allrow": 1097, "type": "text", "inside": ""}
{"page": 44, "allrow": 1098, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 44, "allrow": 1099, "type": "text", "inside": "第七节优先股相关情况"}
{"page": 44, "allrow": 1100, "type": "text", "inside": "□适用√不适用"}
{"page": 44, "allrow": 1101, "type": "text", "inside": "报告期公司不存在优先股。"}
{"page": 44, "allrow": 1102, "type": "页脚", "inside": "44"}
{"page": 45, "allrow": 1103, "type": "text", "inside": ""}
{"page": 45, "allrow": 1104, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 45, "allrow": 1105, "type": "text", "inside": "第八节可转换公司债券相关情况"}
{"page": 45, "allrow": 1106, "type": "text", "inside": "□适用√不适用"}
{"page": 45, "allrow": 1107, "type": "text", "inside": "报告期公司不存在可转换公司债券。"}
{"page": 45, "allrow": 1108, "type": "页脚", "inside": "45"}
{"page": 46, "allrow": 1109, "type": "text", "inside": ""}
{"page": 46, "allrow": 1110, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 46, "allrow": 1111, "type": "text", "inside": "第九节董事、监事、高级管理人员和员工情况"}
{"page": 46, "allrow": 1112, "type": "text", "inside": "一、董事、监事和高级管理人员持股变动"}
{"page": 46, "allrow": 1113, "type": "excel", "inside": "['', '', '任职状', '', '', '任期起', '任期终', '期初持', '本期增持股份', '本期减持股份', '其他增', '期末持']"}
{"page": 46, "allrow": 1114, "type": "excel", "inside": "['姓名', '职务', '态', '性别', '年龄', '始日期', '止日期', '股数', '数量', '数量', '减变动', '股数']"}
{"page": 46, "allrow": 1115, "type": "excel", "inside": "['', '', '', '', '', '', '', '（股）', '（股）', '（股）', '（股）', '（股）']"}
{"page": 46, "allrow": 1116, "type": "excel", "inside": "['', '董事', '', '', '', '2017年', '2020年', '', '', '', '', '']"}
{"page": 46, "allrow": 1117, "type": "excel", "inside": "['祝方猛', '长、总', '现任', '男', '48', '11月07', '04月', '0', '0', '0', '0', '0']"}
{"page": 46, "allrow": 1118, "type": "excel", "inside": "['', '经理', '', '', '', '日', '25日', '', '', '', '', '']"}
{"page": 46, "allrow": 1119, "type": "excel", "inside": "['', '', '', '', '', '2017年', '2020年', '', '', '', '', '']"}
{"page": 46, "allrow": 1120, "type": "excel", "inside": "['徐文财', '董事', '现任', '男', '54', '04月', '04月', '0', '0', '0', '0', '0']"}
{"page": 46, "allrow": 1121, "type": "excel", "inside": "['', '', '', '', '', '25日', '25日', '', '', '', '', '']"}
{"page": 46, "allrow": 1122, "type": "excel", "inside": "['', '', '', '', '', '2017年', '2020年', '', '', '', '', '']"}
{"page": 46, "allrow": 1123, "type": "excel", "inside": "['胡天高', '董事', '现任', '男', '55', '04月', '04月', '0', '0', '0', '0', '0']"}
{"page": 46, "allrow": 1124, "type": "excel", "inside": "['', '', '', '', '', '25日', '25日', '', '', '', '', '']"}
{"page": 46, "allrow": 1125, "type": "excel", "inside": "['', '', '', '', '', '2017年', '2020年', '', '', '', '', '']"}
{"page": 46, "allrow": 1126, "type": "excel", "inside": "['吴兴', '董事', '现任', '男', '48', '04月', '04月', '0', '0', '0', '0', '0']"}
{"page": 46, "allrow": 1127, "type": "excel", "inside": "['', '', '', '', '', '25日', '25日', '', '', '', '', '']"}
{"page": 46, "allrow": 1128, "type": "excel", "inside": "['', '独立董', '', '', '', '2017年', '2020年', '', '', '', '', '']"}
{"page": 46, "allrow": 1129, "type": "excel", "inside": "['姚明龙', '事', '现任', '男', '57', '04月', '04月', '0', '0', '0', '0', '0']"}
{"page": 46, "allrow": 1130, "type": "excel", "inside": "['', '', '', '', '', '25日', '25日', '', '', '', '', '']"}
{"page": 46, "allrow": 1131, "type": "excel", "inside": "['', '独立董', '', '', '', '2017年', '2020年', '', '', '', '', '']"}
{"page": 46, "allrow": 1132, "type": "excel", "inside": "['张淼洪', '事', '现任', '男', '70', '04月', '04月', '0', '0', '0', '0', '0']"}
{"page": 46, "allrow": 1133, "type": "excel", "inside": "['', '', '', '', '', '25日', '25日', '', '', '', '', '']"}
{"page": 46, "allrow": 1134, "type": "excel", "inside": "['', '独立董', '', '', '', '2017年', '2020年', '', '', '', '', '']"}
{"page": 46, "allrow": 1135, "type": "excel", "inside": "['张爱珠', '事', '现任', '女', '55', '04月', '04月', '0', '0', '0', '0', '0']"}
{"page": 46, "allrow": 1136, "type": "excel", "inside": "['', '', '', '', '', '25日', '25日', '', '', '', '', '']"}
{"page": 46, "allrow": 1137, "type": "excel", "inside": "['', '监事会', '', '', '', '2017年', '2020年', '', '', '', '', '']"}
{"page": 46, "allrow": 1138, "type": "excel", "inside": "['厉国平', '主席', '现任', '男', '47', '12月', '04月', '0', '0', '0', '0', '0']"}
{"page": 46, "allrow": 1139, "type": "excel", "inside": "['', '', '', '', '', '04日', '25日', '', '', '', '', '']"}
{"page": 46, "allrow": 1140, "type": "excel", "inside": "['', '', '', '', '', '2017年', '2020年', '', '', '', '', '']"}
{"page": 46, "allrow": 1141, "type": "excel", "inside": "['金龙华', '监事', '现任', '男', '58', '12月', '04月', '0', '0', '0', '0', '0']"}
{"page": 46, "allrow": 1142, "type": "excel", "inside": "['', '', '', '', '', '04日', '25日', '', '', '', '', '']"}
{"page": 46, "allrow": 1143, "type": "excel", "inside": "['', '', '', '', '', '2017年', '2020年', '', '', '', '', '']"}
{"page": 46, "allrow": 1144, "type": "excel", "inside": "['聂文彬', '监事', '现任', '男', '54', '12月', '04月', '0', '0', '0', '0', '0']"}
{"page": 46, "allrow": 1145, "type": "excel", "inside": "['', '', '', '', '', '01日', '25日', '', '', '', '', '']"}
{"page": 46, "allrow": 1146, "type": "text", "inside": ""}
{"page": 46, "allrow": 1147, "type": "页脚", "inside": "46"}
{"page": 47, "allrow": 1148, "type": "text", "inside": ""}
{"page": 47, "allrow": 1149, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 47, "allrow": 1150, "type": "excel", "inside": "['', '高级副', '', '', '', '2018年', '2020年', '', '', '', '', '']"}
{"page": 47, "allrow": 1151, "type": "excel", "inside": "['徐新良', '总经理', '现任', '男', '51', '04月11', '04月', '60,328', '0', '0', '0', '60,328']"}
{"page": 47, "allrow": 1152, "type": "excel", "inside": "['', '', '', '', '', '日', '25日', '', '', '', '', '']"}
{"page": 47, "allrow": 1153, "type": "excel", "inside": "['', '副总经', '', '', '', '2017年', '2020年', '', '', '', '', '']"}
{"page": 47, "allrow": 1154, "type": "excel", "inside": "['金旻', '理', '现任', '男', '51', '12月', '04月', '0', '0', '0', '0', '0']"}
{"page": 47, "allrow": 1155, "type": "excel", "inside": "['', '', '', '', '', '04日', '25日', '', '', '', '', '']"}
{"page": 47, "allrow": 1156, "type": "excel", "inside": "['', '副总经理、董', '', '', '', '2018年', '2020年', '', '', '', '', '']"}
{"page": 47, "allrow": 1157, "type": "excel", "inside": "['周玉旺', '事会秘', '现任', '男', '54', '04月11', '04月', '0', '0', '0', '0', '0']"}
{"page": 47, "allrow": 1158, "type": "excel", "inside": "['', '书', '', '', '', '日', '25日', '', '', '', '', '']"}
{"page": 47, "allrow": 1159, "type": "excel", "inside": "['', '财务总', '', '', '', '2019年', '2020年', '', '', '', '', '']"}
{"page": 47, "allrow": 1160, "type": "excel", "inside": "['张进辉', '监', '现任', '男', '44', '03月', '04月', '0', '0', '0', '0', '0']"}
{"page": 47, "allrow": 1161, "type": "excel", "inside": "['', '', '', '', '', '08日', '25日', '', '', '', '', '']"}
{"page": 47, "allrow": 1162, "type": "excel", "inside": "['', '财务总', '', '', '', '2018年', '2019年', '', '', '', '', '']"}
{"page": 47, "allrow": 1163, "type": "excel", "inside": "['韦平平', '监', '离任', '女', '56', '03月', '03月', '0', '0', '0', '0', '0']"}
{"page": 47, "allrow": 1164, "type": "excel", "inside": "['', '', '', '', '', '10日', '07日', '', '', '', '', '']"}
{"page": 47, "allrow": 1165, "type": "excel", "inside": "['合计', '--', '--', '--', '--', '--', '--', '60,328', '0', '0', '0', '60,328']"}
{"page": 47, "allrow": 1166, "type": "text", "inside": "二、公司董事、监事、高级管理人员变动情况"}
{"page": 47, "allrow": 1167, "type": "text", "inside": "√适用□不适用"}
{"page": 47, "allrow": 1168, "type": "excel", "inside": "['姓名', '担任的职务', '类型', '日期', '原因']"}
{"page": 47, "allrow": 1169, "type": "excel", "inside": "['', '', '', '2019年03月', '']"}
{"page": 47, "allrow": 1170, "type": "excel", "inside": "['张进辉', '财务总监', '任免', '08日', '']"}
{"page": 47, "allrow": 1171, "type": "excel", "inside": "['', '', '', '2019年03月', '']"}
{"page": 47, "allrow": 1172, "type": "excel", "inside": "['韦平平', '财务总监', '离任', '07日', '达到法定退休年龄']"}
{"page": 47, "allrow": 1173, "type": "text", "inside": ""}
{"page": 47, "allrow": 1174, "type": "text", "inside": "三、任职情况"}
{"page": 47, "allrow": 1175, "type": "text", "inside": "公司现任董事、监事、高级管理人员专业背景、主要工作经历以及目前在公司的主要职责"}
{"page": 47, "allrow": 1176, "type": "text", "inside": "1、祝方猛先生，1972年出生，硕士研究生学历，高级工程师，中欧EMBA。曾任公司总经理，优胜美特制药有限公司董事长，浙江优胜美特医药有限公司董事长，浙江普洛得邦制药有限公司董事长，浙江普洛家园药业有限公司董事长。现任公司董事长，本公司控股子公司浙江横店普洛进出口有限公司总经理。"}
{"page": 47, "allrow": 1177, "type": "text", "inside": "2、徐文财先生，1966年出生，博士研究生学历，副教授，注册会计师。曾任浙江大学工商管理系副主任，现任横店集团控股有限公司董事、资深副总裁，兼任普洛药业股份有限公司董事、横店集团东磁股份有限公司董事、英洛华科技股份有限公司董事、横店集团得邦照明股份有限公司董事、横店影视股份有限公司董事，南华期货股份有限公司董事。"}
{"page": 47, "allrow": 1178, "type": "text", "inside": "3、胡天高先生，1965年出生，硕士研究生学历。曾任东阳中国银行副行长；现任横店集团控股有限公司董事、资深副总裁；"}
{"page": 47, "allrow": 1179, "type": "text", "inside": "兼任普洛药业股份有限公司董事、横店集团东磁股份有限公司董事、英洛华科技股份有限公司董事、横店集团得邦照明股份有限公司董事、横店影视股份有限公司董事、浙商银行董事。"}
{"page": 47, "allrow": 1180, "type": "text", "inside": "4、吴兴先生，1972年出生，硕士研究生学历，高级工程师，中欧EMBA。曾任浙江横店进出口有限公司副总经理，横店集团"}
{"page": 47, "allrow": 1181, "type": "text", "inside": "得邦化工有限公司董事长，优胜美特制药有限公司董事长。现任公司董事，横店集团控股有限公司总裁助理，浙江横店进出"}
{"page": 47, "allrow": 1182, "type": "页脚", "inside": "47"}
{"page": 48, "allrow": 1183, "type": "text", "inside": ""}
{"page": 48, "allrow": 1184, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 48, "allrow": 1185, "type": "text", "inside": "口有限公司总经理，浙江横店普洛进出口有限公司董事长，浙江微度医疗器械有限公司董事长。"}
{"page": 48, "allrow": 1186, "type": "text", "inside": "5、姚明龙先生，1963年出生，博士，会计学副教授。现任公司独立董事，浙江大学管理学院教授。"}
{"page": 48, "allrow": 1187, "type": "text", "inside": "6、张淼洪先生，1950年出生，大专学历，高级会计师。曾任浙江大学医学院附属邵逸夫医院总会计师，浙江大学医学院附属第二医院总会计师。现任普洛药业、数源科技、华联控股、电魂网络、广宇集团独立董事。"}
{"page": 48, "allrow": 1188, "type": "text", "inside": "7、张爱珠女士，1965年出生，硕士研究生学历，会计学教授。现任公司独立董事，浙江财经大学会计学院教授。"}
{"page": 48, "allrow": 1189, "type": "text", "inside": "8、厉国平先生：1973年出生，本科学历，浙大EMBA硕士，高级经济师。曾任东阳市公安局李宅派出所民警、东阳市公安局治安大队民警、东阳公安局横店派出所副所长、横店集团控股有限公司总裁助理等职。现任横店集团控股有限公司副总裁兼法纪总监、审计总监，兼任普洛药业股份有限公司监事会主席、横店集团东磁股份有限公司监事会主席、英洛华科技股份有限公司监事会主席、横店集团得邦照明股份有限公司监事会主席、横店影视股份有限公司监事会主席，南华期货股份有限公司监事。"}
{"page": 48, "allrow": 1190, "type": "text", "inside": "9、金龙华先生，1962年出生，大学学历，高级会计师。曾任横店集团控股有限公司财务副总监、财务总监。现任横店集团控股有限公司财务资深总监，兼任普洛药业股份有限公司监事、横店影视股份有限公司监事、南华期货股份有限公司监事。"}
{"page": 48, "allrow": 1191, "type": "text", "inside": "10、聂文彬先生，1966年出生，大专学历，政工师。曾任横店集团报社编辑部主任，浙江普洛得邦制药有限公司办公室主任，普洛得邦家园管理中心行政人力资源总监。现任公司职工代表监事、行政管理部总监。"}
{"page": 48, "allrow": 1192, "type": "text", "inside": "11、徐新良先生，1969年出生，大学学历，高级工程师。曾任公司高级副总经理，浙江普洛医药科技有限公司，浙江普洛家园药业有限公司董事长兼总经理，普洛得邦家园管理中心执行副总经理。现任公司总经理，山东汉兴医药科技有限公司董事长，山东普洛得邦医药有限公司董事长。"}
{"page": 48, "allrow": 1193, "type": "text", "inside": "12、金旻先生，1968年出生，大学学历，高级经济师。曾任公司副总经理，横店集团家园化工有限公司董事长，浙江普洛医药科技有限公司副总经理，普洛得邦家园管理中心副总经理。现任公司高级副总经理兼原料药事业部总经理。"}
{"page": 48, "allrow": 1194, "type": "text", "inside": "13、周玉旺先生，1966年出生，工学学士，经济师。曾任英洛华科技股份有限公司副总经理、董事会秘书。现任公司董事会秘书、副总经理。"}
{"page": 48, "allrow": 1195, "type": "text", "inside": "14、张进辉，张进辉先生，1975年10月出生，硕士研究生，高级会计师。曾任横店集团东磁有限公司下属事业部财务科长，横店集团控股有限公司总裁办高级主管，浙江联宜电机有限公司财务部长，浙江英洛华磁业有限公司财务总监。"}
{"page": 48, "allrow": 1196, "type": "text", "inside": "15、汤二庆先生，1976年出生，硕士研究生学历。曾任公司总经理助理、浙江横店普洛进出口业务一部部长。现任公司副总经理，兼任公司制剂事业部总经理、公司战略投资与商务发展部总监。"}
{"page": 48, "allrow": 1197, "type": "text", "inside": "16、何春先生，1974年出生，本科学历，高级工程师。曾任公司总经理助理、公司人力资源部总监、浙江普洛家园药业有限公司总经理。现任公司副总经理，兼任公司CDMO事业部总经理、浙江普洛家园药业有限公司董事长、上海裕缘生物医药研发有限公司董事长。"}
{"page": 48, "allrow": 1198, "type": "text", "inside": "在股东单位任职情况"}
{"page": 48, "allrow": 1199, "type": "text", "inside": "√适用□不适用"}
{"page": 48, "allrow": 1200, "type": "excel", "inside": "['', '', '在股东单', '', '', '']"}
{"page": 48, "allrow": 1201, "type": "excel", "inside": "['任职人员姓名', '股东单位名称', '位担任的职务', '任期起始日期', '任期终止日期', '在股东单位是否领取报酬津贴']"}
{"page": 48, "allrow": 1202, "type": "excel", "inside": "['', '', '董事、资深', '2001年10月', '', '']"}
{"page": 48, "allrow": 1203, "type": "excel", "inside": "['徐文财', '横店集团控股有限公司', '副总裁', '08日', '', '是']"}
{"page": 48, "allrow": 1204, "type": "excel", "inside": "['', '', '董事、资深', '2013年11月', '', '']"}
{"page": 48, "allrow": 1205, "type": "excel", "inside": "['胡天高', '横店集团控股有限公司', '副总裁', '13日', '', '是']"}
{"page": 48, "allrow": 1206, "type": "text", "inside": ""}
{"page": 48, "allrow": 1207, "type": "页脚", "inside": "48"}
{"page": 49, "allrow": 1208, "type": "text", "inside": ""}
{"page": 49, "allrow": 1209, "type": "text", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 49, "allrow": 1210, "type": "excel", "inside": "['', '', '', '', '', '2017年11月06日', '']"}
{"page": 49, "allrow": 1211, "type": "excel", "inside": "['吴兴', '', '横店集团控股有限公司', '总裁助理', '', '', '否']"}
{"page": 49, "allrow": 1212, "type": "excel", "inside": "['', '横店集团控股有限公司', '', '副总裁兼法纪总监、审计总监', '2015年02月03日', '', '']"}
{"page": 49, "allrow": 1213, "type": "excel", "inside": "['厉国平', '', '横店集团控股有限公司', '', '', '', '是']"}
{"page": 49, "allrow": 1214, "type": "excel", "inside": "['', '横店集团控股有限公司', '', '财务资深总监', '', '2016年07月05日', '']"}
{"page": 49, "allrow": 1215, "type": "excel", "inside": "['金龙华', '', '横店集团控股有限公司', '', '', '', '是']"}
{"page": 49, "allrow": 1216, "type": "text", "inside": ""}
{"page": 49, "allrow": 1217, "type": "text", "inside": "在其他单位任职情况"}
{"page": 49, "allrow": 1218, "type": "text", "inside": "√适用□不适用"}
{"page": 49, "allrow": 1219, "type": "excel", "inside": "['', '', '在其他单', '', '', '在其他单位是']"}
{"page": 49, "allrow": 1220, "type": "excel", "inside": "['任职人员姓名', '其他单位名称', '位担任的职务', '任期起始日期', '任期终止日期', '否领取报酬津贴']"}
{"page": 49, "allrow": 1221, "type": "excel", "inside": "['', '', '', '2006年03月', '', '']"}
{"page": 49, "allrow": 1222, "type": "excel", "inside": "['徐文财', '南华期货股份有限公司', '董事', '08日', '', '否']"}
{"page": 49, "allrow": 1223, "type": "excel", "inside": "['', '', '', '2005年02月', '', '']"}
{"page": 49, "allrow": 1224, "type": "excel", "inside": "['徐文财', '横店集团东磁股份有限公司', '董事', '06日', '', '否']"}
{"page": 49, "allrow": 1225, "type": "excel", "inside": "['', '', '', '2003年08月', '', '']"}
{"page": 49, "allrow": 1226, "type": "excel", "inside": "['徐文财', '英洛华科技股份有限公司', '董事', '28日', '', '否']"}
{"page": 49, "allrow": 1227, "type": "excel", "inside": "['', '', '', '2013年01月', '', '']"}
{"page": 49, "allrow": 1228, "type": "excel", "inside": "['徐文财', '横店集团得邦照明股份有限公司', '董事', '28日', '', '否']"}
{"page": 49, "allrow": 1229, "type": "excel", "inside": "['', '', '', '2015年06月', '', '']"}
{"page": 49, "allrow": 1230, "type": "excel", "inside": "['徐文财', '横店影视股份有限公司', '董事', '29日', '', '否']"}
{"page": 49, "allrow": 1231, "type": "excel", "inside": "['', '', '', '2003年03月', '', '']"}
{"page": 49, "allrow": 1232, "type": "excel", "inside": "['胡天高', '横店集团东磁股份有限公司', '董事', '18日', '', '否']"}
{"page": 49, "allrow": 1233, "type": "excel", "inside": "['', '', '', '2011年04月', '', '']"}
{"page": 49, "allrow": 1234, "type": "excel", "inside": "['胡天高', '英洛华科技股份有限公司', '董事', '21日', '', '否']"}
{"page": 49, "allrow": 1235, "type": "excel", "inside": "['', '', '', '2013年01月', '', '']"}
{"page": 49, "allrow": 1236, "type": "excel", "inside": "['胡天高', '横店集团得邦照明股份有限公司', '董事', '28日', '', '否']"}
{"page": 49, "allrow": 1237, "type": "excel", "inside": "['', '', '', '2015年06月', '', '']"}
{"page": 49, "allrow": 1238, "type": "excel", "inside": "['胡天高', '横店影视股份有限公司', '董事', '29日', '', '否']"}
{"page": 49, "allrow": 1239, "type": "excel", "inside": "['', '', '', '2004年05月', '', '']"}
{"page": 49, "allrow": 1240, "type": "excel", "inside": "['胡天高', '浙商银行股份有限公司', '董事', '01日', '', '否']"}
{"page": 49, "allrow": 1241, "type": "excel", "inside": "['', '', '', '2012年10月', '', '']"}
{"page": 49, "allrow": 1242, "type": "excel", "inside": "['厉国平', '南华期货股份有限公司', '监事', '12日', '', '否']"}
{"page": 49, "allrow": 1243, "type": "excel", "inside": "['', '', '监事会主', '2015年06月', '', '']"}
{"page": 49, "allrow": 1244, "type": "excel", "inside": "['厉国平', '横店影视股份有限公司', '席', '29日', '', '否']"}
{"page": 49, "allrow": 1245, "type": "excel", "inside": "['', '', '监事会主', '2015年09月', '', '']"}
{"page": 49, "allrow": 1246, "type": "excel", "inside": "['厉国平', '英洛华科技股份有限公司', '席', '10日', '', '否']"}
{"page": 50, "allrow": 1247, "type": "text", "inside": ""}
{"page": 50, "allrow": 1248, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 50, "allrow": 1249, "type": "excel", "inside": "['', '', '监事会主', '2016年01月', '']"}
{"page": 50, "allrow": 1250, "type": "excel", "inside": "['厉国平', '横店集团得邦照明股份有限公司', '席', '28日', '否']"}
{"page": 50, "allrow": 1251, "type": "excel", "inside": "['', '', '监事会主', '2017年04月', '']"}
{"page": 50, "allrow": 1252, "type": "excel", "inside": "['厉国平', '横店集团东磁股份有限公司', '席', '11日', '否']"}
{"page": 50, "allrow": 1253, "type": "excel", "inside": "['', '', '', '2018年06月', '']"}
{"page": 50, "allrow": 1254, "type": "excel", "inside": "['金龙华', '横店影视股份有限公司', '监事', '29日', '否']"}
{"page": 50, "allrow": 1255, "type": "excel", "inside": "['', '', '', '2019年11月', '']"}
{"page": 50, "allrow": 1256, "type": "excel", "inside": "['金龙华', '南华期货股份有限公司', '监事', '08日', '否']"}
{"page": 50, "allrow": 1257, "type": "text", "inside": ""}
{"page": 50, "allrow": 1258, "type": "text", "inside": "公司现任及报告期内离任董事、监事和高级管理人员近三年证券监管机构处罚的情况"}
{"page": 50, "allrow": 1259, "type": "text", "inside": "□适用√不适用"}
{"page": 50, "allrow": 1260, "type": "text", "inside": "四、董事、监事、高级管理人员报酬情况"}
{"page": 50, "allrow": 1261, "type": "text", "inside": "董事、监事、高级管理人员报酬的决策程序、确定依据、实际支付情况"}
{"page": 50, "allrow": 1262, "type": "text", "inside": "在公司领取薪酬的董事、监事是其在公司担任其他行政职务领取的薪酬。公司高级管理人员采用年度考核方式。根据岗位性质的不同每季度或月度进行考核目标的实施跟踪及调整。年度考核主要采用360度考评、述职等考核方式，并进行相对应的绩效激励。独立董事的津贴是依据公司股东大会通过的独立董事津贴标准为原则确定的，每年五万元。"}
{"page": 50, "allrow": 1263, "type": "text", "inside": "公司报告期内董事、监事和高级管理人员报酬情况"}
{"page": 50, "allrow": 1264, "type": "text", "inside": "单位：万元"}
{"page": 50, "allrow": 1265, "type": "excel", "inside": "['', '', '', '', '', '从公司获得的', '是否在公司关']"}
{"page": 50, "allrow": 1266, "type": "excel", "inside": "['姓名', '职务', '性别', '年龄', '任职状态', '税前报酬总额', '联方获取报酬']"}
{"page": 50, "allrow": 1267, "type": "excel", "inside": "['祝方猛', '董事长', '男', '48', '现任', '130', '否']"}
{"page": 50, "allrow": 1268, "type": "excel", "inside": "['徐文财', '董事', '男', '54', '现任', '0', '是']"}
{"page": 50, "allrow": 1269, "type": "excel", "inside": "['胡天高', '董事', '男', '55', '现任', '0', '是']"}
{"page": 50, "allrow": 1270, "type": "excel", "inside": "['吴兴', '董事', '男', '48', '现任', '130', '否']"}
{"page": 50, "allrow": 1271, "type": "excel", "inside": "['张淼洪', '独立董事', '男', '70', '现任', '5', '否']"}
{"page": 50, "allrow": 1272, "type": "excel", "inside": "['姚明龙', '独立董事', '男', '57', '现任', '5', '否']"}
{"page": 50, "allrow": 1273, "type": "excel", "inside": "['张爱珠', '独立董事', '女', '55', '现任', '5', '否']"}
{"page": 50, "allrow": 1274, "type": "excel", "inside": "['厉国平', '监事会主席', '男', '47', '现任', '0', '是']"}
{"page": 50, "allrow": 1275, "type": "excel", "inside": "['金龙华', '监事', '男', '58', '现任', '0', '是']"}
{"page": 50, "allrow": 1276, "type": "excel", "inside": "['聂文彬', '职工代表监事', '男', '54', '现任', '35', '否']"}
{"page": 50, "allrow": 1277, "type": "excel", "inside": "['徐新良', '总经理', '男', '51', '现任', '85', '否']"}
{"page": 50, "allrow": 1278, "type": "excel", "inside": "['', '副总经理、董', '', '', '', '', '']"}
{"page": 50, "allrow": 1279, "type": "excel", "inside": "['周玉旺', '事会秘书', '男', '54', '现任', '45', '否']"}
{"page": 50, "allrow": 1280, "type": "excel", "inside": "['金旻', '高级副总经理', '男', '51', '现任', '65', '否']"}
{"page": 50, "allrow": 1281, "type": "excel", "inside": "['张进辉', '财务总监', '男', '44', '现任', '38', '否']"}
{"page": 50, "allrow": 1282, "type": "text", "inside": ""}
{"page": 50, "allrow": 1283, "type": "页脚", "inside": "50"}
{"page": 51, "allrow": 1284, "type": "text", "inside": ""}
{"page": 51, "allrow": 1285, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 51, "allrow": 1286, "type": "excel", "inside": "['韦平平', '财务总监', '女', '56', '离任', '50', '否']"}
{"page": 51, "allrow": 1287, "type": "excel", "inside": "['合计', '--', '--', '--', '--', '593', '--']"}
{"page": 51, "allrow": 1288, "type": "text", "inside": ""}
{"page": 51, "allrow": 1289, "type": "text", "inside": "公司董事、高级管理人员报告期内被授予的股权激励情况"}
{"page": 51, "allrow": 1290, "type": "text", "inside": "□适用√不适用"}
{"page": 51, "allrow": 1291, "type": "text", "inside": "五、公司员工情况"}
{"page": 51, "allrow": 1292, "type": "text", "inside": "1、员工数量、专业构成及教育程度"}
{"page": 51, "allrow": 1293, "type": "excel", "inside": "['母公司在职员工的数量（人）', '', '547']"}
{"page": 51, "allrow": 1294, "type": "excel", "inside": "['主要子公司在职员工的数量（人）', '', '5,172']"}
{"page": 51, "allrow": 1295, "type": "excel", "inside": "['在职员工的数量合计（人）', '', '5,719']"}
{"page": 51, "allrow": 1296, "type": "excel", "inside": "['当期领取薪酬员工总人数（人）', '', '5,719']"}
{"page": 51, "allrow": 1297, "type": "excel", "inside": "['母公司及主要子公司需承担费用的离退休职工人数（人）', '', '0']"}
{"page": 51, "allrow": 1298, "type": "excel", "inside": "['专业构成', '', '']"}
{"page": 51, "allrow": 1299, "type": "excel", "inside": "['专业构成类别', '', '专业构成人数（人）']"}
{"page": 51, "allrow": 1300, "type": "excel", "inside": "['生产人员', '', '3,985']"}
{"page": 51, "allrow": 1301, "type": "excel", "inside": "['销售人员', '', '257']"}
{"page": 51, "allrow": 1302, "type": "excel", "inside": "['技术人员', '', '907']"}
{"page": 51, "allrow": 1303, "type": "excel", "inside": "['财务人员', '', '77']"}
{"page": 51, "allrow": 1304, "type": "excel", "inside": "['行政人员', '', '493']"}
{"page": 51, "allrow": 1305, "type": "excel", "inside": "['合计', '5,719', '']"}
{"page": 51, "allrow": 1306, "type": "excel", "inside": "['教育程度', '', '']"}
{"page": 51, "allrow": 1307, "type": "excel", "inside": "['教育程度类别', '', '数量（人）']"}
{"page": 51, "allrow": 1308, "type": "excel", "inside": "['大学本科及以上', '', '1,191']"}
{"page": 51, "allrow": 1309, "type": "excel", "inside": "['大学专科', '', '959']"}
{"page": 51, "allrow": 1310, "type": "excel", "inside": "['中专及以下', '', '3,569']"}
{"page": 51, "allrow": 1311, "type": "excel", "inside": "['合计', '5,719', '']"}
{"page": 51, "allrow": 1312, "type": "text", "inside": "2、薪酬政策"}
{"page": 51, "allrow": 1313, "type": "text", "inside": "公司薪酬采用市场化原则，实行浮动薪酬制。现共设立五条职业发展通道，分别是管理序列、研究序列、质量分析序列、管理事务序列以及技能序列，并建立对应的晋升标准，实施相应的考核及激励机制。"}
{"page": 51, "allrow": 1314, "type": "页脚", "inside": "51"}
{"page": 52, "allrow": 1315, "type": "text", "inside": ""}
{"page": 52, "allrow": 1316, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 52, "allrow": 1317, "type": "text", "inside": "3、培训计划"}
{"page": 52, "allrow": 1318, "type": "text", "inside": "公司培训采用分级培训管理模式。股份公司负责管理类培训、通用技能类培训以及院校生入职培训，同时整合公司各事业部培训资源开展各专业方向的跨部门培训。各事业部及子公司负责员工岗位所需技能类培训。公司每年10月进行培训需求调研，12月底形成年度培训计划。年度培训计划主要根据公司战略发展的需要及岗位相匹配的能力需求形成培训需求，12"}
{"page": 52, "allrow": 1319, "type": "text", "inside": "月底根据培训需求制定分层级分类别的培训计划。2020年将继续加强培训课程体系、培训师队伍建设。"}
{"page": 52, "allrow": 1320, "type": "text", "inside": "4、劳务外包情况"}
{"page": 52, "allrow": 1321, "type": "text", "inside": "□适用√不适用"}
{"page": 52, "allrow": 1322, "type": "页脚", "inside": "52"}
{"page": 53, "allrow": 1323, "type": "text", "inside": ""}
{"page": 53, "allrow": 1324, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 53, "allrow": 1325, "type": "text", "inside": "第十节公司治理"}
{"page": 53, "allrow": 1326, "type": "text", "inside": "一、公司治理的基本状况"}
{"page": 53, "allrow": 1327, "type": "text", "inside": "（一）公司董事会授权审计部负责内部控制实施有效性的评价与组织工作。"}
{"page": 53, "allrow": 1328, "type": "text", "inside": "（二）公司目前实行“职能＋事业部”的管理模式。董事会层面负责制定产业策略，事业部层面负责决定产品策略；扁平化的机构、职能型的监管和服务、专业化的事业部，有利于进一步推动公司产业策略和产品策略的深入发展和各项工作、业务的持续提高。各事业部按照公司制定的管理制度，合理设置部门和岗位，科学划分职责和权限，建立了完善的决策系统、执行系统和监督反馈系统。在管理层的领导下，各职能部门在各自的职能范围内认真履行部门职责。"}
{"page": 53, "allrow": 1329, "type": "text", "inside": "（三）各子公司在执行《企业内部控制实施细则》的基础上，结合各职能部门自身的业务特点，切实将内部控制实施细则落到实处。"}
{"page": 53, "allrow": 1330, "type": "text", "inside": "（四）公司审计部针对内控的重点或高风险领域，在年度内对所属各子公司进行了一次审计，审计的内容包括企业内控体系建设的开展与落实情况、人力资源管理、资金营运管理、项目投资管理等。根据审计发现的缺陷，适时地提出来预防性的纠正措施，出具了内部控制审计报告，提出了改进建议，下发各公司进行整改，并持续跟踪落实。"}
{"page": 53, "allrow": 1331, "type": "text", "inside": "（五）公司聘请和信会计师事务所对公司内部控制有效性进行独立审计。"}
{"page": 53, "allrow": 1332, "type": "text", "inside": "公司治理的实际状况与中国证监会发布的有关上市公司治理的规范性文件是否存在重大差异"}
{"page": 53, "allrow": 1333, "type": "text", "inside": "□是√否"}
{"page": 53, "allrow": 1334, "type": "text", "inside": "公司治理的实际状况与中国证监会发布的有关上市公司治理的规范性文件不存在重大差异。"}
{"page": 53, "allrow": 1335, "type": "text", "inside": "二、公司相对于控股股东在业务、人员、资产、机构、财务等方面的独立情况"}
{"page": 53, "allrow": 1336, "type": "text", "inside": "¹«Ë¾Ò»Ö±ÒÔÀ´¶¼×ÅÖØÇ¿µ÷Îå·Ö¿ª£¬¼´±£³Ö¹«Ë¾ÒµÎñ¡¢ÈËÔ±¡¢×Ê²ú¡¢»ú¹¹ºÍ²ÆÎñÓë¿Ø¹É¹É¶«ºÍÊµ¼Ê¿ØÖÆÈË¼°Æä¹ØÁªÈËÖ®¼äµÄ¶ÀÁ¢£¬¸÷×Ô¶ÀÁ¢ºËËã¡¢¶ÀÁ¢³Ðµ£ÔðÈÎºÍ·çÏÕ¡£Îª½øÒ»²½Ìá¸ß¶ÀÁ¢ÐÔ£¬²ÉÈ¡´ëÊ©¾¡Á¿¼õÉÙºÍ±ÜÃâÓë¿Ø¹É¹É¶«¡¢Êµ¼Ê¿ØÖÆÈË¼°Æä¹ØÁªÈËÖ®¼äµÄÈÕ³£¹ØÁª½»Ò×¡£¹«Ë¾×Ü¾Àí¼°ÆäËû¸ß¼¶¹ÜÀíÈËÔ±Î´ÔÚ¿Ø¹Éµ¥Î»ÁìÈ¡Ð½³ê£¬²»´æÔÚ¿Ø¹É¹É¶«´ú·¢Ð½³êµÄÇé¿ö¡£¹«Ë¾×Ê²ú¶ÀÁ¢£¬È¨ÊôÇåÎú¡£¹«Ë¾¸÷×éÖ¯»ú¹¹¶ÀÁ¢ÔË×÷£¬Óë¿Ø¹É¹É¶«¼°ÆäÖ°ÄÜ²¿ÃÅÖ®¼äÃ»ÓÐ´æÔÚÉÏÏÂ¼¶¹ØÏµ¡£"}
{"page": 53, "allrow": 1337, "type": "text", "inside": "三、同业竞争情况"}
{"page": 53, "allrow": 1338, "type": "text", "inside": "□适用√不适用"}
{"page": 53, "allrow": 1339, "type": "text", "inside": "四、报告期内召开的年度股东大会和临时股东大会的有关情况"}
{"page": 53, "allrow": 1340, "type": "text", "inside": "1、本报告期股东大会情况"}
{"page": 53, "allrow": 1341, "type": "excel", "inside": "['会议届次', '会议类型', '投资者参与比例', '召开日期', '披露日期', '披露索引']"}
{"page": 53, "allrow": 1342, "type": "text", "inside": ""}
{"page": 53, "allrow": 1343, "type": "页脚", "inside": "53"}
{"page": 54, "allrow": 1344, "type": "text", "inside": ""}
{"page": 54, "allrow": 1345, "type": "text", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 54, "allrow": 1346, "type": "excel", "inside": "['', '年度股东大会', '', '', '', '', 'http://www.cninfo.com.cn/new/disclosure/detail?plate=szse&orgId=gssz00']"}
{"page": 54, "allrow": 1347, "type": "excel", "inside": "['2018年年度股东大会', '', '年度股东大会', '53.32%', '2019年04月03日', '2019年04月04日', '00739&stockCode=000739&announ']"}
{"page": 54, "allrow": 1348, "type": "excel", "inside": "['', '', '', '', '', '', 'cementId=1205992420&announcementTime=2019-04-04']"}
{"page": 54, "allrow": 1349, "type": "excel", "inside": "['', '临时股东大会', '', '', '', '', 'http://www.cninfo.com.cn/new/disclosure/detail?plate=szse&orgId=gssz00']"}
{"page": 54, "allrow": 1350, "type": "excel", "inside": "['2019年第一次临时股东大会', '', '临时股东大会', '50.49%', '2019年05月28日', '2019年05月29日', '00739&stockCode=000739&announ']"}
{"page": 54, "allrow": 1351, "type": "excel", "inside": "['', '', '', '', '', '', 'cementId=1206310741&announcementTime=2019-05-29']"}
{"page": 54, "allrow": 1352, "type": "text", "inside": ""}
{"page": 54, "allrow": 1353, "type": "text", "inside": "2、表决权恢复的优先股股东请求召开临时股东大会"}
{"page": 54, "allrow": 1354, "type": "text", "inside": "□适用√不适用"}
{"page": 54, "allrow": 1355, "type": "text", "inside": "五、报告期内独立董事履行职责的情况"}
{"page": 54, "allrow": 1356, "type": "text", "inside": "1、独立董事出席董事会及股东大会的情况"}
{"page": 54, "allrow": 1357, "type": "excel", "inside": "['', '独立董事出席董事会及股东大会的情况', '', '', '', '', '', '', '']"}
{"page": 54, "allrow": 1358, "type": "excel", "inside": "['独立董事姓名', '', '本报告期应参加董事会次数', '现场出席董事会次数', '以通讯方式参加董事会次数', '委托出席董事会次数', '缺席董事会次数', '是否连续两次未亲自参加董事会会议', '出席股东大会次数']"}
{"page": 54, "allrow": 1359, "type": "excel", "inside": "['', '张淼洪', '6', '2', '4', '0', '0', '否', '2']"}
{"page": 54, "allrow": 1360, "type": "excel", "inside": "['', '姚明龙', '6', '2', '4', '0', '0', '否', '2']"}
{"page": 54, "allrow": 1361, "type": "excel", "inside": "['', '张爱珠', '6', '2', '4', '0', '0', '否', '2']"}
{"page": 55, "allrow": 1362, "type": "text", "inside": ""}
{"page": 55, "allrow": 1363, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 55, "allrow": 1364, "type": "text", "inside": "□是√否"}
{"page": 55, "allrow": 1365, "type": "text", "inside": "报告期内独立董事对公司有关事项未提出异议。"}
{"page": 55, "allrow": 1366, "type": "text", "inside": "3、独立董事履行职责的其他说明"}
{"page": 55, "allrow": 1367, "type": "text", "inside": "独立董事对公司有关建议是否被采纳"}
{"page": 55, "allrow": 1368, "type": "text", "inside": "□是√否"}
{"page": 55, "allrow": 1369, "type": "text", "inside": "独立董事对公司有关建议被采纳或未被采纳的说明"}
{"page": 55, "allrow": 1370, "type": "text", "inside": "报告期内独立董事对公司有关事项未提出异议。"}
{"page": 55, "allrow": 1371, "type": "text", "inside": "六、董事会下设专门委员会在报告期内履行职责情况"}
{"page": 55, "allrow": 1372, "type": "text", "inside": "本公司董事会下设战略委员会、审计委员会、提名委员会、薪酬与考核委员会。公司独立董事根据公司议事细则，在各委员会中认真履行职责，充分发挥了独立董事作用，具体工作内容如下："}
{"page": 55, "allrow": 1373, "type": "text", "inside": "1、战略委员会："}
{"page": 55, "allrow": 1374, "type": "text", "inside": "公司董事会战略委员会由3名独立董事和4名董事组成，其中主任委员由董事长担任。"}
{"page": 55, "allrow": 1375, "type": "text", "inside": "报告期内，战略委员会认真审查了公司第一期员工持股计划相关资料，为了提高职工的凝聚力和公司竞争力，促进公司长期、稳定发展，委员会一致同意公司的股权激励计划。"}
{"page": 55, "allrow": 1376, "type": "text", "inside": "2、审计委员会："}
{"page": 55, "allrow": 1377, "type": "text", "inside": "公司董事会审计委员会由3名独立董事和2名董事组成，其中主任委员由独立董事担任。"}
{"page": 55, "allrow": 1378, "type": "text", "inside": "（1）在会计师事务所正式进场审计前，审计委员会成员认真审阅了公司财务负责人初始提供给事务所的未经审计的年度财务报表。"}
{"page": 55, "allrow": 1379, "type": "text", "inside": "（2）公司年审注册会计师出具初步审计意见后，董事会审计委员会再一次审阅了公司2019年度财务会计报表；董事会审计委员会与公司年审注册会计师就审计过程中发现的问题进行了沟通和交流；"}
{"page": 55, "allrow": 1380, "type": "text", "inside": "（3）公司年审注册会计师出具2019年度审计报告后，董事会审计委员会召开会议，一致同意将公司编制的经年审注册会计师审计的2019年财务报告提交董事会审议。"}
{"page": 55, "allrow": 1381, "type": "text", "inside": "3、提名委员会："}
{"page": 55, "allrow": 1382, "type": "text", "inside": "公司董事会提名委员会由3名独立董事和2名董事组成，其中主任委员由独立董事担任。"}
{"page": 55, "allrow": 1383, "type": "text", "inside": "报告期内，提名委员会认真履职，对报告期内公司财务总监的选举和聘任进行了认真的资格审查，进一步完善了公司治理结构。"}
{"page": 55, "allrow": 1384, "type": "text", "inside": "4、薪酬与考核委员会:"}
{"page": 55, "allrow": 1385, "type": "text", "inside": "公司董事会薪酬与考核委员会由3名独立董事和2名董事组成，其中主任委员由独立董事担任。"}
{"page": 55, "allrow": 1386, "type": "text", "inside": "报告期内，薪酬与考核委员会对公司2019年度董事、监事及高级管理人员薪酬情况进行了审核，认为公司的董事、监事及高级管理人员的薪酬发放符合公司标准和个人履职成效，独立董事津贴发放符合独立董事津贴标准。"}
{"page": 55, "allrow": 1387, "type": "text", "inside": "七、监事会工作情况"}
{"page": 55, "allrow": 1388, "type": "text", "inside": "监事会在报告期内的监督活动中发现公司是否存在风险"}
{"page": 55, "allrow": 1389, "type": "text", "inside": "□是√否"}
{"page": 55, "allrow": 1390, "type": "text", "inside": "监事会对报告期内的监督事项无异议。"}
{"page": 55, "allrow": 1391, "type": "页脚", "inside": "55"}
{"page": 56, "allrow": 1392, "type": "text", "inside": ""}
{"page": 56, "allrow": 1393, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 56, "allrow": 1394, "type": "text", "inside": "八、高级管理人员的考评及激励情况"}
{"page": 56, "allrow": 1395, "type": "text", "inside": "公司高级管理人员采用年度考核方式。根据岗位性质的不同每季度或月度进行考核目标的实施跟踪及调整。公司年度组织360考评及述职考评等考核方式，并进行相对应的绩效激励。"}
{"page": 56, "allrow": 1396, "type": "text", "inside": "九、内部控制情况"}
{"page": 56, "allrow": 1397, "type": "text", "inside": "1、报告期内发现的内部控制重大缺陷的具体情况"}
{"page": 56, "allrow": 1398, "type": "text", "inside": "□是√否"}
{"page": 56, "allrow": 1399, "type": "text", "inside": "2、内控自我评价报告"}
{"page": 56, "allrow": 1400, "type": "excel", "inside": "['内部控制评价报告全文披露日期', '2020年03月12日', '', '', '']"}
{"page": 56, "allrow": 1401, "type": "excel", "inside": "['内部控制评价报告全文披露索引', 'www.cninfo.com', '', '', '']"}
{"page": 56, "allrow": 1402, "type": "excel", "inside": "['纳入评价范围单位资产总额占公司合并财务报表资产总额的比例', '98.38%', '', '', '']"}
{"page": 56, "allrow": 1403, "type": "excel", "inside": "['纳入评价范围单位营业收入占公司合并财务报表营业收入的比例', '100.00%', '', '', '']"}
{"page": 56, "allrow": 1404, "type": "excel", "inside": "['缺陷认定标准', '', '', '', '']"}
{"page": 56, "allrow": 1405, "type": "excel", "inside": "['类别', '财务报告', '', '非财务报告', '']"}
{"page": 56, "allrow": 1406, "type": "excel", "inside": "['', '注册会计师发现当期财务报表存在重大', '', '（1）未根据公司或《基本规范》要求，制定或设计相应的内部控制实施细则；（2）董事、监事和高管人员有舞弊迹象的（无论舞弊是否重大）；（3）公司更正由于舞弊导致的重大', '']"}
{"page": 56, "allrow": 1407, "type": "excel", "inside": "['定性标准', '错报，而内部控制在运行过程中未能发', '', '错报；（4）注册会计师发现当期财务', '']"}
{"page": 56, "allrow": 1408, "type": "excel", "inside": "['', '现该错报。', '', '报表存在重大错报，而内部控制在运行过程中未能发现该错报；（5）内部审计机构对内部控制和监督无效；（6）公司内部控制风险表列示的其他重大缺陷。', '']"}
{"page": 56, "allrow": 1409, "type": "excel", "inside": "['', '（1）一般缺陷：错报指标＜1‰；（2）重要缺陷：错报指标≥1‰，＜5‰；（3', '）', '（1）效益预算偏离幅度30%以上的（2）受到监管或行政机构处罚达资', '；']"}
{"page": 56, "allrow": 1410, "type": "excel", "inside": "['定量标准', '重大缺陷：错报指标≥5‰；（4）错报的', '', '产总额0.1%以上的；（3）给公司造', '']"}
{"page": 56, "allrow": 1411, "type": "excel", "inside": "['', '对应关系为各公司总资产。', '', '成直接经济损失达资产总额0.2%以上的。', '']"}
{"page": 56, "allrow": 1412, "type": "excel", "inside": "['财务报告重大缺陷数量（个）', '0', '', '', '']"}
{"page": 56, "allrow": 1413, "type": "excel", "inside": "['非财务报告重大缺陷数量（个）', '0', '', '', '']"}
{"page": 56, "allrow": 1414, "type": "text", "inside": ""}
{"page": 56, "allrow": 1415, "type": "页脚", "inside": "56"}
{"page": 57, "allrow": 1416, "type": "text", "inside": ""}
{"page": 57, "allrow": 1417, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 57, "allrow": 1418, "type": "excel", "inside": "['财务报告重要缺陷数量（个）', '0']"}
{"page": 57, "allrow": 1419, "type": "excel", "inside": "['非财务报告重要缺陷数量（个）', '0']"}
{"page": 57, "allrow": 1420, "type": "text", "inside": "十、内部控制审计报告"}
{"page": 57, "allrow": 1421, "type": "text", "inside": "√适用□不适用"}
{"page": 57, "allrow": 1422, "type": "excel", "inside": "['内部控制审计报告中的审议意见段', '']"}
{"page": 57, "allrow": 1423, "type": "excel", "inside": "['普洛药业于2019年12月31日按照《企业内部控制基本规范》和相关规定在所有重大方面保持了有效的财务报告内部控制。', '']"}
{"page": 57, "allrow": 1424, "type": "excel", "inside": "['内控审计报告披露情况', '披露']"}
{"page": 57, "allrow": 1425, "type": "excel", "inside": "['内部控制审计报告全文披露日期', '2020年03月21日']"}
{"page": 57, "allrow": 1426, "type": "excel", "inside": "['内部控制审计报告全文披露索引', 'www.cninfo.com']"}
{"page": 57, "allrow": 1427, "type": "excel", "inside": "['内控审计报告意见类型', '标准无保留意见']"}
{"page": 57, "allrow": 1428, "type": "excel", "inside": "['非财务报告是否存在重大缺陷', '否']"}
{"page": 57, "allrow": 1429, "type": "text", "inside": ""}
{"page": 57, "allrow": 1430, "type": "text", "inside": "会计师事务所是否出具非标准意见的内部控制审计报告"}
{"page": 57, "allrow": 1431, "type": "text", "inside": "□是√否"}
{"page": 57, "allrow": 1432, "type": "text", "inside": "会计师事务所出具的内部控制审计报告与董事会的自我评价报告意见是否一致"}
{"page": 57, "allrow": 1433, "type": "text", "inside": "√是□否"}
{"page": 57, "allrow": 1434, "type": "页脚", "inside": "57"}
{"page": 58, "allrow": 1435, "type": "text", "inside": ""}
{"page": 58, "allrow": 1436, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 58, "allrow": 1437, "type": "text", "inside": "第十一节公司债券相关情况"}
{"page": 58, "allrow": 1438, "type": "text", "inside": "公司是否存在公开发行并在证券交易所上市，且在年度报告批准报出日未到期或到期未能全额兑付的公司债券"}
{"page": 58, "allrow": 1439, "type": "text", "inside": "否"}
{"page": 58, "allrow": 1440, "type": "页脚", "inside": "58"}
{"page": 59, "allrow": 1441, "type": "text", "inside": ""}
{"page": 59, "allrow": 1442, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 59, "allrow": 1443, "type": "text", "inside": "第十二节财务报告"}
{"page": 59, "allrow": 1444, "type": "text", "inside": "一、审计报告"}
{"page": 59, "allrow": 1445, "type": "excel", "inside": "['审计意见类型', '标准的无保留意见']"}
{"page": 59, "allrow": 1446, "type": "excel", "inside": "['审计报告签署日期', '2020年03月11日']"}
{"page": 59, "allrow": 1447, "type": "excel", "inside": "['审计机构名称', '和信会计师事务所（特殊普通合伙）']"}
{"page": 59, "allrow": 1448, "type": "excel", "inside": "['审计报告文号', '和信审字(2020)第000042号']"}
{"page": 59, "allrow": 1449, "type": "excel", "inside": "['注册会计师姓名', '左伟、陈征']"}
{"page": 59, "allrow": 1450, "type": "text", "inside": ""}
{"page": 59, "allrow": 1451, "type": "text", "inside": "审计报告正文"}
{"page": 59, "allrow": 1452, "type": "text", "inside": "审计报告"}
{"page": 59, "allrow": 1453, "type": "text", "inside": "和信审字(2020)第000042号普洛药业股份有限公司全体股东："}
{"page": 59, "allrow": 1454, "type": "text", "inside": "一、审计意见"}
{"page": 59, "allrow": 1455, "type": "text", "inside": "我们审计了普洛药业股份有限公司（以下简称“普洛药业”）财务报表，包括2019年12月31日的合并及公司资产负债表，2019年度的合并及公司利润表、合并及公司现金流量表、合并及公司股东权益变动表以及相关财务报表附注。"}
{"page": 59, "allrow": 1456, "type": "text", "inside": "我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制，公允反映了普洛药业2019年12月31日的合并及公司财务状况以及2019年度的合并及公司经营成果和现金流量。"}
{"page": 59, "allrow": 1457, "type": "text", "inside": "二、形成审计意见的基础"}
{"page": 59, "allrow": 1458, "type": "text", "inside": "我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的“注册会计师对财务报表审计的责任”部分进一步阐述了我们在这些准则下的责任。按照中国注册会计师职业道德守则，我们独立于普洛药业，并履行了职业道德方面的其他责任。我们相信，我们获取的审计证据是充分、适当的，为发表审计意见提供了基础。"}
{"page": 59, "allrow": 1459, "type": "text", "inside": "三、关键审计事项"}
{"page": 59, "allrow": 1460, "type": "text", "inside": "关键审计事项是我们根据职业判断，认为对本期财务报表审计最为重要的事项。这些事项的应对以对财务报表整体进行审计并形成审计意见为背景，我们不对这些事项单独发表意见。"}
{"page": 59, "allrow": 1461, "type": "text", "inside": "（一）收入确认"}
{"page": 59, "allrow": 1462, "type": "text", "inside": "1、事项描述"}
{"page": 59, "allrow": 1463, "type": "text", "inside": "普洛药业主要生产并销售原料药及中间体、制剂等产品。2019年度，公司主营业务收入为7,198,139,226.36元，其中国"}
{"page": 59, "allrow": 1464, "type": "text", "inside": "外销售占主营业务收入的42.08%。"}
{"page": 59, "allrow": 1465, "type": "text", "inside": "如附注三、24所述，普洛药业将商品所有权上的主要风险和报酬转移给买方，公司不再对该商品实施继续管理权和实际"}
{"page": 59, "allrow": 1466, "type": "text", "inside": "控制权，与交易相关的经济利益能够流入公司，并且与销售该商品相关的成本能够可靠地计量时，确认销售收入的实现。"}
{"page": 59, "allrow": 1467, "type": "页脚", "inside": "59"}
{"page": 60, "allrow": 1468, "type": "text", "inside": ""}
{"page": 60, "allrow": 1469, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 60, "allrow": 1470, "type": "text", "inside": "由于收入是公司的关键业绩指标之一，从而存在普洛药业管理层通过不恰当的收入确认以达到特定目标或预期的固有风险，因此我们将收入确认识别为关键审计事项。"}
{"page": 60, "allrow": 1471, "type": "text", "inside": "2、审计应对"}
{"page": 60, "allrow": 1472, "type": "text", "inside": "我们针对该事项的审计程序主要包括："}
{"page": 60, "allrow": 1473, "type": "text", "inside": "（1）了解与收入确认相关的关键内部控制，评价其设计和执行是否有效，并测试相关内部控制的运行有效性；"}
{"page": 60, "allrow": 1474, "type": "text", "inside": "（2）访谈管理层及审阅销售合同，了解普洛药业的收入确认政策，检查重要的销售合同，识别与商品所有权上的主要风险和报酬转移相关的条款，评价收入确认政策是否符合企业会计准则的规定；"}
{"page": 60, "allrow": 1475, "type": "text", "inside": "（3）获取普洛药业本年度销售清单，对营业收入实施分析程序，判断本期收入、毛利率变动的合理性；"}
{"page": 60, "allrow": 1476, "type": "text", "inside": "（4）对本年记录的收入进行细节测试，核对销售合同、出库单、验收单、销售发票、报关单等支持性文件；"}
{"page": 60, "allrow": 1477, "type": "text", "inside": "（5）对主要客户及交易实施函证程序，并对重要客户背景进行了解，关注是否存在关联交易；"}
{"page": 60, "allrow": 1478, "type": "text", "inside": "（6）对资产负债表日前后的收入记录进行截止测试，评价收入是否确认在恰当的会计期间；"}
{"page": 60, "allrow": 1479, "type": "text", "inside": "（7）针对外销收入，取得海关2019年度电子口岸信息与账面外销收入记录核对，并对主要客户回款进行测试。"}
{"page": 60, "allrow": 1480, "type": "text", "inside": "（二）应收账款坏账准备"}
{"page": 60, "allrow": 1481, "type": "text", "inside": "1、事项描述"}
{"page": 60, "allrow": 1482, "type": "text", "inside": "截至2019年12月31日，公司应收账款账面余额1,079,717,354.47元，坏账准备金额54,578,758.28元，账面价值为1,025,138,596.19元，账面价值较高。"}
{"page": 60, "allrow": 1483, "type": "text", "inside": "如附注三、10所述，普洛药业管理层（以下简称“管理层”）考虑有关过去事项、当前状况以及对未来经济状况的预测等信息，根据各应收账款的信用风险特征，以单项或组合为基础，按照整个存续期的预期信用损失确定应计提的坏账准备。"}
{"page": 60, "allrow": 1484, "type": "text", "inside": "对于以单项为基础计量预期信用损失的应收账款，如果有客观证据表明某项应收账款已经发生信用损失，则管理层根据预期信用损失对该应收账款单项计提坏准备；对于以组合为基础计量预期信用损失的应收账款，管理层以账龄为依据划分组合，参照历史损失经验并根据对未来的预测，编制应收账款账龄与预期信用损失率对照表，据此确定计算预期信用损失，计提坏账准备。"}
{"page": 60, "allrow": 1485, "type": "text", "inside": "由于应收账款账面价值较高，应收账款坏账准备的计提涉及重大会计估计和判断，且应收账款的可回收性对财务报表具有重大影响，因此我们将应收账款坏账准备确定为关键审计事项。"}
{"page": 60, "allrow": 1486, "type": "text", "inside": "2、审计应对"}
{"page": 60, "allrow": 1487, "type": "text", "inside": "我们针对该事项的审计程序主要包括："}
{"page": 60, "allrow": 1488, "type": "text", "inside": "（1）了解、评价和测试普洛药业与应收账款管理相关的内部控制关键控制点设计和运行的有效性；"}
{"page": 60, "allrow": 1489, "type": "text", "inside": "（2）分析公司应收账款坏账准备的合理性，包括确定应收账款组合的依据、单项计提坏账准备的判断是否符合金融工具准则的相关规定；"}
{"page": 60, "allrow": 1490, "type": "text", "inside": "（3）通过比较前期坏账准备计提数与实际发生数，并结合对期后回款的检查，评价应收账款坏账准备计提的充分性及适当性；"}
{"page": 60, "allrow": 1491, "type": "text", "inside": "（4）对于按账龄组合计提坏账准备的应收账款，复核管理层编制的应收账款账龄分析表的准确性；"}
{"page": 60, "allrow": 1492, "type": "text", "inside": "（5）检查与应收账款减值相关的信息是否已在财务报表中作出恰当列报和披露。"}
{"page": 60, "allrow": 1493, "type": "text", "inside": "四、其他信息"}
{"page": 60, "allrow": 1494, "type": "text", "inside": "普洛药业管理层对其他信息负责。其他信息包括2019年年度报告中涵盖的信息，但不包括财务报表和我们的审计报告。"}
{"page": 60, "allrow": 1495, "type": "text", "inside": "我们对财务报表发表的审计意见不涵盖其他信息，我们也不对其他信息发表任何形式的鉴证结论。"}
{"page": 60, "allrow": 1496, "type": "text", "inside": "结合我们对财务报表的审计，我们的责任是阅读其他信息，在此过程中，考虑其他信息是否与财务报表或我们在审计过程中了解到的情况存在重大不一致或者似乎存在重大错报。"}
{"page": 60, "allrow": 1497, "type": "text", "inside": "基于我们已执行的工作，如果我们确定其他信息存在重大错报，我们应当报告该事实。在这方面，我们无任何事项需要报告。"}
{"page": 60, "allrow": 1498, "type": "text", "inside": "五、管理层和治理层对财务报表的责任"}
{"page": 60, "allrow": 1499, "type": "text", "inside": "管理层负责按照企业会计准则的规定编制财务报表，使其实现公允反映，并设计、执行和维护必要的内部控制，以使财务报表不存在由于舞弊或错误导致的重大错报。"}
{"page": 60, "allrow": 1500, "type": "text", "inside": "在编制财务报表时，管理层负责评估普洛药业的持续经营能力，披露与持续经营相关的事项（如适用），并运用持续经营假"}
{"page": 60, "allrow": 1501, "type": "页脚", "inside": "60"}
{"page": 61, "allrow": 1502, "type": "text", "inside": ""}
{"page": 61, "allrow": 1503, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 61, "allrow": 1504, "type": "text", "inside": "设，除非计划清算、终止运营或别无其他现实的选择。"}
{"page": 61, "allrow": 1505, "type": "text", "inside": "普洛药业股份有限公司治理层（以下简称“治理层”）负责监督普洛药业的财务报告过程。"}
{"page": 61, "allrow": 1506, "type": "text", "inside": "六、注册会计师对财务报表审计的责任"}
{"page": 61, "allrow": 1507, "type": "text", "inside": "我们的目标是对财务报表整体是否不存在由于舞弊或错误导致的重大错报获取合理保证，并出具包含审计意见的审计报告。合理保证是高水平的保证，但并不能保证按照审计准则执行的审计在某一重大错报存在时总能发现。错报可能由于舞弊或错误导致，如果合理预期错报单独或汇总起来可能影响财务报表使用者依据财务报表作出的经济决策，则通常认为错报是重大的。"}
{"page": 61, "allrow": 1508, "type": "text", "inside": "在按照审计准则执行审计工作的过程中，我们运用职业判断，并保持职业怀疑。同时，我们也执行以下工作："}
{"page": 61, "allrow": 1509, "type": "text", "inside": "（一）识别和评估由于舞弊或错误导致的财务报表重大错报风险，设计和实施审计程序以应对这些风险，并获取充分、适当的审计证据，作为发表审计意见的基础。由于舞弊可能涉及串通、伪造、故意遗漏、虚假陈述或凌驾于内部控制之上，未能发现由于舞弊导致的重大错报的风险高于未能发现由于错误导致的重大错报的风险。"}
{"page": 61, "allrow": 1510, "type": "text", "inside": "（二）了解与审计相关的内部控制，以设计恰当的审计程序。"}
{"page": 61, "allrow": 1511, "type": "text", "inside": "（三）评价管理层选用会计政策的恰当性和作出会计估计及相关披露的合理性。"}
{"page": 61, "allrow": 1512, "type": "text", "inside": "（四）对管理层使用持续经营假设的恰当性得出结论。同时，根据获取的审计证据，就可能导致对普洛药业持续经营能力产生重大疑虑的事项或情况是否存在重大不确定性得出结论。如果我们得出结论认为存在重大不确定性，审计准则要求我们在审计报告中提请报表使用者注意财务报表中的相关披露；如果披露不充分，我们应当发表非无保留意见。我们的结论基于截至审计报告日可获得的信息。然而，未来的事项或情况可能导致普洛药业不能持续经营。"}
{"page": 61, "allrow": 1513, "type": "text", "inside": "（五）评价财务报表的总体列报、结构和内容，并评价财务报表是否公允反映相关交易和事项。"}
{"page": 61, "allrow": 1514, "type": "text", "inside": "（六）就普洛药业中实体或业务活动的财务信息获取充分、适当的审计证据，以对财务报表发表审计意见。我们负责指导、监督和执行集团审计，并对审计意见承担全部责任。"}
{"page": 61, "allrow": 1515, "type": "text", "inside": "我们与治理层就计划的审计范围、时间安排和重大审计发现等事项进行沟通，包括沟通我们在审计中识别出的值得关注的内部控制缺陷。"}
{"page": 61, "allrow": 1516, "type": "text", "inside": "我们还就已遵守与独立性相关的职业道德要求向治理层提供声明，并与治理层沟通可能被合理认为影响我们独立性的所有关系和其他事项，以及相关的防范措施（如适用）。"}
{"page": 61, "allrow": 1517, "type": "text", "inside": "从与治理层沟通过的事项中，我们确定哪些事项对本期财务报表审计最为重要，因而构成关键审计事项。我们在审计报告中描述这些事项，除非法律法规禁止公开披露这些事项，或在极少数情形下，如果合理预期在审计报告中沟通某事项造成的负面后果超过在公众利益方面产生的益处，我们确定不应在审计报告中沟通该事项。"}
{"page": 61, "allrow": 1518, "type": "text", "inside": "和信会计师事务所（特殊普通合伙）中国注册会计师:左伟"}
{"page": 61, "allrow": 1519, "type": "text", "inside": "（项目合伙人）"}
{"page": 61, "allrow": 1520, "type": "text", "inside": "中国•济南中国注册会计师:陈征"}
{"page": 61, "allrow": 1521, "type": "页脚", "inside": "61"}
{"page": 62, "allrow": 1522, "type": "text", "inside": ""}
{"page": 62, "allrow": 1523, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 62, "allrow": 1524, "type": "text", "inside": "二〇二〇年三月十一日"}
{"page": 62, "allrow": 1525, "type": "text", "inside": "二、财务报表"}
{"page": 62, "allrow": 1526, "type": "text", "inside": "财务附注中报表的单位为：元"}
{"page": 62, "allrow": 1527, "type": "text", "inside": "1、合并资产负债表"}
{"page": 62, "allrow": 1528, "type": "text", "inside": "编制单位：普洛药业股份有限公司"}
{"page": 62, "allrow": 1529, "type": "text", "inside": "2019年12月31日"}
{"page": 62, "allrow": 1530, "type": "text", "inside": "单位：元"}
{"page": 62, "allrow": 1531, "type": "excel", "inside": "['项目', '2019年12月31日', '2018年12月31日']"}
{"page": 62, "allrow": 1532, "type": "excel", "inside": "['流动资产：', '', '']"}
{"page": 62, "allrow": 1533, "type": "excel", "inside": "['货币资金', '1,035,809,494.05', '644,375,303.19']"}
{"page": 62, "allrow": 1534, "type": "excel", "inside": "['结算备付金', '', '']"}
{"page": 62, "allrow": 1535, "type": "excel", "inside": "['拆出资金', '', '']"}
{"page": 62, "allrow": 1536, "type": "excel", "inside": "['交易性金融资产', '463,858,356.17', '']"}
{"page": 62, "allrow": 1537, "type": "excel", "inside": "['以公允价值计量且其变动计入当期损益的金融资产', '', '']"}
{"page": 62, "allrow": 1538, "type": "excel", "inside": "['衍生金融资产', '', '']"}
{"page": 62, "allrow": 1539, "type": "excel", "inside": "['应收票据', '0.00', '210,813,018.23']"}
{"page": 62, "allrow": 1540, "type": "excel", "inside": "['应收账款', '1,025,138,596.19', '1,024,424,679.11']"}
{"page": 62, "allrow": 1541, "type": "excel", "inside": "['应收款项融资', '224,310,858.75', '']"}
{"page": 62, "allrow": 1542, "type": "excel", "inside": "['预付款项', '120,808,641.96', '124,923,892.89']"}
{"page": 62, "allrow": 1543, "type": "excel", "inside": "['应收保费', '', '']"}
{"page": 62, "allrow": 1544, "type": "excel", "inside": "['应收分保账款', '', '']"}
{"page": 62, "allrow": 1545, "type": "excel", "inside": "['应收分保合同准备金', '', '']"}
{"page": 62, "allrow": 1546, "type": "excel", "inside": "['其他应收款', '7,275,197.34', '7,566,657.24']"}
{"page": 62, "allrow": 1547, "type": "excel", "inside": "['其中：应收利息', '', '']"}
{"page": 62, "allrow": 1548, "type": "excel", "inside": "['应收股利', '', '']"}
{"page": 62, "allrow": 1549, "type": "excel", "inside": "['买入返售金融资产', '', '']"}
{"page": 62, "allrow": 1550, "type": "excel", "inside": "['存货', '993,043,012.37', '901,643,879.75']"}
{"page": 62, "allrow": 1551, "type": "excel", "inside": "['合同资产', '', '']"}
{"page": 62, "allrow": 1552, "type": "excel", "inside": "['持有待售资产', '', '']"}
{"page": 62, "allrow": 1553, "type": "text", "inside": ""}
{"page": 62, "allrow": 1554, "type": "页脚", "inside": "62"}
{"page": 63, "allrow": 1555, "type": "text", "inside": ""}
{"page": 63, "allrow": 1556, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 63, "allrow": 1557, "type": "excel", "inside": "['一年内到期的非流动资产', '', '']"}
{"page": 63, "allrow": 1558, "type": "excel", "inside": "['其他流动资产', '87,728,730.60', '161,784,771.70']"}
{"page": 63, "allrow": 1559, "type": "excel", "inside": "['流动资产合计', '3,957,972,887.43', '3,075,532,202.11']"}
{"page": 63, "allrow": 1560, "type": "excel", "inside": "['非流动资产：', '', '']"}
{"page": 63, "allrow": 1561, "type": "excel", "inside": "['发放贷款和垫款', '', '']"}
{"page": 63, "allrow": 1562, "type": "excel", "inside": "['债权投资', '', '']"}
{"page": 63, "allrow": 1563, "type": "excel", "inside": "['可供出售金融资产', '', '']"}
{"page": 63, "allrow": 1564, "type": "excel", "inside": "['其他债权投资', '', '']"}
{"page": 63, "allrow": 1565, "type": "excel", "inside": "['持有至到期投资', '', '']"}
{"page": 63, "allrow": 1566, "type": "excel", "inside": "['长期应收款', '', '']"}
{"page": 63, "allrow": 1567, "type": "excel", "inside": "['长期股权投资', '122,214,608.04', '100,871,723.22']"}
{"page": 63, "allrow": 1568, "type": "excel", "inside": "['其他权益工具投资', '', '']"}
{"page": 63, "allrow": 1569, "type": "excel", "inside": "['其他非流动金融资产', '', '']"}
{"page": 63, "allrow": 1570, "type": "excel", "inside": "['投资性房地产', '', '']"}
{"page": 63, "allrow": 1571, "type": "excel", "inside": "['固定资产', '1,898,972,408.21', '1,971,680,172.58']"}
{"page": 63, "allrow": 1572, "type": "excel", "inside": "['在建工程', '118,847,992.45', '151,569,855.81']"}
{"page": 63, "allrow": 1573, "type": "excel", "inside": "['生产性生物资产', '', '']"}
{"page": 63, "allrow": 1574, "type": "excel", "inside": "['油气资产', '', '']"}
{"page": 63, "allrow": 1575, "type": "excel", "inside": "['使用权资产', '', '']"}
{"page": 63, "allrow": 1576, "type": "excel", "inside": "['无形资产', '331,210,820.87', '343,159,065.40']"}
{"page": 63, "allrow": 1577, "type": "excel", "inside": "['开发支出', '', '20,066,420.36']"}
{"page": 63, "allrow": 1578, "type": "excel", "inside": "['商誉', '20,310,091.31', '29,504,402.57']"}
{"page": 63, "allrow": 1579, "type": "excel", "inside": "['长期待摊费用', '10,214,687.07', '7,223,899.26']"}
{"page": 63, "allrow": 1580, "type": "excel", "inside": "['递延所得税资产', '49,035,416.36', '40,747,235.56']"}
{"page": 63, "allrow": 1581, "type": "excel", "inside": "['其他非流动资产', '13,807,011.68', '11,406,417.12']"}
{"page": 63, "allrow": 1582, "type": "excel", "inside": "['非流动资产合计', '2,564,613,035.99', '2,676,229,191.88']"}
{"page": 63, "allrow": 1583, "type": "excel", "inside": "['资产总计', '6,522,585,923.42', '5,751,761,393.99']"}
{"page": 63, "allrow": 1584, "type": "excel", "inside": "['流动负债：', '', '']"}
{"page": 63, "allrow": 1585, "type": "excel", "inside": "['短期借款', '50,000,000.00', '614,100,000.00']"}
{"page": 63, "allrow": 1586, "type": "excel", "inside": "['向中央银行借款', '', '']"}
{"page": 63, "allrow": 1587, "type": "excel", "inside": "['拆入资金', '', '']"}
{"page": 63, "allrow": 1588, "type": "excel", "inside": "['交易性金融负债', '16,231,031.94', '']"}
{"page": 63, "allrow": 1589, "type": "excel", "inside": "['以公允价值计量且其变动计入当期损益的金融负债', '', '2,486,145.90']"}
{"page": 63, "allrow": 1590, "type": "text", "inside": ""}
{"page": 63, "allrow": 1591, "type": "页脚", "inside": "63"}
{"page": 64, "allrow": 1592, "type": "text", "inside": ""}
{"page": 64, "allrow": 1593, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 64, "allrow": 1594, "type": "excel", "inside": "['衍生金融负债', '', '']"}
{"page": 64, "allrow": 1595, "type": "excel", "inside": "['应付票据', '923,961,227.56', '322,056,386.67']"}
{"page": 64, "allrow": 1596, "type": "excel", "inside": "['应付账款', '1,086,293,844.38', '791,292,436.92']"}
{"page": 64, "allrow": 1597, "type": "excel", "inside": "['预收款项', '140,451,754.93', '143,275,906.92']"}
{"page": 64, "allrow": 1598, "type": "excel", "inside": "['合同负债', '', '']"}
{"page": 64, "allrow": 1599, "type": "excel", "inside": "['卖出回购金融资产款', '', '']"}
{"page": 64, "allrow": 1600, "type": "excel", "inside": "['吸收存款及同业存放', '', '']"}
{"page": 64, "allrow": 1601, "type": "excel", "inside": "['代理买卖证券款', '', '']"}
{"page": 64, "allrow": 1602, "type": "excel", "inside": "['代理承销证券款', '', '']"}
{"page": 64, "allrow": 1603, "type": "excel", "inside": "['应付职工薪酬', '161,039,045.33', '95,955,596.01']"}
{"page": 64, "allrow": 1604, "type": "excel", "inside": "['应交税费', '83,323,212.06', '87,321,744.85']"}
{"page": 64, "allrow": 1605, "type": "excel", "inside": "['其他应付款', '100,255,101.69', '147,229,056.40']"}
{"page": 64, "allrow": 1606, "type": "excel", "inside": "['其中：应付利息', '1,890,441.90', '1,161,561.41']"}
{"page": 64, "allrow": 1607, "type": "excel", "inside": "['应付股利', '', '']"}
{"page": 64, "allrow": 1608, "type": "excel", "inside": "['应付手续费及佣金', '', '']"}
{"page": 64, "allrow": 1609, "type": "excel", "inside": "['应付分保账款', '', '']"}
{"page": 64, "allrow": 1610, "type": "excel", "inside": "['持有待售负债', '', '']"}
{"page": 64, "allrow": 1611, "type": "excel", "inside": "['一年内到期的非流动负债', '', '']"}
{"page": 64, "allrow": 1612, "type": "excel", "inside": "['其他流动负债', '', '']"}
{"page": 64, "allrow": 1613, "type": "excel", "inside": "['流动负债合计', '2,561,555,217.89', '2,203,717,273.67']"}
{"page": 64, "allrow": 1614, "type": "excel", "inside": "['非流动负债：', '', '']"}
{"page": 64, "allrow": 1615, "type": "excel", "inside": "['保险合同准备金', '', '']"}
{"page": 64, "allrow": 1616, "type": "excel", "inside": "['长期借款', '', '']"}
{"page": 64, "allrow": 1617, "type": "excel", "inside": "['应付债券', '', '']"}
{"page": 64, "allrow": 1618, "type": "excel", "inside": "['其中：优先股', '', '']"}
{"page": 64, "allrow": 1619, "type": "excel", "inside": "['永续债', '', '']"}
{"page": 64, "allrow": 1620, "type": "excel", "inside": "['租赁负债', '', '']"}
{"page": 64, "allrow": 1621, "type": "excel", "inside": "['长期应付款', '72,000,000.00', '72,000,000.00']"}
{"page": 64, "allrow": 1622, "type": "excel", "inside": "['长期应付职工薪酬', '', '']"}
{"page": 64, "allrow": 1623, "type": "excel", "inside": "['预计负债', '', '']"}
{"page": 64, "allrow": 1624, "type": "excel", "inside": "['递延收益', '119,801,389.49', '130,052,096.06']"}
{"page": 64, "allrow": 1625, "type": "excel", "inside": "['递延所得税负债', '1,242,528.76', '731,931.53']"}
{"page": 64, "allrow": 1626, "type": "excel", "inside": "['其他非流动负债', '', '']"}
{"page": 64, "allrow": 1627, "type": "excel", "inside": "['非流动负债合计', '193,043,918.25', '202,784,027.59']"}
{"page": 64, "allrow": 1628, "type": "text", "inside": ""}
{"page": 64, "allrow": 1629, "type": "页脚", "inside": "64"}
{"page": 65, "allrow": 1630, "type": "text", "inside": ""}
{"page": 65, "allrow": 1631, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 65, "allrow": 1632, "type": "excel", "inside": "['负债合计', '2,754,599,136.14', '2,406,501,301.26']"}
{"page": 65, "allrow": 1633, "type": "excel", "inside": "['所有者权益：', '', '']"}
{"page": 65, "allrow": 1634, "type": "excel", "inside": "['股本', '1,178,523,492.00', '1,178,523,492.00']"}
{"page": 65, "allrow": 1635, "type": "excel", "inside": "['其他权益工具', '', '']"}
{"page": 65, "allrow": 1636, "type": "excel", "inside": "['其中：优先股', '', '']"}
{"page": 65, "allrow": 1637, "type": "excel", "inside": "['永续债', '', '']"}
{"page": 65, "allrow": 1638, "type": "excel", "inside": "['资本公积', '438,005,920.01', '438,985,920.01']"}
{"page": 65, "allrow": 1639, "type": "excel", "inside": "['减：库存股', '', '']"}
{"page": 65, "allrow": 1640, "type": "excel", "inside": "['其他综合收益', '-147,378.53', '-90,895.78']"}
{"page": 65, "allrow": 1641, "type": "excel", "inside": "['专项储备', '', '']"}
{"page": 65, "allrow": 1642, "type": "excel", "inside": "['盈余公积', '132,760,241.95', '112,256,875.56']"}
{"page": 65, "allrow": 1643, "type": "excel", "inside": "['一般风险准备', '', '']"}
{"page": 65, "allrow": 1644, "type": "excel", "inside": "['未分配利润', '2,018,844,511.85', '1,615,584,700.94']"}
{"page": 65, "allrow": 1645, "type": "excel", "inside": "['归属于母公司所有者权益合计', '3,767,986,787.28', '3,345,260,092.73']"}
{"page": 65, "allrow": 1646, "type": "excel", "inside": "['少数股东权益', '', '']"}
{"page": 65, "allrow": 1647, "type": "excel", "inside": "['所有者权益合计', '3,767,986,787.28', '3,345,260,092.73']"}
{"page": 65, "allrow": 1648, "type": "excel", "inside": "['负债和所有者权益总计', '6,522,585,923.42', '5,751,761,393.99']"}
{"page": 65, "allrow": 1649, "type": "text", "inside": "法定代表人：祝方猛主管会计工作负责人：张进辉会计机构负责人：张进辉2、母公司资产负债表"}
{"page": 65, "allrow": 1650, "type": "text", "inside": "单位：元"}
{"page": 65, "allrow": 1651, "type": "excel", "inside": "['项目', '2019年12月31日', '2018年12月31日']"}
{"page": 65, "allrow": 1652, "type": "excel", "inside": "['流动资产：', '', '']"}
{"page": 65, "allrow": 1653, "type": "excel", "inside": "['货币资金', '42,012,144.57', '636,111.19']"}
{"page": 65, "allrow": 1654, "type": "excel", "inside": "['交易性金融资产', '50,000,000.00', '']"}
{"page": 65, "allrow": 1655, "type": "excel", "inside": "['以公允价值计量且其变动计入当期损益的金融资产', '', '']"}
{"page": 65, "allrow": 1656, "type": "excel", "inside": "['衍生金融资产', '', '']"}
{"page": 65, "allrow": 1657, "type": "excel", "inside": "['应收票据', '', '']"}
{"page": 65, "allrow": 1658, "type": "excel", "inside": "['应收账款', '0.00', '0.00']"}
{"page": 65, "allrow": 1659, "type": "excel", "inside": "['应收款项融资', '', '']"}
{"page": 65, "allrow": 1660, "type": "excel", "inside": "['预付款项', '65,540.23', '99,108.49']"}
{"page": 65, "allrow": 1661, "type": "excel", "inside": "['其他应收款', '557,471,512.40', '553,510,132.66']"}
{"page": 65, "allrow": 1662, "type": "excel", "inside": "['其中：应收利息', '', '']"}
{"page": 65, "allrow": 1663, "type": "text", "inside": ""}
{"page": 65, "allrow": 1664, "type": "页脚", "inside": "65"}
{"page": 66, "allrow": 1665, "type": "text", "inside": ""}
{"page": 66, "allrow": 1666, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 66, "allrow": 1667, "type": "excel", "inside": "['应收股利', '200,000,000.00', '126,400,000.00']"}
{"page": 66, "allrow": 1668, "type": "excel", "inside": "['存货', '', '']"}
{"page": 66, "allrow": 1669, "type": "excel", "inside": "['合同资产', '', '']"}
{"page": 66, "allrow": 1670, "type": "excel", "inside": "['持有待售资产', '', '']"}
{"page": 66, "allrow": 1671, "type": "excel", "inside": "['一年内到期的非流动资产', '', '']"}
{"page": 66, "allrow": 1672, "type": "excel", "inside": "['其他流动资产', '', '23,900,000.00']"}
{"page": 66, "allrow": 1673, "type": "excel", "inside": "['流动资产合计', '649,549,197.20', '578,145,352.34']"}
{"page": 66, "allrow": 1674, "type": "excel", "inside": "['非流动资产：', '', '']"}
{"page": 66, "allrow": 1675, "type": "excel", "inside": "['债权投资', '', '']"}
{"page": 66, "allrow": 1676, "type": "excel", "inside": "['可供出售金融资产', '', '']"}
{"page": 66, "allrow": 1677, "type": "excel", "inside": "['其他债权投资', '', '']"}
{"page": 66, "allrow": 1678, "type": "excel", "inside": "['持有至到期投资', '', '']"}
{"page": 66, "allrow": 1679, "type": "excel", "inside": "['长期应收款', '', '']"}
{"page": 66, "allrow": 1680, "type": "excel", "inside": "['长期股权投资', '1,742,971,011.84', '1,741,996,456.86']"}
{"page": 66, "allrow": 1681, "type": "excel", "inside": "['其他权益工具投资', '', '']"}
{"page": 66, "allrow": 1682, "type": "excel", "inside": "['其他非流动金融资产', '', '']"}
{"page": 66, "allrow": 1683, "type": "excel", "inside": "['投资性房地产', '', '']"}
{"page": 66, "allrow": 1684, "type": "excel", "inside": "['固定资产', '499,351.50', '393,816.68']"}
{"page": 66, "allrow": 1685, "type": "excel", "inside": "['在建工程', '', '']"}
{"page": 66, "allrow": 1686, "type": "excel", "inside": "['生产性生物资产', '', '']"}
{"page": 66, "allrow": 1687, "type": "excel", "inside": "['油气资产', '', '']"}
{"page": 66, "allrow": 1688, "type": "excel", "inside": "['使用权资产', '', '']"}
{"page": 66, "allrow": 1689, "type": "excel", "inside": "['无形资产', '', '']"}
{"page": 66, "allrow": 1690, "type": "excel", "inside": "['开发支出', '', '']"}
{"page": 66, "allrow": 1691, "type": "excel", "inside": "['商誉', '', '']"}
{"page": 66, "allrow": 1692, "type": "excel", "inside": "['长期待摊费用', '', '']"}
{"page": 66, "allrow": 1693, "type": "excel", "inside": "['递延所得税资产', '', '']"}
{"page": 66, "allrow": 1694, "type": "excel", "inside": "['其他非流动资产', '', '']"}
{"page": 66, "allrow": 1695, "type": "excel", "inside": "['非流动资产合计', '1,743,470,363.34', '1,742,390,273.54']"}
{"page": 66, "allrow": 1696, "type": "excel", "inside": "['资产总计', '2,393,019,560.54', '2,320,535,625.88']"}
{"page": 66, "allrow": 1697, "type": "excel", "inside": "['流动负债：', '', '']"}
{"page": 66, "allrow": 1698, "type": "excel", "inside": "['短期借款', '', '']"}
{"page": 66, "allrow": 1699, "type": "excel", "inside": "['交易性金融负债', '', '']"}
{"page": 66, "allrow": 1700, "type": "text", "inside": ""}
{"page": 66, "allrow": 1701, "type": "页脚", "inside": "66"}
{"page": 67, "allrow": 1702, "type": "text", "inside": ""}
{"page": 67, "allrow": 1703, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 67, "allrow": 1704, "type": "excel", "inside": "['以公允价值计量且其变动计入当期损益的金融负债', '', '']"}
{"page": 67, "allrow": 1705, "type": "excel", "inside": "['衍生金融负债', '', '']"}
{"page": 67, "allrow": 1706, "type": "excel", "inside": "['应付票据', '', '']"}
{"page": 67, "allrow": 1707, "type": "excel", "inside": "['应付账款', '', '']"}
{"page": 67, "allrow": 1708, "type": "excel", "inside": "['预收款项', '', '']"}
{"page": 67, "allrow": 1709, "type": "excel", "inside": "['合同负债', '', '']"}
{"page": 67, "allrow": 1710, "type": "excel", "inside": "['应付职工薪酬', '18,043,317.53', '3,041,640.59']"}
{"page": 67, "allrow": 1711, "type": "excel", "inside": "['应交税费', '1,440,395.93', '31,072.77']"}
{"page": 67, "allrow": 1712, "type": "excel", "inside": "['其他应付款', '53,481,047.07', '72,798,747.22']"}
{"page": 67, "allrow": 1713, "type": "excel", "inside": "['其中：应付利息', '', '']"}
{"page": 67, "allrow": 1714, "type": "excel", "inside": "['应付股利', '', '']"}
{"page": 67, "allrow": 1715, "type": "excel", "inside": "['持有待售负债', '', '']"}
{"page": 67, "allrow": 1716, "type": "excel", "inside": "['一年内到期的非流动负债', '', '']"}
{"page": 67, "allrow": 1717, "type": "excel", "inside": "['其他流动负债', '', '']"}
{"page": 67, "allrow": 1718, "type": "excel", "inside": "['流动负债合计', '72,964,760.53', '75,871,460.58']"}
{"page": 67, "allrow": 1719, "type": "excel", "inside": "['非流动负债：', '', '']"}
{"page": 67, "allrow": 1720, "type": "excel", "inside": "['长期借款', '', '']"}
{"page": 67, "allrow": 1721, "type": "excel", "inside": "['应付债券', '', '']"}
{"page": 67, "allrow": 1722, "type": "excel", "inside": "['其中：优先股', '', '']"}
{"page": 67, "allrow": 1723, "type": "excel", "inside": "['永续债', '', '']"}
{"page": 67, "allrow": 1724, "type": "excel", "inside": "['租赁负债', '', '']"}
{"page": 67, "allrow": 1725, "type": "excel", "inside": "['长期应付款', '', '']"}
{"page": 67, "allrow": 1726, "type": "excel", "inside": "['长期应付职工薪酬', '', '']"}
{"page": 67, "allrow": 1727, "type": "excel", "inside": "['预计负债', '', '']"}
{"page": 67, "allrow": 1728, "type": "excel", "inside": "['递延收益', '', '']"}
{"page": 67, "allrow": 1729, "type": "excel", "inside": "['递延所得税负债', '', '']"}
{"page": 67, "allrow": 1730, "type": "excel", "inside": "['其他非流动负债', '', '']"}
{"page": 67, "allrow": 1731, "type": "excel", "inside": "['非流动负债合计', '', '']"}
{"page": 67, "allrow": 1732, "type": "excel", "inside": "['负债合计', '72,964,760.53', '75,871,460.58']"}
{"page": 67, "allrow": 1733, "type": "excel", "inside": "['所有者权益：', '', '']"}
{"page": 67, "allrow": 1734, "type": "excel", "inside": "['股本', '1,178,523,492.00', '1,178,523,492.00']"}
{"page": 67, "allrow": 1735, "type": "excel", "inside": "['其他权益工具', '', '']"}
{"page": 67, "allrow": 1736, "type": "excel", "inside": "['其中：优先股', '', '']"}
{"page": 67, "allrow": 1737, "type": "text", "inside": ""}
{"page": 67, "allrow": 1738, "type": "页脚", "inside": "67"}
{"page": 68, "allrow": 1739, "type": "text", "inside": ""}
{"page": 68, "allrow": 1740, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 68, "allrow": 1741, "type": "excel", "inside": "['永续债', '', '']"}
{"page": 68, "allrow": 1742, "type": "excel", "inside": "['资本公积', '860,944,340.09', '860,949,785.11']"}
{"page": 68, "allrow": 1743, "type": "excel", "inside": "['减：库存股', '', '']"}
{"page": 68, "allrow": 1744, "type": "excel", "inside": "['其他综合收益', '', '']"}
{"page": 68, "allrow": 1745, "type": "excel", "inside": "['专项储备', '', '']"}
{"page": 68, "allrow": 1746, "type": "excel", "inside": "['盈余公积', '76,663,195.25', '56,159,828.86']"}
{"page": 68, "allrow": 1747, "type": "excel", "inside": "['未分配利润', '203,923,772.67', '149,031,059.33']"}
{"page": 68, "allrow": 1748, "type": "excel", "inside": "['所有者权益合计', '2,320,054,800.01', '2,244,664,165.30']"}
{"page": 68, "allrow": 1749, "type": "excel", "inside": "['负债和所有者权益总计', '2,393,019,560.54', '2,320,535,625.88']"}
{"page": 68, "allrow": 1750, "type": "text", "inside": "3、合并利润表"}
{"page": 68, "allrow": 1751, "type": "text", "inside": "单位：元"}
{"page": 68, "allrow": 1752, "type": "excel", "inside": "['项目', '2019年度', '2018年度']"}
{"page": 68, "allrow": 1753, "type": "excel", "inside": "['一、营业总收入', '7,210,711,386.14', '6,375,980,498.49']"}
{"page": 68, "allrow": 1754, "type": "excel", "inside": "['其中：营业收入', '7,210,711,386.14', '6,375,980,498.49']"}
{"page": 68, "allrow": 1755, "type": "excel", "inside": "['利息收入', '', '']"}
{"page": 68, "allrow": 1756, "type": "excel", "inside": "['已赚保费', '', '']"}
{"page": 68, "allrow": 1757, "type": "excel", "inside": "['手续费及佣金收入', '', '']"}
{"page": 68, "allrow": 1758, "type": "excel", "inside": "['二、营业总成本', '6,587,200,487.77', '5,928,448,362.51']"}
{"page": 68, "allrow": 1759, "type": "excel", "inside": "['其中：营业成本', '4,876,578,494.29', '4,340,107,076.74']"}
{"page": 68, "allrow": 1760, "type": "excel", "inside": "['利息支出', '', '']"}
{"page": 68, "allrow": 1761, "type": "excel", "inside": "['手续费及佣金支出', '', '']"}
{"page": 68, "allrow": 1762, "type": "excel", "inside": "['退保金', '', '']"}
{"page": 68, "allrow": 1763, "type": "excel", "inside": "['赔付支出净额', '', '']"}
{"page": 68, "allrow": 1764, "type": "excel", "inside": "['提取保险责任合同准备金净额', '', '']"}
{"page": 68, "allrow": 1765, "type": "excel", "inside": "['保单红利支出', '', '']"}
{"page": 68, "allrow": 1766, "type": "excel", "inside": "['分保费用', '', '']"}
{"page": 68, "allrow": 1767, "type": "excel", "inside": "['税金及附加', '44,415,326.98', '46,190,978.67']"}
{"page": 68, "allrow": 1768, "type": "excel", "inside": "['销售费用', '835,337,733.34', '808,934,578.51']"}
{"page": 68, "allrow": 1769, "type": "excel", "inside": "['管理费用', '458,116,308.60', '461,126,486.80']"}
{"page": 68, "allrow": 1770, "type": "excel", "inside": "['研发费用', '359,893,448.82', '269,650,776.53']"}
{"page": 68, "allrow": 1771, "type": "excel", "inside": "['财务费用', '12,859,175.74', '2,438,465.26']"}
{"page": 68, "allrow": 1772, "type": "excel", "inside": "['其中：利息费用', '13,143,665.93', '42,006,549.96']"}
{"page": 68, "allrow": 1773, "type": "text", "inside": ""}
{"page": 68, "allrow": 1774, "type": "页脚", "inside": "68"}
{"page": 69, "allrow": 1775, "type": "text", "inside": ""}
{"page": 69, "allrow": 1776, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 69, "allrow": 1777, "type": "excel", "inside": "['利息收入', '7,290,382.10', '5,366,962.74']"}
{"page": 69, "allrow": 1778, "type": "excel", "inside": "['加：其他收益', '89,408,796.26', '69,285,803.03']"}
{"page": 69, "allrow": 1779, "type": "excel", "inside": "['投资收益（损失以“－”号填列）', '-20,733,157.79', '13,466,089.65']"}
{"page": 69, "allrow": 1780, "type": "excel", "inside": "['其中：对联营企业和合营企业的投资收益', '31,142,884.82', '16,007,148.92']"}
{"page": 69, "allrow": 1781, "type": "excel", "inside": "['以摊余成本计量的金融资产终止确认收益', '', '']"}
{"page": 69, "allrow": 1782, "type": "excel", "inside": "['汇兑收益（损失以“-”号填列）', '', '']"}
{"page": 69, "allrow": 1783, "type": "excel", "inside": "['净敞口套期收益（损失以“－”号填列）', '', '']"}
{"page": 69, "allrow": 1784, "type": "excel", "inside": "['公允价值变动收益（损失以“－”号填列）', '-9,886,529.87', '-6,666,404.76']"}
{"page": 69, "allrow": 1785, "type": "excel", "inside": "['信用减值损失（损失以“-”号填列）', '318,297.90', '']"}
{"page": 69, "allrow": 1786, "type": "excel", "inside": "['资产减值损失（损失以“-”号填列）', '-42,698,765.82', '-36,978,361.77']"}
{"page": 69, "allrow": 1787, "type": "excel", "inside": "['资产处置收益（损失以“-”号填列）', '4,234,859.77', '3,893,468.85']"}
{"page": 69, "allrow": 1788, "type": "excel", "inside": "['三、营业利润（亏损以“－”号填列）', '644,154,398.82', '490,532,730.98']"}
{"page": 69, "allrow": 1789, "type": "excel", "inside": "['加：营业外收入', '1,571,992.53', '2,205,643.36']"}
{"page": 69, "allrow": 1790, "type": "excel", "inside": "['减：营业外支出', '12,000,132.87', '30,547,132.30']"}
{"page": 69, "allrow": 1791, "type": "excel", "inside": "['四、利润总额（亏损总额以“－”号填列）', '633,726,258.48', '462,191,242.04']"}
{"page": 69, "allrow": 1792, "type": "excel", "inside": "['减：所得税费用', '80,325,497.06', '91,630,213.76']"}
{"page": 69, "allrow": 1793, "type": "excel", "inside": "['五、净利润（净亏损以“－”号填列）', '553,400,761.42', '370,561,028.28']"}
{"page": 69, "allrow": 1794, "type": "excel", "inside": "['（一）按经营持续性分类', '', '']"}
{"page": 69, "allrow": 1795, "type": "excel", "inside": "['1.持续经营净利润（净亏损以“－”号填列）', '553,400,761.42', '370,561,028.28']"}
{"page": 69, "allrow": 1796, "type": "excel", "inside": "['2.终止经营净利润（净亏损以“－”号填列）', '', '']"}
{"page": 69, "allrow": 1797, "type": "excel", "inside": "['（二）按所有权归属分类', '', '']"}
{"page": 69, "allrow": 1798, "type": "excel", "inside": "['1.归属于母公司所有者的净利润', '553,400,761.42', '370,561,028.28']"}
{"page": 69, "allrow": 1799, "type": "excel", "inside": "['2.少数股东损益', '', '']"}
{"page": 69, "allrow": 1800, "type": "excel", "inside": "['六、其他综合收益的税后净额', '-56,482.75', '328,103.40']"}
{"page": 69, "allrow": 1801, "type": "text", "inside": ""}
{"page": 69, "allrow": 1802, "type": "页脚", "inside": "69"}
{"page": 70, "allrow": 1803, "type": "text", "inside": ""}
{"page": 70, "allrow": 1804, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 70, "allrow": 1805, "type": "excel", "inside": "['归属母公司所有者的其他综合收益的税后净额', '-56,482.75', '328,103.40']"}
{"page": 70, "allrow": 1806, "type": "excel", "inside": "['（一）不能重分类进损益的其他综合收益', '', '']"}
{"page": 70, "allrow": 1807, "type": "excel", "inside": "['1.重新计量设定受益计划变动额', '', '']"}
{"page": 70, "allrow": 1808, "type": "excel", "inside": "['2.权益法下不能转损益的其他综合收益', '', '']"}
{"page": 70, "allrow": 1809, "type": "excel", "inside": "['3.其他权益工具投资公允价值变动', '', '']"}
{"page": 70, "allrow": 1810, "type": "excel", "inside": "['4.企业自身信用风险公允价值变动', '', '']"}
{"page": 70, "allrow": 1811, "type": "excel", "inside": "['5.其他', '', '']"}
{"page": 70, "allrow": 1812, "type": "excel", "inside": "['（二）将重分类进损益的其他综合收益', '-56,482.75', '328,103.40']"}
{"page": 70, "allrow": 1813, "type": "excel", "inside": "['1.权益法下可转损益的其他综合收益', '', '']"}
{"page": 70, "allrow": 1814, "type": "excel", "inside": "['2.其他债权投资公允价值变动', '', '']"}
{"page": 70, "allrow": 1815, "type": "excel", "inside": "['3.可供出售金融资产公允价值变动损益', '', '']"}
{"page": 70, "allrow": 1816, "type": "excel", "inside": "['4.金融资产重分类计入其他综合收益的金额', '', '']"}
{"page": 70, "allrow": 1817, "type": "excel", "inside": "['5.持有至到期投资重分类为可供出售金融资产损益', '', '']"}
{"page": 70, "allrow": 1818, "type": "excel", "inside": "['6.其他债权投资信用减值准备', '', '']"}
{"page": 70, "allrow": 1819, "type": "excel", "inside": "['7.现金流量套期储备', '', '']"}
{"page": 70, "allrow": 1820, "type": "excel", "inside": "['8.外币财务报表折算差额', '-56,482.75', '328,103.40']"}
{"page": 70, "allrow": 1821, "type": "excel", "inside": "['9.其他', '', '']"}
{"page": 70, "allrow": 1822, "type": "excel", "inside": "['归属于少数股东的其他综合收益的税后净额', '', '']"}
{"page": 70, "allrow": 1823, "type": "excel", "inside": "['七、综合收益总额', '553,344,278.67', '370,889,131.68']"}
{"page": 70, "allrow": 1824, "type": "excel", "inside": "['归属于母公司所有者的综合收益总额', '553,344,278.67', '370,889,131.68']"}
{"page": 70, "allrow": 1825, "type": "excel", "inside": "['归属于少数股东的综合收益总额', '', '']"}
{"page": 70, "allrow": 1826, "type": "excel", "inside": "['八、每股收益：', '', '']"}
{"page": 70, "allrow": 1827, "type": "text", "inside": ""}
{"page": 70, "allrow": 1828, "type": "页脚", "inside": "70"}
{"page": 71, "allrow": 1829, "type": "text", "inside": ""}
{"page": 71, "allrow": 1830, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 71, "allrow": 1831, "type": "excel", "inside": "['（一）基本每股收益', '0.4696', '0.3144']"}
{"page": 71, "allrow": 1832, "type": "excel", "inside": "['（二）稀释每股收益', '0.4696', '0.3144']"}
{"page": 71, "allrow": 1833, "type": "text", "inside": "本期发生同一控制下企业合并的，被合并方在合并前实现的净利润为：元，上期被合并方实现的净利润为：元。"}
{"page": 71, "allrow": 1834, "type": "text", "inside": "法定代表人：祝方猛主管会计工作负责人：张进辉会计机构负责人：张进辉4、母公司利润表"}
{"page": 71, "allrow": 1835, "type": "text", "inside": "单位：元"}
{"page": 71, "allrow": 1836, "type": "excel", "inside": "['项目', '2019年度', '2018年度']"}
{"page": 71, "allrow": 1837, "type": "excel", "inside": "['一、营业收入', '44,952,830.12', '35,660,377.38']"}
{"page": 71, "allrow": 1838, "type": "excel", "inside": "['减：营业成本', '0.00', '0.00']"}
{"page": 71, "allrow": 1839, "type": "excel", "inside": "['税金及附加', '242,878.63', '195,521.11']"}
{"page": 71, "allrow": 1840, "type": "excel", "inside": "['销售费用', '6,377,067.24', '']"}
{"page": 71, "allrow": 1841, "type": "excel", "inside": "['管理费用', '34,631,465.28', '19,644,334.16']"}
{"page": 71, "allrow": 1842, "type": "excel", "inside": "['研发费用', '', '']"}
{"page": 71, "allrow": 1843, "type": "excel", "inside": "['财务费用', '-664,655.63', '-106,925.47']"}
{"page": 71, "allrow": 1844, "type": "excel", "inside": "['其中：利息费用', '', '']"}
{"page": 71, "allrow": 1845, "type": "excel", "inside": "['利息收入', '733,364.24', '152,716.25']"}
{"page": 71, "allrow": 1846, "type": "excel", "inside": "['加：其他收益', '149,600.00', '']"}
{"page": 71, "allrow": 1847, "type": "excel", "inside": "['投资收益（损失以“－”号填列）', '200,114,711.03', '127,345,117.35']"}
{"page": 71, "allrow": 1848, "type": "excel", "inside": "['其中：对联营企业和合营企业的投资收益', '', '']"}
{"page": 71, "allrow": 1849, "type": "excel", "inside": "['以摊余成本计量的金融资产终止确认收益（损失以“-”号填列）', '', '']"}
{"page": 71, "allrow": 1850, "type": "excel", "inside": "['净敞口套期收益（损失以“－”号填列）', '', '']"}
{"page": 71, "allrow": 1851, "type": "excel", "inside": "['公允价值变动收益（损失以“－”号填列）', '', '']"}
{"page": 71, "allrow": 1852, "type": "excel", "inside": "['信用减值损失（损失以“-”号填列）', '1,278.22', '']"}
{"page": 71, "allrow": 1853, "type": "excel", "inside": "['资产减值损失（损失以“-”号填列）', '', '-3,484.95']"}
{"page": 71, "allrow": 1854, "type": "excel", "inside": "['资产处置收益（损失以“-”号填列）', '', '109,800.00']"}
{"page": 71, "allrow": 1855, "type": "text", "inside": ""}
{"page": 71, "allrow": 1856, "type": "页脚", "inside": "71"}
{"page": 72, "allrow": 1857, "type": "text", "inside": ""}
{"page": 72, "allrow": 1858, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 72, "allrow": 1859, "type": "excel", "inside": "['二、营业利润（亏损以“－”号填列）', '204,631,663.85', '143,378,879.98']"}
{"page": 72, "allrow": 1860, "type": "excel", "inside": "['加：营业外收入', '402,000.00', '824,900.00']"}
{"page": 72, "allrow": 1861, "type": "excel", "inside": "['减：营业外支出', '', '']"}
{"page": 72, "allrow": 1862, "type": "excel", "inside": "['三、利润总额（亏损总额以“－”号填列）', '205,033,663.85', '144,203,779.98']"}
{"page": 72, "allrow": 1863, "type": "excel", "inside": "['减：所得税费用', '', '']"}
{"page": 72, "allrow": 1864, "type": "excel", "inside": "['四、净利润（净亏损以“－”号填列）', '205,033,663.85', '144,203,779.98']"}
{"page": 72, "allrow": 1865, "type": "excel", "inside": "['（一）持续经营净利润（净亏损以“－”号填列）', '205,033,663.85', '144,203,779.98']"}
{"page": 72, "allrow": 1866, "type": "excel", "inside": "['（二）终止经营净利润（净亏损以“－”号填列）', '', '']"}
{"page": 72, "allrow": 1867, "type": "excel", "inside": "['五、其他综合收益的税后净额', '', '']"}
{"page": 72, "allrow": 1868, "type": "excel", "inside": "['（一）不能重分类进损益的其他综合收益', '', '']"}
{"page": 72, "allrow": 1869, "type": "excel", "inside": "['1.重新计量设定受益计划变动额', '', '']"}
{"page": 72, "allrow": 1870, "type": "excel", "inside": "['2.权益法下不能转损益的其他综合收益', '', '']"}
{"page": 72, "allrow": 1871, "type": "excel", "inside": "['3.其他权益工具投资公允价值变动', '', '']"}
{"page": 72, "allrow": 1872, "type": "excel", "inside": "['4.企业自身信用风险公允价值变动', '', '']"}
{"page": 72, "allrow": 1873, "type": "excel", "inside": "['5.其他', '', '']"}
{"page": 72, "allrow": 1874, "type": "excel", "inside": "['（二）将重分类进损益的其他综合收益', '', '']"}
{"page": 72, "allrow": 1875, "type": "excel", "inside": "['1.权益法下可转损益的其他综合收益', '', '']"}
{"page": 72, "allrow": 1876, "type": "excel", "inside": "['2.其他债权投资公允价值变动', '', '']"}
{"page": 72, "allrow": 1877, "type": "excel", "inside": "['3.可供出售金融资产公允价值变动损益', '', '']"}
{"page": 72, "allrow": 1878, "type": "excel", "inside": "['4.金融资产重分类计入其他综合收益的金额', '', '']"}
{"page": 72, "allrow": 1879, "type": "excel", "inside": "['5.持有至到期投资重分类为可供出售金融资产损益', '', '']"}
{"page": 72, "allrow": 1880, "type": "text", "inside": ""}
{"page": 72, "allrow": 1881, "type": "页脚", "inside": "72"}
{"page": 73, "allrow": 1882, "type": "text", "inside": ""}
{"page": 73, "allrow": 1883, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 73, "allrow": 1884, "type": "excel", "inside": "['6.其他债权投资信用减值准备', '', '']"}
{"page": 73, "allrow": 1885, "type": "excel", "inside": "['7.现金流量套期储备', '', '']"}
{"page": 73, "allrow": 1886, "type": "excel", "inside": "['8.外币财务报表折算差额', '', '']"}
{"page": 73, "allrow": 1887, "type": "excel", "inside": "['9.其他', '', '']"}
{"page": 73, "allrow": 1888, "type": "excel", "inside": "['六、综合收益总额', '205,033,663.85', '144,203,779.98']"}
{"page": 73, "allrow": 1889, "type": "excel", "inside": "['七、每股收益：', '', '']"}
{"page": 73, "allrow": 1890, "type": "excel", "inside": "['（一）基本每股收益', '', '']"}
{"page": 73, "allrow": 1891, "type": "excel", "inside": "['（二）稀释每股收益', '', '']"}
{"page": 73, "allrow": 1892, "type": "text", "inside": ""}
{"page": 73, "allrow": 1893, "type": "text", "inside": "5、合并现金流量表"}
{"page": 73, "allrow": 1894, "type": "text", "inside": "单位：元"}
{"page": 73, "allrow": 1895, "type": "excel", "inside": "['项目', '2019年度', '2018年度']"}
{"page": 73, "allrow": 1896, "type": "excel", "inside": "['一、经营活动产生的现金流量：', '', '']"}
{"page": 73, "allrow": 1897, "type": "excel", "inside": "['销售商品、提供劳务收到的现金', '5,028,758,968.55', '4,612,703,054.16']"}
{"page": 73, "allrow": 1898, "type": "excel", "inside": "['客户存款和同业存放款项净增加额', '', '']"}
{"page": 73, "allrow": 1899, "type": "excel", "inside": "['向中央银行借款净增加额', '', '']"}
{"page": 73, "allrow": 1900, "type": "excel", "inside": "['向其他金融机构拆入资金净增加额', '', '']"}
{"page": 73, "allrow": 1901, "type": "excel", "inside": "['收到原保险合同保费取得的现金', '', '']"}
{"page": 73, "allrow": 1902, "type": "excel", "inside": "['收到再保业务现金净额', '', '']"}
{"page": 73, "allrow": 1903, "type": "excel", "inside": "['保户储金及投资款净增加额', '', '']"}
{"page": 73, "allrow": 1904, "type": "excel", "inside": "['收取利息、手续费及佣金的现金', '', '']"}
{"page": 73, "allrow": 1905, "type": "excel", "inside": "['拆入资金净增加额', '', '']"}
{"page": 73, "allrow": 1906, "type": "excel", "inside": "['回购业务资金净增加额', '', '']"}
{"page": 73, "allrow": 1907, "type": "excel", "inside": "['代理买卖证券收到的现金净额', '', '']"}
{"page": 73, "allrow": 1908, "type": "excel", "inside": "['收到的税费返还', '263,356,738.52', '266,664,454.88']"}
{"page": 73, "allrow": 1909, "type": "excel", "inside": "['收到其他与经营活动有关的现金', '104,033,270.06', '97,993,508.64']"}
{"page": 73, "allrow": 1910, "type": "excel", "inside": "['经营活动现金流入小计', '5,396,148,977.13', '4,977,361,017.68']"}
{"page": 73, "allrow": 1911, "type": "text", "inside": ""}
{"page": 73, "allrow": 1912, "type": "页脚", "inside": "73"}
{"page": 74, "allrow": 1913, "type": "text", "inside": ""}
{"page": 74, "allrow": 1914, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 74, "allrow": 1915, "type": "excel", "inside": "['购买商品、接受劳务支付的现金', '2,179,847,002.37', '2,359,986,308.70']"}
{"page": 74, "allrow": 1916, "type": "excel", "inside": "['客户贷款及垫款净增加额', '', '']"}
{"page": 74, "allrow": 1917, "type": "excel", "inside": "['存放中央银行和同业款项净增加额', '', '']"}
{"page": 74, "allrow": 1918, "type": "excel", "inside": "['支付原保险合同赔付款项的现金', '', '']"}
{"page": 74, "allrow": 1919, "type": "excel", "inside": "['拆出资金净增加额', '', '']"}
{"page": 74, "allrow": 1920, "type": "excel", "inside": "['支付利息、手续费及佣金的现金', '', '']"}
{"page": 74, "allrow": 1921, "type": "excel", "inside": "['支付保单红利的现金', '', '']"}
{"page": 74, "allrow": 1922, "type": "excel", "inside": "['支付给职工以及为职工支付的现金', '556,748,082.79', '567,790,219.01']"}
{"page": 74, "allrow": 1923, "type": "excel", "inside": "['支付的各项税费', '391,540,152.10', '379,482,026.13']"}
{"page": 74, "allrow": 1924, "type": "excel", "inside": "['支付其他与经营活动有关的现金', '907,947,549.51', '837,281,379.88']"}
{"page": 74, "allrow": 1925, "type": "excel", "inside": "['经营活动现金流出小计', '4,036,082,786.77', '4,144,539,933.72']"}
{"page": 74, "allrow": 1926, "type": "excel", "inside": "['经营活动产生的现金流量净额', '1,360,066,190.36', '832,821,083.96']"}
{"page": 74, "allrow": 1927, "type": "excel", "inside": "['二、投资活动产生的现金流量：', '', '']"}
{"page": 74, "allrow": 1928, "type": "excel", "inside": "['收回投资收到的现金', '505,400,000.00', '255,100,000.00']"}
{"page": 74, "allrow": 1929, "type": "excel", "inside": "['取得投资收益收到的现金', '11,457,997.68', '1,981,245.07']"}
{"page": 74, "allrow": 1930, "type": "excel", "inside": "['处置固定资产、无形资产和其他长期资产收回的现金净额', '6,591,688.13', '1,614,457.85']"}
{"page": 74, "allrow": 1931, "type": "excel", "inside": "['处置子公司及其他营业单位收到的现金净额', '', '16,342,307.84']"}
{"page": 74, "allrow": 1932, "type": "excel", "inside": "['收到其他与投资活动有关的现金', '', '']"}
{"page": 74, "allrow": 1933, "type": "excel", "inside": "['投资活动现金流入小计', '523,449,685.81', '275,038,010.76']"}
{"page": 74, "allrow": 1934, "type": "excel", "inside": "['购建固定资产、无形资产和其他长期资产支付的现金', '31,845,884.12', '81,623,163.73']"}
{"page": 74, "allrow": 1935, "type": "excel", "inside": "['投资支付的现金', '864,000,000.00', '356,500,000.00']"}
{"page": 74, "allrow": 1936, "type": "excel", "inside": "['质押贷款净增加额', '', '']"}
{"page": 74, "allrow": 1937, "type": "excel", "inside": "['取得子公司及其他营业单位支付的现金净额', '980,000.00', '']"}
{"page": 74, "allrow": 1938, "type": "excel", "inside": "['支付其他与投资活动有关的现金', '67,458,939.61', '15,894,253.68']"}
{"page": 74, "allrow": 1939, "type": "excel", "inside": "['投资活动现金流出小计', '964,284,823.73', '454,017,417.41']"}
{"page": 74, "allrow": 1940, "type": "text", "inside": ""}
{"page": 74, "allrow": 1941, "type": "页脚", "inside": "74"}
{"page": 75, "allrow": 1942, "type": "text", "inside": ""}
{"page": 75, "allrow": 1943, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 75, "allrow": 1944, "type": "excel", "inside": "['投资活动产生的现金流量净额', '-440,835,137.92', '-178,979,406.65']"}
{"page": 75, "allrow": 1945, "type": "excel", "inside": "['三、筹资活动产生的现金流量：', '', '']"}
{"page": 75, "allrow": 1946, "type": "excel", "inside": "['吸收投资收到的现金', '', '']"}
{"page": 75, "allrow": 1947, "type": "excel", "inside": "['其中：子公司吸收少数股东投资收到的现金', '', '']"}
{"page": 75, "allrow": 1948, "type": "excel", "inside": "['取得借款收到的现金', '380,000,000.00', '1,165,087,344.47']"}
{"page": 75, "allrow": 1949, "type": "excel", "inside": "['收到其他与筹资活动有关的现金', '', '']"}
{"page": 75, "allrow": 1950, "type": "excel", "inside": "['筹资活动现金流入小计', '380,000,000.00', '1,165,087,344.47']"}
{"page": 75, "allrow": 1951, "type": "excel", "inside": "['偿还债务支付的现金', '944,100,000.00', '1,638,995,870.03']"}
{"page": 75, "allrow": 1952, "type": "excel", "inside": "['分配股利、利润或偿付利息支付的现金', '142,052,369.56', '119,835,984.46']"}
{"page": 75, "allrow": 1953, "type": "excel", "inside": "['其中：子公司支付给少数股东的股利、利润', '', '']"}
{"page": 75, "allrow": 1954, "type": "excel", "inside": "['支付其他与筹资活动有关的现金', '', '']"}
{"page": 75, "allrow": 1955, "type": "excel", "inside": "['筹资活动现金流出小计', '1,086,152,369.56', '1,758,831,854.49']"}
{"page": 75, "allrow": 1956, "type": "excel", "inside": "['筹资活动产生的现金流量净额', '-706,152,369.56', '-593,744,510.02']"}
{"page": 75, "allrow": 1957, "type": "excel", "inside": "['四、汇率变动对现金及现金等价物的影响', '3,274,209.02', '7,250,500.17']"}
{"page": 75, "allrow": 1958, "type": "excel", "inside": "['五、现金及现金等价物净增加额', '216,352,891.90', '67,347,667.46']"}
{"page": 75, "allrow": 1959, "type": "excel", "inside": "['加：期初现金及现金等价物余额', '501,720,448.13', '434,372,780.67']"}
{"page": 75, "allrow": 1960, "type": "excel", "inside": "['六、期末现金及现金等价物余额', '718,073,340.03', '501,720,448.13']"}
{"page": 75, "allrow": 1961, "type": "text", "inside": "6、母公司现金流量表"}
{"page": 75, "allrow": 1962, "type": "text", "inside": "单位：元"}
{"page": 75, "allrow": 1963, "type": "excel", "inside": "['项目', '2019年度', '2018年度']"}
{"page": 75, "allrow": 1964, "type": "excel", "inside": "['一、经营活动产生的现金流量：', '', '']"}
{"page": 75, "allrow": 1965, "type": "excel", "inside": "['销售商品、提供劳务收到的现金', '47,650,000.00', '37,800,000.00']"}
{"page": 75, "allrow": 1966, "type": "excel", "inside": "['收到的税费返还', '', '']"}
{"page": 75, "allrow": 1967, "type": "excel", "inside": "['收到其他与经营活动有关的现金', '126,065,129.99', '162,379,470.73']"}
{"page": 75, "allrow": 1968, "type": "excel", "inside": "['经营活动现金流入小计', '173,715,129.99', '200,179,470.73']"}
{"page": 75, "allrow": 1969, "type": "text", "inside": ""}
{"page": 75, "allrow": 1970, "type": "页脚", "inside": "75"}
{"page": 76, "allrow": 1971, "type": "text", "inside": ""}
{"page": 76, "allrow": 1972, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 76, "allrow": 1973, "type": "excel", "inside": "['购买商品、接受劳务支付的现金', '', '']"}
{"page": 76, "allrow": 1974, "type": "excel", "inside": "['支付给职工以及为职工支付的现金', '12,397,385.78', '10,892,787.24']"}
{"page": 76, "allrow": 1975, "type": "excel", "inside": "['支付的各项税费', '1,225,888.83', '2,144,659.21']"}
{"page": 76, "allrow": 1976, "type": "excel", "inside": "['支付其他与经营活动有关的现金', '88,296,801.64', '211,086,980.29']"}
{"page": 76, "allrow": 1977, "type": "excel", "inside": "['经营活动现金流出小计', '101,920,076.25', '224,124,426.74']"}
{"page": 76, "allrow": 1978, "type": "excel", "inside": "['经营活动产生的现金流量净额', '71,795,053.74', '-23,944,956.01']"}
{"page": 76, "allrow": 1979, "type": "excel", "inside": "['二、投资活动产生的现金流量：', '', '']"}
{"page": 76, "allrow": 1980, "type": "excel", "inside": "['收回投资收到的现金', '23,900,000.00', '71,100,000.00']"}
{"page": 76, "allrow": 1981, "type": "excel", "inside": "['取得投资收益收到的现金', '126,514,711.03', '80,784,965.02']"}
{"page": 76, "allrow": 1982, "type": "excel", "inside": "['处置固定资产、无形资产和其他长期资产收回的现金净额', '', '150,000.00']"}
{"page": 76, "allrow": 1983, "type": "excel", "inside": "['处置子公司及其他营业单位收到的现金净额', '', '17,500,000.00']"}
{"page": 76, "allrow": 1984, "type": "excel", "inside": "['收到其他与投资活动有关的现金', '', '']"}
{"page": 76, "allrow": 1985, "type": "excel", "inside": "['投资活动现金流入小计', '150,414,711.03', '169,534,965.02']"}
{"page": 76, "allrow": 1986, "type": "excel", "inside": "['购建固定资产、无形资产和其他长期资产支付的现金', '216,147.27', '439,995.60']"}
{"page": 76, "allrow": 1987, "type": "excel", "inside": "['投资支付的现金', '50,000,000.00', '95,000,000.00']"}
{"page": 76, "allrow": 1988, "type": "excel", "inside": "['取得子公司及其他营业单位支付的现金净额', '980,000.00', '']"}
{"page": 76, "allrow": 1989, "type": "excel", "inside": "['支付其他与投资活动有关的现金', '', '']"}
{"page": 76, "allrow": 1990, "type": "excel", "inside": "['投资活动现金流出小计', '51,196,147.27', '95,439,995.60']"}
{"page": 76, "allrow": 1991, "type": "excel", "inside": "['投资活动产生的现金流量净额', '99,218,563.76', '74,094,969.42']"}
{"page": 76, "allrow": 1992, "type": "excel", "inside": "['三、筹资活动产生的现金流量：', '', '']"}
{"page": 76, "allrow": 1993, "type": "excel", "inside": "['吸收投资收到的现金', '', '']"}
{"page": 76, "allrow": 1994, "type": "excel", "inside": "['取得借款收到的现金', '', '']"}
{"page": 76, "allrow": 1995, "type": "excel", "inside": "['收到其他与筹资活动有关的现金', '', '']"}
{"page": 76, "allrow": 1996, "type": "excel", "inside": "['筹资活动现金流入小计', '', '']"}
{"page": 76, "allrow": 1997, "type": "excel", "inside": "['偿还债务支付的现金', '', '']"}
{"page": 76, "allrow": 1998, "type": "excel", "inside": "['分配股利、利润或偿付利息支付的现金', '129,637,584.12', '76,604,016.50']"}
{"page": 76, "allrow": 1999, "type": "text", "inside": ""}
{"page": 76, "allrow": 2000, "type": "页脚", "inside": "76"}
{"page": 77, "allrow": 2001, "type": "text", "inside": ""}
{"page": 77, "allrow": 2002, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 77, "allrow": 2003, "type": "excel", "inside": "['支付其他与筹资活动有关的现金', '', '']"}
{"page": 77, "allrow": 2004, "type": "excel", "inside": "['筹资活动现金流出小计', '129,637,584.12', '76,604,016.50']"}
{"page": 77, "allrow": 2005, "type": "excel", "inside": "['筹资活动产生的现金流量净额', '-129,637,584.12', '-76,604,016.50']"}
{"page": 77, "allrow": 2006, "type": "excel", "inside": "['四、汇率变动对现金及现金等价物的影响', '', '']"}
{"page": 77, "allrow": 2007, "type": "excel", "inside": "['五、现金及现金等价物净增加额', '41,376,033.38', '-26,454,003.09']"}
{"page": 77, "allrow": 2008, "type": "excel", "inside": "['加：期初现金及现金等价物余额', '636,111.19', '27,090,114.28']"}
{"page": 77, "allrow": 2009, "type": "excel", "inside": "['六、期末现金及现金等价物余额', '42,012,144.57', '636,111.19']"}
{"page": 77, "allrow": 2010, "type": "text", "inside": "7、合并所有者权益变动表"}
{"page": 77, "allrow": 2011, "type": "text", "inside": "本期金额"}
{"page": 77, "allrow": 2012, "type": "text", "inside": "单位：元"}
{"page": 77, "allrow": 2013, "type": "excel", "inside": "['', '2019年度归属于母公司所有者权益', '其他权益工具', '', '', '', '', '', '', '', '', '', '', '', '少数', '所有']"}
{"page": 77, "allrow": 2014, "type": "excel", "inside": "['项目', '股', '优', '永', '', '资本', '减：', '其他', '专项', '盈余', '一般', '未分', '', '', '股东', '者权']"}
{"page": 77, "allrow": 2015, "type": "excel", "inside": "['', '本', '先股', '续债', '其他', '公积', '库存股', '综合收益', '储备', '公积', '风险准备', '配利润', '其他', '小计', '权益', '益合计']"}
{"page": 77, "allrow": 2016, "type": "excel", "inside": "['', '1,178,', '', '', '', '438,', '', '-90,', '', '112,', '', '1,61', '', '3,34', '', '3,34']"}
{"page": 77, "allrow": 2017, "type": "excel", "inside": "['一、上年期末余额', '523,49', '', '', '', '985,920.', '', '895.78', '', '256,875.', '', '5,584,70', '', '5,260,09', '', '5,260,09']"}
{"page": 77, "allrow": 2018, "type": "excel", "inside": "['', '2.00', '', '', '', '01', '', '', '', '56', '', '0.94', '', '2.73', '', '2.73']"}
{"page": 77, "allrow": 2019, "type": "excel", "inside": "['加：会计政策变更', '', '', '', '', '', '', '', '', '', '', '', '', '', '', '']"}
{"page": 77, "allrow": 2020, "type": "excel", "inside": "['前期差错更正', '', '', '', '', '', '', '', '', '', '', '', '', '', '', '']"}
{"page": 77, "allrow": 2021, "type": "excel", "inside": "['同一控制下企业合并', '', '', '', '', '', '', '', '', '', '', '', '', '', '', '']"}
{"page": 77, "allrow": 2022, "type": "excel", "inside": "['其他', '', '', '', '', '', '', '', '', '', '', '', '', '', '', '']"}
{"page": 77, "allrow": 2023, "type": "text", "inside": ""}
{"page": 77, "allrow": 2024, "type": "页脚", "inside": "77"}
{"page": 78, "allrow": 2025, "type": "text", "inside": ""}
{"page": 78, "allrow": 2026, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 78, "allrow": 2027, "type": "excel", "inside": "['', '1,178,', '438,', '-90,', '112,', '1,61', '3,34', '3,34']"}
{"page": 78, "allrow": 2028, "type": "excel", "inside": "['二、本年期初余额', '523,49', '985,920.', '895.78', '256,875.', '5,584,70', '5,260,09', '5,260,09']"}
{"page": 78, "allrow": 2029, "type": "excel", "inside": "['', '2.00', '01', '', '56', '0.94', '2.73', '2.73']"}
{"page": 78, "allrow": 2030, "type": "excel", "inside": "['三、本期增减变动金额（减少以“－”号填列）', '', '-980,000.00', '-56,482.75', '20,503,366.39', '403,259,810.91', '422,726,694.55', '422,726,694.55']"}
{"page": 78, "allrow": 2031, "type": "excel", "inside": "['', '', '', '-56,', '', '553,', '553,', '553,']"}
{"page": 78, "allrow": 2032, "type": "excel", "inside": "['（一）综合收益总额', '', '', '482.75', '', '400,761.', '344,278.', '344,278.']"}
{"page": 78, "allrow": 2033, "type": "excel", "inside": "['', '', '', '', '', '42', '67', '67']"}
{"page": 78, "allrow": 2034, "type": "excel", "inside": "['（二）所有者投入和减少资本', '', '', '', '', '', '', '']"}
{"page": 78, "allrow": 2035, "type": "excel", "inside": "['1．所有者投入的普通股', '', '', '', '', '', '', '']"}
{"page": 78, "allrow": 2036, "type": "excel", "inside": "['2．其他权益工具持有者投入资本', '', '', '', '', '', '', '']"}
{"page": 78, "allrow": 2037, "type": "excel", "inside": "['3．股份支付计入所有者权益的金额', '', '', '', '', '', '', '']"}
{"page": 78, "allrow": 2038, "type": "excel", "inside": "['4．其他', '', '', '', '', '', '', '']"}
{"page": 78, "allrow": 2039, "type": "excel", "inside": "['', '', '', '', '20,5', '-150', '-129', '-129']"}
{"page": 78, "allrow": 2040, "type": "excel", "inside": "['（三）利润分配', '', '', '', '03,366.3', ',140,950.', ',637,584.', ',637,584.']"}
{"page": 78, "allrow": 2041, "type": "excel", "inside": "['', '', '', '', '9', '51', '12', '12']"}
{"page": 78, "allrow": 2042, "type": "excel", "inside": "['', '', '', '', '20,5', '-20,', '', '']"}
{"page": 78, "allrow": 2043, "type": "excel", "inside": "['1．提取盈余公积', '', '', '', '03,366.3', '503,366.', '', '']"}
{"page": 78, "allrow": 2044, "type": "excel", "inside": "['', '', '', '', '9', '39', '', '']"}
{"page": 78, "allrow": 2045, "type": "excel", "inside": "['2．提取一般风险准备', '', '', '', '', '', '', '']"}
{"page": 78, "allrow": 2046, "type": "excel", "inside": "['', '', '', '', '', '-129', '-129', '-129']"}
{"page": 78, "allrow": 2047, "type": "excel", "inside": "['3．对所有者（或股东）的分配', '', '', '', '', ',637,584.12', ',637,584.12', ',637,584.12']"}
{"page": 78, "allrow": 2048, "type": "text", "inside": ""}
{"page": 78, "allrow": 2049, "type": "页脚", "inside": "78"}
{"page": 79, "allrow": 2050, "type": "text", "inside": ""}
{"page": 79, "allrow": 2051, "type": "text", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 79, "allrow": 2052, "type": "excel", "inside": "['4．其他', '', '', '', '', '', '', '', '']"}
{"page": 79, "allrow": 2053, "type": "excel", "inside": "['（四）所有者权益内部结转', '', '', '', '', '', '', '', '']"}
{"page": 79, "allrow": 2054, "type": "excel", "inside": "['1．资本公积转增资本（或股本）', '', '', '', '', '', '', '', '']"}
{"page": 79, "allrow": 2055, "type": "excel", "inside": "['2．盈余公积转增资本（或股本）', '', '', '', '', '', '', '', '']"}
{"page": 79, "allrow": 2056, "type": "excel", "inside": "['3．盈余公积弥补亏损', '', '', '', '', '', '', '', '']"}
{"page": 79, "allrow": 2057, "type": "excel", "inside": "['4．设定受益计划变动额结转留存收益', '', '', '', '', '', '', '', '']"}
{"page": 79, "allrow": 2058, "type": "excel", "inside": "['5．其他综合收益结转留存收益', '', '', '', '', '', '', '', '']"}
{"page": 79, "allrow": 2059, "type": "excel", "inside": "['6．其他', '', '', '', '', '', '', '', '']"}
{"page": 79, "allrow": 2060, "type": "excel", "inside": "['（五）专项储备', '', '', '', '', '', '', '', '']"}
{"page": 79, "allrow": 2061, "type": "excel", "inside": "['1．本期提取', '', '', '', '', '', '', '', '']"}
{"page": 79, "allrow": 2062, "type": "excel", "inside": "['2．本期使用', '', '', '', '', '', '', '', '']"}
{"page": 79, "allrow": 2063, "type": "excel", "inside": "['', '', '-980,000.00', '', '', '', '-980', '', '-980']"}
{"page": 79, "allrow": 2064, "type": "excel", "inside": "['（六）其他', '', '', '', '', '', ',000.', '', ',000.']"}
{"page": 79, "allrow": 2065, "type": "excel", "inside": "['', '', '', '', '', '', '00', '', '00']"}
{"page": 79, "allrow": 2066, "type": "excel", "inside": "['', '1,178,523,492.00', '438,005,920.01', '-147,378.53', '132,', '2,01', '3,76', '3,767,986,787.28', '']"}
{"page": 79, "allrow": 2067, "type": "excel", "inside": "['四、本期期末余额', '', '', '', '760,241.', '8,844,51', '7,986,78', '', '']"}
{"page": 79, "allrow": 2068, "type": "excel", "inside": "['', '', '', '', '95', '1.85', '7.28', '', '']"}
{"page": 79, "allrow": 2069, "type": "text", "inside": ""}
{"page": 79, "allrow": 2070, "type": "text", "inside": "上期金额"}
{"page": 79, "allrow": 2071, "type": "text", "inside": "单位：元"}
{"page": 79, "allrow": 2072, "type": "excel", "inside": "['', '2018年年度', '', '', '', '', '', '', '', '', '', '', '', '']"}
{"page": 79, "allrow": 2073, "type": "excel", "inside": "['项目', '归属于母公司所有者权益', '', '', '', '', '', '', '', '', '', '', '少数', '所有者权']"}
{"page": 79, "allrow": 2074, "type": "excel", "inside": "['', '股', '其他权益工具', '资本', '减：', '其他', '专项', '盈余', '一般', '未分', '其', '小', '股东', '']"}
{"page": 80, "allrow": 2075, "type": "text", "inside": ""}
{"page": 80, "allrow": 2076, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 80, "allrow": 2077, "type": "excel", "inside": "['', '本', '优先股', '永续债', '其他', '公积', '库存股', '综合收益', '储备', '公积', '风险准备', '配利润', '他', '计', '', '权益', '益合计']"}
{"page": 80, "allrow": 2078, "type": "excel", "inside": "['', '1,178,', '', '', '', '438,', '', '-418', '', '97,8', '', '1,33', '', '', '3,05', '', '3,050']"}
{"page": 80, "allrow": 2079, "type": "excel", "inside": "['一、上年期末余额', '523,49', '', '', '', '985,920.', '', ',999.18', '', '36,497.5', '', '6,048,06', '', '', '0,974,97', '', ',974,977.5']"}
{"page": 80, "allrow": 2080, "type": "excel", "inside": "['', '2.00', '', '', '', '01', '', '', '', '6', '', '7.16', '', '', '7.55', '', '5']"}
{"page": 80, "allrow": 2081, "type": "excel", "inside": "['加：会计政策变更', '', '', '', '', '', '', '', '', '', '', '', '', '', '', '', '']"}
{"page": 80, "allrow": 2082, "type": "excel", "inside": "['前期差错更正', '', '', '', '', '', '', '', '', '', '', '', '', '', '', '', '']"}
{"page": 80, "allrow": 2083, "type": "excel", "inside": "['同一控制下企业合并', '', '', '', '', '', '', '', '', '', '', '', '', '', '', '', '']"}
{"page": 80, "allrow": 2084, "type": "excel", "inside": "['其他', '', '', '', '', '', '', '', '', '', '', '', '', '', '', '', '']"}
{"page": 80, "allrow": 2085, "type": "excel", "inside": "['', '1,178,', '', '', '', '438,', '', '-418', '', '97,8', '', '1,33', '', '', '3,05', '', '3,050']"}
{"page": 80, "allrow": 2086, "type": "excel", "inside": "['二、本年期初余额', '523,49', '', '', '', '985,920.', '', ',999.18', '', '36,497.5', '', '6,048,06', '', '', '0,974,97', '', ',974,977.5']"}
{"page": 80, "allrow": 2087, "type": "excel", "inside": "['', '2.00', '', '', '', '01', '', '', '', '6', '', '7.16', '', '', '7.55', '', '5']"}
{"page": 80, "allrow": 2088, "type": "excel", "inside": "['三、本期增减变动金额（减少以“－”号填列）', '', '', '', '', '', '', '328,103.40', '', '14,420,378.00', '', '279,536,633.78', '', '', '294,285,115.18', '', '294,285,115.18']"}
{"page": 80, "allrow": 2089, "type": "excel", "inside": "['', '', '', '', '', '', '', '328,', '', '', '', '370,', '', '', '370,', '', '370,8']"}
{"page": 80, "allrow": 2090, "type": "excel", "inside": "['（一）综合收益总额', '', '', '', '', '', '', '103.40', '', '', '', '561,028.', '', '', '889,131.', '', '89,131.68']"}
{"page": 80, "allrow": 2091, "type": "excel", "inside": "['', '', '', '', '', '', '', '', '', '', '', '28', '', '', '68', '', '']"}
{"page": 80, "allrow": 2092, "type": "excel", "inside": "['（二）所有者投入和减少资本', '', '', '', '', '', '', '', '', '', '', '', '', '', '', '', '']"}
{"page": 80, "allrow": 2093, "type": "excel", "inside": "['1．所有者投入的普通股', '', '', '', '', '', '', '', '', '', '', '', '', '', '', '', '']"}
{"page": 80, "allrow": 2094, "type": "excel", "inside": "['2．其他权益工具持有者投入资本', '', '', '', '', '', '', '', '', '', '', '', '', '', '', '', '']"}
{"page": 80, "allrow": 2095, "type": "text", "inside": ""}
{"page": 80, "allrow": 2096, "type": "页脚", "inside": "80"}
{"page": 81, "allrow": 2097, "type": "text", "inside": ""}
{"page": 81, "allrow": 2098, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 81, "allrow": 2099, "type": "excel", "inside": "['3．股份支付计入所有者权益的金额', '', '', '', '']"}
{"page": 81, "allrow": 2100, "type": "excel", "inside": "['4．其他', '', '', '', '']"}
{"page": 81, "allrow": 2101, "type": "excel", "inside": "['', '14,4', '-91,', '-76,', '-76,6']"}
{"page": 81, "allrow": 2102, "type": "excel", "inside": "['（三）利润分配', '20,378.0', '024,394.', '604,016.', '04,016.50']"}
{"page": 81, "allrow": 2103, "type": "excel", "inside": "['', '0', '50', '50', '']"}
{"page": 81, "allrow": 2104, "type": "excel", "inside": "['', '14,4', '-14,', '', '']"}
{"page": 81, "allrow": 2105, "type": "excel", "inside": "['1．提取盈余公积', '20,378.0', '420,378.', '', '']"}
{"page": 81, "allrow": 2106, "type": "excel", "inside": "['', '0', '00', '', '']"}
{"page": 81, "allrow": 2107, "type": "excel", "inside": "['2．提取一般风险准备', '', '', '', '']"}
{"page": 81, "allrow": 2108, "type": "excel", "inside": "['', '', '-76,', '-76,', '']"}
{"page": 81, "allrow": 2109, "type": "excel", "inside": "['3．对所有者（或股东）的分配', '', '604,016.50', '604,016.50', '-76,604,016.50']"}
{"page": 81, "allrow": 2110, "type": "excel", "inside": "['4．其他', '', '', '', '']"}
{"page": 81, "allrow": 2111, "type": "excel", "inside": "['（四）所有者权益内部结转', '', '', '', '']"}
{"page": 81, "allrow": 2112, "type": "excel", "inside": "['1．资本公积转增资本（或股本）', '', '', '', '']"}
{"page": 81, "allrow": 2113, "type": "excel", "inside": "['2．盈余公积转增资本（或股本）', '', '', '', '']"}
{"page": 81, "allrow": 2114, "type": "excel", "inside": "['3．盈余公积弥补亏损', '', '', '', '']"}
{"page": 81, "allrow": 2115, "type": "excel", "inside": "['4．设定受益计划变动额结转留存收益', '', '', '', '']"}
{"page": 81, "allrow": 2116, "type": "excel", "inside": "['5．其他综合收益结转留存收益', '', '', '', '']"}
{"page": 81, "allrow": 2117, "type": "excel", "inside": "['6．其他', '', '', '', '']"}
{"page": 81, "allrow": 2118, "type": "excel", "inside": "['（五）专项储备', '', '', '', '']"}
{"page": 81, "allrow": 2119, "type": "text", "inside": ""}
{"page": 81, "allrow": 2120, "type": "页脚", "inside": "81"}
{"page": 82, "allrow": 2121, "type": "text", "inside": ""}
{"page": 82, "allrow": 2122, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 82, "allrow": 2123, "type": "excel", "inside": "['1．本期提取', '', '', '', '', '', '', '']"}
{"page": 82, "allrow": 2124, "type": "excel", "inside": "['2．本期使用', '', '', '', '', '', '', '']"}
{"page": 82, "allrow": 2125, "type": "excel", "inside": "['（六）其他', '', '', '', '', '', '', '']"}
{"page": 82, "allrow": 2126, "type": "excel", "inside": "['', '1,178,', '438,985,920.01', '-90,', '112,256,875.56', '1,61', '3,34', '3,345']"}
{"page": 82, "allrow": 2127, "type": "excel", "inside": "['四、本期期末余额', '523,49', '', '895.78', '', '5,584,70', '5,260,09', ',260,092.7']"}
{"page": 82, "allrow": 2128, "type": "excel", "inside": "['', '2.00', '', '', '', '0.94', '2.73', '3']"}
{"page": 82, "allrow": 2129, "type": "text", "inside": ""}
{"page": 82, "allrow": 2130, "type": "text", "inside": "8、母公司所有者权益变动表"}
{"page": 82, "allrow": 2131, "type": "text", "inside": "本期金额"}
{"page": 82, "allrow": 2132, "type": "text", "inside": "单位：元"}
{"page": 82, "allrow": 2133, "type": "excel", "inside": "['', '2019年度', '其他权益工具', '', '', '', '', '其他综合收益', '', '', '未分', '', '所有者']"}
{"page": 82, "allrow": 2134, "type": "excel", "inside": "['项目', '股本', '优先', '永续债', '', '资本', '减：库', '', '专项储备', '盈余', '配利', '其他', '权益合']"}
{"page": 82, "allrow": 2135, "type": "excel", "inside": "['', '', '股', '', '其他', '公积', '存股', '', '', '公积', '润', '', '计']"}
{"page": 82, "allrow": 2136, "type": "excel", "inside": "['', '1,178', '', '', '', '860,94', '', '', '', '56,159', '149,', '', '']"}
{"page": 82, "allrow": 2137, "type": "excel", "inside": "['一、上年期末余额', ',523,492.0', '', '', '', '9,785.11', '', '', '', ',828.86', '031,059.', '', '2,244,664,165.30']"}
{"page": 82, "allrow": 2138, "type": "excel", "inside": "['', '0', '', '', '', '', '', '', '', '', '33', '', '']"}
{"page": 82, "allrow": 2139, "type": "excel", "inside": "['加：会计政策变更', '', '', '', '', '', '', '', '', '', '', '', '']"}
{"page": 82, "allrow": 2140, "type": "excel", "inside": "['前期差错更正', '', '', '', '', '', '', '', '', '', '', '', '']"}
{"page": 82, "allrow": 2141, "type": "excel", "inside": "['其他', '', '', '', '', '', '', '', '', '', '', '', '']"}
{"page": 82, "allrow": 2142, "type": "excel", "inside": "['', '1,178', '', '', '', '860,94', '', '', '', '56,159', '149,', '', '']"}
{"page": 82, "allrow": 2143, "type": "excel", "inside": "['二、本年期初余额', ',523,492.0', '', '', '', '9,785.11', '', '', '', ',828.86', '031,059.', '', '2,244,664,165.30']"}
{"page": 82, "allrow": 2144, "type": "excel", "inside": "['', '0', '', '', '', '', '', '', '', '', '33', '', '']"}
{"page": 82, "allrow": 2145, "type": "excel", "inside": "['三、本期增减变动金额（减少以“－”号填列）', '', '', '', '', '-5,445.02', '', '', '', '20,503,366.39', '54,892,713.34', '', '75,390,634.71']"}
{"page": 82, "allrow": 2146, "type": "excel", "inside": "['', '', '', '', '', '', '', '', '', '', '205,', '', '']"}
{"page": 82, "allrow": 2147, "type": "excel", "inside": "['（一）综合收益总额', '', '', '', '', '', '', '', '', '', '033,663.', '', '205,033,663.85']"}
{"page": 82, "allrow": 2148, "type": "excel", "inside": "['', '', '', '', '', '', '', '', '', '', '85', '', '']"}
{"page": 82, "allrow": 2149, "type": "text", "inside": ""}
{"page": 82, "allrow": 2150, "type": "页脚", "inside": "82"}
{"page": 83, "allrow": 2151, "type": "text", "inside": ""}
{"page": 83, "allrow": 2152, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 83, "allrow": 2153, "type": "excel", "inside": "['（二）所有者投入和减少资本', '', '', '']"}
{"page": 83, "allrow": 2154, "type": "excel", "inside": "['1．所有者投入的普通股', '', '', '']"}
{"page": 83, "allrow": 2155, "type": "excel", "inside": "['2．其他权益工具持有者投入资本', '', '', '']"}
{"page": 83, "allrow": 2156, "type": "excel", "inside": "['3．股份支付计入所有者权益的金额', '', '', '']"}
{"page": 83, "allrow": 2157, "type": "excel", "inside": "['4．其他', '', '', '']"}
{"page": 83, "allrow": 2158, "type": "excel", "inside": "['', '20,503', '-150,', '']"}
{"page": 83, "allrow": 2159, "type": "excel", "inside": "['（三）利润分配', ',366.39', '140,950.', '-129,637,584.12']"}
{"page": 83, "allrow": 2160, "type": "excel", "inside": "['', '', '51', '']"}
{"page": 83, "allrow": 2161, "type": "excel", "inside": "['', '20,503', '-20,5', '']"}
{"page": 83, "allrow": 2162, "type": "excel", "inside": "['1．提取盈余公积', ',366.39', '03,366.3', '']"}
{"page": 83, "allrow": 2163, "type": "excel", "inside": "['', '', '9', '']"}
{"page": 83, "allrow": 2164, "type": "excel", "inside": "['', '', '-129,', '']"}
{"page": 83, "allrow": 2165, "type": "excel", "inside": "['2．对所有者（或股东）的分配', '', '637,584.12', '-129,637,584.12']"}
{"page": 83, "allrow": 2166, "type": "excel", "inside": "['3．其他', '', '', '']"}
{"page": 83, "allrow": 2167, "type": "excel", "inside": "['（四）所有者权益内部结转', '', '', '']"}
{"page": 83, "allrow": 2168, "type": "excel", "inside": "['1．资本公积转增资本（或股本）', '', '', '']"}
{"page": 83, "allrow": 2169, "type": "excel", "inside": "['2．盈余公积转增资本（或股本）', '', '', '']"}
{"page": 83, "allrow": 2170, "type": "excel", "inside": "['3．盈余公积弥补亏损', '', '', '']"}
{"page": 83, "allrow": 2171, "type": "excel", "inside": "['4．设定受益计划变动额结转留存收益', '', '', '']"}
{"page": 83, "allrow": 2172, "type": "text", "inside": ""}
{"page": 83, "allrow": 2173, "type": "页脚", "inside": "83"}
{"page": 84, "allrow": 2174, "type": "text", "inside": ""}
{"page": 84, "allrow": 2175, "type": "text", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 84, "allrow": 2176, "type": "excel", "inside": "['5．其他综合收益结转留存收益', '', '', '', '', '', '', '']"}
{"page": 84, "allrow": 2177, "type": "excel", "inside": "['6．其他', '', '', '', '', '', '', '']"}
{"page": 84, "allrow": 2178, "type": "excel", "inside": "['（五）专项储备', '', '', '', '', '', '', '']"}
{"page": 84, "allrow": 2179, "type": "excel", "inside": "['1．本期提取', '', '', '', '', '', '', '']"}
{"page": 84, "allrow": 2180, "type": "excel", "inside": "['2．本期使用', '', '', '', '', '', '', '']"}
{"page": 84, "allrow": 2181, "type": "excel", "inside": "['', '', '-5,445.', '', '', '', '', '-5,445.0']"}
{"page": 84, "allrow": 2182, "type": "excel", "inside": "['（六）其他', '', '02', '', '', '', '', '2']"}
{"page": 84, "allrow": 2183, "type": "excel", "inside": "['', '1,178', '860,94', '76,663', '203', ',,.', '2,320,054,800.01', '']"}
{"page": 84, "allrow": 2184, "type": "excel", "inside": "['四、本期期末余额', ',523,492.0', '4,340.09', ',195.25', '923772', '', '', '']"}
{"page": 84, "allrow": 2185, "type": "excel", "inside": "['', '0', '', '', '67', '', '', '']"}
{"page": 84, "allrow": 2186, "type": "text", "inside": ""}
{"page": 84, "allrow": 2187, "type": "text", "inside": "上期金额"}
{"page": 84, "allrow": 2188, "type": "text", "inside": "单位：元"}
{"page": 84, "allrow": 2189, "type": "excel", "inside": "['', '2018年年度', '其他权益工具', '', '', '', '', '其他', '', '', '', '其他', '所有者权益合计']"}
{"page": 84, "allrow": 2190, "type": "excel", "inside": "['项目', '股本', '优', '永', '其他', '资本', '减：库', '综合', '专项储', '盈余', '未分配', '', '']"}
{"page": 84, "allrow": 2191, "type": "excel", "inside": "['', '', '先股', '续债', '', '公积', '存股', '收益', '备', '公积', '利润', '', '']"}
{"page": 84, "allrow": 2192, "type": "excel", "inside": "['', '1,178,523,492.00', '', '', '', '860,9', '', '', '', '41,73', '', '', '']"}
{"page": 84, "allrow": 2193, "type": "excel", "inside": "['一、上年期末余额', '', '', '', '', '49,785.11', '', '', '', '9,450.86', '95,851,673.85', '', '2,177,064,401.82']"}
{"page": 84, "allrow": 2194, "type": "excel", "inside": "['加：会计政策变更', '', '', '', '', '', '', '', '', '', '', '', '']"}
{"page": 84, "allrow": 2195, "type": "excel", "inside": "['前期差错更正', '', '', '', '', '', '', '', '', '', '', '', '']"}
{"page": 84, "allrow": 2196, "type": "excel", "inside": "['其他', '', '', '', '', '', '', '', '', '', '', '', '']"}
{"page": 84, "allrow": 2197, "type": "excel", "inside": "['', '1,178,523,492.00', '', '', '', '860,9', '', '', '', '41,73', '', '', '']"}
{"page": 84, "allrow": 2198, "type": "excel", "inside": "['二、本年期初余额', '', '', '', '', '49,785.11', '', '', '', '9,450.86', '95,851,673.85', '', '2,177,064,401.82']"}
{"page": 84, "allrow": 2199, "type": "excel", "inside": "['三、本期增减变动金额（减少以“－”号填列）', '', '', '', '', '', '', '', '', '14,420,378.00', '53,179,385.48', '', '67,599,763.48']"}
{"page": 85, "allrow": 2200, "type": "text", "inside": ""}
{"page": 85, "allrow": 2201, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 85, "allrow": 2202, "type": "excel", "inside": "['', '', '144,20', '']"}
{"page": 85, "allrow": 2203, "type": "excel", "inside": "['（一）综合收益总额', '', '3,779.98', '144,203,779.98']"}
{"page": 85, "allrow": 2204, "type": "excel", "inside": "['（二）所有者投入和减少资本', '', '', '']"}
{"page": 85, "allrow": 2205, "type": "excel", "inside": "['1．所有者投入的普通股', '', '', '']"}
{"page": 85, "allrow": 2206, "type": "excel", "inside": "['2．其他权益工具持有者投入资本', '', '', '']"}
{"page": 85, "allrow": 2207, "type": "excel", "inside": "['3．股份支付计入所有者权益的金额', '', '', '']"}
{"page": 85, "allrow": 2208, "type": "excel", "inside": "['4．其他', '', '', '']"}
{"page": 85, "allrow": 2209, "type": "excel", "inside": "['', '14,42', '', '']"}
{"page": 85, "allrow": 2210, "type": "excel", "inside": "['（三）利润分配', '0,378.00', '-91,024,394.50', '-76,604,016.50']"}
{"page": 85, "allrow": 2211, "type": "excel", "inside": "['', '14,42', '', '']"}
{"page": 85, "allrow": 2212, "type": "excel", "inside": "['1．提取盈余公积', '0,378.00', '-14,420,378.00', '']"}
{"page": 85, "allrow": 2213, "type": "excel", "inside": "['2．对所有者（或股东）的分配', '', '-76,604,016.50', '-76,604,016.50']"}
{"page": 85, "allrow": 2214, "type": "excel", "inside": "['3．其他', '', '', '']"}
{"page": 85, "allrow": 2215, "type": "excel", "inside": "['（四）所有者权益内部结转', '', '', '']"}
{"page": 85, "allrow": 2216, "type": "excel", "inside": "['1．资本公积转增资本（或股本）', '', '', '']"}
{"page": 85, "allrow": 2217, "type": "excel", "inside": "['2．盈余公积转增资本（或股本）', '', '', '']"}
{"page": 85, "allrow": 2218, "type": "excel", "inside": "['3．盈余公积弥补亏损', '', '', '']"}
{"page": 85, "allrow": 2219, "type": "excel", "inside": "['4．设定受益计划变动额结转留存收益', '', '', '']"}
{"page": 85, "allrow": 2220, "type": "text", "inside": ""}
{"page": 85, "allrow": 2221, "type": "页脚", "inside": "85"}
{"page": 86, "allrow": 2222, "type": "text", "inside": ""}
{"page": 86, "allrow": 2223, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 86, "allrow": 2224, "type": "excel", "inside": "['5．其他综合收益结转留存收益', '', '', '', '', '']"}
{"page": 86, "allrow": 2225, "type": "excel", "inside": "['6．其他', '', '', '', '', '']"}
{"page": 86, "allrow": 2226, "type": "excel", "inside": "['（五）专项储备', '', '', '', '', '']"}
{"page": 86, "allrow": 2227, "type": "excel", "inside": "['1．本期提取', '', '', '', '', '']"}
{"page": 86, "allrow": 2228, "type": "excel", "inside": "['2．本期使用', '', '', '', '', '']"}
{"page": 86, "allrow": 2229, "type": "excel", "inside": "['（六）其他', '', '', '', '', '']"}
{"page": 86, "allrow": 2230, "type": "excel", "inside": "['', '1,17', '860,9', '56,15', '149,03', '']"}
{"page": 86, "allrow": 2231, "type": "excel", "inside": "['四、本期期末余额', '8,523,49', '49,785.11', '9,828.86', '1,059.33', '2,244,664,165.30']"}
{"page": 86, "allrow": 2232, "type": "excel", "inside": "['', '2.00', '', '', '', '']"}
{"page": 86, "allrow": 2233, "type": "text", "inside": ""}
{"page": 86, "allrow": 2234, "type": "text", "inside": "三、公司基本情况"}
{"page": 86, "allrow": 2235, "type": "text", "inside": "普洛药业股份有限公司（以下简称“本公司”或“公司”），原名称为普洛股份有限公司、普洛康裕股份有限公司、青岛普洛药业股份有限公司、青岛东方集团股份有限公司、青岛东方贸易大厦股份有限公司，是1997年1月20日经青岛市经济体制改革委员会青体改发【1997】5号文件批准，在原青岛东方贸易大厦的基础上，由五家发起人共同发起设立。经中国证券监督管理委员会证监发字【1997】152、153号文件批准，向社会公开发行3000万股人民币普通股股票，并于1997年5月9日在深圳证券交易所上市流通。"}
{"page": 86, "allrow": 2236, "type": "text", "inside": "1998年7月，公司以1997年末总股本6,300万股为基数，以资本公积向公司全体股东每10股转增2股，公司注册资本增至7,560万元。"}
{"page": 86, "allrow": 2237, "type": "text", "inside": "1999年5月，公司以1998年末总股本7,560万股为基数，以资本公积向公司全体股东每10股转增5.5股，转增股本4,158万股，同时，按每10股送红股2.5股的比例，派送红股1,890万股，公司注册资本增至13,608万元。"}
{"page": 86, "allrow": 2238, "type": "text", "inside": "1999年9月，经中国证监会证监公司字[1999]77号文批准，公司以1998年末总股本7,560万股为基数每10股配2.5股，配股价为每股7.80元；实际配售966.923万股，其中社会公众配售900万股，青岛市供销社配售66.923万股，公司注册资本增至14,574.923万元。"}
{"page": 86, "allrow": 2239, "type": "text", "inside": "2001年12月，公司对原有的资产进行重组，主营业务发生了根本性的变化，即由原先的商业零售领域转向医药化工等高新技术领域。"}
{"page": 86, "allrow": 2240, "type": "text", "inside": "2007年4月2日，公司经中国证券监督管理委员会证监发行字【2007】59号文批准，公开发行25,407,894股人民币普通股股票，公司注册资本增至171,157,124.00元。"}
{"page": 86, "allrow": 2241, "type": "text", "inside": "2007年7月，公司以2007年增发后的总股本171,157,124股为基数，以资本公积金向公司全体股东每10股转增2股，转增股本34,231,425股，同时，按每10股送红股3股的比例，派送红股51,347,137股，公司注册资本增至256,735,686.00元。"}
{"page": 86, "allrow": 2242, "type": "text", "inside": "2012年12月21日，经中国证券监督管理委员会《关于核准普洛股份有限公司及向横店集团控股有限公司等发行股份购买资产并募集配套资金的批复》（证监许可【2012】1724号）文件核准：公司向横店集团控股有限公司发行17,400,615股股份、向横店集团康裕药业有限公司（以下简称“横店康裕药业”）发行股份22,907,880股股份、向横店集团家园化工有限公司（以下简称“横店家园化工”）发行17,211,607股股份、向浙江横店进出口有限公司（以下简称“横店进出口”）发行60,212,655"}
{"page": 86, "allrow": 2243, "type": "text", "inside": "股股份，合计发行117,732,757股股份购买相关资产（含负债）；公司非公开发行不超过40,983,600股新股募集此次发行股份购买资产的配套资金。根据公司与横店集团控股有限公司、横店康裕药业、横店家园化工和横店进出口签署的《关于非公开"}
{"page": 86, "allrow": 2244, "type": "text", "inside": "发行股份购买资产协议》约定，公司与横店集团控股有限公司等公司于2012年12月24日和25日进行了相关资产（含负债）的"}
{"page": 86, "allrow": 2245, "type": "text", "inside": "交付。2012年12月26日，山东汇德会计师事务所有限公司出具了（2012）汇所验字第5-019号验资报告，对定向发行的"}
{"page": 86, "allrow": 2246, "type": "页脚", "inside": "86"}
{"page": 87, "allrow": 2247, "type": "text", "inside": ""}
{"page": 87, "allrow": 2248, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 87, "allrow": 2249, "type": "text", "inside": "117,732,757股股份予以了验证。"}
{"page": 87, "allrow": 2250, "type": "text", "inside": "2013年3月11日，公司以非公开发行方式向江信基金公司－工行－中江国际信托定增二号资产管理计划、尚建华、华宝信托有限责任公司、常州投资集团有限公司、高安良和毕磊六名特定投资者发行33,259,423股人民币普通股（A股）募集配套资金，每股面值1元，每股发行价格9.02元，相关特定投资者股东以现金认购299,999,995.46元，扣除与发行有关的费用24,680,983.53元，公司实际募集资金净额为275,319,011.93元。2013年3月18日，山东汇德会计师事务所有限公司出具了（2013）汇所验字第5-001号验资报告，对定向发行的33,259,423股股份予以了验证。"}
{"page": 87, "allrow": 2251, "type": "text", "inside": "2013年6月，公司以2013年增发后的总股本407,727,866股为基数，以资本公积金向公司全体股东每10股转增10股，转增股本407,727,866股，公司注册资本增至815,455,732.00元。"}
{"page": 87, "allrow": 2252, "type": "text", "inside": "2014年5月，公司以2013年末的总股本815,455,732股为基数，以资本公积金向公司全体股东每10股转增3股，转增股本244,636,719股，公司注册资本增至1,060,092,451.00元。"}
{"page": 87, "allrow": 2253, "type": "text", "inside": "2014年9月，根据公司2013年度第五届董事会第二十次会议决议和2013年度股东大会决议并经中国证券监督管理委员会证监许可[2014]804号《关于核准普洛药业股份有限公司非公开发行股票的批复》文件，公司于2014年9月11日以非公开发行方式向横店集团控股有限公司、杨晓轩、朱素平等三名特定投资者发行86,776,859股人民币普通股（A股），本次发行后公司的注册资本为人民币1,146,869,310.00元。"}
{"page": 87, "allrow": 2254, "type": "text", "inside": "2017年11月，根据公司第六届董事会第十一次会议决议、第十九次会议决议和2014年度股东大会决议、2016年第二次临时股东大会决议，并经中国证券监督管理委员会证监许可[2017]1646号《关于核准普洛药业股份有限公司非公开发行股票的批复》文件，公司以非公开发行方式向横店集团控股有限公司发行人民币普通股（A股）31,654,182股，本次发行后公司的注册资本为人民币1,178,523,492.00元。"}
{"page": 87, "allrow": 2255, "type": "text", "inside": "公司统一信用代码：913300002646284831，法人代表：祝方猛。截至报告日公司注册资本为1,178,523,492.00元，股本为1,178,523,492.00元。"}
{"page": 87, "allrow": 2256, "type": "text", "inside": "本公司组织形式：股份有限公司。"}
{"page": 87, "allrow": 2257, "type": "text", "inside": "公司注册地：浙江省东阳市横店江南路399号。"}
{"page": 87, "allrow": 2258, "type": "text", "inside": "本公司的母公司为横店集团控股有限公司，实际控制人为横店社团经济企业联合会。"}
{"page": 87, "allrow": 2259, "type": "text", "inside": "公司经营范围：医药行业投资、网络投资、股权投资管理、生物制药技术的研究、开发、转让，国内贸易；经营进出口业务。（依法须经批准的项目，经相关部门批准后方可开展经营活动）"}
{"page": 87, "allrow": 2260, "type": "text", "inside": "本财务报表业经公司董事会于二〇二〇年三月十一日批准报出。"}
{"page": 87, "allrow": 2261, "type": "text", "inside": "纳入公司本期合并报表范围的公司："}
{"page": 87, "allrow": 2262, "type": "excel", "inside": "['序号', '子公司名称']"}
{"page": 87, "allrow": 2263, "type": "excel", "inside": "['1', '浙江普洛康裕制药有限公司']"}
{"page": 87, "allrow": 2264, "type": "excel", "inside": "['2', '浙江普洛得邦制药有限公司']"}
{"page": 87, "allrow": 2265, "type": "excel", "inside": "['3', '浙江普洛家园药业有限公司']"}
{"page": 87, "allrow": 2266, "type": "excel", "inside": "['4', '安徽普洛生物科技有限公司']"}
{"page": 87, "allrow": 2267, "type": "excel", "inside": "['5', '上海裕缘生物医药研发有限公司']"}
{"page": 87, "allrow": 2268, "type": "excel", "inside": "['6', '浙江优胜美特医药有限公司']"}
{"page": 87, "allrow": 2269, "type": "excel", "inside": "['7', '浙江优胜美特中药有限公司']"}
{"page": 87, "allrow": 2270, "type": "excel", "inside": "['8', '浙江普洛生物科技有限公司']"}
{"page": 87, "allrow": 2271, "type": "excel", "inside": "['9', '山东汉兴医药科技有限公司']"}
{"page": 87, "allrow": 2272, "type": "excel", "inside": "['10', '浙江横店普洛进出口有限公司']"}
{"page": 87, "allrow": 2273, "type": "excel", "inside": "['11', '浙江巨泰药业有限公司']"}
{"page": 87, "allrow": 2274, "type": "excel", "inside": "['12', '横店集团成都分子实验室有限公司']"}
{"page": 87, "allrow": 2275, "type": "text", "inside": ""}
{"page": 87, "allrow": 2276, "type": "页脚", "inside": "87"}
{"page": 88, "allrow": 2277, "type": "text", "inside": ""}
{"page": 88, "allrow": 2278, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 88, "allrow": 2279, "type": "excel", "inside": "['13', '山东普洛得邦医药有限公司']"}
{"page": 88, "allrow": 2280, "type": "excel", "inside": "['14', '山西优胜美特药业有限公司']"}
{"page": 88, "allrow": 2281, "type": "excel", "inside": "['15', '成都邦瑞医药科技有限公司']"}
{"page": 88, "allrow": 2282, "type": "excel", "inside": "['16', '普洛香港有限公司']"}
{"page": 88, "allrow": 2283, "type": "excel", "inside": "['17', 'JT Pharmaceutical Inc']"}
{"page": 88, "allrow": 2284, "type": "excel", "inside": "['18', '宁波普洛进出口有限公司']"}
{"page": 88, "allrow": 2285, "type": "excel", "inside": "['19', '杭州优胜美特药物研究院有限公司']"}
{"page": 88, "allrow": 2286, "type": "excel", "inside": "['20', '东阳普洛康裕保健食品有限公司']"}
{"page": 88, "allrow": 2287, "type": "text", "inside": ""}
{"page": 88, "allrow": 2288, "type": "text", "inside": "报告期内增加合并单位原因：本期公司以同一控制下企业合并方式取得东阳普洛康裕保健食品有限公司100%股权，故增加了合并单位。"}
{"page": 88, "allrow": 2289, "type": "text", "inside": "报告期内减少合并单位原因：本期公司子公司优胜美特中药通过整体吸收合并的方式合并康裕保健品，合并完成后优胜美特中药存续经营，康裕保健品的独立法人资格注销，故减少了合并单位。"}
{"page": 88, "allrow": 2290, "type": "text", "inside": "四、财务报表的编制基础"}
{"page": 88, "allrow": 2291, "type": "text", "inside": "1、编制基础"}
{"page": 88, "allrow": 2292, "type": "text", "inside": "本公司财务报表以持续经营为基础，根据实际发生的交易和事项，按照财政部颁布的《企业会计准则》及相关规定，以及中国证券监督管理委员会《公开发行证券的公司信息披露编报规则第15号——财务报告的一般规定》(2014年修订)的披露规定，并基于以下所述重要会计政策、会计估计进行编制。"}
{"page": 88, "allrow": 2293, "type": "text", "inside": "本公司会计核算以权责发生制为基础。除某些金融工具外，本财务报表均以历史成本为计量基础。资产如果发生减值，则按照相关规定计提相应的减值准备。"}
{"page": 88, "allrow": 2294, "type": "text", "inside": "2、持续经营"}
{"page": 88, "allrow": 2295, "type": "text", "inside": "本公司不存在导致对报告期末起12个月内的持续经营假设产生重大疑虑的的事项或情况。"}
{"page": 88, "allrow": 2296, "type": "text", "inside": "五、重要会计政策及会计估计"}
{"page": 88, "allrow": 2297, "type": "text", "inside": "具体会计政策和会计估计提示："}
{"page": 88, "allrow": 2298, "type": "text", "inside": "重要提示：本公司根据实际生产经营特点针对应收款项坏账准备计提、固定资产折旧、无形资产摊销、收入确认等交易或事项制定了具体会计政策和会计估计。"}
{"page": 88, "allrow": 2299, "type": "text", "inside": "1、遵循企业会计准则的声明"}
{"page": 88, "allrow": 2300, "type": "text", "inside": "本公司所编制的财务报表符合企业会计准则的要求，真实、完整地反映了公司的财务状况、经营成果、股东权益变动和现金流量等有关信息。"}
{"page": 88, "allrow": 2301, "type": "页脚", "inside": "88"}
{"page": 89, "allrow": 2302, "type": "text", "inside": ""}
{"page": 89, "allrow": 2303, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 89, "allrow": 2304, "type": "text", "inside": "2、会计期间"}
{"page": 89, "allrow": 2305, "type": "text", "inside": "本公司会计年度为公历年度，即每年1月1日起至12月31日止。"}
{"page": 89, "allrow": 2306, "type": "text", "inside": "3、营业周期"}
{"page": 89, "allrow": 2307, "type": "text", "inside": "正常营业周期，是指本公司从购买用于加工的资产起至实现现金或现金等价物的期间。本公司以12个月作为一个营业周期，并以其作为资产和负债的流动性划分标准。"}
{"page": 89, "allrow": 2308, "type": "text", "inside": "4、记账本位币"}
{"page": 89, "allrow": 2309, "type": "text", "inside": "本公司以人民币作为记账本位币。"}
{"page": 89, "allrow": 2310, "type": "text", "inside": "5、同一控制下和非同一控制下企业合并的会计处理方法"}
{"page": 89, "allrow": 2311, "type": "text", "inside": "企业合并，是指将两个或两个以上单独的企业合并形成一个报告主体的交易或事项。企业合并分为同一控制下企业合并和非同一控制下企业合并。"}
{"page": 89, "allrow": 2312, "type": "text", "inside": "（1）同一控制下企业合并"}
{"page": 89, "allrow": 2313, "type": "text", "inside": "同一控制下企业合并形成的长期股权投资合并方以支付现金、转让非现金资产或承担债务方式作为合并对价的，本公司在合并日按照所取得的被合并方在最终控制方合并财务报表中的净资产的账面价值的份额作为长期股权投资的初始投资成本。被合并方在合并日的净资产账面价值为负数的，长期股权投资成本按零确定。如果被合并方在被合并以前，是最终控制方通过非同一控制下的企业合并所控制的，则合并方长期股权投资的初始投资成本包含了相关的商誉金额。长期股权投资的初始投资成本与支付的现金、转让的非现金资产及所承担债务账面价值之间的差额，应当调整资本公积（资本溢价或股本溢价）；资本公积（资本溢价或股本溢价）的余额不足冲减的，依次冲减盈余公积和未分配利润。合并方以发行权益性工具作为合并对价的，按发行股份的面值总额作为股本，长期股权投资的初始投资成本与所发行股份面值总额之间的差额，调整资本公积（资本溢价或股本溢价）；资本公积（资本溢价或股本溢价）不足冲减的，依次冲减盈余公积和未分配利润。"}
{"page": 89, "allrow": 2314, "type": "text", "inside": "合并方发生的审计、法律服务、评估咨询等中介费用以及其他相关管理费用，于发生时计入当期损益。与发行权益性工具作为合并对价直接相关的交易费用，冲减资本公积（股本溢价），资本公积（股本溢价）不足冲减的，依次冲减盈余公积和未分配利润。与发行债务性工具作为合并对价直接相关的交易费用，计入债务性工具的初始确认金额。"}
{"page": 89, "allrow": 2315, "type": "text", "inside": "通过多次交易分步实现同一控制下企业合并，属于一揽子交易的，合并方应当将各项交易作为一项取得控制权的交易进行会计处理。不属于“一揽子交易”的，在母公司财务报表中，以合并日持股比例计算的合并日应享有被合并方净资产在最终控制方合并财务报表中的账面价值的份额，确定长期股权投资的初始投资成本。初始投资成本与其原长期股权投资账面价值加上合并日取得进一步股份新支付对价的账面价值之和的差额，调整资本公积（股本溢价），资本公积不足冲减的，冲减留存收益。"}
{"page": 89, "allrow": 2316, "type": "text", "inside": "（2）非同一控制下的企业合并"}
{"page": 89, "allrow": 2317, "type": "text", "inside": "对于非同一控制下的企业合并，合并成本为购买方在购买日为取得对被购买方的控制权而付出的资产、发生或承担的负债以及发行的权益性证券的公允价值之和。购买方为企业合并发生的审计、法律服务、评估咨询等中介费用以及其他相关管理费用，应于发生时计入当期损益。购买方作为合并对价发行的权益性工具或债务性工具的交易费用，应当计入权益性工具或债务性工具的初始确认金额。"}
{"page": 89, "allrow": 2318, "type": "text", "inside": "非同一控制下企业合并中所取得的被购买方符合确认条件的可辨认资产、负债及或有负债，在购买日以公允价值计量。"}
{"page": 89, "allrow": 2319, "type": "text", "inside": "购买方对合并成本大于合并中取得的被购买方可辨认净资产公允价值份额的差额，体现为商誉价值。购买方对合并成本小于合并中取得的被购买方可辨认净资产公允价值份额的，经复核后合并成本仍小于合并中取得的被购买方可辨认净资产公允价"}
{"page": 89, "allrow": 2320, "type": "页脚", "inside": "89"}
{"page": 90, "allrow": 2321, "type": "text", "inside": ""}
{"page": 90, "allrow": 2322, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 90, "allrow": 2323, "type": "text", "inside": "值份额的差额，计入当期营业外收入。"}
{"page": 90, "allrow": 2324, "type": "text", "inside": "通过多次交易分步实现非同一控制下企业合并的，在母公司财务报表中，以购买日之前所持被购买方的股权投资的账面价值与购买日新增投资成本之和，作为该项投资的初始投资成本。"}
{"page": 90, "allrow": 2325, "type": "text", "inside": "对于分步实现的非同一控制下企业合并，购买日之前持有的被购买方的股权，应当按"}
{"page": 90, "allrow": 2326, "type": "text", "inside": "照该股权在购买日的公允价值进行重新计量，公允价值与其账面价值的差额计入当期投资收益；购买日之前持有的被购买方的股权涉及权益法核算下的其他综合收益、其他所有者权益变动的，应当转为购买日所属当期收益，由于被投资方重新计量设定受益计划净负债或净资产变动而产生的其他综合收益除外。"}
{"page": 90, "allrow": 2327, "type": "text", "inside": "本公司以购买日之前所持被购买方的股权于购买日的公允价值与与购买日新购入股权所支付对价的公允价值之和作为合并成本，与购买方取得的按购买日持股比例计算应享有的被购买方可辨认净资产于购买日的公允价值的份额比较，确定购买日应予确认的商誉或应计入合并当期损益的金额。"}
{"page": 90, "allrow": 2328, "type": "text", "inside": "6、合并财务报表的编制方法"}
{"page": 90, "allrow": 2329, "type": "text", "inside": "（1）合并财务报表范围"}
{"page": 90, "allrow": 2330, "type": "text", "inside": "本公司将所有控制的子公司（包括本公司所控制的单独主体）纳入合并财务报表范围，包括被本公司控制的企业、被投资单位中可分割的部分以及结构化主体。控制是指本公司拥有对被投资方的权力，通过参与被投资方的相关活动而享有可变回报，并且有能力运用对被投资方的权力影响该回报金额。"}
{"page": 90, "allrow": 2331, "type": "text", "inside": "（2）合并财务报表编制的方法"}
{"page": 90, "allrow": 2332, "type": "text", "inside": "从取得子公司的净资产和生产经营决策的实际控制权之日起，本公司开始将其纳入合并范围；从丧失实际控制权之日起停止纳入合并范围。对于处置的子公司，处置日前的经营成果和现金流量已经适当地包括在合并利润表和合并现金流量表中；"}
{"page": 90, "allrow": 2333, "type": "text", "inside": "当期处置的子公司，不调整合并资产负债表的期初数。非同一控制下企业合并增加的子公司，其购买日后的经营成果及现金流量已经适当地包括在合并利润表和合并现金流量表中，且不调整合并财务报表的期初数和对比数。同一控制下企业合并增加的子公司，其自合并当期期初至合并日的经营成果和现金流量已经适当地包括在合并利润表和合并现金流量表中，并且同时调整合并财务报表的对比数。"}
{"page": 90, "allrow": 2334, "type": "text", "inside": "在编制合并财务报表时，子公司与本公司采用的会计政策或会计期间不一致的，按照本公司的会计政策和会计期间对子公司财务报表进行必要的调整。对于非同一控制下企业合并取得的子公司，以购买日可辨认净资产公允价值为基础对其财务报表进行调整。"}
{"page": 90, "allrow": 2335, "type": "text", "inside": "合并财务报表以本公司和子公司的财务报表为基础，根据其他有关资料，由本公司编制。在编制合并财务报表时，本公司与子公司、子公司相互之间所有重大往来余额、交易及未实现利润予以抵销。本公司编制合并财务报表，将整个企业集团视为一个会计主体，依据相关企业会计准则的确认、计量和列报要求，按照统一的会计政策，反映本企业集团整体财务状况、经营成果和现金流量。子公司所有者权益中不属于本公司的份额，作为少数股东权益，在合并资产负债表中所有者权益项目下以“少数股东权益”项目单独列示。子公司当期净损益中属于少数股东权益的份额，在合并利润表中净利润项目下以“少数股东损益”项目列示。少数股东分担的子公司的亏损超过了少数股东在该子公司期初股东权益中所享有的份额，仍然冲减少数股东权益。子公司持有本公司的长期股权投资，视为企业集团的库存股，作为所有者权益的减项，在合并资产负债表中所有者权益项目下以“减：库存股”项目列示。"}
{"page": 90, "allrow": 2336, "type": "text", "inside": "当因处置部分股权投资或其他原因丧失了对原有子公司的控制权时，对于剩余股权，按照其在丧失控制权日的公允价值进行重新计量。处置股权取得的对价与剩余股权公允价值之和，减去按原持股比例计算应享有原有子公司自购买日开始持续计算的净资产的份额与商誉之和的差额，计入丧失控制权当期的投资收益。与原有子公司股权投资相关的其他综合收益、其他所有者权益变动，在丧失控制权时采用与被购买方直接处置相关资产或负债相同的基础进行会计处理（即，除了在该原有子公司重新计量设定受益计划净负债或净资产导致的变动以外，其余一并转为当期损益）。其后，对该部分剩余股权按照《企业会计准则第2号——长期股权投资》或《企业会计准则第22号——金融工具确认和计量》等相关规定进行后续计量。"}
{"page": 90, "allrow": 2337, "type": "text", "inside": "本公司通过多次交易分步处置对子公司股权投资直至丧失控制权的，需区分处置对子公司股权投资直至丧失控制权的各项交易是否属于一揽子交易。处置对子公司股权投资的各项交易的条款、条件以及经济影响符合以下一种或多种情况，通常"}
{"page": 90, "allrow": 2338, "type": "页脚", "inside": "90"}
{"page": 91, "allrow": 2339, "type": "text", "inside": ""}
{"page": 91, "allrow": 2340, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 91, "allrow": 2341, "type": "text", "inside": "表明应将多次交易事项作为一揽子交易进行会计处理：①这些交易是同时或者在考虑了彼此影响的情况下订立的；②这些交易整体才能达成一项完整的商业结果；③一项交易的发生取决于其他至少一项交易的发生；④一项交易单独看是不经济的，但是和其他交易一并考虑时是经济的。不属于一揽子交易的，对其中的每一项交易视情况分别按照“不丧失控制权的情况下部分处置对子公司的长期股权投资”和“因处置部分股权投资或其他原因丧失了对原有子公司的控制权”适用的原则进行会计处理。处置对子公司股权投资直至丧失控制权的各项交易属于一揽子交易的，将各项交易作为一项处置子公司并丧失控制权的交易进行会计处理；但是，在丧失控制权之前每一次处置价款与处置投资对应的享有该子公司净资产份额的差额，在合并财务报表中确认为其他综合收益，在丧失控制权时一并转入丧失控制权当期的损益。"}
{"page": 91, "allrow": 2342, "type": "text", "inside": "本公司因购买少数股权新取得的长期股权投资成本与按照新增持股比例计算应享有子公司自购买日（或合并日）开始持续计算的净资产份额之间的差额，调整合并资产负债表中的资本公积中的股本溢价，资本公积中的股本溢价不足冲减的，调整留存收益。"}
{"page": 91, "allrow": 2343, "type": "text", "inside": "7、合营安排分类及共同经营会计处理方法"}
{"page": 91, "allrow": 2344, "type": "text", "inside": "合营安排的分类："}
{"page": 91, "allrow": 2345, "type": "text", "inside": "本公司根据合营安排的结构、法律形式以及合营安排中约定的条款、其他相关事实和情况等因素，将合营安排分为共同经营和合营企业。未通过单独主体达成的合营安排，划分为共同经营；通过单独主体达成的合营安排，通常划分为合营企业；"}
{"page": 91, "allrow": 2346, "type": "text", "inside": "但有确凿证据表明满足下列任一条件并且符合相关法律法规规定的合营安排划分为共同经营："}
{"page": 91, "allrow": 2347, "type": "text", "inside": "（1）合营安排的法律形式表明，合营方对该安排中的相关资产和负债分别享有权利和承担义务。"}
{"page": 91, "allrow": 2348, "type": "text", "inside": "（2）合营安排的合同条款约定，合营方对该安排中的相关资产和负债分别享有权利和承担义务。"}
{"page": 91, "allrow": 2349, "type": "text", "inside": "（3）其他相关事实和情况表明，合营方对该安排中的相关资产和负债分别享有权利和承担义务，如合营方享有与合营安排相关的几乎所有产出，并且该安排中负债的清偿持续依赖于合营方的支持。"}
{"page": 91, "allrow": 2350, "type": "text", "inside": "共同经营会计处理方法："}
{"page": 91, "allrow": 2351, "type": "text", "inside": "本公司确认共同经营中利益份额中与本公司相关的下列项目，并按照相关企业会计准则的规定进行会计处理：（1）确认单独所持有的资产，以及按其份额确认共同持有的资产；"}
{"page": 91, "allrow": 2352, "type": "text", "inside": "（2）确认单独所承担的负债，以及按其份额确认共同承担的负债；"}
{"page": 91, "allrow": 2353, "type": "text", "inside": "（3）确认出售其享有的共同经营产出份额所产生的收入；"}
{"page": 91, "allrow": 2354, "type": "text", "inside": "（4）按其份额确认共同经营因出售产出所产生的收入；"}
{"page": 91, "allrow": 2355, "type": "text", "inside": "（5）确认单独所发生的费用，以及按其份额确认共同经营发生的费用。"}
{"page": 91, "allrow": 2356, "type": "text", "inside": "本公司向共同经营投出或出售资产等（该资产构成业务的除外），在该资产等由共同经营出售给第三方之前，仅确认因该交易产生的损益中归属于共同经营其他参与方的部分。投出或出售的资产发生符合《企业会计准则第8号——资产减值》等规定的资产减值损失的，本公司全额确认该损失。"}
{"page": 91, "allrow": 2357, "type": "text", "inside": "本公司自共同经营购买资产等（该资产构成业务的除外），在将该资产等出售给第三方之前，仅确认因该交易产生的损益中归属于共同经营其他参与方的部分。购入的资产发生符合《企业会计准则第8号——资产减值》等规定的资产减值损失的，本公司按承担的份额确认该部分损失。"}
{"page": 91, "allrow": 2358, "type": "text", "inside": "本公司对共同经营不享有共同控制，如果本公司享有该共同经营相关资产且承担该共同经营相关负债的，仍按上述原则进行会计处理，否则，应当按照相关企业会计准则的规定进行会计处理。"}
{"page": 91, "allrow": 2359, "type": "text", "inside": "8、现金及现金等价物的确定标准"}
{"page": 91, "allrow": 2360, "type": "text", "inside": "现金流量表之现金指库存现金以及可以随时用于支付的存款。"}
{"page": 91, "allrow": 2361, "type": "text", "inside": "现金流量表之现金等价物是指本公司持有的期限短（一般是指从购买日起3个月内到期）、流动性强、易于转换为已知金"}
{"page": 91, "allrow": 2362, "type": "text", "inside": "额现金、价值变动风险很小的投资。"}
{"page": 91, "allrow": 2363, "type": "页脚", "inside": "91"}
{"page": 92, "allrow": 2364, "type": "text", "inside": ""}
{"page": 92, "allrow": 2365, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 92, "allrow": 2366, "type": "text", "inside": "9、外币业务和外币报表折算"}
{"page": 92, "allrow": 2367, "type": "text", "inside": "（1）外币业务折算"}
{"page": 92, "allrow": 2368, "type": "text", "inside": "本公司对发生的外币交易，采用与交易发生日汇率折合本位币入账。"}
{"page": 92, "allrow": 2369, "type": "text", "inside": "资产负债表日，本公司对于外币货币性项目采用资产负债表日即期汇率折算，由此产生的汇兑差额，除：①属于与购建符合资本化条件的资产相关的外币专门借款产生的汇兑差额按照借款费用资本化的原则处理；②可供出售的外币货币性项目除摊余成本之外的其他账面余额变动产生的汇兑差额计入其他综合收益之外，均计入当期损益。"}
{"page": 92, "allrow": 2370, "type": "text", "inside": "以历史成本计量的外币非货币性项目，本公司仍采用交易发生日的即期汇率折算，不改变其记账本位币金额。以公允价值计量的外币非货币性项目，采用公允价值确定日的即期汇率折算，折算后的记账本位币金额与原记账本位币金额的差额，作为公允价值变动(含汇率变动)处理，计入当期损益或确认为其他综合收益。"}
{"page": 92, "allrow": 2371, "type": "text", "inside": "（2）外币财务报表折算"}
{"page": 92, "allrow": 2372, "type": "text", "inside": "本公司的控股子公司、合营企业、联营企业等，若采用与本公司不同的记账本位币，需对其外币财务报表折算后，再进行会计核算及合并财务报表的编报。"}
{"page": 92, "allrow": 2373, "type": "text", "inside": "外币资产负债表中的资产和负债项目，本公司采用资产负债表日的即期汇率折算，所有者权益项目除“未分配利润”项目外，其他项目采用发生时的即期汇率折算。外币利润表中的收入和费用项目，采用交易发生日即期汇率的近似汇率折算。"}
{"page": 92, "allrow": 2374, "type": "text", "inside": "折算产生的外币财务报表折算差额，在资产负债表中所有者权益项目其他综合收益下列示。"}
{"page": 92, "allrow": 2375, "type": "text", "inside": "外币现金流量按照系统合理方法确定的，采用交易发生日即期汇率的近似汇率折算。汇率变动对现金的影响额，在现金流量表中单独列示。"}
{"page": 92, "allrow": 2376, "type": "text", "inside": "处置境外经营时，与该境外经营有关的外币报表折算差额，全部或按处置该境外经营的比例转入处置当期损益。"}
{"page": 92, "allrow": 2377, "type": "text", "inside": "10、金融工具"}
{"page": 92, "allrow": 2378, "type": "text", "inside": "在本公司成为金融工具合同的一方时确认一项金融资产或金融负债。"}
{"page": 92, "allrow": 2379, "type": "text", "inside": "（1）金融资产的分类、确认和计量"}
{"page": 92, "allrow": 2380, "type": "text", "inside": "本公司根据管理金融资产的业务模式和金融资产的合同现金流量特征，将金融资产划分为：以摊余成本计量的金融资产；"}
{"page": 92, "allrow": 2381, "type": "text", "inside": "以公允价值计量且其变动计入其他综合收益的金融资产；以公允价值计量且其变动计入当期损益的金融资产。"}
{"page": 92, "allrow": 2382, "type": "text", "inside": "金融资产在初始确认时以公允价值计量。对于以公允价值计量且其变动计入当期损益的金融资产，相关交易费用直接计入当期损益；对于其他类别的金融资产，相关交易费用计入初始确认金额。因销售产品或提供劳务而产生的、未包含或不考虑重大融资成分的应收账款或应收票据等，本公司按照预期有权收取的对价金额作为初始确认金额。"}
{"page": 92, "allrow": 2383, "type": "text", "inside": "债务工具："}
{"page": 92, "allrow": 2384, "type": "text", "inside": "①以摊余成本计量的金融资产"}
{"page": 92, "allrow": 2385, "type": "text", "inside": "本公司管理此类金融资产的业务模式为以收取合同现金流量为目标，且此类金融资产的合同现金流量特征与基本借贷安排相一致，即在特定日期产生的现金流量，仅为对本金和以未偿付本金金额为基础的利息的支付。本公司对于此类金融资产按照实际利率法确认利息收入，按照摊余成本进行后续计量，其摊销或减值产生的利得或损失，计入当期损益。本公司的此类金融资产主要包括货币资金、应收票据、应收账款、其他应收款、交易性金融资产和长期应收款等，本公司将自资产负债表日起一年内(含一年)到期的债权投资和长期应收款，列示为一年内到期的非流动资产；取得时期限在一年内(含一年)的债权投资列示为其他流动资产。"}
{"page": 92, "allrow": 2386, "type": "text", "inside": "②以公允价值计量且其变动计入其他综合收益的金融资产"}
{"page": 92, "allrow": 2387, "type": "text", "inside": "本公司管理此类金融资产的业务模式为既以收取合同现金流量为目标又以出售为目标，且此类金融资产的合同现金流量特征与基本借贷安排相一致。此类金融资产按照公允价值计量且其变动计入其他综合收益，但减值损失或利得、汇兑损益和按照实际利率法计算的利息收入计入当期损益。此类金融资产主要包括应收款项融资、其他债权投资等，本公司将自资产负"}
{"page": 92, "allrow": 2388, "type": "text", "inside": "债表日起一年内(含一年)到期的其他债权投资，列示为一年内到期的非流动资产；取得时期限在一年内(含一年)的其他债权"}
{"page": 92, "allrow": 2389, "type": "页脚", "inside": "92"}
{"page": 93, "allrow": 2390, "type": "text", "inside": ""}
{"page": 93, "allrow": 2391, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 93, "allrow": 2392, "type": "text", "inside": "投资列示为其他流动资产。"}
{"page": 93, "allrow": 2393, "type": "text", "inside": "③以公允价值计量且其变动计入当期损益的金融资产"}
{"page": 93, "allrow": 2394, "type": "text", "inside": "本公司将上述以摊余成本计量的金融资产和以公允价值计量且其变动计入其他综合收益的金融资产之外的金融资产，分类为以公允价值计量且其变动计入当期损益的金融资产，列示为交易性金融资产。此外，在初始确认时，本公司为了消除或显著减少会计错配，将部分金融资产指定为以公允价值计量且其变动计入当期损益的金融资产。对于此类金融资产，本公司采用公允价值进行后续计量，公允价值变动计入当期损益。自资产负债表日起超过一年到期且预期持有超过一年的，列示为其他非流动金融资产。"}
{"page": 93, "allrow": 2395, "type": "text", "inside": "权益工具："}
{"page": 93, "allrow": 2396, "type": "text", "inside": "本公司将对其没有控制、共同控制和重大影响的权益工具分类为以公允价值计量且其变动计入当期损益的金融资产，列示为交易性金融资产；自资产负债表日起预期持有超过一年的，列示为其他非流动金融资产。"}
{"page": 93, "allrow": 2397, "type": "text", "inside": "此外，本公司将部分非交易性权益工具投资指定为以公允价值计量且其变动计入其他综合收益的金融资产，列示为其他权益工具投资，且该指定一经作出不得撤销。本公司将该类金融资产的相关股利收入计入当期损益，公允价值变动计入其他综合收益。当该金融资产终止确认时，之前计入其他综合收益的累计利得或损失将从其他综合收益转入留存收益，不计入当期损益。"}
{"page": 93, "allrow": 2398, "type": "text", "inside": "（2）金融负债的分类、确认和计量"}
{"page": 93, "allrow": 2399, "type": "text", "inside": "本公司根据所发行金融工具的合同条款及其所反映的经济实质而非仅以法律形式，结合金融负债和权益工具的定义，在初始确认时将该金融工具或其组成部分分类为金融负债或权益工具。"}
{"page": 93, "allrow": 2400, "type": "text", "inside": "金融负债于初始确认时分类为以公允价值计量且其变动计入当期损益的金融负债和其他金融负债。对于以公允价值计量且其变动计入当期损益的金融负债，相关交易费用直接计入当期损益，其他金融负债的相关交易费用计入其初始确认金额。"}
{"page": 93, "allrow": 2401, "type": "text", "inside": "本公司的金融负债主要为以摊余成本计量的金融负债，包括应付票据及应付账款、其他应付款、借款及应付债券等。该类金融负债按其公允价值扣除交易费用后的金额进行初始计量，并采用实际利率法进行后续计量。期限在一年以下(含一年)的，列示为流动负债；期限在一年以上但自资产负债表日起一年内(含一年)到期的，列示为一年内到期的非流动负债；其余列示为非流动负债。"}
{"page": 93, "allrow": 2402, "type": "text", "inside": "当金融负债的现时义务全部或部分已经解除时，本公司终止确认该金融负债或义务已解除的部分。终止确认部分的账面价值与支付的对价之间的差额，计入当期损益。"}
{"page": 93, "allrow": 2403, "type": "text", "inside": "（3）金融资产转移的确认依据和计量方法"}
{"page": 93, "allrow": 2404, "type": "text", "inside": "本公司将满足下列条件之一的金融资产，予以终止确认：①收取该金融资产现金流量的合同权利终止；②该金融资产已转移，且将金融资产所有权上几乎所有的风险和报酬转移给转入方；③该金融资产已转移，虽然本公司既没有转移也没有保留金融资产所有权上几乎所有的风险和报酬，但是放弃了对该金融资产的控制。若本公司既没有转移也没有保留金融资产所有权上几乎所有的风险和报酬，且未放弃对该金融资产的控制的，按照继续涉入所转移金融资产的程度确认有关金融资产，并相应确认有关负债。继续涉入所转移金融资产的程度，是指该金融资产价值变动使企业面临的风险水平。"}
{"page": 93, "allrow": 2405, "type": "text", "inside": "其他权益工具投资终止确认时，本公司将其账面价值与收到的对价以及原直接计入其他综合收益的公允价值变动累计额之和的差额，计入留存收益；其余金融资产终止确认时，其账面价值与收到的对价以及原直接计入其他综合收益的公允价值变动累计额之和的差额，计入当期损益。"}
{"page": 93, "allrow": 2406, "type": "text", "inside": "本公司对采用附追索权方式出售的金融资产，或将持有的金融资产背书转让，需确定该金融资产所有权上几乎所有的风险和报酬是否已经转移。已将该金融资产所有权上几乎所有的风险和报酬转移给转入方的，终止确认该金融资产；保留了金融资产所有权上几乎所有的风险和报酬的，不终止确认该金融资产；既没有转移也没有保留金融资产所有权上几乎所有的风险和报酬的，则继续判断企业是否对该资产保留了控制，并根据前面各段所述的原则进行会计处理。"}
{"page": 93, "allrow": 2407, "type": "text", "inside": "（4）金融负债的终止确认"}
{"page": 93, "allrow": 2408, "type": "text", "inside": "金融负债（或其一部分）的现时义务已经解除的，本公司终止确认该金融负债（或该部分金融负债）。本公司（借入方）与借出方签订协议，以承担新金融负债的方式替换原金融负债，且新金融负债与原金融负债的合同条款实质上不同的，终止确认原金融负债，同时确认一项新金融负债。本公司对原金融负债（或其一部分）的合同条款作出实质性修改的，终止确认原金融负债，同时按照修改后的条款确认一项新金融负债。"}
{"page": 93, "allrow": 2409, "type": "text", "inside": "金融负债（或其一部分）终止确认的，本公司将其账面价值与支付的对价（包括转出的非现金资产或承担的负债）之间"}
{"page": 93, "allrow": 2410, "type": "页脚", "inside": "93"}
{"page": 94, "allrow": 2411, "type": "text", "inside": ""}
{"page": 94, "allrow": 2412, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 94, "allrow": 2413, "type": "text", "inside": "的差额，计入当期损益。"}
{"page": 94, "allrow": 2414, "type": "text", "inside": "（5）金融资产和金融负债的抵销"}
{"page": 94, "allrow": 2415, "type": "text", "inside": "当本公司具有抵销已确认金额的金融资产和金融负债的法定权利，且该种法定权利是当前可执行的，同时本公司计划以净额结算或同时变现该金融资产和清偿该金融负债时，金融资产和金融负债以相互抵销后的净额在资产负债表内列示。除此以外，本公司的金融资产和金融负债在资产负债表内分别列示，不予相互抵销。"}
{"page": 94, "allrow": 2416, "type": "text", "inside": "（6）金融资产和金融负债的公允价值确定方法"}
{"page": 94, "allrow": 2417, "type": "text", "inside": "公允价值，是指市场参与者在计量日发生的有序交易中，出售一项资产所能收到或者转移一项负债所需支付的价格。金融工具存在活跃市场的，本公司采用活跃市场中的报价确定其公允价值。活跃市场中的报价是指易于定期从交易所、经纪商、行业协会、定价服务机构等获得的价格，且代表了在公平交易中实际发生的市场交易的价格。金融工具不存在活跃市场的，本公司采用估值技术确定其公允价值。估值技术包括参考熟悉情况并自愿交易的各方最近进行的市场交易中使用的价格、参照实质上相同的其他金融工具当前的公允价值、现金流量折现法和期权定价模型等。在估值时，公司采用在当前情况下适用并且有足够可利用数据和其他信息支持的估值技术，选择与市场参与者在相关资产或负债的交易中所考虑的资产或负债特征相一致的输入值，并尽可能优先使用相关可观察输入值。在相关可观察输入值无法取得或取得不切实可行的情况下，使用不可输入值。"}
{"page": 94, "allrow": 2418, "type": "text", "inside": "（7）金融资产减值"}
{"page": 94, "allrow": 2419, "type": "text", "inside": "本公司对于以摊余成本计量的金融资产、以公允价值计量且其变动计入其他综合收益的债权投资、合同资产、租赁应收款、贷款承诺及财务担保合同等，以预期信用损失为基础确认损失准备。"}
{"page": 94, "allrow": 2420, "type": "text", "inside": "①预期信用损失的计量"}
{"page": 94, "allrow": 2421, "type": "text", "inside": "本公司考虑有关过去事项、当前状况以及对未来经济状况的预测等合理且有依据的信息，以发生违约的风险为权重，计算合同应收的现金流量与预期能收到的现金流量之间差额的现值的概率加权金额，确认预期信用损失。"}
{"page": 94, "allrow": 2422, "type": "text", "inside": "在每个资产负债表日，本公司对于处于不同阶段的金融工具的预期信用损失分别进行计量。金融工具自初始确认后信用风险未显著增加的，处于第一阶段，本公司按照未来12个月内的预期信用损失计量损失准备；金融工具自初始确认后信用风险已显著增加但尚未发生信用减值的，处于第二阶段，本公司按照该工具整个存续期的预期信用损失计量损失准备；金融工具自初始确认后已经发生信用减值的，处于第三阶段，本公司按照该工具整个存续期的预期信用损失计量损失准备。"}
{"page": 94, "allrow": 2423, "type": "text", "inside": "对于在资产负债表日具有较低信用风险的金融工具，本公司假设其信用风险自初始确认后并未显著增加，按照未来12个月内的预期信用损失计量损失准备。"}
{"page": 94, "allrow": 2424, "type": "text", "inside": "本公司对于处于第一阶段和第二阶段、以及较低信用风险的金融工具，按照其未扣除减值准备的账面余额和实际利率计算利息收入。对于处于第三阶段的金融工具，按照其账面余额减已计提减值准备后的摊余成本和实际利率计算利息收入。"}
{"page": 94, "allrow": 2425, "type": "text", "inside": "本公司对于因销售商品、提供劳务等日常经营活动形成的应收票据、应收账款、合同资产和应收款项融资，无论是否存在重大融资成分，均按照整个存续期的预期信用损失计量损失准备。"}
{"page": 94, "allrow": 2426, "type": "text", "inside": "A应收款项："}
{"page": 94, "allrow": 2427, "type": "text", "inside": "对于存在客观证据表明存在减值，以及其他适用于单项评估的应收票据、应收账款、其他应收款、应收款项融资及长期应收款等单独进行减值测试，确认预期信用损失，计提单项减值准备。对于不存在减值客观证据的应收票据、应收账款、其他应收款及应收款项融资或当单项金融资产无法以合理成本评估预期信用损失的信息时，本公司依据信用风险特征将应收票据、应收账款、其他应收款、应收款项融资及长期应收款等划分为若干组合，在组合基础上计算预期信用损失，确定组合的依据如下："}
{"page": 94, "allrow": 2428, "type": "text", "inside": "a、应收票据确定组合的依据如下："}
{"page": 94, "allrow": 2429, "type": "excel", "inside": "['应收票据组合1--银行承兑汇票']"}
{"page": 94, "allrow": 2430, "type": "excel", "inside": "['应收票据组合2--商业承兑汇票']"}
{"page": 94, "allrow": 2431, "type": "text", "inside": ""}
{"page": 94, "allrow": 2432, "type": "text", "inside": "对于划分为组合的应收票据，本公司参考历史信用损失经验，结合当前状况以及对未来经济状况的预测，通过违约风险敞口和整个存续期预期信用损失率，计算预期信用损失。"}
{"page": 94, "allrow": 2433, "type": "text", "inside": "b、应收账款确定组合的依据如下："}
{"page": 94, "allrow": 2434, "type": "excel", "inside": "['应收账款组合1']"}
{"page": 94, "allrow": 2435, "type": "excel", "inside": "['应收账款组合2']"}
{"page": 94, "allrow": 2436, "type": "text", "inside": ""}
{"page": 94, "allrow": 2437, "type": "页脚", "inside": "94"}
{"page": 95, "allrow": 2438, "type": "text", "inside": ""}
{"page": 95, "allrow": 2439, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 95, "allrow": 2440, "type": "text", "inside": "对于划分为组合的应收账款，本公司参考历史信用损失经验，结合当前状况以及对未来经济状况的预测，编制应收账款账龄与整个存续期预期信用损失率对照表，计算预期信用损失。"}
{"page": 95, "allrow": 2441, "type": "text", "inside": "c、其他应收款确定组合的依据如下："}
{"page": 95, "allrow": 2442, "type": "excel", "inside": "['其他应收款组合1']"}
{"page": 95, "allrow": 2443, "type": "excel", "inside": "['其他应收款组合2']"}
{"page": 95, "allrow": 2444, "type": "excel", "inside": "['其他应收款组合3']"}
{"page": 95, "allrow": 2445, "type": "excel", "inside": "['其他应收款组合4']"}
{"page": 95, "allrow": 2446, "type": "excel", "inside": "['其他应收款组合5']"}
{"page": 95, "allrow": 2447, "type": "text", "inside": ""}
{"page": 95, "allrow": 2448, "type": "text", "inside": "对于划分为组合的其他应收款，本公司参考历史信用损失经验，结合当前状况以及对未来经济状况的预测，编制其他应收款账龄与整个存续期预期信用损失率对照表，计算预期信用损失。"}
{"page": 95, "allrow": 2449, "type": "text", "inside": "d、应收账款、其他应收款信用风险特征组合的账龄与整个存续期预期信用损失率对照表："}
{"page": 95, "allrow": 2450, "type": "excel", "inside": "['账龄']"}
{"page": 95, "allrow": 2451, "type": "excel", "inside": "['1年以内']"}
{"page": 95, "allrow": 2452, "type": "excel", "inside": "['1-2年']"}
{"page": 95, "allrow": 2453, "type": "excel", "inside": "['2-3年']"}
{"page": 95, "allrow": 2454, "type": "excel", "inside": "['3-5年']"}
{"page": 95, "allrow": 2455, "type": "excel", "inside": "['5年以上']"}
{"page": 95, "allrow": 2456, "type": "text", "inside": ""}
{"page": 95, "allrow": 2457, "type": "text", "inside": "②具有较低的信用风险"}
{"page": 95, "allrow": 2458, "type": "text", "inside": "如果金融工具的违约风险较低，借款人在短期内履行其合同现金流量义务的能力很强，并且即便较长时期内经济形势和经营环境存在不利变化但未必一定降低借款人履行其合同现金流量义务的能力，该金融工具被视为具有较低的信用风险。"}
{"page": 95, "allrow": 2459, "type": "text", "inside": "③信用风险显著增加"}
{"page": 95, "allrow": 2460, "type": "text", "inside": "本公司通过比较金融工具在资产负债表日所确定的预计存续期内的违约概率与在初始确认时所确定的预计存续期内的违约概率，以确定金融工具预计存续期内发生违约概率的相对变化，以评估金融工具的信用风险自初始确认后是否已显著增加。"}
{"page": 95, "allrow": 2461, "type": "text", "inside": "在确定信用风险自初始确认后是否显著增加时，本公司考虑无须付出不必要的额外成本或努力即可获得的合理且有依据的信息，包括前瞻性信息。本公司考虑的信息包括："}
{"page": 95, "allrow": 2462, "type": "text", "inside": "A.信用风险变化所导致的内部价格指标是否发生显著变化；"}
{"page": 95, "allrow": 2463, "type": "text", "inside": "B.预期将导致债务人履行其偿债义务的能力是否发生显著变化的业务、财务或经济状况的不利变化；"}
{"page": 95, "allrow": 2464, "type": "text", "inside": "C.债务人经营成果实际或预期是否发生显著变化；债务人所处的监管、经济或技术环境是否发生显著不利变化；"}
{"page": 95, "allrow": 2465, "type": "text", "inside": "D.作为债务抵押的担保物价值或第三方提供的担保或信用增级质量是否发生显著变化。这些变化预期将降低债务人按合同规定期限还款的经济动机或者影响违约概率；"}
{"page": 95, "allrow": 2466, "type": "text", "inside": "E.预期将降低债务人按合同约定期限还款的经济动机是否发生显著变化；"}
{"page": 95, "allrow": 2467, "type": "text", "inside": "F.借款合同的预期变更，包括预计违反合同的行为是否可能导致的合同义务的免除或修订、给予免息期、利率跳升、要求追加抵押品或担保或者对金融工具的合同框架做出其他变更；"}
{"page": 95, "allrow": 2468, "type": "text", "inside": "G.债务人预期表现和还款行为是否发生显著变化；"}
{"page": 95, "allrow": 2469, "type": "text", "inside": "H.合同付款是否发生逾期超过（含）30日。"}
{"page": 95, "allrow": 2470, "type": "text", "inside": "根据金融工具的性质，本公司以单项金融工具或金融工具组合为基础评估信用风险是否显著增加。以金融工具组合为基础进行评估时，本公司可基于共同信用风险特征对金融工具进行分类，例如逾期信息和信用风险评级。"}
{"page": 95, "allrow": 2471, "type": "text", "inside": "通常情况下，如果逾期超过30日，本公司确定金融工具的信用风险已经显著增加。除非本公司无需付出过多成本或努力即可获得合理且有依据的信息，证明虽然超过合同约定的付款期限30天，但信用风险自初始确认以来并未显著增加。"}
{"page": 95, "allrow": 2472, "type": "text", "inside": "④已发生信用减值的金融资产"}
{"page": 95, "allrow": 2473, "type": "text", "inside": "本公司在资产负债表日评估以摊余成本计量的金融资产和以公允价值计量且其变动计入其他综合收益的债权投资是否"}
{"page": 95, "allrow": 2474, "type": "text", "inside": "已发生信用减值。当对金融资产预期未来现金流量具有不利影响的一项或多项事件发生时，该金融资产成为已发生信用减值"}
{"page": 95, "allrow": 2475, "type": "页脚", "inside": "95"}
{"page": 96, "allrow": 2476, "type": "text", "inside": ""}
{"page": 96, "allrow": 2477, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 96, "allrow": 2478, "type": "text", "inside": "的金融资产。金融资产已发生信用减值的证据包括下列可观察信息：发行方或债务人发生重大财务困难；债务人违反合同，如偿付利息或本金违约或逾期等；债权人出于与债务人财务困难有关的经济或合同考虑，给予债务人在任何其他情况下都不会做出的让步；债务人很可能破产或进行其他财务重组；发行方或债务人财务困难导致该金融资产的活跃市场消失；以大幅折扣购买或源生一项金融资产，该折扣反映了发生信用损失的事实。"}
{"page": 96, "allrow": 2479, "type": "text", "inside": "⑤预期信用损失准备的列报"}
{"page": 96, "allrow": 2480, "type": "text", "inside": "为反映金融工具的信用风险自初始确认后的变化，本公司在每个资产负债表日重新计量预期信用损失，由此形成的损失准备的增加或转回金额，应当作为减值损失或利得计入当期损益。对于以摊余成本计量的金融资产，损失准备抵减该金融资产在资产负债表中列示的账面价值；对于以公允价值计量且其变动计入其他综合收益的债权投资，本公司在其他综合收益中确认其损失准备，不抵减该金融资产的账面价值。"}
{"page": 96, "allrow": 2481, "type": "text", "inside": "⑥核销"}
{"page": 96, "allrow": 2482, "type": "text", "inside": "如果本公司不再合理预期金融资产合同现金流量能够全部或部分收回，则直接减记该金融资产的账面余额，这种减记构成相关金融资产的终止确认。这种情况通常发生在本公司确定债务人没有资产或收入来源可产生足够的现金流量以偿还将被减记的金额。已减记的金融资产以后又收回的，作为减值损失的转回计入收回当期的损益。"}
{"page": 96, "allrow": 2483, "type": "text", "inside": "11、应收票据"}
{"page": 96, "allrow": 2484, "type": "text", "inside": "当应收票据和应收账款同时满足以下条件时，本公司将其划分为以公允价值计量且其变动计入其他综合收益的金融资产，相关具体会计处理方式见金融工具，在报表中列示为应收款项融资："}
{"page": 96, "allrow": 2485, "type": "text", "inside": "（1）合同现金流量为对本金和以未偿付本金金额为基础的利息的支付；"}
{"page": 96, "allrow": 2486, "type": "text", "inside": "（2）本公司管理应收票据和应收账款的业务模式既以收取合同现金流量为目标又以出售为目标。"}
{"page": 96, "allrow": 2487, "type": "text", "inside": "12、应收账款"}
{"page": 96, "allrow": 2488, "type": "text", "inside": "13、应收款项融资"}
{"page": 96, "allrow": 2489, "type": "text", "inside": "当应收票据和应收账款同时满足以下条件时，本公司将其划分为以公允价值计量且其变动计入其他综合收益的金融资产，相关具体会计处理方式见金融工具，在报表中列示为应收款项融资："}
{"page": 96, "allrow": 2490, "type": "text", "inside": "（1）合同现金流量为对本金和以未偿付本金金额为基础的利息的支付；"}
{"page": 96, "allrow": 2491, "type": "text", "inside": "（2）本公司管理应收票据和应收账款的业务模式既以收取合同现金流量为目标又以出售为目标。"}
{"page": 96, "allrow": 2492, "type": "text", "inside": "14、其他应收款"}
{"page": 96, "allrow": 2493, "type": "text", "inside": "其他应收款的预期信用损失的确定方法及会计处理方法"}
{"page": 96, "allrow": 2494, "type": "text", "inside": "15、存货"}
{"page": 96, "allrow": 2495, "type": "text", "inside": "（1）存货分类："}
{"page": 96, "allrow": 2496, "type": "text", "inside": "本公司存货包括生产经营过程中为销售或耗用而持有的原材料、包装物、低值易耗品、在产品、库存商品等。"}
{"page": 96, "allrow": 2497, "type": "text", "inside": "（2）存货取得和发出的计价方法"}
{"page": 96, "allrow": 2498, "type": "页脚", "inside": "96"}
{"page": 97, "allrow": 2499, "type": "text", "inside": ""}
{"page": 97, "allrow": 2500, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 97, "allrow": 2501, "type": "text", "inside": "①原材料、包装物采用实际成本核算，发出采用“加权平均法”计价；"}
{"page": 97, "allrow": 2502, "type": "text", "inside": "②低值易耗品采用实际成本核算，领用时按一次摊销法进行摊销；"}
{"page": 97, "allrow": 2503, "type": "text", "inside": "③库存商品按实际成本核算，发出产品的成本按“加权平均法”计价。"}
{"page": 97, "allrow": 2504, "type": "text", "inside": "（3）存货盘存制度：本公司存货盘存采用永续盘存制。"}
{"page": 97, "allrow": 2505, "type": "text", "inside": "（4）存货跌价准备确认标准及计提方法：期末存货按照成本与可变现净值孰低计量。"}
{"page": 97, "allrow": 2506, "type": "text", "inside": "存货跌价准备按单个存货项目的成本与可变现净值计量，但如果某些存货与在同一地区生产和销售的产品系列相关、具有相同或类似最终用途或目的，且难以与其他项目分开计量，可以合并计量成本与可变现净值；对于数量繁多、单价较低的存货，可以按照存货类别计量成本与可变现净值。产成品、商品和用于出售的材料等可直接用于出售的存货，其可变现净值按该等存货的估计售价减去估计的销售费用和相关税费后的金额确定；用于生产而持有的材料等存货，其可变现净值按所生产的产成品的估计售价减去至完工时估计将要发生的成本、估计的销售费用和相关税费后的金额确定；为执行销售合同或者劳务合同而持有的存货，其可变现净值以合同价格为基础计算；企业持有存货的数量多于销售合同订购数量的，超出部分的存货可变现净值以一般销售价格为基础计算。对于存货因遭受毁损、全部或部分陈旧过时或销售价格低于成本等原因，预计其成本不可收回的部分，提取存货跌价准备。"}
{"page": 97, "allrow": 2507, "type": "text", "inside": "16、合同资产"}
{"page": 97, "allrow": 2508, "type": "text", "inside": "17、合同成本"}
{"page": 97, "allrow": 2509, "type": "text", "inside": "18、持有待售资产"}
{"page": 97, "allrow": 2510, "type": "text", "inside": "（1）持有待售的非流动资产或处置组的分类与计量"}
{"page": 97, "allrow": 2511, "type": "text", "inside": "本公司主要通过出售（包括具有商业实质的非货币性资产交换）而非持续使用一项非流动资产或处置组收回其账面价值时，该非流动资产或处置组被划分为持有待售类别。"}
{"page": 97, "allrow": 2512, "type": "text", "inside": "处置组，是指在一项交易中作为整体通过出售或其他方式一并处置的一组资产，以及在该交易中转让的与这些资产直接相关的负债。处置组所属的资产组或资产组组合按照《企业会计准则第8号——资产减值》分摊了企业合并中取得的商誉的，该处置组应当包含分摊至处置组的商誉。"}
{"page": 97, "allrow": 2513, "type": "text", "inside": "同时满足下列条件的非流动资产或处置组被划分为持有待售类别：根据类似交易中出售此类资产或处置组的惯例，该非流动资产或处置组在当前状况下即可立即出售；出售极可能发生，即已经就一项出售计划作出决议且获得确定的购买承诺，预计出售将在一年内完成。"}
{"page": 97, "allrow": 2514, "type": "text", "inside": "因出售对子公司的投资等原因导致丧失对子公司控制权的，无论出售后本公司是否保留部分权益性投资，在拟出售的对子公司投资满足持有待售类别划分条件时，在个别财务报表中将对子公司投资整体划分为持有待售类别，在合并财务报表中将子公司所有资产和负债划分为持有待售类别。"}
{"page": 97, "allrow": 2515, "type": "text", "inside": "初始计量或在资产负债表日重新计量持有待售的非流动资产或处置组时，账面价值高于公允价值减去出售费用后净额的差额确认为资产减值损失。对于持有待售的处置组确认的资产减值损失金额，先抵减处置组中商誉的账面价值，再根据处置组中的各项非流动资产账面价值所占比重，按比例抵减其账面价值。"}
{"page": 97, "allrow": 2516, "type": "text", "inside": "后续资产负债表日持有待售的非流动资产或处置组公允价值减去出售费用后的净额增加的，以前减记的金额予以恢复，并在划分为持有待售类别后确认的资产减值损失金额内转回，转回金额计入当期损益。已抵减的商誉账面价值和划分为持有待售类别前确认的资产减值损失不得转回。"}
{"page": 97, "allrow": 2517, "type": "text", "inside": "持有待售的非流动资产和持有待售的处置组中的资产不计提折旧或进行摊销；持有待售的处置组中负债的利息和其他费用继续予以确认。"}
{"page": 97, "allrow": 2518, "type": "text", "inside": "某项非流动资产或处置组被划分为持有待售类别，但后来不再满足持有待售类别划分条件的，本公司停止将其划分为持有待售类别，并按照下列两项金额中较低者计量："}
{"page": 97, "allrow": 2519, "type": "text", "inside": "①该资产或处置组被划分为持有待售类别之前的账面价值，按照其假定在没有被划分为持有待售类别的情况下本应确认"}
{"page": 97, "allrow": 2520, "type": "text", "inside": "的折旧、摊销或减值进行调整后的金额；"}
{"page": 97, "allrow": 2521, "type": "页脚", "inside": "97"}
{"page": 98, "allrow": 2522, "type": "text", "inside": ""}
{"page": 98, "allrow": 2523, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 98, "allrow": 2524, "type": "text", "inside": "②可收回金额。"}
{"page": 98, "allrow": 2525, "type": "text", "inside": "（2）终止经营"}
{"page": 98, "allrow": 2526, "type": "text", "inside": "终止经营，是指满足下列条件之一的已被本公司处置或被本公司划分为持有待售类别的、能够单独区分的组成部分：①该组成部分代表一项独立的主要业务或一个单独的主要经营地区。"}
{"page": 98, "allrow": 2527, "type": "text", "inside": "②该组成部分是拟对一项独立的主要业务或一个单独的主要经营地区进行处置的一项相关联计划的一部分。"}
{"page": 98, "allrow": 2528, "type": "text", "inside": "③该组成部分是专为转售而取得的子公司。"}
{"page": 98, "allrow": 2529, "type": "text", "inside": "（3）列报"}
{"page": 98, "allrow": 2530, "type": "text", "inside": "本公司在资产负债表中将持有待售的非流动资产或持有待售的处置组中的资产列报于“持有待售资产”，将持有待售的处置组中的负债列报于“持有待售负债”。"}
{"page": 98, "allrow": 2531, "type": "text", "inside": "本公司在利润表中分别列示持续经营损益和终止经营损益。不符合终止经营定义的持有待售的非流动资产或处置组，其减值损失和转回金额及处置损益作为持续经营损益列报。终止经营的减值损失和转回金额等经营损益及处置损益作为终止经营损益列报。"}
{"page": 98, "allrow": 2532, "type": "text", "inside": "拟结束使用而非出售且满足终止经营定义中有关组成部分的条件的处置组，自其停止使用日起作为终止经营列报。"}
{"page": 98, "allrow": 2533, "type": "text", "inside": "对于当期列报的终止经营，在当期财务报表中，原来作为持续经营损益列报的信息被重新作为可比会计期间的终止经营损益列报。终止经营不再满足持有待售类别划分条件的，在当期财务报表中，原来作为终止经营损益列报的信息被重新作为可比会计期间的持续经营损益列报。"}
{"page": 98, "allrow": 2534, "type": "text", "inside": "19、债权投资"}
{"page": 98, "allrow": 2535, "type": "text", "inside": "20、其他债权投资"}
{"page": 98, "allrow": 2536, "type": "text", "inside": "21、长期应收款"}
{"page": 98, "allrow": 2537, "type": "text", "inside": "22、长期股权投资"}
{"page": 98, "allrow": 2538, "type": "text", "inside": "本部分所指的长期股权投资是指本公司对被投资单位具有控制、共同控制或重大影响的长期股权投资。"}
{"page": 98, "allrow": 2539, "type": "text", "inside": "（1）初始投资成本确定"}
{"page": 98, "allrow": 2540, "type": "text", "inside": "①对于本公司合并取得的长期股权投资，如为同一控制下的企业合并，应当按照取得被合并方所有者权益账面价值的份额确认为初始成本；如为非同一控制下的企业合并，应当按购买日确定的合并成本确认为初始成本；"}
{"page": 98, "allrow": 2541, "type": "text", "inside": "②除合并形成的长期股权投资外的其他股权投资，以支付现金取得的长期股权投资，初始投资成本为实际支付的购买价款；以发行权益性证券取得的长期股权投资，初始投资成本为发行权益性证券的公允价值；通过债务重组取得的长期股权投资，其初始投资成本应当按照《企业会计准则第12号——债务重组》的有关规定确定；非货币性资产交换取得，初始投资成本根据准则相关规定确定。"}
{"page": 98, "allrow": 2542, "type": "text", "inside": "（2）后续计量及损益确认方法"}
{"page": 98, "allrow": 2543, "type": "text", "inside": "①成本法核算"}
{"page": 98, "allrow": 2544, "type": "text", "inside": "本公司能够对被投资单位实施控制的长期股权投资应当采用成本法核算。采用成本法核算的长期股权投资，除追加或收回投资外，账面价值一般不变。对被投资企业宣告分派的利润或现金股利，本公司计算应分得的部分，确认为投资收益。"}
{"page": 98, "allrow": 2545, "type": "text", "inside": "②权益法核算"}
{"page": 98, "allrow": 2546, "type": "text", "inside": "本公司对联营企业和合营企业的长期股权投资采用权益法核算。采用权益法核算时，长期股权投资的初始投资成本大于投资时应享有被投资单位可辨认净资产公允价值份额的，不调整长期股权投资的初始投资成本；初始投资成本小于投资时应享有被投资单位可辨认净资产公允价值份额的，其差额计入当期损益，同时调整长期股权投资的成本。"}
{"page": 98, "allrow": 2547, "type": "text", "inside": "采用权益法核算时，本公司按照应享有或应分担的被投资单位实现的净损益和其他综合收益的份额，分别确认投资收益和其他综合收益，同时调整长期股权投资的账面价值；按照被投资单位宣告分派的利润或现金股利计算应享有的部分，相应"}
{"page": 98, "allrow": 2548, "type": "text", "inside": "减少长期股权投资的账面价值；对于被投资单位除净损益、其他综合收益和利润分配以外所有者权益的其他变动，调整长期"}
{"page": 98, "allrow": 2549, "type": "页脚", "inside": "98"}
{"page": 99, "allrow": 2550, "type": "text", "inside": ""}
{"page": 99, "allrow": 2551, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 99, "allrow": 2552, "type": "text", "inside": "股权投资的账面价值并计入资本公积。在确认应享有被投资单位净损益的份额时，以取得投资时被投资单位各项可辨认资产等的公允价值为基础，对被投资单位的净利润进行调整后确认。被投资单位采用的会计政策及会计期间与本公司不一致的，按照本公司的会计政策及会计期间对被投资单位的财务报表进行调整，并据以确认投资收益和其他综合收益。"}
{"page": 99, "allrow": 2553, "type": "text", "inside": "本公司在确认应分担被投资单位发生的净亏损时，以长期股权投资的账面价值和其他实质上构成对被投资单位净投资的长期权益减记至零为限。此外，如本公司对被投资单位负有承担额外损失的义务，则按预计承担的义务确认预计负债，计入当期投资损失。被投资单位以后期间实现净利润的，本公司在收益分享额弥补未确认的亏损分担额后，恢复确认收益分享额。"}
{"page": 99, "allrow": 2554, "type": "text", "inside": "（3）长期股权投资核算方法的转换"}
{"page": 99, "allrow": 2555, "type": "text", "inside": "①公允价值计量转权益法核算：本公司原持有的对被投资单位的股权投资（不具有控制、共同控制或重大影响的），按照金融工具确认和计量准则进行会计处理的，因追加投资等原因导致持股比例上升，能够对被投资单位施加共同控制或重大影响的，在转按权益法核算时，本公司应当按照金融工具确认和计量准则确定的原股权投资的公允价值加上为取得新增投资而应支付对价的公允价值，作为改按权益法核算的初始投资成本。"}
{"page": 99, "allrow": 2556, "type": "text", "inside": "②公允价值计量或权益法核算转成本法核算：本公司原持有的对被投资单位不具有控制、共同控制或重大影响的按照金融工具确认和计量准则进行会计处理的权益性投资，或者原持有对联营企业、合营企业的长期股权投资，因追加投资等原因，能够对被投资单位实施控制的，按有关企业合并形成的长期股权投资进行会计处理。"}
{"page": 99, "allrow": 2557, "type": "text", "inside": "③权益法核算转公允价值计量：本公司原持有的对被投资单位具有共同控制或重大影响的长期股权投资，因部分处置等原因导致持股比例下降，不能再对被投资单位实施共同控制或重大影响的，改按金融工具确认和计量准则对剩余股权投资进行会计处理，其在丧失共同控制或重大影响之日的公允价值与账面价值之间的差额计入当期损益。"}
{"page": 99, "allrow": 2558, "type": "text", "inside": "④成本法转权益法或公允价值计量：本公司因处置部分权益性投资等原因丧失了对被投资单位的控制的，在编制个别财务报表时，处置后的剩余股权能够对被投资单位实施共同控制或施加重大影响的，本公司改按权益法核算，并对该剩余股权视同自取得时即采用权益法核算进行调整；处置后的剩余股权不能对被投资单位实施共同控制或施加重大影响的，本公司改按《企业会计准则第22号——金融工具确认和计量》的有关规定进行会计处理，其在丧失控制之日的公允价值与账面价值间的差额计入当期损益。在编制合并财务报表时，应当按照《企业会计准则第33号——合并财务报表》的有关规定进行会计处理。"}
{"page": 99, "allrow": 2559, "type": "text", "inside": "（4）确定对被投资单位具有共同控制、重大影响的依据"}
{"page": 99, "allrow": 2560, "type": "text", "inside": "共同控制，是指按照相关约定对某项安排所共有的控制，并且该安排的相关活动必须经过分享控制权的参与方一致同意后才能决策。如果所有参与方或一组参与方必须一致行动才能决定某项安排的相关活动，则认为所有参与方或一组参与方集体控制该安排。在判断是否存在共同控制时，首先判断是否由所有参与方或参与方组合集体控制该安排，其次再判断该安排相关活动的决策是否必须经过这些集体控制该安排的参与方一致同意。如果存在两个或两个以上的参与方组合能够集体控制某项安排的，不构成共同控制。判断是否存在共同控制时，不考虑享有的保护性权利。"}
{"page": 99, "allrow": 2561, "type": "text", "inside": "重大影响，是指投资方对被投资单位的财务和经营政策有参与决策的权力，但并不能够控制或者与其他方一起共同控制这些政策的制定。本公司在确定能否对被投资单位施加重大影响时，考虑直接或间接持有被投资单位的表决权股份以及本公司及其他方持有的当期可执行潜在表决权在假定转换为对被投资方单位的股权后产生的影响，包括被投资单位发行的当期可转换的认股权证、股份期权及可转换公司债券等的影响。"}
{"page": 99, "allrow": 2562, "type": "text", "inside": "当本公司直接或通过子公司间接拥有被投资单位20%（含20%）以上但低于50%的表决权股份时，一般认为对被投资单位具有重大影响，除非有明确证据表明该种情况下不能参与被投资单位的生产经营决策，不形成重大影响。"}
{"page": 99, "allrow": 2563, "type": "text", "inside": "本公司通常通过以下一种或几种情形来判断是否对被投资单位具有重大影响："}
{"page": 99, "allrow": 2564, "type": "text", "inside": "①在被投资单位的董事会或类似权力机构中派有代表。"}
{"page": 99, "allrow": 2565, "type": "text", "inside": "②参与被投资单位财务和经营政策制定过程。"}
{"page": 99, "allrow": 2566, "type": "text", "inside": "③与被投资单位之间发生重要交易。"}
{"page": 99, "allrow": 2567, "type": "text", "inside": "④向被投资单位派出管理人员。"}
{"page": 99, "allrow": 2568, "type": "text", "inside": "⑤向被投资单位提供关键技术资料。"}
{"page": 99, "allrow": 2569, "type": "text", "inside": "存在上述一种或多种情形并不意味着本公司一定对被投资单位具有重大影响，本公司需要综合考虑所有事实和情况来做出恰当的判断。"}
{"page": 99, "allrow": 2570, "type": "text", "inside": "（5）减值测试方法及减值准备计提方法"}
{"page": 99, "allrow": 2571, "type": "页脚", "inside": "99"}
{"page": 100, "allrow": 2572, "type": "text", "inside": ""}
{"page": 100, "allrow": 2573, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 100, "allrow": 2574, "type": "text", "inside": "资产负债表日，本公司对长期股权投资检查是否存在可能发生减值的迹象，当存在减值迹象时应进行减值测试确认其可收回金额，按可收回金额低于账面价值部分计提减值准备，减值损失一经计提，在以后会计期间不再转回。"}
{"page": 100, "allrow": 2575, "type": "text", "inside": "可收回金额按照长期股权投资出售的公允价值净额与预计未来现金流量的现值之间孰高确定。"}
{"page": 100, "allrow": 2576, "type": "text", "inside": "（6）长期股权投资处置"}
{"page": 100, "allrow": 2577, "type": "text", "inside": "本公司处置长期股权投资时，投资账面价值与实际取得价款之间的差额，计入当期损益。采用权益法核算的长期股权投资，在处置该项投资时，采用与被投资单位直接处置相关资产或负债相同的基础，按相应比例对原计入其他综合收益的部分进行会计处理。"}
{"page": 100, "allrow": 2578, "type": "text", "inside": "23、投资性房地产"}
{"page": 100, "allrow": 2579, "type": "text", "inside": "投资性房地产计量模式"}
{"page": 100, "allrow": 2580, "type": "text", "inside": "不适用"}
{"page": 100, "allrow": 2581, "type": "text", "inside": "24、固定资产"}
{"page": 100, "allrow": 2582, "type": "text", "inside": "（1）确认条件"}
{"page": 100, "allrow": 2583, "type": "text", "inside": "（1）固定资产的标准：固定资产是本公司为销售商品、提供劳务、出租或经营管理而持有，使用年限超过一年，单位价值较高的有形资产。在满足下列条件时方确认固定资产："}
{"page": 100, "allrow": 2584, "type": "text", "inside": "①与该固定资产有关的经济利益很可能流入企业；"}
{"page": 100, "allrow": 2585, "type": "text", "inside": "②该固定资产的成本能够可靠地计量。"}
{"page": 100, "allrow": 2586, "type": "text", "inside": "（2）固定资产计价：固定资产按取得时实际成本计价。其中："}
{"page": 100, "allrow": 2587, "type": "text", "inside": "外购的固定资产的成本包括买价、进口关税等相关税费，以及为使固定资产达到预定可使用状态前所发生的可直接归属于该资产的其他支出。"}
{"page": 100, "allrow": 2588, "type": "text", "inside": "自行建造固定资产的成本，由建造该项资产达到预定可使用状态前所发生的必要支出构成。"}
{"page": 100, "allrow": 2589, "type": "text", "inside": "投资者投入的固定资产，按投资合同或协议约定的价值作为入账价值，合同或协议约定价值不公允的按公允价值入账。"}
{"page": 100, "allrow": 2590, "type": "text", "inside": "融资租赁租入的固定资产，按租赁开始日租赁资产公允价值与最低租赁付款额的现值两者中较低者，作为入账价值。通过非货币资产交换取得的固定资产，具有商业实质的，按换出资产的公允价值入账；不具有商业实质的，按换出资产的账面价值入账。通过债务重组取得的固定资产，按公允价值确认。"}
{"page": 100, "allrow": 2591, "type": "text", "inside": "（2）折旧方法"}
{"page": 100, "allrow": 2592, "type": "excel", "inside": "['类别', '折旧方法', '折旧年限', '残值率', '年折旧率']"}
{"page": 100, "allrow": 2593, "type": "excel", "inside": "['房屋及建筑物', '年限平均法', '5-40年', '3%', '2.43%-19.40%']"}
{"page": 100, "allrow": 2594, "type": "excel", "inside": "['机器设备', '年限平均法', '5-10年', '3%', '9.70%-19.40%']"}
{"page": 100, "allrow": 2595, "type": "excel", "inside": "['运输设备', '年限平均法', '5-8年', '3%', '12.13%-19.40%']"}
{"page": 100, "allrow": 2596, "type": "excel", "inside": "['其他设备', '年限平均法', '5-8年', '3%', '12.13%-19.40%']"}
{"page": 100, "allrow": 2597, "type": "text", "inside": ""}
{"page": 100, "allrow": 2598, "type": "页脚", "inside": "100"}
{"page": 101, "allrow": 2599, "type": "text", "inside": ""}
{"page": 101, "allrow": 2600, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 101, "allrow": 2601, "type": "text", "inside": "（3）融资租入固定资产的认定依据、计价和折旧方法"}
{"page": 101, "allrow": 2602, "type": "text", "inside": "公司在租入的固定资产实质上转移了与资产有关的全部风险和报酬时确认该项固定资产的租赁为融资租赁。公司融资租赁取得的固定资产的成本，按租赁开始日租赁资产公允价值与最低租赁付款额现值两者中较低者确定。公司融资租入的固定资产采用与自有应计折旧资产相一致的折旧政策。能够合理确定租赁期届满时取得租赁资产所有权的，在租赁资产尚可使用年限内计提折旧；无法合理确定租赁期届满时能够取得租赁资产所有权的，在租赁期与租赁资产尚可使用年限两者中较短的期间内计提折旧。"}
{"page": 101, "allrow": 2603, "type": "text", "inside": "25、在建工程"}
{"page": 101, "allrow": 2604, "type": "text", "inside": "（1）在建工程是指正在兴建中的资本性资产，以实际成本入账。成本包括机器设备的购置成本、建筑费用及其他直接费用，以及建设期间专门用于在建工程的借款的利息费用与汇兑损益。在建工程达到预定可使用状态时，停止其借款利息的资本化。"}
{"page": 101, "allrow": 2605, "type": "text", "inside": "（2）在建工程结转为固定资产的时点：在建工程按各项工程实际发生的支出分项目核算，并在工程达到预定可使用状态之日起，根据工程预算、造价或工程实际成本等，按估计的价值转入固定资产，并计提折旧，待办理了竣工决算手续后再作调整。"}
{"page": 101, "allrow": 2606, "type": "text", "inside": "（3）在建工程减值准备的计提：本公司于期末对在建工程进行全面检查，当存在下列一项或若干项情况时，按单项资产可收回金额低于在建工程账面价值的差额，提取在建工程减值准备。减值准备一经计提，在资产存续期内不予转回。"}
{"page": 101, "allrow": 2607, "type": "text", "inside": "①长期停建并且预计未来3年内不会重新开工的在建工程；"}
{"page": 101, "allrow": 2608, "type": "text", "inside": "②所建项目无论在性能上，还是在技术上已经落后，并且给企业带来的经济利益具有很大的不确定性；"}
{"page": 101, "allrow": 2609, "type": "text", "inside": "③其他足以证明在建工程已经发生减值的情形。"}
{"page": 101, "allrow": 2610, "type": "text", "inside": "26、借款费用"}
{"page": 101, "allrow": 2611, "type": "text", "inside": "（1）借款费用资本化的确认原则："}
{"page": 101, "allrow": 2612, "type": "text", "inside": "借款费用包括因借款而发生的利息、折价或溢价的摊销和辅助费用，以及因外币借款而发生的汇兑差额。本公司发生的借款费用，属于需要经过1年以上（含1年）时间购建的固定资产、开发投资性房地产或存货所占用的专门借款或一般借款所产生的，予以资本化，计入相关资产成本；其他借款费用，在发生时确认为费用，计入当期损益。相关借款费用应当同时具备以下三个条件时开始资本化："}
{"page": 101, "allrow": 2613, "type": "text", "inside": "①资产支出已经发生；"}
{"page": 101, "allrow": 2614, "type": "text", "inside": "②借款费用已经发生；"}
{"page": 101, "allrow": 2615, "type": "text", "inside": "③为使资产达到预定可使用状态所必要的购建活动已经开始。"}
{"page": 101, "allrow": 2616, "type": "text", "inside": "（2）借款费用资本化的期间："}
{"page": 101, "allrow": 2617, "type": "text", "inside": "为购建固定资产、投资性房地产、存货所发生的借款费用，满足上述资本化条件的，在该资产达到预定可使用状态或可销售状态前所发生的，计入资产成本；若固定资产、投资性房地产、存货的购建活动发生非正常中断，并且中断时间连续超过3个月，暂停借款费用的资本化，将其确认为当期费用，直至资产的购建活动重新开始；在达到预定可使用状态或可销售状态时，停止借款费用的资本化，之后发生的借款费用于发生当期直接计入财务费用。"}
{"page": 101, "allrow": 2618, "type": "text", "inside": "（3）借款费用资本化金额的计算方法："}
{"page": 101, "allrow": 2619, "type": "text", "inside": "为购建或者生产开发符合资本化条件的资产而借入专门借款的，以专门借款当期实际发生的利息费用，减去尚未动用的借款资金存入银行取得的利息收入或进行暂时性投资取得的投资收益后的金额确定。"}
{"page": 101, "allrow": 2620, "type": "text", "inside": "为购建或者生产开发符合资本化条件的资产而占用了一般借款的，根据累计资产支出超过专门借款部分的资产支出加权平均数乘以所占用一般借款的资本化率，计算确定一般借款应予资本化的利息金额。资本化率根据一般借款加权平均利率计算确定。"}
{"page": 101, "allrow": 2621, "type": "页脚", "inside": "101"}
{"page": 102, "allrow": 2622, "type": "text", "inside": ""}
{"page": 102, "allrow": 2623, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 102, "allrow": 2624, "type": "text", "inside": "27、生物资产"}
{"page": 102, "allrow": 2625, "type": "text", "inside": "28、油气资产"}
{"page": 102, "allrow": 2626, "type": "text", "inside": "29、使用权资产"}
{"page": 102, "allrow": 2627, "type": "text", "inside": "30、无形资产"}
{"page": 102, "allrow": 2628, "type": "text", "inside": "（1）计价方法、使用寿命、减值测试"}
{"page": 102, "allrow": 2629, "type": "text", "inside": "（1）无形资产的计价：公司的无形资产包括土地使用权、专利技术和非专利技术等。"}
{"page": 102, "allrow": 2630, "type": "text", "inside": "购入的无形资产，按实际支付的价款和相关的其他支出作为实际成本。"}
{"page": 102, "allrow": 2631, "type": "text", "inside": "投资者投入的无形资产，按投资合同或协议约定的价值确定实际成本，但合同或协议约定价值不公允的，按公允价值确定实际成本。"}
{"page": 102, "allrow": 2632, "type": "text", "inside": "通过非货币资产交换取得的无形资产，具有商业实质的，按换出资产的公允价值入账；不具有商业实质的，按换出资产的账面价值入账。"}
{"page": 102, "allrow": 2633, "type": "text", "inside": "通过债务重组取得的无形资产，按公允价值确认。"}
{"page": 102, "allrow": 2634, "type": "text", "inside": "自行研究开发的无形资产，其研究阶段的支出，应当于发生时计入当期损益；其开发阶段的支出，同时满足下列条件的，确认为无形资产（专利技术和非专利技术）："}
{"page": 102, "allrow": 2635, "type": "text", "inside": "①完成该无形资产以使其能够使用或出售在技术上具有可行性；"}
{"page": 102, "allrow": 2636, "type": "text", "inside": "②具有完成该无形资产并使用或出售的意图；"}
{"page": 102, "allrow": 2637, "type": "text", "inside": "③运用该无形资产生产的产品存在市场或无形资产自身存在市场；"}
{"page": 102, "allrow": 2638, "type": "text", "inside": "④有足够的技术、财务资源和其他资源支持，以完成该无形资产的开发，并有能力使用或出售该无形资产；"}
{"page": 102, "allrow": 2639, "type": "text", "inside": "⑤归属于该无形资产开发阶段的支出能够可靠地计量。"}
{"page": 102, "allrow": 2640, "type": "text", "inside": "（2）无形资产的摊销方法：本公司无形资产自取得当月起在预计使用年限内分期平均摊销，计入损益。如果预计使用年限超过了相关合同规定的受益年限或法律规定的有效年限，该无形资产的摊销年限按如下原则确定："}
{"page": 102, "allrow": 2641, "type": "text", "inside": "①合同规定受益年限但法律没有规定有效年限的，按合同规定的受益年限摊销；"}
{"page": 102, "allrow": 2642, "type": "text", "inside": "②合同没有规定受益年限但法律规定有效年限的，按法律规定的有效年限摊销；"}
{"page": 102, "allrow": 2643, "type": "text", "inside": "③合同规定了受益年限，法律也规定了有效年限的，按受益年限和有效年限两者之中较短者摊销；"}
{"page": 102, "allrow": 2644, "type": "text", "inside": "④合同没有规定受益年限，法律也没有规定有效年限的，摊销年限不超过10年。"}
{"page": 102, "allrow": 2645, "type": "text", "inside": "（3）无形资产减值准备确认标准、计提方法"}
{"page": 102, "allrow": 2646, "type": "text", "inside": "当存在下列一项或若干项情况时，本公司按无形资产可收回金额低于账面净值的差额计提无形资产减值准备："}
{"page": 102, "allrow": 2647, "type": "text", "inside": "①某项无形资产已被其他新技术所替代，使其为企业创造经济利益的能力受到重大不利影响；"}
{"page": 102, "allrow": 2648, "type": "text", "inside": "②某项无形资产的市价在当期大幅下跌，在剩余摊销年限内预计不会恢复；"}
{"page": 102, "allrow": 2649, "type": "text", "inside": "③某项无形资产已超过法律保护期限，但仍然具有部分使用价值；"}
{"page": 102, "allrow": 2650, "type": "text", "inside": "④其他足以证明某项无形资产实质上已经发生减值的情形。"}
{"page": 102, "allrow": 2651, "type": "text", "inside": "无形资产减值准备一经计提，不予转回。"}
{"page": 102, "allrow": 2652, "type": "text", "inside": "（4）当存在下列一项或若干项情况时，将该项无形资产的账面价值全部转入当期损益："}
{"page": 102, "allrow": 2653, "type": "text", "inside": "①某项无形资产已被其他新技术所替代，并且该项无形资产已无使用价值和转让价值；"}
{"page": 102, "allrow": 2654, "type": "text", "inside": "②某项无形资产已超过法律保护期限，并且已不能为企业带来经济利益；"}
{"page": 102, "allrow": 2655, "type": "text", "inside": "③其他足以证明某项无形资产已经丧失了使用价值和转让价值的情形。"}
{"page": 102, "allrow": 2656, "type": "页脚", "inside": "102"}
{"page": 103, "allrow": 2657, "type": "text", "inside": ""}
{"page": 103, "allrow": 2658, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 103, "allrow": 2659, "type": "text", "inside": "（5）使用寿命的估计"}
{"page": 103, "allrow": 2660, "type": "text", "inside": "对使用寿命有限的无形资产，估计其使用寿命时通常考虑以下因素："}
{"page": 103, "allrow": 2661, "type": "text", "inside": "①运用该资产生产的产品通常的寿命周期、可获得的类似资产使用寿命的信息；"}
{"page": 103, "allrow": 2662, "type": "text", "inside": "②技术、工艺等方面的现阶段情况及对未来发展趋势的估计；"}
{"page": 103, "allrow": 2663, "type": "text", "inside": "③以该资产生产的产品或提供劳务的市场需求情况；"}
{"page": 103, "allrow": 2664, "type": "text", "inside": "④现在或潜在的竞争者预期采取的行动；"}
{"page": 103, "allrow": 2665, "type": "text", "inside": "⑤为维持该资产带来经济利益能力的预期维护支出，以及公司预计支付有关支出的能力；"}
{"page": 103, "allrow": 2666, "type": "text", "inside": "⑥对该资产控制期限的相关法律规定或类似限制，如特许试用期、租赁期等；"}
{"page": 103, "allrow": 2667, "type": "text", "inside": "⑦与公司持有其他资产使用寿命的关联性等。"}
{"page": 103, "allrow": 2668, "type": "text", "inside": "（1）无形资产的计价：公司的无形资产包括土地使用权、专利技术和非专利技术等。"}
{"page": 103, "allrow": 2669, "type": "text", "inside": "购入的无形资产，按实际支付的价款和相关的其他支出作为实际成本。"}
{"page": 103, "allrow": 2670, "type": "text", "inside": "投资者投入的无形资产，按投资合同或协议约定的价值确定实际成本，但合同或协议约定价值不公允的，按公允价值确定实际成本。"}
{"page": 103, "allrow": 2671, "type": "text", "inside": "通过非货币资产交换取得的无形资产，具有商业实质的，按换出资产的公允价值入账；不具有商业实质的，按换出资产的账面价值入账。"}
{"page": 103, "allrow": 2672, "type": "text", "inside": "通过债务重组取得的无形资产，按公允价值确认。"}
{"page": 103, "allrow": 2673, "type": "text", "inside": "自行研究开发的无形资产，其研究阶段的支出，应当于发生时计入当期损益；其开发阶段的支出，同时满足下列条件的，确认为无形资产（专利技术和非专利技术）："}
{"page": 103, "allrow": 2674, "type": "text", "inside": "①完成该无形资产以使其能够使用或出售在技术上具有可行性；"}
{"page": 103, "allrow": 2675, "type": "text", "inside": "②具有完成该无形资产并使用或出售的意图；"}
{"page": 103, "allrow": 2676, "type": "text", "inside": "③运用该无形资产生产的产品存在市场或无形资产自身存在市场；"}
{"page": 103, "allrow": 2677, "type": "text", "inside": "④有足够的技术、财务资源和其他资源支持，以完成该无形资产的开发，并有能力使用或出售该无形资产；"}
{"page": 103, "allrow": 2678, "type": "text", "inside": "⑤归属于该无形资产开发阶段的支出能够可靠地计量。"}
{"page": 103, "allrow": 2679, "type": "text", "inside": "（2）无形资产的摊销方法：本公司无形资产自取得当月起在预计使用年限内分期平均摊销，计入损益。如果预计使用年限超过了相关合同规定的受益年限或法律规定的有效年限，该无形资产的摊销年限按如下原则确定："}
{"page": 103, "allrow": 2680, "type": "text", "inside": "①合同规定受益年限但法律没有规定有效年限的，按合同规定的受益年限摊销；"}
{"page": 103, "allrow": 2681, "type": "text", "inside": "②合同没有规定受益年限但法律规定有效年限的，按法律规定的有效年限摊销；"}
{"page": 103, "allrow": 2682, "type": "text", "inside": "③合同规定了受益年限，法律也规定了有效年限的，按受益年限和有效年限两者之中较短者摊销；"}
{"page": 103, "allrow": 2683, "type": "text", "inside": "④合同没有规定受益年限，法律也没有规定有效年限的，摊销年限不超过10年。"}
{"page": 103, "allrow": 2684, "type": "text", "inside": "（3）无形资产减值准备确认标准、计提方法"}
{"page": 103, "allrow": 2685, "type": "text", "inside": "当存在下列一项或若干项情况时，本公司按无形资产可收回金额低于账面净值的差额计提无形资产减值准备："}
{"page": 103, "allrow": 2686, "type": "text", "inside": "①某项无形资产已被其他新技术所替代，使其为企业创造经济利益的能力受到重大不利影响；"}
{"page": 103, "allrow": 2687, "type": "text", "inside": "②某项无形资产的市价在当期大幅下跌，在剩余摊销年限内预计不会恢复；"}
{"page": 103, "allrow": 2688, "type": "text", "inside": "③某项无形资产已超过法律保护期限，但仍然具有部分使用价值；"}
{"page": 103, "allrow": 2689, "type": "text", "inside": "④其他足以证明某项无形资产实质上已经发生减值的情形。"}
{"page": 103, "allrow": 2690, "type": "text", "inside": "无形资产减值准备一经计提，不予转回。"}
{"page": 103, "allrow": 2691, "type": "text", "inside": "（4）当存在下列一项或若干项情况时，将该项无形资产的账面价值全部转入当期损益："}
{"page": 103, "allrow": 2692, "type": "text", "inside": "①某项无形资产已被其他新技术所替代，并且该项无形资产已无使用价值和转让价值；"}
{"page": 103, "allrow": 2693, "type": "text", "inside": "②某项无形资产已超过法律保护期限，并且已不能为企业带来经济利益；"}
{"page": 103, "allrow": 2694, "type": "text", "inside": "③其他足以证明某项无形资产已经丧失了使用价值和转让价值的情形。"}
{"page": 103, "allrow": 2695, "type": "text", "inside": "（5）使用寿命的估计"}
{"page": 103, "allrow": 2696, "type": "页脚", "inside": "103"}
{"page": 104, "allrow": 2697, "type": "text", "inside": ""}
{"page": 104, "allrow": 2698, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 104, "allrow": 2699, "type": "text", "inside": "对使用寿命有限的无形资产，估计其使用寿命时通常考虑以下因素："}
{"page": 104, "allrow": 2700, "type": "text", "inside": "①运用该资产生产的产品通常的寿命周期、可获得的类似资产使用寿命的信息；"}
{"page": 104, "allrow": 2701, "type": "text", "inside": "②技术、工艺等方面的现阶段情况及对未来发展趋势的估计；"}
{"page": 104, "allrow": 2702, "type": "text", "inside": "③以该资产生产的产品或提供劳务的市场需求情况；"}
{"page": 104, "allrow": 2703, "type": "text", "inside": "④现在或潜在的竞争者预期采取的行动；"}
{"page": 104, "allrow": 2704, "type": "text", "inside": "⑤为维持该资产带来经济利益能力的预期维护支出，以及公司预计支付有关支出的能力；"}
{"page": 104, "allrow": 2705, "type": "text", "inside": "⑥对该资产控制期限的相关法律规定或类似限制，如特许试用期、租赁期等；"}
{"page": 104, "allrow": 2706, "type": "text", "inside": "⑦与公司持有其他资产使用寿命的关联性等。"}
{"page": 104, "allrow": 2707, "type": "text", "inside": "（2）内部研究开发支出会计政策"}
{"page": 104, "allrow": 2708, "type": "text", "inside": "公司内部研究开发项目的支出分为研究阶段支出与开发阶段支出。"}
{"page": 104, "allrow": 2709, "type": "text", "inside": "研究阶段的支出，于发生时计入当期损益。"}
{"page": 104, "allrow": 2710, "type": "text", "inside": "开发阶段的支出同时满足下列条件的，确认为无形资产，不能满足下述条件的开发阶段的支出计入当期损益："}
{"page": 104, "allrow": 2711, "type": "text", "inside": "①完成该无形资产以使其能够使用或出售在技术上具有可行性；"}
{"page": 104, "allrow": 2712, "type": "text", "inside": "②具有完成该无形资产并使用或出售的意图；"}
{"page": 104, "allrow": 2713, "type": "text", "inside": "③无形资产产生经济利益的方式，包括能够证明运用该无形资产生产的产品存在市场或无形资产自身存在市场，无形资产将在内部使用的，能够证明其有用性；"}
{"page": 104, "allrow": 2714, "type": "text", "inside": "④有足够的技术、财务资源和其他资源支持，以完成该无形资产的开发，并有能力使用或出售该无形资产；"}
{"page": 104, "allrow": 2715, "type": "text", "inside": "⑤归属于该无形资产开发阶段的支出能够可靠地计量。"}
{"page": 104, "allrow": 2716, "type": "text", "inside": "无法区分研究阶段支出和开发阶段支出的，将发生的研发支出全部计入当期损益。"}
{"page": 104, "allrow": 2717, "type": "text", "inside": "31、长期资产减值"}
{"page": 104, "allrow": 2718, "type": "text", "inside": "对长期股权投资、采用成本模式计量的投资性房地产、固定资产、在建工程、使用寿命有限的无形资产等长期资产，在资产负债表日有迹象表明发生减值的，估计其可收回金额。对因企业合并所形成的商誉和使用寿命不确定的无形资产，无论是否存在减值迹象，每年都进行减值测试。商誉结合与其相关的资产组或者资产组组合进行减值测试。"}
{"page": 104, "allrow": 2719, "type": "text", "inside": "可收回金额的计量结果表明，该等长期资产的可收回金额低于其账面价值的，将资产的账面价值减记至可收回金额，减记的金额确认为资产减值损失，计入当期损益，同时计提相应的资产减值准备。"}
{"page": 104, "allrow": 2720, "type": "text", "inside": "（1）减值测试"}
{"page": 104, "allrow": 2721, "type": "text", "inside": "本公司在资产负债表日对存在下列迹象的资产进行减值测试："}
{"page": 104, "allrow": 2722, "type": "text", "inside": "①资产的市价当期大幅度下跌，其跌幅明显高于因时间的推移或者正常使用而预计的下跌。"}
{"page": 104, "allrow": 2723, "type": "text", "inside": "②公司经营所处的经济、技术或者法律等环境以及资产所处的市场在当期或者将在近期发生重大变化，从而对企业产生不利影响。"}
{"page": 104, "allrow": 2724, "type": "text", "inside": "③市场利率或者其他市场投资报酬率在当期已经提高，从而导致资产可收回金额大幅度降低。"}
{"page": 104, "allrow": 2725, "type": "text", "inside": "④有证据表明资产已经陈旧过时或者其实体已经损坏。"}
{"page": 104, "allrow": 2726, "type": "text", "inside": "⑤资产已经或者将被闲置、终止使用或者计划提前处置。"}
{"page": 104, "allrow": 2727, "type": "text", "inside": "⑥有证据表明资产的经济绩效已经低于或者将低于预期。"}
{"page": 104, "allrow": 2728, "type": "text", "inside": "⑦其他表明资产可能已经发生减值的迹象。"}
{"page": 104, "allrow": 2729, "type": "text", "inside": "使用寿命不确定的无形资产，无论是否存在减值迹象，每年都进行减值测试。"}
{"page": 104, "allrow": 2730, "type": "text", "inside": "（2）资产组的认定"}
{"page": 104, "allrow": 2731, "type": "text", "inside": "对于难以估计可收回金额的单项资产，按照该资产所属的资产组为基础确定资产组的可收回金额。资产组的认定以若干"}
{"page": 104, "allrow": 2732, "type": "页脚", "inside": "104"}
{"page": 105, "allrow": 2733, "type": "text", "inside": ""}
{"page": 105, "allrow": 2734, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 105, "allrow": 2735, "type": "text", "inside": "资产的组合能够产生独立于其他资产或资产组合的现金流入为依据。"}
{"page": 105, "allrow": 2736, "type": "text", "inside": "（3）资产或资产组可收回金额的确定"}
{"page": 105, "allrow": 2737, "type": "text", "inside": "进行减值测试时，可收回金额根据资产的公允价值减去处置费用后的净额与资产预计未来现金流量的现值两者之间较高者确定。"}
{"page": 105, "allrow": 2738, "type": "text", "inside": "资产或资产组公允价值减去处置费用后的净额按照下列方法确定："}
{"page": 105, "allrow": 2739, "type": "text", "inside": "①采用公平交易中销售协议价格减去可直接归属于该资产处置费用的金额。"}
{"page": 105, "allrow": 2740, "type": "text", "inside": "②不存在销售协议但存在资产活跃市场的，采用该资产的市场价格减去处置费用后的金额。其中，资产的市场价格根据资产的买方出价确定。"}
{"page": 105, "allrow": 2741, "type": "text", "inside": "③不存在销售协议和资产活跃市场的，参考同行业类似资产的最近交易价格或者结果进行估计。"}
{"page": 105, "allrow": 2742, "type": "text", "inside": "按照上述规定仍然无法可靠估计资产的公允价值减去处置费用后的净额，以该资产预计未来现金流量的现值作为其可收回金额。"}
{"page": 105, "allrow": 2743, "type": "text", "inside": "资产或资产组预计未来现金流量的现值，按照资产或资产组在预计使用寿命内，持续使用过程中和最终处置时所产生的预计未来现金流量，以企业的加权平均资金成本、增量借款利率或其他能够反映当前市场货币时间价值和资产特定风险的税前利率合理调整后作为折现率对其进行折现。"}
{"page": 105, "allrow": 2744, "type": "text", "inside": "（4）减值处理及转回"}
{"page": 105, "allrow": 2745, "type": "text", "inside": "资产的可收回金额低于其账面价值的，将资产的账面价值减记至可收回金额，减记的金额确认为资产减值损失，计入当期损益，同时计提相应的资产减值准备。"}
{"page": 105, "allrow": 2746, "type": "text", "inside": "资产减值损失一经确认，在以后会计期间不予转回，在处置相关资产时一并转出。"}
{"page": 105, "allrow": 2747, "type": "text", "inside": "32、长期待摊费用"}
{"page": 105, "allrow": 2748, "type": "text", "inside": "长期待摊费用核算已经支出，但摊销期限在1年以上（不含1年）的各项费用。长期待摊费用按实际发生额入账，在受益期或规定的期限内分期平均摊销。如果长期待摊的费用项目不能使以后会计期间受益则将尚未摊销的该项目的摊余价值全部转入当期损益。"}
{"page": 105, "allrow": 2749, "type": "text", "inside": "33、合同负债"}
{"page": 105, "allrow": 2750, "type": "text", "inside": "34、职工薪酬"}
{"page": 105, "allrow": 2751, "type": "text", "inside": "（1）短期薪酬的会计处理方法"}
{"page": 105, "allrow": 2752, "type": "text", "inside": "短期薪酬是指本公司在职工提供相关服务的年度报告期间结束后十二个月内需要全部予以支付的职工薪酬，离职后福利和辞退福利除外。本公司在职工提供服务的会计期间，将应付的短期薪酬确认为负债，并根据职工提供服务的受益对象计入相关资产成本和费用。"}
{"page": 105, "allrow": 2753, "type": "text", "inside": "（2）离职后福利的会计处理方法"}
{"page": 105, "allrow": 2754, "type": "text", "inside": "离职后福利是指本公司为获得职工提供的服务而在职工退休或与企业解除劳动关系后，提供的各种形式的报酬和福利，短期薪酬和辞退福利除外。离职后福利计划分类为设定提存计划和设定受益计划。"}
{"page": 105, "allrow": 2755, "type": "text", "inside": "离职后福利设定提存计划主要为参加由各地劳动及社会保障机构组织实施的社会基本养老保险、失业保险等。在职工为本公司提供服务的会计期间，将根据设定提存计划计算的应缴存金额确认为负债，并计入当期损益或相关资产成本。"}
{"page": 105, "allrow": 2756, "type": "text", "inside": "本公司按照国家规定的标准定期缴付上述款项后，不再有其他的支付义务。"}
{"page": 105, "allrow": 2757, "type": "页脚", "inside": "105"}
{"page": 106, "allrow": 2758, "type": "text", "inside": ""}
{"page": 106, "allrow": 2759, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 106, "allrow": 2760, "type": "text", "inside": "（3）辞退福利的会计处理方法"}
{"page": 106, "allrow": 2761, "type": "text", "inside": "辞退福利是指本公司在职工劳动合同到期之前解除与职工的劳动关系，或者为鼓励职工自愿接受裁减而给予职工的补偿，在发生当期计入当期损益。"}
{"page": 106, "allrow": 2762, "type": "text", "inside": "职工内部退休计划采用上述辞退福利相同的原则处理。本公司将自职工停止提供服务日至正常退休日期间拟支付的内退人员工资和缴纳的社会保险费等，计入当期损益。"}
{"page": 106, "allrow": 2763, "type": "text", "inside": "（4）其他长期职工福利的会计处理方法"}
{"page": 106, "allrow": 2764, "type": "text", "inside": "其他长期职工福利是指除短期薪酬、离职后福利、辞退福利之外的其他所有职工福利。"}
{"page": 106, "allrow": 2765, "type": "text", "inside": "对符合设定提存计划条件的其他长期职工福利，在职工为本公司提供服务的会计期间，将应缴存金额确认为负债，并计入当期损益或相关资产成本；除上述情形外的其他长期职工福利，在资产负债表日，将设定受益计划产生的福利义务归属于职工提供服务的期间，并计入当期损益或相关资产成本。"}
{"page": 106, "allrow": 2766, "type": "text", "inside": "35、租赁负债"}
{"page": 106, "allrow": 2767, "type": "text", "inside": "36、预计负债"}
{"page": 106, "allrow": 2768, "type": "text", "inside": "（1）预计负债的确认标准"}
{"page": 106, "allrow": 2769, "type": "text", "inside": "当与或有事项相关的义务是本公司承担的现时义务，且履行该义务很可能导致经济利益流出，同时其金额能够可靠地计量时确认该义务为预计负债。"}
{"page": 106, "allrow": 2770, "type": "text", "inside": "（2）预计负债的计量方法"}
{"page": 106, "allrow": 2771, "type": "text", "inside": "本公司预计负债按照履行相关现时义务所需支出的最佳估计数进行初始计量，如所需支出存在一个连续范围，且该范围内各种结果发生的可能性相同，最佳估计数按照该范围内的中间值确定；如涉及多个项目，按照各种可能结果及相关概率计算确定最佳估计数。"}
{"page": 106, "allrow": 2772, "type": "text", "inside": "本公司于资产负债表日对预计负债账面价值进行复核，有确凿证据表明该账面价值不能真实反映当前最佳估计数，按照当前最佳估计数对该账面价值进行调整。"}
{"page": 106, "allrow": 2773, "type": "text", "inside": "如果清偿预计负债所需支出全部或部分预期由第三方补偿的，补偿金额在基本确定能够收到时，作为资产单独确认，且确认的补偿金额不超过预计负债的账面价值。"}
{"page": 106, "allrow": 2774, "type": "text", "inside": "37、股份支付"}
{"page": 106, "allrow": 2775, "type": "text", "inside": "本公司的股份支付分为以现金结算的股份支付和以权益结算的股份支付。"}
{"page": 106, "allrow": 2776, "type": "text", "inside": "（1）以现金结算的股份支付"}
{"page": 106, "allrow": 2777, "type": "text", "inside": "以现金结算的股份支付，按照本公司承担的以股份或其他权益工具为基础计算确定的负债的公允价值计量。授予后立即可行权的以现金结算的股份支付，在授予日以本公司承担负债的公允价值计入相关成本或费用，相应增加负债。存在等待期的以现金结算的股份支付，在等待期内的每个资产负债表日以对可行权情况的最佳估计为基础，按本公司承担负债的公允价值金额，将当期取得的服务计入成本或费用和相应的负债。"}
{"page": 106, "allrow": 2778, "type": "text", "inside": "（2）以权益工具结算的股份支付"}
{"page": 106, "allrow": 2779, "type": "text", "inside": "以权益结算的股份支付，以授予职工权益工具的公允价值计量。授予后立即可行权的以权益结算的股份支付，在授予日以权益工具的公允价值计入相关成本或费用，相应增加资本公积。存在等待期的以权益结算的股份支付，在等待期内的每个资产负债表日，以对可行权权益工具数量的最佳估计为基础，按权益工具授予日的公允价值，将当期取得的服务计入成本或费用和资本公积。"}
{"page": 106, "allrow": 2780, "type": "页脚", "inside": "106"}
{"page": 107, "allrow": 2781, "type": "text", "inside": ""}
{"page": 107, "allrow": 2782, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 107, "allrow": 2783, "type": "text", "inside": "38、优先股、永续债等其他金融工具"}
{"page": 107, "allrow": 2784, "type": "text", "inside": "39、收入"}
{"page": 107, "allrow": 2785, "type": "text", "inside": "是否已执行新收入准则"}
{"page": 107, "allrow": 2786, "type": "text", "inside": "√是□否"}
{"page": 107, "allrow": 2787, "type": "text", "inside": "收入确认和计量所采用的会计政策"}
{"page": 107, "allrow": 2788, "type": "text", "inside": "（1）销售商品"}
{"page": 107, "allrow": 2789, "type": "text", "inside": "将商品所有权上的主要风险和报酬转移给买方，本公司不再对该商品实施继续管理权和实际控制权，与交易相关的经济利益能够流入公司，并且与销售该商品相关的成本能够可靠地计量时，确认销售收入的实现。"}
{"page": 107, "allrow": 2790, "type": "text", "inside": "（2）提供劳务"}
{"page": 107, "allrow": 2791, "type": "text", "inside": "以劳务总收入和总成本能够可靠地计量，与交易相关的经济利益能够流入本公司，劳务的完成程度能够可靠地确定时，确认劳务收入的实现。在同一年度内开始并完成的劳务，在完成劳务时确认收入；劳务的开始和完成分属不同的会计年度，在提供劳务交易的结果能够可靠估计的情况下，于资产负债表日按完工百分比法确认相关的劳务收入，完工百分比按已完工作的测量（或已经提供的劳务占应提供劳务总量的比例或已经发生的成本占估计总成本的比例）确认。"}
{"page": 107, "allrow": 2792, "type": "text", "inside": "（3）让渡资产使用权"}
{"page": 107, "allrow": 2793, "type": "text", "inside": "让渡无形资产（如商标权、专利权、专营权、软件、版权等）以及其他资产的使用权而形成的使用费收入，按有关合同或协议规定的收费时间和方法确定，并同时满足与交易相关的经济利益能够流入公司和收入的金额能够可靠计量的条件。"}
{"page": 107, "allrow": 2794, "type": "text", "inside": "同类业务采用不同经营模式导致收入确认会计政策存在差异的情况"}
{"page": 107, "allrow": 2795, "type": "text", "inside": "40、政府补助"}
{"page": 107, "allrow": 2796, "type": "text", "inside": "（1）确认原则：政府补助同时满足下列条件的，予以确认："}
{"page": 107, "allrow": 2797, "type": "text", "inside": "①、企业能够满足政府补助所附条件；"}
{"page": 107, "allrow": 2798, "type": "text", "inside": "②、企业能够收到政府补助。"}
{"page": 107, "allrow": 2799, "type": "text", "inside": "（2）计量：政府补助为货币性资产的，按照收到或应收的金额计量。政府补助为非货币性资产的，按照公允价值计量；"}
{"page": 107, "allrow": 2800, "type": "text", "inside": "公允价值不能可靠取得的，按照名义金额计量。"}
{"page": 107, "allrow": 2801, "type": "text", "inside": "（3）会计处理："}
{"page": 107, "allrow": 2802, "type": "text", "inside": "①、与资产相关的政府补助，是指本公司取得的、用于购建或以其他方式形成长期资产的政府补助。本公司对与资产相关的政府补助，冲减相关资产账面价值或确认为递延收益。确认为递延收益的，在相关资产使用寿命内按照合理、系统的方法分期计入当期损益（与本公司日常活动相关的，计入其他收益；与本公司日常活动无关的，计入营业外收入）。"}
{"page": 107, "allrow": 2803, "type": "text", "inside": "②、与收益相关的政府补助，是指本公司取得的除与资产相关的政府补助之外的政府补助。本公司对与收益相关的政府补助，用于补偿本公司以后期间的相关成本费用或损失的，确认为递延收益，并在确认相关成本费用或损失的期间，计入当期损益（与本公司日常活动相关的，计入其他收益；与本公司日常活动无关的，计入营业外收入）或冲减相关成本费用或损失；用于补偿本公司已发生的相关成本费用或损失的，直接计入当期损益（与本公司日常活动相关的，计入其他收益；与本公司日常活动无关的，计入营业外收入）或冲减相关成本费用或损失。"}
{"page": 107, "allrow": 2804, "type": "text", "inside": "③、对于同时包含与资产相关和与收益相关的政府补助，按照实际金额进行区分，并相应进行会计处理，金额难以区分的，全额作为与收益相关的政府补助。"}
{"page": 107, "allrow": 2805, "type": "页脚", "inside": "107"}
{"page": 108, "allrow": 2806, "type": "text", "inside": ""}
{"page": 108, "allrow": 2807, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 108, "allrow": 2808, "type": "text", "inside": "41、递延所得税资产/递延所得税负债"}
{"page": 108, "allrow": 2809, "type": "text", "inside": "（1）当期所得税"}
{"page": 108, "allrow": 2810, "type": "text", "inside": "资产负债表日，对于当期和以前期间形成的当期所得税负债（或资产），以按照税法规定计算的预期应交纳（或返还）的所得税金额计量。计算当期所得税费用所依据的应纳税所得额系根据有关税法规定对本年度税前会计利润作相应调整后计算得出。"}
{"page": 108, "allrow": 2811, "type": "text", "inside": "（2）递延所得税资产及递延所得税负债"}
{"page": 108, "allrow": 2812, "type": "text", "inside": "某些资产、负债项目的账面价值与其计税基础之间的差额，以及未作为资产和负债确认但按照税法规定可以确定其计税基础的项目的账面价值与计税基础之间的差额产生的暂时性差异，采用资产负债表债务法确认递延所得税资产及递延所得税负债。"}
{"page": 108, "allrow": 2813, "type": "text", "inside": "与商誉的初始确认有关，以及与既不是企业合并、发生时也不影响会计利润和应纳税所得额（或可抵扣亏损）的交易中产生的资产或负债的初始确认有关的应纳税暂时性差异，不予确认有关的递延所得税负债。此外，对与子公司、联营企业及合营企业投资相关的应纳税暂时性差异，如果本公司能够控制暂时性差异转回的时间，而且该暂时性差异在可预见的未来很可能不会转回，也不予确认有关的递延所得税负债。除上述例外情况，本公司确认其他所有应纳税暂时性差异产生的递延所得税负债。"}
{"page": 108, "allrow": 2814, "type": "text", "inside": "与既不是企业合并、发生时也不影响会计利润和应纳税所得额（或可抵扣亏损）的交易中产生的资产或负债的初始确认有关的可抵扣暂时性差异，不予确认有关的递延所得税资产。此外，对与子公司、联营企业及合营企业投资相关的可抵扣暂时性差异，如果暂时性差异在可预见的未来不是很可能转回，或者未来不是很可能获得用来抵扣可抵扣暂时性差异的应纳税所得额，不予确认有关的递延所得税资产。除上述例外情况，本公司以很可能取得用来抵扣可抵扣暂时性差异的应纳税所得额为限，确认其他可抵扣暂时性差异产生的递延所得税资产。"}
{"page": 108, "allrow": 2815, "type": "text", "inside": "对于能够结转以后年度的可抵扣亏损和税款抵减，以很可能获得用来抵扣可抵扣亏损和税款抵减的未来应纳税所得额为限，确认相应的递延所得税资产。"}
{"page": 108, "allrow": 2816, "type": "text", "inside": "资产负债表日，对于递延所得税资产和递延所得税负债，根据税法规定，按照预期收回相关资产或清偿相关负债期间的适用税率计量。"}
{"page": 108, "allrow": 2817, "type": "text", "inside": "于资产负债表日，对递延所得税资产的账面价值进行复核，如果未来很可能无法获得足够的应纳税所得额用以抵扣递延所得税资产的利益，则减记递延所得税资产的账面价值。在很可能获得足够的应纳税所得额时，减记的金额予以转回。"}
{"page": 108, "allrow": 2818, "type": "text", "inside": "（3）所得税费用"}
{"page": 108, "allrow": 2819, "type": "text", "inside": "所得税费用包括当期所得税和递延所得税。"}
{"page": 108, "allrow": 2820, "type": "text", "inside": "除确认为其他综合收益或直接计入股东权益的交易和事项相关的当期所得税和递延所得税计入其他综合收益或股东权益，以及企业合并产生的递延所得税调整商誉的账面价值外，其余当期所得税和递延所得税费用或收益计入当期损益。"}
{"page": 108, "allrow": 2821, "type": "text", "inside": "42、租赁"}
{"page": 108, "allrow": 2822, "type": "text", "inside": "（1）经营租赁的会计处理方法"}
{"page": 108, "allrow": 2823, "type": "text", "inside": "本公司作为承租人对于经营租赁的租金，在租赁期内各个期间按照直线法计入相关资产成本或当期损益；发生的初始直接费用，计入当期损益；或有租金在实际发生时计入当期损益。"}
{"page": 108, "allrow": 2824, "type": "text", "inside": "本公司作为出租人按资产的性质，将用作经营租赁的资产包括在资产负债表中的相关项目内；"}
{"page": 108, "allrow": 2825, "type": "text", "inside": "经营租赁的租金，在租赁期内各个期间按照直线法确认为当期损益；发生的初始直接费用，计入当期损益；对于经营租赁资产中的固定资产，出租人应当采用类似资产的折旧政策计提折旧；对于其他经营租赁资产，应当采用系统合理的方法进行摊销；或有租金在实际发生时计入当期损益。"}
{"page": 108, "allrow": 2826, "type": "页脚", "inside": "108"}
{"page": 109, "allrow": 2827, "type": "text", "inside": ""}
{"page": 109, "allrow": 2828, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 109, "allrow": 2829, "type": "text", "inside": "（2）融资租赁的会计处理方法"}
{"page": 109, "allrow": 2830, "type": "text", "inside": "本公司在租赁期开始日将租赁开始日租赁资产公允价值与最低租赁付款额现值两者中较低者作为租入资产的入账价值，将最低租赁付款额作为长期应付款的入账价值，其差额作为未确认融资费用；本公司在租赁谈判和签订租赁合同过程中发生的，可归属于租赁项目的手续费、律师费、差旅费、印花税等初始直接费用，计入租入资产价值；未确认融资费用在租赁期内各个期间进行分摊，采用实际利率法计算确认当期的融资费用；或有租金在实际发生时计入当期损益。"}
{"page": 109, "allrow": 2831, "type": "text", "inside": "本公司在计算最低租赁付款额的现值时，能够取得出租人租赁内含利率的，采用租赁内含利率作为折现率；否则采用租赁合同规定的利率作为折现率。无法取得出租人的租赁内含利率且租赁合同没有规定利率的，采用同期银行贷款利率作为折现率。"}
{"page": 109, "allrow": 2832, "type": "text", "inside": "本公司采用与自有固定资产相一致的折旧政策计提租赁资产折旧。能够合理确定租赁期届满时取得租赁资产所有权的，在租赁资产使用寿命内计提折旧。无法合理确定租赁期届满时能够取得租赁资产所有权的，在租赁期与租赁资产使用寿命两者中较短的期间内计提折旧。"}
{"page": 109, "allrow": 2833, "type": "text", "inside": "在形成融资租赁的售后租回交易方式下，本公司出售资产的售价与出售前资产的账面价值之间的差额，作为未实现售后租回损益递延并按资产的折旧进度进行分摊，作为折旧费用的调整。"}
{"page": 109, "allrow": 2834, "type": "text", "inside": "43、其他重要的会计政策和会计估计"}
{"page": 109, "allrow": 2835, "type": "text", "inside": "44、重要会计政策和会计估计变更"}
{"page": 109, "allrow": 2836, "type": "text", "inside": "（1）重要会计政策变更"}
{"page": 109, "allrow": 2837, "type": "text", "inside": "√适用□不适用"}
{"page": 109, "allrow": 2838, "type": "excel", "inside": "['会计政策变更的内容和原因', '审批程序', '备注']"}
{"page": 109, "allrow": 2839, "type": "text", "inside": ""}
{"page": 109, "allrow": 2840, "type": "text", "inside": "1、2019年4月30日，财政部发布的《关于修订印发2019年度一般企业财务报表格式的通知》（财会【2019】6号），要求对已执行新金融工具准则但未执行新收入准则和新租赁准则的企业应按如下规定编制财务报表："}
{"page": 109, "allrow": 2841, "type": "text", "inside": "资产负债表中将“应收票据及应收账款”行项目拆分为“应收票据”及“应收账款”；增加“应收款项融资”项目，反映资产负债表日以公允价值计量且其变动计入其他综合收益的应收票据和应收账款等；将“应付票据及应付账款”行项目拆分为“应付票据”及“应付账款”。"}
{"page": 109, "allrow": 2842, "type": "text", "inside": "利润表中在投资收益项目下增加“以摊余成本计量的金融资产终止确认收益（损失以“-”号填列）”的明细项目。"}
{"page": 109, "allrow": 2843, "type": "text", "inside": "2019年9月19日，财政部发布了《关于修订印发《合并财务报表格式（2019版）》的通知》（财会【2019】16号），与财会【2019】6号配套执行。"}
{"page": 109, "allrow": 2844, "type": "text", "inside": "本公司根据财会【2019】6号、财会【2019】16号规定的财务报表格式编制比较报表，并采用追溯调整法变更了相关财务报表列报。本次会计政策变更对公司2018年度财务报表项目列报影响如下："}
{"page": 109, "allrow": 2845, "type": "excel", "inside": "['2018年12月31日', '调整前', '调整后']"}
{"page": 109, "allrow": 2846, "type": "excel", "inside": "['应收票据及应收账款', '1,235,237,697.34', '-']"}
{"page": 109, "allrow": 2847, "type": "excel", "inside": "['应收票据', '-', '210,813,018.23']"}
{"page": 109, "allrow": 2848, "type": "excel", "inside": "['应收账款', '-', '1,024,424,679.11']"}
{"page": 109, "allrow": 2849, "type": "excel", "inside": "['应付票据及应付账款', '1,113,348,823.59', '-']"}
{"page": 109, "allrow": 2850, "type": "excel", "inside": "['应付票据', '', '322,056,386.67']"}
{"page": 109, "allrow": 2851, "type": "excel", "inside": "['应付账款', '', '791,292,436.92']"}
{"page": 109, "allrow": 2852, "type": "text", "inside": ""}
{"page": 109, "allrow": 2853, "type": "text", "inside": "2、财政部于2017年3月31日分别发布了《企业会计准则第22号——金融工具确认和计量（2017年修订）》（财会〔2017〕"}
{"page": 109, "allrow": 2854, "type": "text", "inside": "7号）、《企业会计准则第23号——金融资产转移（2017年修订）》（财会〔2017〕8号）、《企业会计准则第24号——"}
{"page": 109, "allrow": 2855, "type": "text", "inside": "套期会计（2017年修订）》（财会〔2017〕9号），于2017年5月2日发布了《企业会计准则第37号——金融工具列报"}
{"page": 109, "allrow": 2856, "type": "页脚", "inside": "109"}
{"page": 110, "allrow": 2857, "type": "text", "inside": ""}
{"page": 110, "allrow": 2858, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 110, "allrow": 2859, "type": "text", "inside": "（2017年修订）》（财会〔2017〕14号）（上述准则以下统称“新金融工具准则”）。要求境内上市企业自2019年1月1日起施行。根据新金融工具准则的实施时间要求，公司于2019年1月1日起执行上述新金融工具，并依据上述新金融工具准则的规定对相关会计政策进行变更。根据新金融工具准则中衔接规定相关要求，公司对上年同期比较报表不进行追溯调整，本次会计政策变更不会对公司以前年度的财务状况、经营成果产生影响。"}
{"page": 110, "allrow": 2860, "type": "text", "inside": "3、2019年5月9日，财政部发布《企业会计准则第7号—非货币性资产交换》（财会【2019】8号），根据要求，本公司对2019年1月1日至执行日之间发生的非货币性资产交换，根据本准则进行调整，对2019年1月1日之前发生的非货币性资产交换，不进行追溯调整。"}
{"page": 110, "allrow": 2861, "type": "text", "inside": "（2）重要会计估计变更"}
{"page": 110, "allrow": 2862, "type": "text", "inside": "□适用√不适用"}
{"page": 110, "allrow": 2863, "type": "text", "inside": "（3）2019年起执行新金融工具准则、新收入准则或新租赁准则调整执行当年年初财务报表相关项目情况√适用□不适用"}
{"page": 110, "allrow": 2864, "type": "text", "inside": "合并资产负债表"}
{"page": 110, "allrow": 2865, "type": "text", "inside": "单位：元"}
{"page": 110, "allrow": 2866, "type": "excel", "inside": "['项目', '2018年12月31日', '2019年01月01日', '调整数']"}
{"page": 110, "allrow": 2867, "type": "excel", "inside": "['流动资产：', '', '', '']"}
{"page": 110, "allrow": 2868, "type": "excel", "inside": "['货币资金', '644,375,303.19', '644,375,303.19', '']"}
{"page": 110, "allrow": 2869, "type": "excel", "inside": "['结算备付金', '', '', '']"}
{"page": 110, "allrow": 2870, "type": "excel", "inside": "['拆出资金', '', '', '']"}
{"page": 110, "allrow": 2871, "type": "excel", "inside": "['交易性金融资产', '', '101,400,000.00', '101,400,000.00']"}
{"page": 110, "allrow": 2872, "type": "excel", "inside": "['以公允价值计量且其变动计入当期损益的金融资产', '', '', '']"}
{"page": 110, "allrow": 2873, "type": "excel", "inside": "['衍生金融资产', '', '', '']"}
{"page": 110, "allrow": 2874, "type": "excel", "inside": "['应收票据', '210,813,018.23', '', '-210,813,018.23']"}
{"page": 110, "allrow": 2875, "type": "excel", "inside": "['应收账款', '1,024,424,679.11', '1,024,424,679.11', '']"}
{"page": 110, "allrow": 2876, "type": "excel", "inside": "['应收款项融资', '', '210,813,018.23', '210,813,018.23']"}
{"page": 110, "allrow": 2877, "type": "excel", "inside": "['预付款项', '124,923,892.89', '124,923,892.89', '']"}
{"page": 110, "allrow": 2878, "type": "excel", "inside": "['应收保费', '', '', '']"}
{"page": 110, "allrow": 2879, "type": "excel", "inside": "['应收分保账款', '', '', '']"}
{"page": 110, "allrow": 2880, "type": "excel", "inside": "['应收分保合同准备金', '', '', '']"}
{"page": 110, "allrow": 2881, "type": "excel", "inside": "['其他应收款', '7,566,657.24', '7,566,657.24', '']"}
{"page": 110, "allrow": 2882, "type": "excel", "inside": "['其中：应收利息', '', '', '']"}
{"page": 110, "allrow": 2883, "type": "excel", "inside": "['应收股利', '', '', '']"}
{"page": 110, "allrow": 2884, "type": "text", "inside": ""}
{"page": 110, "allrow": 2885, "type": "页脚", "inside": "110"}
{"page": 111, "allrow": 2886, "type": "text", "inside": ""}
{"page": 111, "allrow": 2887, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 111, "allrow": 2888, "type": "excel", "inside": "['买入返售金融资产', '', '']"}
{"page": 111, "allrow": 2889, "type": "excel", "inside": "['存货', '901,643,879.75', '901,643,879.75']"}
{"page": 111, "allrow": 2890, "type": "excel", "inside": "['合同资产', '', '']"}
{"page": 111, "allrow": 2891, "type": "excel", "inside": "['持有待售资产', '', '']"}
{"page": 111, "allrow": 2892, "type": "excel", "inside": "['一年内到期的非流动资产', '', '']"}
{"page": 111, "allrow": 2893, "type": "excel", "inside": "['其他流动资产', '161,784,771.70', '60,384,771.70']"}
{"page": 111, "allrow": 2894, "type": "excel", "inside": "['流动资产合计', '3,075,532,202.11', '3,075,532,202.11']"}
{"page": 111, "allrow": 2895, "type": "excel", "inside": "['非流动资产：', '', '']"}
{"page": 111, "allrow": 2896, "type": "excel", "inside": "['发放贷款和垫款', '', '']"}
{"page": 111, "allrow": 2897, "type": "excel", "inside": "['债权投资', '', '']"}
{"page": 111, "allrow": 2898, "type": "excel", "inside": "['可供出售金融资产', '', '']"}
{"page": 111, "allrow": 2899, "type": "excel", "inside": "['其他债权投资', '', '']"}
{"page": 111, "allrow": 2900, "type": "excel", "inside": "['持有至到期投资', '', '']"}
{"page": 111, "allrow": 2901, "type": "excel", "inside": "['长期应收款', '', '']"}
{"page": 111, "allrow": 2902, "type": "excel", "inside": "['长期股权投资', '100,871,723.22', '100,871,723.22']"}
{"page": 111, "allrow": 2903, "type": "excel", "inside": "['其他权益工具投资', '', '']"}
{"page": 111, "allrow": 2904, "type": "excel", "inside": "['其他非流动金融资产', '', '']"}
{"page": 111, "allrow": 2905, "type": "excel", "inside": "['投资性房地产', '', '']"}
{"page": 111, "allrow": 2906, "type": "excel", "inside": "['固定资产', '1,971,680,172.58', '1,971,680,172.58']"}
{"page": 111, "allrow": 2907, "type": "excel", "inside": "['在建工程', '151,569,855.81', '151,569,855.81']"}
{"page": 111, "allrow": 2908, "type": "excel", "inside": "['生产性生物资产', '', '']"}
{"page": 111, "allrow": 2909, "type": "excel", "inside": "['油气资产', '', '']"}
{"page": 111, "allrow": 2910, "type": "excel", "inside": "['使用权资产', '', '']"}
{"page": 111, "allrow": 2911, "type": "excel", "inside": "['无形资产', '343,159,065.40', '343,159,065.40']"}
{"page": 111, "allrow": 2912, "type": "excel", "inside": "['开发支出', '20,066,420.36', '20,066,420.36']"}
{"page": 111, "allrow": 2913, "type": "excel", "inside": "['商誉', '29,504,402.57', '29,504,402.57']"}
{"page": 111, "allrow": 2914, "type": "excel", "inside": "['长期待摊费用', '7,223,899.26', '7,223,899.26']"}
{"page": 111, "allrow": 2915, "type": "excel", "inside": "['递延所得税资产', '40,747,235.56', '40,747,235.56']"}
{"page": 111, "allrow": 2916, "type": "excel", "inside": "['其他非流动资产', '11,406,417.12', '11,406,417.12']"}
{"page": 111, "allrow": 2917, "type": "excel", "inside": "['非流动资产合计', '2,676,229,191.88', '2,676,229,191.88']"}
{"page": 111, "allrow": 2918, "type": "excel", "inside": "['资产总计', '5,751,761,393.99', '5,751,761,393.99']"}
{"page": 111, "allrow": 2919, "type": "excel", "inside": "['流动负债：', '', '']"}
{"page": 111, "allrow": 2920, "type": "excel", "inside": "['短期借款', '614,100,000.00', '614,100,000.00']"}
{"page": 111, "allrow": 2921, "type": "text", "inside": ""}
{"page": 111, "allrow": 2922, "type": "页脚", "inside": "111"}
{"page": 112, "allrow": 2923, "type": "text", "inside": ""}
{"page": 112, "allrow": 2924, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 112, "allrow": 2925, "type": "excel", "inside": "['向中央银行借款', '', '', '']"}
{"page": 112, "allrow": 2926, "type": "excel", "inside": "['拆入资金', '', '', '']"}
{"page": 112, "allrow": 2927, "type": "excel", "inside": "['交易性金融负债', '', '2,486,145.90', '2,486,145.90']"}
{"page": 112, "allrow": 2928, "type": "excel", "inside": "['以公允价值计量且其变动计入当期损益的金融负债', '2,486,145.90', '', '-2,486,145.90']"}
{"page": 112, "allrow": 2929, "type": "excel", "inside": "['衍生金融负债', '', '', '']"}
{"page": 112, "allrow": 2930, "type": "excel", "inside": "['应付票据', '322,056,386.67', '322,056,386.67', '']"}
{"page": 112, "allrow": 2931, "type": "excel", "inside": "['应付账款', '791,292,436.92', '791,292,436.92', '']"}
{"page": 112, "allrow": 2932, "type": "excel", "inside": "['预收款项', '143,275,906.92', '143,275,906.92', '']"}
{"page": 112, "allrow": 2933, "type": "excel", "inside": "['合同负债', '', '', '']"}
{"page": 112, "allrow": 2934, "type": "excel", "inside": "['卖出回购金融资产款', '', '', '']"}
{"page": 112, "allrow": 2935, "type": "excel", "inside": "['吸收存款及同业存放', '', '', '']"}
{"page": 112, "allrow": 2936, "type": "excel", "inside": "['代理买卖证券款', '', '', '']"}
{"page": 112, "allrow": 2937, "type": "excel", "inside": "['代理承销证券款', '', '', '']"}
{"page": 112, "allrow": 2938, "type": "excel", "inside": "['应付职工薪酬', '95,955,596.01', '95,955,596.01', '']"}
{"page": 112, "allrow": 2939, "type": "excel", "inside": "['应交税费', '87,321,744.85', '87,321,744.85', '']"}
{"page": 112, "allrow": 2940, "type": "excel", "inside": "['其他应付款', '147,229,056.40', '147,229,056.40', '']"}
{"page": 112, "allrow": 2941, "type": "excel", "inside": "['其中：应付利息', '1,161,561.41', '1,161,561.41', '']"}
{"page": 112, "allrow": 2942, "type": "excel", "inside": "['应付股利', '', '', '']"}
{"page": 112, "allrow": 2943, "type": "excel", "inside": "['应付手续费及佣金', '', '', '']"}
{"page": 112, "allrow": 2944, "type": "excel", "inside": "['应付分保账款', '', '', '']"}
{"page": 112, "allrow": 2945, "type": "excel", "inside": "['持有待售负债', '', '', '']"}
{"page": 112, "allrow": 2946, "type": "excel", "inside": "['一年内到期的非流动负债', '', '', '']"}
{"page": 112, "allrow": 2947, "type": "excel", "inside": "['其他流动负债', '', '', '']"}
{"page": 112, "allrow": 2948, "type": "excel", "inside": "['流动负债合计', '2,203,717,273.67', '2,203,717,273.67', '']"}
{"page": 112, "allrow": 2949, "type": "excel", "inside": "['非流动负债：', '', '', '']"}
{"page": 112, "allrow": 2950, "type": "excel", "inside": "['保险合同准备金', '', '', '']"}
{"page": 112, "allrow": 2951, "type": "excel", "inside": "['长期借款', '', '', '']"}
{"page": 112, "allrow": 2952, "type": "excel", "inside": "['应付债券', '', '', '']"}
{"page": 112, "allrow": 2953, "type": "excel", "inside": "['其中：优先股', '', '', '']"}
{"page": 112, "allrow": 2954, "type": "excel", "inside": "['永续债', '', '', '']"}
{"page": 112, "allrow": 2955, "type": "excel", "inside": "['租赁负债', '', '', '']"}
{"page": 112, "allrow": 2956, "type": "excel", "inside": "['长期应付款', '72,000,000.00', '72,000,000.00', '']"}
{"page": 112, "allrow": 2957, "type": "text", "inside": ""}
{"page": 112, "allrow": 2958, "type": "页脚", "inside": "112"}
{"page": 113, "allrow": 2959, "type": "text", "inside": ""}
{"page": 113, "allrow": 2960, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 113, "allrow": 2961, "type": "excel", "inside": "['长期应付职工薪酬', '', '']"}
{"page": 113, "allrow": 2962, "type": "excel", "inside": "['预计负债', '', '']"}
{"page": 113, "allrow": 2963, "type": "excel", "inside": "['递延收益', '130,052,096.06', '130,052,096.06']"}
{"page": 113, "allrow": 2964, "type": "excel", "inside": "['递延所得税负债', '731,931.53', '731,931.53']"}
{"page": 113, "allrow": 2965, "type": "excel", "inside": "['其他非流动负债', '', '']"}
{"page": 113, "allrow": 2966, "type": "excel", "inside": "['非流动负债合计', '202,784,027.59', '202,784,027.59']"}
{"page": 113, "allrow": 2967, "type": "excel", "inside": "['负债合计', '2,406,501,301.26', '2,406,501,301.26']"}
{"page": 113, "allrow": 2968, "type": "excel", "inside": "['所有者权益：', '', '']"}
{"page": 113, "allrow": 2969, "type": "excel", "inside": "['股本', '1,178,523,492.00', '1,178,523,492.00']"}
{"page": 113, "allrow": 2970, "type": "excel", "inside": "['其他权益工具', '', '']"}
{"page": 113, "allrow": 2971, "type": "excel", "inside": "['其中：优先股', '', '']"}
{"page": 113, "allrow": 2972, "type": "excel", "inside": "['永续债', '', '']"}
{"page": 113, "allrow": 2973, "type": "excel", "inside": "['资本公积', '438,985,920.01', '438,985,920.01']"}
{"page": 113, "allrow": 2974, "type": "excel", "inside": "['减：库存股', '', '']"}
{"page": 113, "allrow": 2975, "type": "excel", "inside": "['其他综合收益', '-90,895.78', '-90,895.78']"}
{"page": 113, "allrow": 2976, "type": "excel", "inside": "['专项储备', '', '']"}
{"page": 113, "allrow": 2977, "type": "excel", "inside": "['盈余公积', '112,256,875.56', '112,256,875.56']"}
{"page": 113, "allrow": 2978, "type": "excel", "inside": "['一般风险准备', '', '']"}
{"page": 113, "allrow": 2979, "type": "excel", "inside": "['未分配利润', '1,615,584,700.94', '1,615,584,700.94']"}
{"page": 113, "allrow": 2980, "type": "excel", "inside": "['归属于母公司所有者权益合计', '3,345,260,092.73', '3,345,260,092.73']"}
{"page": 113, "allrow": 2981, "type": "excel", "inside": "['少数股东权益', '', '']"}
{"page": 113, "allrow": 2982, "type": "excel", "inside": "['所有者权益合计', '3,345,260,092.73', '3,345,260,092.73']"}
{"page": 113, "allrow": 2983, "type": "excel", "inside": "['负债和所有者权益总计', '5,751,761,393.99', '5,751,761,393.99']"}
{"page": 113, "allrow": 2984, "type": "text", "inside": ""}
{"page": 113, "allrow": 2985, "type": "text", "inside": "调整情况说明"}
{"page": 113, "allrow": 2986, "type": "text", "inside": "母公司资产负债表"}
{"page": 113, "allrow": 2987, "type": "text", "inside": "单位：元"}
{"page": 113, "allrow": 2988, "type": "excel", "inside": "['项目', '2018年12月31日', '2019年01月01日', '调整数']"}
{"page": 113, "allrow": 2989, "type": "excel", "inside": "['流动资产：', '', '', '']"}
{"page": 113, "allrow": 2990, "type": "excel", "inside": "['货币资金', '636,111.19', '636,111.19', '']"}
{"page": 113, "allrow": 2991, "type": "excel", "inside": "['交易性金融资产', '', '23,900,000.00', '23,900,000.00']"}
{"page": 113, "allrow": 2992, "type": "excel", "inside": "['以公允价值计量且其变动计入当期损益的金融资产', '', '', '']"}
{"page": 113, "allrow": 2993, "type": "excel", "inside": "['衍生金融资产', '', '', '']"}
{"page": 113, "allrow": 2994, "type": "text", "inside": ""}
{"page": 113, "allrow": 2995, "type": "页脚", "inside": "113"}
{"page": 114, "allrow": 2996, "type": "text", "inside": ""}
{"page": 114, "allrow": 2997, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 114, "allrow": 2998, "type": "excel", "inside": "['应收票据', '', '', '']"}
{"page": 114, "allrow": 2999, "type": "excel", "inside": "['应收账款', '0.00', '', '']"}
{"page": 114, "allrow": 3000, "type": "excel", "inside": "['应收款项融资', '', '', '']"}
{"page": 114, "allrow": 3001, "type": "excel", "inside": "['预付款项', '99,108.49', '99,108.49', '']"}
{"page": 114, "allrow": 3002, "type": "excel", "inside": "['其他应收款', '553,510,132.66', '553,510,132.66', '']"}
{"page": 114, "allrow": 3003, "type": "excel", "inside": "['其中：应收利息', '', '', '']"}
{"page": 114, "allrow": 3004, "type": "excel", "inside": "['应收股利', '126,400,000.00', '126,400,000.00', '']"}
{"page": 114, "allrow": 3005, "type": "excel", "inside": "['存货', '', '', '']"}
{"page": 114, "allrow": 3006, "type": "excel", "inside": "['合同资产', '', '', '']"}
{"page": 114, "allrow": 3007, "type": "excel", "inside": "['持有待售资产', '', '', '']"}
{"page": 114, "allrow": 3008, "type": "excel", "inside": "['一年内到期的非流动资产', '', '', '']"}
{"page": 114, "allrow": 3009, "type": "excel", "inside": "['其他流动资产', '23,900,000.00', '', '-23,900,000.00']"}
{"page": 114, "allrow": 3010, "type": "excel", "inside": "['流动资产合计', '578,145,352.34', '578,145,352.34', '']"}
{"page": 114, "allrow": 3011, "type": "excel", "inside": "['非流动资产：', '', '', '']"}
{"page": 114, "allrow": 3012, "type": "excel", "inside": "['债权投资', '', '', '']"}
{"page": 114, "allrow": 3013, "type": "excel", "inside": "['可供出售金融资产', '', '', '']"}
{"page": 114, "allrow": 3014, "type": "excel", "inside": "['其他债权投资', '', '', '']"}
{"page": 114, "allrow": 3015, "type": "excel", "inside": "['持有至到期投资', '', '', '']"}
{"page": 114, "allrow": 3016, "type": "excel", "inside": "['长期应收款', '', '', '']"}
{"page": 114, "allrow": 3017, "type": "excel", "inside": "['长期股权投资', '1,741,996,456.86', '1,741,996,456.86', '']"}
{"page": 114, "allrow": 3018, "type": "excel", "inside": "['其他权益工具投资', '', '', '']"}
{"page": 114, "allrow": 3019, "type": "excel", "inside": "['其他非流动金融资产', '', '', '']"}
{"page": 114, "allrow": 3020, "type": "excel", "inside": "['投资性房地产', '', '', '']"}
{"page": 114, "allrow": 3021, "type": "excel", "inside": "['固定资产', '393,816.68', '393,816.68', '']"}
{"page": 114, "allrow": 3022, "type": "excel", "inside": "['在建工程', '', '', '']"}
{"page": 114, "allrow": 3023, "type": "excel", "inside": "['生产性生物资产', '', '', '']"}
{"page": 114, "allrow": 3024, "type": "excel", "inside": "['油气资产', '', '', '']"}
{"page": 114, "allrow": 3025, "type": "excel", "inside": "['使用权资产', '', '', '']"}
{"page": 114, "allrow": 3026, "type": "excel", "inside": "['无形资产', '', '', '']"}
{"page": 114, "allrow": 3027, "type": "excel", "inside": "['开发支出', '', '', '']"}
{"page": 114, "allrow": 3028, "type": "excel", "inside": "['商誉', '', '', '']"}
{"page": 114, "allrow": 3029, "type": "excel", "inside": "['长期待摊费用', '', '', '']"}
{"page": 114, "allrow": 3030, "type": "excel", "inside": "['递延所得税资产', '', '', '']"}
{"page": 114, "allrow": 3031, "type": "text", "inside": ""}
{"page": 114, "allrow": 3032, "type": "页脚", "inside": "114"}
{"page": 115, "allrow": 3033, "type": "text", "inside": ""}
{"page": 115, "allrow": 3034, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 115, "allrow": 3035, "type": "excel", "inside": "['其他非流动资产', '', '']"}
{"page": 115, "allrow": 3036, "type": "excel", "inside": "['非流动资产合计', '1,742,390,273.54', '1,742,390,273.54']"}
{"page": 115, "allrow": 3037, "type": "excel", "inside": "['资产总计', '2,320,535,625.88', '2,320,535,625.88']"}
{"page": 115, "allrow": 3038, "type": "excel", "inside": "['流动负债：', '', '']"}
{"page": 115, "allrow": 3039, "type": "excel", "inside": "['短期借款', '', '']"}
{"page": 115, "allrow": 3040, "type": "excel", "inside": "['交易性金融负债', '', '']"}
{"page": 115, "allrow": 3041, "type": "excel", "inside": "['以公允价值计量且其变动计入当期损益的金融负债', '', '']"}
{"page": 115, "allrow": 3042, "type": "excel", "inside": "['衍生金融负债', '', '']"}
{"page": 115, "allrow": 3043, "type": "excel", "inside": "['应付票据', '', '']"}
{"page": 115, "allrow": 3044, "type": "excel", "inside": "['应付账款', '', '']"}
{"page": 115, "allrow": 3045, "type": "excel", "inside": "['预收款项', '', '']"}
{"page": 115, "allrow": 3046, "type": "excel", "inside": "['合同负债', '', '']"}
{"page": 115, "allrow": 3047, "type": "excel", "inside": "['应付职工薪酬', '3,041,640.59', '3,041,640.59']"}
{"page": 115, "allrow": 3048, "type": "excel", "inside": "['应交税费', '31,072.77', '31,072.77']"}
{"page": 115, "allrow": 3049, "type": "excel", "inside": "['其他应付款', '72,798,747.22', '72,798,747.22']"}
{"page": 115, "allrow": 3050, "type": "excel", "inside": "['其中：应付利息', '', '']"}
{"page": 115, "allrow": 3051, "type": "excel", "inside": "['应付股利', '', '']"}
{"page": 115, "allrow": 3052, "type": "excel", "inside": "['持有待售负债', '', '']"}
{"page": 115, "allrow": 3053, "type": "excel", "inside": "['一年内到期的非流动负债', '', '']"}
{"page": 115, "allrow": 3054, "type": "excel", "inside": "['其他流动负债', '', '']"}
{"page": 115, "allrow": 3055, "type": "excel", "inside": "['流动负债合计', '75,871,460.58', '75,871,460.58']"}
{"page": 115, "allrow": 3056, "type": "excel", "inside": "['非流动负债：', '', '']"}
{"page": 115, "allrow": 3057, "type": "excel", "inside": "['长期借款', '', '']"}
{"page": 115, "allrow": 3058, "type": "excel", "inside": "['应付债券', '', '']"}
{"page": 115, "allrow": 3059, "type": "excel", "inside": "['其中：优先股', '', '']"}
{"page": 115, "allrow": 3060, "type": "excel", "inside": "['永续债', '', '']"}
{"page": 115, "allrow": 3061, "type": "excel", "inside": "['租赁负债', '', '']"}
{"page": 115, "allrow": 3062, "type": "excel", "inside": "['长期应付款', '', '']"}
{"page": 115, "allrow": 3063, "type": "excel", "inside": "['长期应付职工薪酬', '', '']"}
{"page": 115, "allrow": 3064, "type": "excel", "inside": "['预计负债', '', '']"}
{"page": 115, "allrow": 3065, "type": "excel", "inside": "['递延收益', '', '']"}
{"page": 115, "allrow": 3066, "type": "excel", "inside": "['递延所得税负债', '', '']"}
{"page": 115, "allrow": 3067, "type": "text", "inside": ""}
{"page": 115, "allrow": 3068, "type": "页脚", "inside": "115"}
{"page": 116, "allrow": 3069, "type": "text", "inside": ""}
{"page": 116, "allrow": 3070, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 116, "allrow": 3071, "type": "excel", "inside": "['其他非流动负债', '', '']"}
{"page": 116, "allrow": 3072, "type": "excel", "inside": "['非流动负债合计', '', '']"}
{"page": 116, "allrow": 3073, "type": "excel", "inside": "['负债合计', '75,871,460.58', '75,871,460.58']"}
{"page": 116, "allrow": 3074, "type": "excel", "inside": "['所有者权益：', '', '']"}
{"page": 116, "allrow": 3075, "type": "excel", "inside": "['股本', '1,178,523,492.00', '1,178,523,492.00']"}
{"page": 116, "allrow": 3076, "type": "excel", "inside": "['其他权益工具', '', '']"}
{"page": 116, "allrow": 3077, "type": "excel", "inside": "['其中：优先股', '', '']"}
{"page": 116, "allrow": 3078, "type": "excel", "inside": "['永续债', '', '']"}
{"page": 116, "allrow": 3079, "type": "excel", "inside": "['资本公积', '860,949,785.11', '860,949,785.11']"}
{"page": 116, "allrow": 3080, "type": "excel", "inside": "['减：库存股', '', '']"}
{"page": 116, "allrow": 3081, "type": "excel", "inside": "['其他综合收益', '', '']"}
{"page": 116, "allrow": 3082, "type": "excel", "inside": "['专项储备', '', '']"}
{"page": 116, "allrow": 3083, "type": "excel", "inside": "['盈余公积', '56,159,828.86', '56,159,828.86']"}
{"page": 116, "allrow": 3084, "type": "excel", "inside": "['未分配利润', '149,031,059.33', '149,031,059.33']"}
{"page": 116, "allrow": 3085, "type": "excel", "inside": "['所有者权益合计', '2,244,664,165.30', '2,244,664,165.30']"}
{"page": 116, "allrow": 3086, "type": "excel", "inside": "['负债和所有者权益总计', '2,320,535,625.88', '2,320,535,625.88']"}
{"page": 116, "allrow": 3087, "type": "text", "inside": ""}
{"page": 116, "allrow": 3088, "type": "text", "inside": "调整情况说明"}
{"page": 116, "allrow": 3089, "type": "text", "inside": "（4）2019年起执行新金融工具准则或新租赁准则追溯调整前期比较数据说明"}
{"page": 116, "allrow": 3090, "type": "text", "inside": "□适用√不适用"}
{"page": 116, "allrow": 3091, "type": "text", "inside": "45、其他"}
{"page": 116, "allrow": 3092, "type": "text", "inside": "六、税项"}
{"page": 116, "allrow": 3093, "type": "text", "inside": "1、主要税种及税率"}
{"page": 116, "allrow": 3094, "type": "excel", "inside": "['税种', '计税依据', '税率']"}
{"page": 116, "allrow": 3095, "type": "excel", "inside": "['增值税', '增值额', '16%、13%，10%，9%']"}
{"page": 116, "allrow": 3096, "type": "excel", "inside": "['城市维护建设税', '流转税', '5%，7%、1%']"}
{"page": 116, "allrow": 3097, "type": "excel", "inside": "['企业所得税', '应纳税所得额', '15%、25%、16.5%']"}
{"page": 116, "allrow": 3098, "type": "text", "inside": ""}
{"page": 116, "allrow": 3099, "type": "text", "inside": "存在不同企业所得税税率纳税主体的，披露情况说明"}
{"page": 116, "allrow": 3100, "type": "excel", "inside": "['纳税主体名称', '所得税税率']"}
{"page": 116, "allrow": 3101, "type": "excel", "inside": "['普洛康裕制药', '15%']"}
{"page": 116, "allrow": 3102, "type": "excel", "inside": "['普洛家园药业', '15%']"}
{"page": 116, "allrow": 3103, "type": "excel", "inside": "['浙江普洛生物', '15%']"}
{"page": 116, "allrow": 3104, "type": "text", "inside": ""}
{"page": 116, "allrow": 3105, "type": "页脚", "inside": "116"}
{"page": 117, "allrow": 3106, "type": "text", "inside": ""}
{"page": 117, "allrow": 3107, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 117, "allrow": 3108, "type": "excel", "inside": "['汉兴医药科技', '15%']"}
{"page": 117, "allrow": 3109, "type": "excel", "inside": "['普洛得邦制药', '15%']"}
{"page": 117, "allrow": 3110, "type": "excel", "inside": "['浙江巨泰药业', '15%']"}
{"page": 117, "allrow": 3111, "type": "excel", "inside": "['普洛香港', '16.5%']"}
{"page": 117, "allrow": 3112, "type": "excel", "inside": "['普洛得邦医药', '15%']"}
{"page": 117, "allrow": 3113, "type": "text", "inside": ""}
{"page": 117, "allrow": 3114, "type": "text", "inside": "2、税收优惠"}
{"page": 117, "allrow": 3115, "type": "text", "inside": "根据《高新技术企业认定管理办法》（国科发火〔2016〕32号）和《高新技术企业认定管理工作指引》（国科发火〔2016〕195号）有关规定，普洛康裕制药被认定为浙江省高新技术企业。证书编号：GR201733001282，发证日期：2017年11月13日，有效期：3年，故本年企业所得税按15%的税率计缴。"}
{"page": 117, "allrow": 3116, "type": "text", "inside": "根据《高新技术企业认定管理办法》（国科发火〔2016〕32号）和《高新技术企业认定管理工作指引》（国科发火〔2016〕195号）有关规定，浙江普洛生物被认定为浙江省高新技术企业。证书编号：GR201733001585，发证日期：2017年11月13日，有效期：3年，故本年企业所得税按15%的税率计缴。"}
{"page": 117, "allrow": 3117, "type": "text", "inside": "根据《高新技术企业认定管理办法》（国科发火〔2016〕32号）和《高新技术企业认定管理工作指引》（国科发火〔2016〕195号）有关规定，浙江巨泰药业被认定为浙江省高新技术企业，证书编号：GR201833000836，发证日期：2018年11月30日，有效期：3年，故本年企业所得税按15%的税率计缴。"}
{"page": 117, "allrow": 3118, "type": "text", "inside": "根据《高新技术企业认定管理办法》（国科发火〔2016〕32号）和《高新技术企业认定管理工作指引》（国科发火〔2016〕195号）有关规定，普洛得邦制药被认定为浙江省高新技术企业，证书编号：GR201833000136，发证日期：2018年11月30日，有效期：3年，故本年企业所得税按15%的税率计缴。"}
{"page": 117, "allrow": 3119, "type": "text", "inside": "根据《高新技术企业认定管理办法》（国科发火〔2016〕32号）和《高新技术企业认定管理工作指引》（国科发火〔2016〕195号）有关规定，普洛得邦医药被认定为山东省高新技术企业，证书编号：GR201837000109，发证日期：2018年8月16日，有效期：3年，故本年企业所得税按15%的税率计缴。"}
{"page": 117, "allrow": 3120, "type": "text", "inside": "根据《高新技术企业认定管理办法》（国科发火〔2016〕32号）和《高新技术企业认定管理工作指引》（国科发火〔2016〕195号）有关规定，汉兴医药科技被认定为山东省高新技术企业，证书编号：GR201737001205，发证日期：2017年12月28日，有效期3年，故本年企业所得税按15%的税率计缴。"}
{"page": 117, "allrow": 3121, "type": "text", "inside": "根据《高新技术企业认定管理办法》（国科发火〔2016〕32号）和《高新技术企业认定管理工作指引》（国科发火〔2016〕195号）有关规定，普洛家园药业被认定为浙江省高新技术企业，证书编号：GR201933005745，发证日期：2019年12月4日，有效期3年，故本年企业所得税按15%的税率计缴。"}
{"page": 117, "allrow": 3122, "type": "text", "inside": "3、其他"}
{"page": 117, "allrow": 3123, "type": "text", "inside": "七、合并财务报表项目注释"}
{"page": 117, "allrow": 3124, "type": "text", "inside": "1、货币资金"}
{"page": 117, "allrow": 3125, "type": "text", "inside": "单位：元"}
{"page": 117, "allrow": 3126, "type": "excel", "inside": "['项目', '期末余额', '期初余额']"}
{"page": 117, "allrow": 3127, "type": "excel", "inside": "['库存现金', '81,402.84', '216,433.61']"}
{"page": 117, "allrow": 3128, "type": "excel", "inside": "['银行存款', '717,991,937.19', '501,504,014.52']"}
{"page": 117, "allrow": 3129, "type": "text", "inside": ""}
{"page": 117, "allrow": 3130, "type": "页脚", "inside": "117"}
{"page": 118, "allrow": 3131, "type": "text", "inside": ""}
{"page": 118, "allrow": 3132, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 118, "allrow": 3133, "type": "excel", "inside": "['其他货币资金', '', '317,736,154.02', '142,654,855.06']"}
{"page": 118, "allrow": 3134, "type": "excel", "inside": "['合计', '1,035,809,494.05', '', '644,375,303.19']"}
{"page": 118, "allrow": 3135, "type": "text", "inside": "其他说明"}
{"page": 118, "allrow": 3136, "type": "text", "inside": "2、交易性金融资产"}
{"page": 118, "allrow": 3137, "type": "text", "inside": "单位：元"}
{"page": 118, "allrow": 3138, "type": "excel", "inside": "['项目', '', '期末余额', '期初余额']"}
{"page": 118, "allrow": 3139, "type": "excel", "inside": "['以公允价值计量且其变动计入当期损益的金融资产', '', '463,858,356.17', '101,400,000.00']"}
{"page": 118, "allrow": 3140, "type": "excel", "inside": "['其中：', '', '', '']"}
{"page": 118, "allrow": 3141, "type": "excel", "inside": "['债务工具投资', '', '', '']"}
{"page": 118, "allrow": 3142, "type": "excel", "inside": "['权益工具投资', '', '', '']"}
{"page": 118, "allrow": 3143, "type": "excel", "inside": "['衍生金融资产', '', '', '']"}
{"page": 118, "allrow": 3144, "type": "excel", "inside": "['理财产品', '', '463,858,356.17', '101,400,000.00']"}
{"page": 118, "allrow": 3145, "type": "excel", "inside": "['其中：', '', '', '']"}
{"page": 118, "allrow": 3146, "type": "excel", "inside": "['合计', '463,858,356.17', '', '101,400,000.00']"}
{"page": 118, "allrow": 3147, "type": "text", "inside": "其他说明："}
{"page": 118, "allrow": 3148, "type": "text", "inside": "3、衍生金融资产"}
{"page": 118, "allrow": 3149, "type": "text", "inside": "单位：元"}
{"page": 118, "allrow": 3150, "type": "excel", "inside": "['项目', '期末余额', '期初余额']"}
{"page": 118, "allrow": 3151, "type": "text", "inside": ""}
{"page": 118, "allrow": 3152, "type": "text", "inside": "其他说明："}
{"page": 118, "allrow": 3153, "type": "text", "inside": "4、应收票据"}
{"page": 118, "allrow": 3154, "type": "text", "inside": "（1）应收票据分类列示"}
{"page": 118, "allrow": 3155, "type": "text", "inside": "单位：元"}
{"page": 118, "allrow": 3156, "type": "excel", "inside": "['项目', '', '期末余额', '期初余额']"}
{"page": 118, "allrow": 3157, "type": "excel", "inside": "['合计', '0.00', '', '']"}
{"page": 118, "allrow": 3158, "type": "text", "inside": ""}
{"page": 118, "allrow": 3159, "type": "text", "inside": "单位：元"}
{"page": 118, "allrow": 3160, "type": "excel", "inside": "['', '期末余额账面余额', '', '坏账准备', '', '', '期初余额账面余额', '', '坏账准备', '', '']"}
{"page": 118, "allrow": 3161, "type": "excel", "inside": "['类别', '', '', '', '计提比', '账面价', '', '', '', '计提比', '账面价']"}
{"page": 118, "allrow": 3162, "type": "excel", "inside": "['', '金额', '比例', '金额', '例', '值', '金额', '比例', '金额', '例', '值']"}
{"page": 118, "allrow": 3163, "type": "excel", "inside": "['其中：', '', '', '', '', '', '', '', '', '', '']"}
{"page": 118, "allrow": 3164, "type": "text", "inside": ""}
{"page": 118, "allrow": 3165, "type": "页脚", "inside": "118"}
{"page": 119, "allrow": 3166, "type": "text", "inside": ""}
{"page": 119, "allrow": 3167, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 119, "allrow": 3168, "type": "excel", "inside": "['其中：']"}
{"page": 119, "allrow": 3169, "type": "text", "inside": ""}
{"page": 119, "allrow": 3170, "type": "text", "inside": "按单项计提坏账准备："}
{"page": 119, "allrow": 3171, "type": "text", "inside": "单位：元"}
{"page": 119, "allrow": 3172, "type": "excel", "inside": "['', '期末余额', '', '', '']"}
{"page": 119, "allrow": 3173, "type": "excel", "inside": "['名称', '账面余额', '坏账准备', '计提比例', '计提理由']"}
{"page": 119, "allrow": 3174, "type": "text", "inside": ""}
{"page": 119, "allrow": 3175, "type": "text", "inside": "按组合计提坏账准备："}
{"page": 119, "allrow": 3176, "type": "text", "inside": "单位：元"}
{"page": 119, "allrow": 3177, "type": "excel", "inside": "['', '期末余额', '', '']"}
{"page": 119, "allrow": 3178, "type": "excel", "inside": "['名称', '账面余额', '坏账准备', '计提比例']"}
{"page": 119, "allrow": 3179, "type": "text", "inside": ""}
{"page": 119, "allrow": 3180, "type": "text", "inside": "确定该组合依据的说明："}
{"page": 119, "allrow": 3181, "type": "text", "inside": "如是按照预期信用损失一般模型计提应收票据坏账准备，请参照其他应收款的披露方式披露坏账准备的相关信息：□适用√不适用"}
{"page": 119, "allrow": 3182, "type": "text", "inside": "（2）本期计提、收回或转回的坏账准备情况"}
{"page": 119, "allrow": 3183, "type": "text", "inside": "本期计提坏账准备情况："}
{"page": 119, "allrow": 3184, "type": "text", "inside": "单位：元"}
{"page": 119, "allrow": 3185, "type": "excel", "inside": "['', '', '本期变动金额', '', '', '']"}
{"page": 119, "allrow": 3186, "type": "excel", "inside": "['类别', '期初余额', '计提', '收回或转回', '核销', '期末余额']"}
{"page": 119, "allrow": 3187, "type": "text", "inside": ""}
{"page": 119, "allrow": 3188, "type": "text", "inside": "其中本期坏账准备收回或转回金额重要的："}
{"page": 119, "allrow": 3189, "type": "text", "inside": "□适用√不适用"}
{"page": 119, "allrow": 3190, "type": "text", "inside": "（3）期末公司已质押的应收票据"}
{"page": 119, "allrow": 3191, "type": "text", "inside": "单位：元"}
{"page": 119, "allrow": 3192, "type": "excel", "inside": "['项目', '期末已质押金额']"}
{"page": 119, "allrow": 3193, "type": "text", "inside": ""}
{"page": 119, "allrow": 3194, "type": "text", "inside": "（4）期末公司已背书或贴现且在资产负债表日尚未到期的应收票据"}
{"page": 119, "allrow": 3195, "type": "text", "inside": "单位：元"}
{"page": 119, "allrow": 3196, "type": "excel", "inside": "['项目', '期末终止确认金额', '期末未终止确认金额']"}
{"page": 119, "allrow": 3197, "type": "text", "inside": ""}
{"page": 119, "allrow": 3198, "type": "text", "inside": "（5）期末公司因出票人未履约而将其转应收账款的票据"}
{"page": 119, "allrow": 3199, "type": "text", "inside": "单位：元"}
{"page": 119, "allrow": 3200, "type": "excel", "inside": "['项目', '期末转应收账款金额']"}
{"page": 119, "allrow": 3201, "type": "text", "inside": ""}
{"page": 119, "allrow": 3202, "type": "text", "inside": "其他说明"}
{"page": 119, "allrow": 3203, "type": "页脚", "inside": "119"}
{"page": 120, "allrow": 3204, "type": "text", "inside": ""}
{"page": 120, "allrow": 3205, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 120, "allrow": 3206, "type": "text", "inside": "（6）本期实际核销的应收票据情况"}
{"page": 120, "allrow": 3207, "type": "text", "inside": "单位：元"}
{"page": 120, "allrow": 3208, "type": "excel", "inside": "['项目', '核销金额']"}
{"page": 120, "allrow": 3209, "type": "text", "inside": ""}
{"page": 120, "allrow": 3210, "type": "text", "inside": "其中重要的应收票据核销情况："}
{"page": 120, "allrow": 3211, "type": "text", "inside": "单位：元"}
{"page": 120, "allrow": 3212, "type": "excel", "inside": "['', '', '', '', '', '款项是否由关联']"}
{"page": 120, "allrow": 3213, "type": "excel", "inside": "['单位名称', '应收票据性质', '核销金额', '核销原因', '履行的核销程序', '交易产生']"}
{"page": 120, "allrow": 3214, "type": "text", "inside": "应收票据核销说明："}
{"page": 120, "allrow": 3215, "type": "text", "inside": "5、应收账款"}
{"page": 120, "allrow": 3216, "type": "text", "inside": "（1）应收账款分类披露"}
{"page": 120, "allrow": 3217, "type": "text", "inside": "单位：元"}
{"page": 120, "allrow": 3218, "type": "excel", "inside": "['', '期末余额账面余额', '', '坏账准备', '', '', '', '期初余额账面余额', '', '坏账准备', '', '']"}
{"page": 120, "allrow": 3219, "type": "excel", "inside": "['类别', '', '', '', '计提比', '', '账面价', '', '', '', '计提比', '账面价']"}
{"page": 120, "allrow": 3220, "type": "excel", "inside": "['', '金额', '比例', '金额', '例', '', '值', '金额', '比例', '金额', '例', '值']"}
{"page": 120, "allrow": 3221, "type": "excel", "inside": "['其中：', '', '', '', '', '', '', '', '', '', '', '']"}
{"page": 120, "allrow": 3222, "type": "excel", "inside": "['', '1,079,7', '', '', '', '', '1,025,1', '1,079,6', '', '', '', '']"}
{"page": 120, "allrow": 3223, "type": "excel", "inside": "['按组合计提坏账准备的应收账款', '17,354.47', '100.00%', '54,578,758.28', '5.05%', '', '38,596.19', '29,344.76', '100.00%', '55,204,665.65', '5.11%', '1,024,424,679.11']"}
{"page": 120, "allrow": 3224, "type": "excel", "inside": "['其中：', '', '', '', '', '', '', '', '', '', '', '']"}
{"page": 120, "allrow": 3225, "type": "excel", "inside": "['', '1,079,7', '100.00', '54,578,', '', '1,025,138,596.19', '', '1,079,6', '100.00', '55,204,', '', '1,024,42']"}
{"page": 120, "allrow": 3226, "type": "excel", "inside": "['合计', '17,354.', '%', '758.28', '5.05%', '', '', '29,344.', '%', '665.65', '5.11%', '4,679.11']"}
{"page": 120, "allrow": 3227, "type": "excel", "inside": "['', '47', '', '', '', '', '', '76', '', '', '', '']"}
{"page": 120, "allrow": 3228, "type": "text", "inside": ""}
{"page": 120, "allrow": 3229, "type": "text", "inside": "按单项计提坏账准备："}
{"page": 120, "allrow": 3230, "type": "text", "inside": "单位：元"}
{"page": 120, "allrow": 3231, "type": "excel", "inside": "['', '期末余额', '', '', '']"}
{"page": 120, "allrow": 3232, "type": "excel", "inside": "['名称', '账面余额', '坏账准备', '计提比例', '计提理由']"}
{"page": 120, "allrow": 3233, "type": "text", "inside": ""}
{"page": 120, "allrow": 3234, "type": "text", "inside": "按组合计提坏账准备："}
{"page": 120, "allrow": 3235, "type": "text", "inside": "单位：元"}
{"page": 120, "allrow": 3236, "type": "excel", "inside": "['', '期末余额', '', '']"}
{"page": 120, "allrow": 3237, "type": "excel", "inside": "['名称', '账面余额', '坏账准备', '计提比例']"}
{"page": 120, "allrow": 3238, "type": "excel", "inside": "['1年以内', '1,072,608,367.22', '53,630,418.36', '5.00%']"}
{"page": 120, "allrow": 3239, "type": "excel", "inside": "['1-2年', '6,070,428.05', '607,042.81', '10.00%']"}
{"page": 120, "allrow": 3240, "type": "excel", "inside": "['2-3年', '895,162.38', '268,548.70', '30.00%']"}
{"page": 120, "allrow": 3241, "type": "text", "inside": ""}
{"page": 120, "allrow": 3242, "type": "页脚", "inside": "120"}
{"page": 121, "allrow": 3243, "type": "text", "inside": ""}
{"page": 121, "allrow": 3244, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 121, "allrow": 3245, "type": "excel", "inside": "['3-5年', '141,296.82', '70,648.41', '50.00%']"}
{"page": 121, "allrow": 3246, "type": "excel", "inside": "['5年以上', '2,100.00', '2,100.00', '100.00%']"}
{"page": 121, "allrow": 3247, "type": "excel", "inside": "['合计', '1,079,717,354.47', '54,578,758.28', '--']"}
{"page": 121, "allrow": 3248, "type": "text", "inside": ""}
{"page": 121, "allrow": 3249, "type": "text", "inside": "确定该组合依据的说明："}
{"page": 121, "allrow": 3250, "type": "text", "inside": "按组合计提坏账准备："}
{"page": 121, "allrow": 3251, "type": "text", "inside": "单位：元"}
{"page": 121, "allrow": 3252, "type": "excel", "inside": "['', '期末余额', '', '']"}
{"page": 121, "allrow": 3253, "type": "excel", "inside": "['名称', '账面余额', '坏账准备', '计提比例']"}
{"page": 121, "allrow": 3254, "type": "text", "inside": ""}
{"page": 121, "allrow": 3255, "type": "text", "inside": "确定该组合依据的说明："}
{"page": 121, "allrow": 3256, "type": "text", "inside": "如是按照预期信用损失一般模型计提应收账款坏账准备，请参照其他应收款的披露方式披露坏账准备的相关信息：√适用□不适用"}
{"page": 121, "allrow": 3257, "type": "text", "inside": "按账龄披露"}
{"page": 121, "allrow": 3258, "type": "text", "inside": "单位：元"}
{"page": 121, "allrow": 3259, "type": "excel", "inside": "['账龄', '', '账面余额']"}
{"page": 121, "allrow": 3260, "type": "excel", "inside": "['1年以内（含1年）', '', '1,072,608,367.22']"}
{"page": 121, "allrow": 3261, "type": "excel", "inside": "['1至2年', '', '6,070,428.05']"}
{"page": 121, "allrow": 3262, "type": "excel", "inside": "['2至3年', '', '895,162.38']"}
{"page": 121, "allrow": 3263, "type": "excel", "inside": "['3年以上', '', '143,396.82']"}
{"page": 121, "allrow": 3264, "type": "excel", "inside": "['3至4年', '', '141,296.82']"}
{"page": 121, "allrow": 3265, "type": "excel", "inside": "['4至5年', '', '0.00']"}
{"page": 121, "allrow": 3266, "type": "excel", "inside": "['5年以上', '', '2,100.00']"}
{"page": 121, "allrow": 3267, "type": "excel", "inside": "['合计', '1,079,717,354.47', '']"}
{"page": 121, "allrow": 3268, "type": "text", "inside": "（2）本期计提、收回或转回的坏账准备情况"}
{"page": 121, "allrow": 3269, "type": "text", "inside": "本期计提坏账准备情况："}
{"page": 121, "allrow": 3270, "type": "text", "inside": "单位：元"}
{"page": 121, "allrow": 3271, "type": "excel", "inside": "['', '', '本期变动金额', '', '', '']"}
{"page": 121, "allrow": 3272, "type": "excel", "inside": "['类别', '期初余额', '计提', '收回或转回', '核销', '期末余额']"}
{"page": 121, "allrow": 3273, "type": "text", "inside": ""}
{"page": 121, "allrow": 3274, "type": "text", "inside": "其中本期坏账准备收回或转回金额重要的："}
{"page": 121, "allrow": 3275, "type": "text", "inside": "单位：元"}
{"page": 121, "allrow": 3276, "type": "excel", "inside": "['单位名称', '收回或转回金额', '收回方式']"}
{"page": 121, "allrow": 3277, "type": "text", "inside": ""}
{"page": 121, "allrow": 3278, "type": "text", "inside": "（3）本期实际核销的应收账款情况"}
{"page": 121, "allrow": 3279, "type": "text", "inside": "单位：元"}
{"page": 121, "allrow": 3280, "type": "excel", "inside": "['项目', '核销金额']"}
{"page": 121, "allrow": 3281, "type": "text", "inside": ""}
{"page": 121, "allrow": 3282, "type": "页脚", "inside": "121"}
{"page": 122, "allrow": 3283, "type": "text", "inside": ""}
{"page": 122, "allrow": 3284, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 122, "allrow": 3285, "type": "text", "inside": "其中重要的应收账款核销情况："}
{"page": 122, "allrow": 3286, "type": "text", "inside": "单位：元"}
{"page": 122, "allrow": 3287, "type": "excel", "inside": "['', '', '', '', '', '款项是否由关联']"}
{"page": 122, "allrow": 3288, "type": "excel", "inside": "['单位名称', '应收账款性质', '核销金额', '核销原因', '履行的核销程序', '交易产生']"}
{"page": 122, "allrow": 3289, "type": "text", "inside": "应收账款核销说明："}
{"page": 122, "allrow": 3290, "type": "text", "inside": "（4）按欠款方归集的期末余额前五名的应收账款情况"}
{"page": 122, "allrow": 3291, "type": "text", "inside": "单位：元"}
{"page": 122, "allrow": 3292, "type": "excel", "inside": "['', '', '占应收账款期末余额合计数', '']"}
{"page": 122, "allrow": 3293, "type": "excel", "inside": "['单位名称', '应收账款期末余额', '的比例', '坏账准备期末余额']"}
{"page": 122, "allrow": 3294, "type": "excel", "inside": "['A', '48,522,826.55', '4.49%', '2,426,141.33']"}
{"page": 122, "allrow": 3295, "type": "excel", "inside": "['B', '37,523,052.21', '3.48%', '1,876,152.61']"}
{"page": 122, "allrow": 3296, "type": "excel", "inside": "['C', '32,480,639.18', '3.01%', '1,624,031.96']"}
{"page": 122, "allrow": 3297, "type": "excel", "inside": "['D', '31,741,710.00', '2.94%', '1,587,085.50']"}
{"page": 122, "allrow": 3298, "type": "excel", "inside": "['E', '30,431,509.88', '2.82%', '1,521,575.49']"}
{"page": 122, "allrow": 3299, "type": "excel", "inside": "['合计', '180,699,737.82', '16.74%', '']"}
{"page": 122, "allrow": 3300, "type": "text", "inside": ""}
{"page": 122, "allrow": 3301, "type": "text", "inside": "（5）因金融资产转移而终止确认的应收账款"}
{"page": 122, "allrow": 3302, "type": "text", "inside": "（6）转移应收账款且继续涉入形成的资产、负债金额"}
{"page": 122, "allrow": 3303, "type": "text", "inside": "其他说明："}
{"page": 122, "allrow": 3304, "type": "text", "inside": "6、应收款项融资"}
{"page": 122, "allrow": 3305, "type": "text", "inside": "单位：元"}
{"page": 122, "allrow": 3306, "type": "excel", "inside": "['项目', '', '期末余额', '期初余额']"}
{"page": 122, "allrow": 3307, "type": "excel", "inside": "['银行承兑汇票', '', '224,310,858.75', '210,813,018.23']"}
{"page": 122, "allrow": 3308, "type": "excel", "inside": "['合计', '224,310,858.75', '', '210,813,018.23']"}
{"page": 122, "allrow": 3309, "type": "text", "inside": "应收款项融资本期增减变动及公允价值变动情况"}
{"page": 122, "allrow": 3310, "type": "text", "inside": "□适用√不适用"}
{"page": 122, "allrow": 3311, "type": "text", "inside": "如是按照预期信用损失一般模型计提应收款项融资减值准备，请参照其他应收款的披露方式披露减值准备的相关信息：□适用√不适用"}
{"page": 122, "allrow": 3312, "type": "text", "inside": "其他说明："}
{"page": 122, "allrow": 3313, "type": "页脚", "inside": "122"}
{"page": 123, "allrow": 3314, "type": "text", "inside": ""}
{"page": 123, "allrow": 3315, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 123, "allrow": 3316, "type": "text", "inside": "7、预付款项"}
{"page": 123, "allrow": 3317, "type": "text", "inside": "（1）预付款项按账龄列示"}
{"page": 123, "allrow": 3318, "type": "text", "inside": "单位：元"}
{"page": 123, "allrow": 3319, "type": "excel", "inside": "['', '', '期末余额', '', '期初余额', '']"}
{"page": 123, "allrow": 3320, "type": "excel", "inside": "['账龄', '', '金额', '比例', '金额', '比例']"}
{"page": 123, "allrow": 3321, "type": "excel", "inside": "['1年以内', '', '120,551,338.04', '99.79%', '122,776,392.89', '98.28%']"}
{"page": 123, "allrow": 3322, "type": "excel", "inside": "['1至2年', '', '257,303.92', '0.21%', '2,147,500.00', '1.72%']"}
{"page": 123, "allrow": 3323, "type": "excel", "inside": "['合计', '120,808,641.96', '', '--', '124,923,892.89', '--']"}
{"page": 123, "allrow": 3324, "type": "text", "inside": ""}
{"page": 123, "allrow": 3325, "type": "text", "inside": "账龄超过1年且金额重要的预付款项未及时结算原因的说明："}
{"page": 123, "allrow": 3326, "type": "text", "inside": "期末无账龄超过1年且金额重大的预付款项。"}
{"page": 123, "allrow": 3327, "type": "text", "inside": "（2）按预付对象归集的期末余额前五名的预付款情况"}
{"page": 123, "allrow": 3328, "type": "text", "inside": "公司期末预付款项余额前五名汇总金额为36,398,911.03元，占预付款项期末余额合计数的30.13%。"}
{"page": 123, "allrow": 3329, "type": "text", "inside": "其他说明："}
{"page": 123, "allrow": 3330, "type": "text", "inside": "8、其他应收款"}
{"page": 123, "allrow": 3331, "type": "text", "inside": "单位：元"}
{"page": 123, "allrow": 3332, "type": "excel", "inside": "['项目', '', '期末余额', '期初余额']"}
{"page": 123, "allrow": 3333, "type": "excel", "inside": "['其他应收款', '', '7,275,197.34', '7,566,657.24']"}
{"page": 123, "allrow": 3334, "type": "excel", "inside": "['合计', '7,275,197.34', '', '7,566,657.24']"}
{"page": 123, "allrow": 3335, "type": "text", "inside": "（1）应收利息"}
{"page": 123, "allrow": 3336, "type": "text", "inside": "1）应收利息分类"}
{"page": 123, "allrow": 3337, "type": "text", "inside": "单位：元"}
{"page": 123, "allrow": 3338, "type": "excel", "inside": "['项目', '期末余额', '期初余额']"}
{"page": 123, "allrow": 3339, "type": "text", "inside": ""}
{"page": 123, "allrow": 3340, "type": "text", "inside": "2）重要逾期利息"}
{"page": 123, "allrow": 3341, "type": "text", "inside": "单位：元"}
{"page": 123, "allrow": 3342, "type": "excel", "inside": "['', '', '', '', '是否发生减值及其判']"}
{"page": 123, "allrow": 3343, "type": "excel", "inside": "['借款单位', '期末余额', '逾期时间', '逾期原因', '断依据']"}
{"page": 123, "allrow": 3344, "type": "text", "inside": ""}
{"page": 123, "allrow": 3345, "type": "text", "inside": "其他说明："}
{"page": 123, "allrow": 3346, "type": "页脚", "inside": "123"}
{"page": 124, "allrow": 3347, "type": "text", "inside": ""}
{"page": 124, "allrow": 3348, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 124, "allrow": 3349, "type": "text", "inside": "3）坏账准备计提情况"}
{"page": 124, "allrow": 3350, "type": "text", "inside": "□适用√不适用"}
{"page": 124, "allrow": 3351, "type": "text", "inside": "（2）应收股利"}
{"page": 124, "allrow": 3352, "type": "text", "inside": "1）应收股利分类"}
{"page": 124, "allrow": 3353, "type": "text", "inside": "单位：元"}
{"page": 124, "allrow": 3354, "type": "excel", "inside": "['项目(或被投资单位)', '期末余额', '期初余额']"}
{"page": 124, "allrow": 3355, "type": "text", "inside": ""}
{"page": 124, "allrow": 3356, "type": "text", "inside": "2）重要的账龄超过1年的应收股利"}
{"page": 124, "allrow": 3357, "type": "text", "inside": "单位：元"}
{"page": 124, "allrow": 3358, "type": "excel", "inside": "['', '', '', '', '是否发生减值及其判']"}
{"page": 124, "allrow": 3359, "type": "excel", "inside": "['项目(或被投资单位)', '期末余额', '账龄', '未收回的原因', '断依据']"}
{"page": 124, "allrow": 3360, "type": "text", "inside": ""}
{"page": 124, "allrow": 3361, "type": "text", "inside": "3）坏账准备计提情况"}
{"page": 124, "allrow": 3362, "type": "text", "inside": "□适用√不适用"}
{"page": 124, "allrow": 3363, "type": "text", "inside": "其他说明："}
{"page": 124, "allrow": 3364, "type": "text", "inside": "（3）其他应收款"}
{"page": 124, "allrow": 3365, "type": "text", "inside": "1）其他应收款按款项性质分类情况"}
{"page": 124, "allrow": 3366, "type": "text", "inside": "单位：元"}
{"page": 124, "allrow": 3367, "type": "excel", "inside": "['款项性质', '期末账面余额', '期初账面余额']"}
{"page": 124, "allrow": 3368, "type": "excel", "inside": "['押金、保证金', '3,896,707.73', '5,514,600.70']"}
{"page": 124, "allrow": 3369, "type": "excel", "inside": "['往来款、备用金', '5,362,991.54', '3,772,381.48']"}
{"page": 124, "allrow": 3370, "type": "excel", "inside": "['合计', '9,259,699.27', '9,286,982.18']"}
{"page": 124, "allrow": 3371, "type": "text", "inside": "2）坏账准备计提情况"}
{"page": 124, "allrow": 3372, "type": "text", "inside": "单位：元"}
{"page": 124, "allrow": 3373, "type": "excel", "inside": "['', '第一阶段', '第二阶段', '第三阶段', '']"}
{"page": 124, "allrow": 3374, "type": "excel", "inside": "['坏账准备', '未来12个月预期', '整个存续期预期信用损', '整个存续期预期信用损', '合计']"}
{"page": 124, "allrow": 3375, "type": "excel", "inside": "['', '信用损失', '失(未发生信用减值)', '失(已发生信用减值)', '']"}
{"page": 124, "allrow": 3376, "type": "excel", "inside": "['2019年1月1日余额', '', '1,720,324.94', '', '1,720,324.94']"}
{"page": 124, "allrow": 3377, "type": "excel", "inside": "['2019年1月1日余额在本期', '——', '——', '——', '——']"}
{"page": 124, "allrow": 3378, "type": "text", "inside": ""}
{"page": 124, "allrow": 3379, "type": "页脚", "inside": "124"}
{"page": 125, "allrow": 3380, "type": "text", "inside": ""}
{"page": 125, "allrow": 3381, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 125, "allrow": 3382, "type": "excel", "inside": "['本期计提', '270,110.99', '270,110.99']"}
{"page": 125, "allrow": 3383, "type": "excel", "inside": "['本期核销', '5,934.00', '5,934.00']"}
{"page": 125, "allrow": 3384, "type": "excel", "inside": "['2019年12月31日余额', '1,984,501.93', '1,984,501.93']"}
{"page": 125, "allrow": 3385, "type": "text", "inside": ""}
{"page": 125, "allrow": 3386, "type": "text", "inside": "损失准备本期变动金额重大的账面余额变动情况"}
{"page": 125, "allrow": 3387, "type": "text", "inside": "□适用√不适用"}
{"page": 125, "allrow": 3388, "type": "text", "inside": "按账龄披露"}
{"page": 125, "allrow": 3389, "type": "text", "inside": "单位：元"}
{"page": 125, "allrow": 3390, "type": "excel", "inside": "['账龄', '账面余额']"}
{"page": 125, "allrow": 3391, "type": "excel", "inside": "['1年以内（含1年）', '5,138,274.92']"}
{"page": 125, "allrow": 3392, "type": "excel", "inside": "['1至2年', '1,403,243.72']"}
{"page": 125, "allrow": 3393, "type": "excel", "inside": "['2至3年', '507,635.00']"}
{"page": 125, "allrow": 3394, "type": "excel", "inside": "['3年以上', '2,210,545.63']"}
{"page": 125, "allrow": 3395, "type": "excel", "inside": "['3至4年', '1,529,800.00']"}
{"page": 125, "allrow": 3396, "type": "excel", "inside": "['4至5年', '21,344.60']"}
{"page": 125, "allrow": 3397, "type": "excel", "inside": "['5年以上', '659,401.03']"}
{"page": 125, "allrow": 3398, "type": "excel", "inside": "['合计', '9,259,699.27']"}
{"page": 125, "allrow": 3399, "type": "text", "inside": "3）本期计提、收回或转回的坏账准备情况"}
{"page": 125, "allrow": 3400, "type": "text", "inside": "本期计提坏账准备情况："}
{"page": 125, "allrow": 3401, "type": "text", "inside": "单位：元"}
{"page": 125, "allrow": 3402, "type": "excel", "inside": "['', '', '本期变动金额', '', '', '']"}
{"page": 125, "allrow": 3403, "type": "excel", "inside": "['类别', '期初余额', '计提', '收回或转回', '核销', '期末余额']"}
{"page": 125, "allrow": 3404, "type": "text", "inside": ""}
{"page": 125, "allrow": 3405, "type": "text", "inside": "其中本期坏账准备转回或收回金额重要的："}
{"page": 125, "allrow": 3406, "type": "text", "inside": "单位：元"}
{"page": 125, "allrow": 3407, "type": "excel", "inside": "['单位名称', '转回或收回金额', '收回方式']"}
{"page": 125, "allrow": 3408, "type": "text", "inside": ""}
{"page": 125, "allrow": 3409, "type": "text", "inside": "4）本期实际核销的其他应收款情况"}
{"page": 125, "allrow": 3410, "type": "text", "inside": "单位：元"}
{"page": 125, "allrow": 3411, "type": "excel", "inside": "['项目', '核销金额']"}
{"page": 125, "allrow": 3412, "type": "excel", "inside": "['往来款', '5,934.00']"}
{"page": 125, "allrow": 3413, "type": "text", "inside": "其中重要的其他应收款核销情况："}
{"page": 125, "allrow": 3414, "type": "text", "inside": "单位：元"}
{"page": 125, "allrow": 3415, "type": "excel", "inside": "['', '', '', '', '', '款项是否由关联']"}
{"page": 125, "allrow": 3416, "type": "excel", "inside": "['单位名称', '其他应收款性质', '核销金额', '核销原因', '履行的核销程序', '交易产生']"}
{"page": 125, "allrow": 3417, "type": "text", "inside": ""}
{"page": 125, "allrow": 3418, "type": "页脚", "inside": "125"}
{"page": 126, "allrow": 3419, "type": "text", "inside": ""}
{"page": 126, "allrow": 3420, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 126, "allrow": 3421, "type": "text", "inside": "其他应收款核销说明："}
{"page": 126, "allrow": 3422, "type": "text", "inside": "5）按欠款方归集的期末余额前五名的其他应收款情况"}
{"page": 126, "allrow": 3423, "type": "text", "inside": "单位：元"}
{"page": 126, "allrow": 3424, "type": "excel", "inside": "['', '', '', '', '占其他应收款期', '坏账准备期末余']"}
{"page": 126, "allrow": 3425, "type": "excel", "inside": "['单位名称', '款项的性质', '期末余额', '账龄', '末余额合计数的', '额']"}
{"page": 126, "allrow": 3426, "type": "excel", "inside": "['', '', '', '', '比例', '']"}
{"page": 126, "allrow": 3427, "type": "excel", "inside": "['云南昊邦制药有限公司', '保证金', '1,500,000.00', '3-4年', '16.20%', '750,000.00']"}
{"page": 126, "allrow": 3428, "type": "excel", "inside": "['中华人民共和国金华海关', '保证金', '725,000.00', '1-2年', '7.83%', '72,500.00']"}
{"page": 126, "allrow": 3429, "type": "excel", "inside": "['山东海化集团有限公司', '保证金', '450,000.00', '2-3年及5年以上', '4.86%', '177,000.00']"}
{"page": 126, "allrow": 3430, "type": "excel", "inside": "['李开波', '往来款', '271,949.00', '1年以内', '2.94%', '13,597.45']"}
{"page": 126, "allrow": 3431, "type": "excel", "inside": "['王道良', '往来款', '271,589.03', '1年以内', '2.93%', '13,579.45']"}
{"page": 126, "allrow": 3432, "type": "excel", "inside": "['合计', '--', '3,218,538.03', '--', '34.76%', '1,026,676.90']"}
{"page": 126, "allrow": 3433, "type": "text", "inside": "6）涉及政府补助的应收款项"}
{"page": 126, "allrow": 3434, "type": "text", "inside": "单位：元"}
{"page": 126, "allrow": 3435, "type": "excel", "inside": "['', '', '', '', '预计收取的时间、金']"}
{"page": 126, "allrow": 3436, "type": "excel", "inside": "['单位名称', '政府补助项目名称', '期末余额', '期末账龄', '额及依据']"}
{"page": 126, "allrow": 3437, "type": "text", "inside": ""}
{"page": 126, "allrow": 3438, "type": "text", "inside": "7）因金融资产转移而终止确认的其他应收款"}
{"page": 126, "allrow": 3439, "type": "text", "inside": "8）转移其他应收款且继续涉入形成的资产、负债金额"}
{"page": 126, "allrow": 3440, "type": "text", "inside": "其他说明："}
{"page": 126, "allrow": 3441, "type": "text", "inside": "9、存货"}
{"page": 126, "allrow": 3442, "type": "text", "inside": "是否已执行新收入准则"}
{"page": 126, "allrow": 3443, "type": "text", "inside": "□是√否"}
{"page": 126, "allrow": 3444, "type": "text", "inside": "（1）存货分类"}
{"page": 126, "allrow": 3445, "type": "text", "inside": "单位：元"}
{"page": 126, "allrow": 3446, "type": "excel", "inside": "['', '期末余额', '', '', '期初余额', '', '']"}
{"page": 126, "allrow": 3447, "type": "excel", "inside": "['项目', '账面余额', '跌价准备', '账面价值', '账面余额', '跌价准备', '账面价值']"}
{"page": 126, "allrow": 3448, "type": "excel", "inside": "['原材料', '207,659,094.64', '16,549,708.51', '191,109,386.13', '189,506,436.33', '12,900,881.18', '176,605,555.15']"}
{"page": 126, "allrow": 3449, "type": "text", "inside": ""}
{"page": 126, "allrow": 3450, "type": "页脚", "inside": "126"}
{"page": 127, "allrow": 3451, "type": "text", "inside": ""}
{"page": 127, "allrow": 3452, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 127, "allrow": 3453, "type": "excel", "inside": "['在产品', '187,262,629.15', '3,456,415.57', '183,806,213.58', '189,914,790.07', '3,005,808.21', '186,908,981.86']"}
{"page": 127, "allrow": 3454, "type": "excel", "inside": "['库存商品', '643,514,126.74', '25,386,714.08', '618,127,412.66', '553,828,087.34', '15,698,744.60', '538,129,342.74']"}
{"page": 127, "allrow": 3455, "type": "excel", "inside": "['', '1,038,435,850.', '', '', '', '', '']"}
{"page": 127, "allrow": 3456, "type": "excel", "inside": "['合计', '53', '45,392,838.16', '993,043,012.37', '933,249,313.74', '31,605,433.99', '901,643,879.75']"}
{"page": 127, "allrow": 3457, "type": "text", "inside": ""}
{"page": 127, "allrow": 3458, "type": "text", "inside": "（2）存货跌价准备"}
{"page": 127, "allrow": 3459, "type": "text", "inside": "单位：元"}
{"page": 127, "allrow": 3460, "type": "excel", "inside": "['', '', '本期增加金额', '', '本期减少金额', '', '']"}
{"page": 127, "allrow": 3461, "type": "excel", "inside": "['项目', '期初余额', '计提', '其他', '转回或转销', '其他', '期末余额']"}
{"page": 127, "allrow": 3462, "type": "excel", "inside": "['原材料', '12,900,881.18', '10,869,821.28', '', '7,220,993.95', '', '16,549,708.51']"}
{"page": 127, "allrow": 3463, "type": "excel", "inside": "['在产品', '3,005,808.21', '3,456,415.58', '', '3,005,808.22', '', '3,456,415.57']"}
{"page": 127, "allrow": 3464, "type": "excel", "inside": "['库存商品', '15,698,744.60', '19,178,217.70', '', '9,490,248.22', '', '25,386,714.08']"}
{"page": 127, "allrow": 3465, "type": "excel", "inside": "['合计', '31,605,433.99', '33,504,454.56', '', '19,717,050.39', '', '45,392,838.16']"}
{"page": 127, "allrow": 3466, "type": "text", "inside": "（3）存货期末余额含有借款费用资本化金额的说明"}
{"page": 127, "allrow": 3467, "type": "text", "inside": "（4）期末建造合同形成的已完工未结算资产情况"}
{"page": 127, "allrow": 3468, "type": "text", "inside": "单位：元"}
{"page": 127, "allrow": 3469, "type": "excel", "inside": "['项目', '金额']"}
{"page": 127, "allrow": 3470, "type": "text", "inside": ""}
{"page": 127, "allrow": 3471, "type": "text", "inside": "其他说明："}
{"page": 127, "allrow": 3472, "type": "text", "inside": "10、合同资产"}
{"page": 127, "allrow": 3473, "type": "text", "inside": "单位：元"}
{"page": 127, "allrow": 3474, "type": "excel", "inside": "['', '期末余额', '', '', '期初余额', '', '']"}
{"page": 127, "allrow": 3475, "type": "excel", "inside": "['项目', '账面余额', '减值准备', '账面价值', '账面余额', '减值准备', '账面价值']"}
{"page": 127, "allrow": 3476, "type": "text", "inside": "合同资产的账面价值在本期内发生的重大变动金额和原因："}
{"page": 127, "allrow": 3477, "type": "text", "inside": "单位：元"}
{"page": 127, "allrow": 3478, "type": "excel", "inside": "['项目', '变动金额', '变动原因']"}
{"page": 127, "allrow": 3479, "type": "text", "inside": ""}
{"page": 127, "allrow": 3480, "type": "text", "inside": "如是按照预期信用损失一般模型计提合同资产坏账准备，请参照其他应收款的披露方式披露坏账准备的相关信息：□适用√不适用"}
{"page": 127, "allrow": 3481, "type": "text", "inside": "本期合同资产计提减值准备情况"}
{"page": 127, "allrow": 3482, "type": "text", "inside": "单位：元"}
{"page": 127, "allrow": 3483, "type": "excel", "inside": "['项目', '本期计提', '本期转回', '本期转销/核销', '原因']"}
{"page": 127, "allrow": 3484, "type": "text", "inside": ""}
{"page": 127, "allrow": 3485, "type": "text", "inside": "其他说明："}
{"page": 127, "allrow": 3486, "type": "页脚", "inside": "127"}
{"page": 128, "allrow": 3487, "type": "text", "inside": ""}
{"page": 128, "allrow": 3488, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 128, "allrow": 3489, "type": "text", "inside": "11、持有待售资产"}
{"page": 128, "allrow": 3490, "type": "text", "inside": "单位：元"}
{"page": 128, "allrow": 3491, "type": "excel", "inside": "['项目', '期末账面余额', '减值准备', '期末账面价值', '公允价值', '预计处置费用', '预计处置时间']"}
{"page": 128, "allrow": 3492, "type": "text", "inside": "其他说明："}
{"page": 128, "allrow": 3493, "type": "text", "inside": "12、一年内到期的非流动资产"}
{"page": 128, "allrow": 3494, "type": "text", "inside": "单位：元"}
{"page": 128, "allrow": 3495, "type": "excel", "inside": "['项目', '期末余额', '期初余额']"}
{"page": 128, "allrow": 3496, "type": "text", "inside": ""}
{"page": 128, "allrow": 3497, "type": "text", "inside": "重要的债权投资/其他债权投资"}
{"page": 128, "allrow": 3498, "type": "text", "inside": "单位：元"}
{"page": 128, "allrow": 3499, "type": "excel", "inside": "['', '期末余额', '', '', '', '期初余额', '', '', '']"}
{"page": 128, "allrow": 3500, "type": "excel", "inside": "['债权项目', '面值', '票面利率', '实际利率', '到期日', '面值', '票面利率', '实际利率', '到期日']"}
{"page": 128, "allrow": 3501, "type": "text", "inside": "其他说明："}
{"page": 128, "allrow": 3502, "type": "text", "inside": "13、其他流动资产"}
{"page": 128, "allrow": 3503, "type": "text", "inside": "是否已执行新收入准则"}
{"page": 128, "allrow": 3504, "type": "text", "inside": "□是√否"}
{"page": 128, "allrow": 3505, "type": "text", "inside": "单位：元"}
{"page": 128, "allrow": 3506, "type": "excel", "inside": "['项目', '期末余额', '期初余额']"}
{"page": 128, "allrow": 3507, "type": "excel", "inside": "['待抵扣、待认证及留抵进项税', '78,736,031.06', '57,643,027.24']"}
{"page": 128, "allrow": 3508, "type": "excel", "inside": "['预缴税费', '8,992,699.54', '2,741,744.46']"}
{"page": 128, "allrow": 3509, "type": "excel", "inside": "['合计', '87,728,730.60', '60,384,771.70']"}
{"page": 128, "allrow": 3510, "type": "text", "inside": "其他说明："}
{"page": 128, "allrow": 3511, "type": "text", "inside": "14、债权投资"}
{"page": 128, "allrow": 3512, "type": "text", "inside": "单位：元"}
{"page": 128, "allrow": 3513, "type": "excel", "inside": "['', '期末余额', '', '', '期初余额', '', '']"}
{"page": 128, "allrow": 3514, "type": "excel", "inside": "['项目', '账面余额', '减值准备', '账面价值', '账面余额', '减值准备', '账面价值']"}
{"page": 128, "allrow": 3515, "type": "text", "inside": "重要的债权投资"}
{"page": 128, "allrow": 3516, "type": "text", "inside": "单位：元"}
{"page": 128, "allrow": 3517, "type": "excel", "inside": "['', '期末余额', '', '', '', '期初余额', '', '', '']"}
{"page": 128, "allrow": 3518, "type": "excel", "inside": "['债权项目', '面值', '票面利率', '实际利率', '到期日', '面值', '票面利率', '实际利率', '到期日']"}
{"page": 128, "allrow": 3519, "type": "text", "inside": ""}
{"page": 128, "allrow": 3520, "type": "text", "inside": "减值准备计提情况"}
{"page": 128, "allrow": 3521, "type": "text", "inside": "单位：元"}
{"page": 128, "allrow": 3522, "type": "页脚", "inside": "128"}
{"page": 129, "allrow": 3523, "type": "text", "inside": ""}
{"page": 129, "allrow": 3524, "type": "text", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 129, "allrow": 3525, "type": "excel", "inside": "['', '第一阶段', '第二阶段', '第三阶段', '']"}
{"page": 129, "allrow": 3526, "type": "excel", "inside": "['坏账准备', '未来12个月预期', '整个存续期预期信用损失(未发生信用减值)', '整个存续期预期信用损', '合计']"}
{"page": 129, "allrow": 3527, "type": "excel", "inside": "['', '信用损失', '', '失(已发生信用减值)', '']"}
{"page": 129, "allrow": 3528, "type": "excel", "inside": "['2019年1月1日余额在本期', '——', '——', '——', '——']"}
{"page": 129, "allrow": 3529, "type": "text", "inside": ""}
{"page": 129, "allrow": 3530, "type": "text", "inside": "损失准备本期变动金额重大的账面余额变动情况"}
{"page": 129, "allrow": 3531, "type": "text", "inside": "□适用√不适用"}
{"page": 129, "allrow": 3532, "type": "text", "inside": "其他说明："}
{"page": 129, "allrow": 3533, "type": "text", "inside": "15、其他债权投资"}
{"page": 129, "allrow": 3534, "type": "text", "inside": "单位：元"}
{"page": 129, "allrow": 3535, "type": "excel", "inside": "['', '', '', '本期公允', '', '', '累计公允价值变动', '累计在其他综合收', '']"}
{"page": 129, "allrow": 3536, "type": "excel", "inside": "['项目', '期初余额', '应计利息', '价值变动', '期末余额', '成本', '', '益中确认', '备注']"}
{"page": 129, "allrow": 3537, "type": "excel", "inside": "['', '', '', '', '', '', '', '的损失准备', '']"}
{"page": 129, "allrow": 3538, "type": "text", "inside": ""}
{"page": 129, "allrow": 3539, "type": "text", "inside": "重要的其他债权投资"}
{"page": 129, "allrow": 3540, "type": "text", "inside": "单位：元"}
{"page": 129, "allrow": 3541, "type": "excel", "inside": "['', '期末余额', '', '', '', '', '期初余额', '', '', '']"}
{"page": 129, "allrow": 3542, "type": "excel", "inside": "['其他债权项目', '面值', '票面利', '率', '实际利率', '到期日', '面值', '票面利率', '实际利率', '到期日']"}
{"page": 129, "allrow": 3543, "type": "text", "inside": "减值准备计提情况"}
{"page": 129, "allrow": 3544, "type": "text", "inside": "单位：元"}
{"page": 129, "allrow": 3545, "type": "excel", "inside": "['', '第一阶段', '第二阶段', '第三阶段', '']"}
{"page": 129, "allrow": 3546, "type": "excel", "inside": "['坏账准备', '未来12个月预期', '整个存续期预期信用损失(未发生信用减值)', '整个存续期预期信用损', '合计']"}
{"page": 129, "allrow": 3547, "type": "excel", "inside": "['', '信用损失', '', '失(已发生信用减值)', '']"}
{"page": 129, "allrow": 3548, "type": "excel", "inside": "['2019年1月1日余额在本期', '——', '——', '——', '——']"}
{"page": 129, "allrow": 3549, "type": "text", "inside": ""}
{"page": 129, "allrow": 3550, "type": "text", "inside": "损失准备本期变动金额重大的账面余额变动情况"}
{"page": 129, "allrow": 3551, "type": "text", "inside": "□适用√不适用"}
{"page": 129, "allrow": 3552, "type": "text", "inside": "其他说明："}
{"page": 129, "allrow": 3553, "type": "text", "inside": "16、长期应收款"}
{"page": 129, "allrow": 3554, "type": "text", "inside": "（1）长期应收款情况"}
{"page": 129, "allrow": 3555, "type": "text", "inside": "单位：元"}
{"page": 129, "allrow": 3556, "type": "excel", "inside": "['', '期末余额', '', '', '期初余额', '', '', '']"}
{"page": 129, "allrow": 3557, "type": "excel", "inside": "['项目', '账面余额', '坏账准备', '账面价值', '账面余额', '坏账准备', '账面价值', '折现率区间']"}
{"page": 130, "allrow": 3558, "type": "text", "inside": ""}
{"page": 130, "allrow": 3559, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 130, "allrow": 3560, "type": "text", "inside": "坏账准备减值情况"}
{"page": 130, "allrow": 3561, "type": "text", "inside": "单位：元"}
{"page": 130, "allrow": 3562, "type": "excel", "inside": "['', '第一阶段', '第二阶段', '第三阶段', '']"}
{"page": 130, "allrow": 3563, "type": "excel", "inside": "['坏账准备', '未来12个月预期', '整个存续期预期信用损', '整个存续期预期信用损', '合计']"}
{"page": 130, "allrow": 3564, "type": "excel", "inside": "['', '信用损失', '失(未发生信用减值)', '失(已发生信用减值)', '']"}
{"page": 130, "allrow": 3565, "type": "excel", "inside": "['2019年1月1日余额在本期', '——', '——', '——', '——']"}
{"page": 130, "allrow": 3566, "type": "text", "inside": ""}
{"page": 130, "allrow": 3567, "type": "text", "inside": "损失准备本期变动金额重大的账面余额变动情况"}
{"page": 130, "allrow": 3568, "type": "text", "inside": "□适用√不适用"}
{"page": 130, "allrow": 3569, "type": "text", "inside": "（2）因金融资产转移而终止确认的长期应收款"}
{"page": 130, "allrow": 3570, "type": "text", "inside": "（3）转移长期应收款且继续涉入形成的资产、负债金额"}
{"page": 130, "allrow": 3571, "type": "text", "inside": "其他说明"}
{"page": 130, "allrow": 3572, "type": "text", "inside": "17、长期股权投资"}
{"page": 130, "allrow": 3573, "type": "text", "inside": "单位：元"}
{"page": 130, "allrow": 3574, "type": "excel", "inside": "['', '期初余', '本期增减变动', '', '权益法', '', '', '宣告发', '', '', '期末余', '减值准']"}
{"page": 130, "allrow": 3575, "type": "excel", "inside": "['被投资单位', '额(账面价', '追加投资', '减少投资', '下确认的投资', '其他综合收益', '其他权益变动', '放现金股利或', '计提减值准备', '其他', '额(账面价', '备期末余额']"}
{"page": 130, "allrow": 3576, "type": "excel", "inside": "['', '值)', '', '', '损益', '调整', '', '利润', '', '', '值)', '']"}
{"page": 130, "allrow": 3577, "type": "excel", "inside": "['一、合营企业', '', '', '', '', '', '', '', '', '', '', '']"}
{"page": 130, "allrow": 3578, "type": "excel", "inside": "['二、联营企业', '', '', '', '', '', '', '', '', '', '', '']"}
{"page": 130, "allrow": 3579, "type": "excel", "inside": "['昌邑华普医药科技有限公司', '52,462,227.09', '', '', '33,026,549.22', '', '', '9,800,000.00', '', '', '75,688,776.31', '']"}
{"page": 130, "allrow": 3580, "type": "excel", "inside": "['亿帆优胜美特医药科技有限公司', '48,409,496.13', '', '', '-1,883,664.40', '', '', '', '', '', '46,525,831.73', '']"}
{"page": 130, "allrow": 3581, "type": "excel", "inside": "['', '100,87', '', '', '31,142,', '', '', '9,800,0', '', '', '122,21', '']"}
{"page": 130, "allrow": 3582, "type": "excel", "inside": "['小计', '1,723.2', '', '', '884.82', '', '', '00.00', '', '', '4,608.0', '']"}
{"page": 130, "allrow": 3583, "type": "excel", "inside": "['', '2', '', '', '', '', '', '', '', '', '4', '']"}
{"page": 130, "allrow": 3584, "type": "excel", "inside": "['', '100,87', '', '', '31,142,', '', '', '9,800,0', '', '', '122,21', '']"}
{"page": 130, "allrow": 3585, "type": "excel", "inside": "['合计', '1,723.2', '', '', '884.82', '', '', '00.00', '', '', '4,608.0', '']"}
{"page": 130, "allrow": 3586, "type": "excel", "inside": "['', '2', '', '', '', '', '', '', '', '', '4', '']"}
{"page": 130, "allrow": 3587, "type": "text", "inside": ""}
{"page": 130, "allrow": 3588, "type": "页脚", "inside": "130"}
{"page": 131, "allrow": 3589, "type": "text", "inside": ""}
{"page": 131, "allrow": 3590, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 131, "allrow": 3591, "type": "text", "inside": "其他说明"}
{"page": 131, "allrow": 3592, "type": "text", "inside": "18、其他权益工具投资"}
{"page": 131, "allrow": 3593, "type": "text", "inside": "单位：元"}
{"page": 131, "allrow": 3594, "type": "excel", "inside": "['项目', '期末余额', '期初余额']"}
{"page": 131, "allrow": 3595, "type": "text", "inside": ""}
{"page": 131, "allrow": 3596, "type": "text", "inside": "分项披露本期非交易性权益工具投资"}
{"page": 131, "allrow": 3597, "type": "text", "inside": "单位：元"}
{"page": 131, "allrow": 3598, "type": "excel", "inside": "['', '确认的股利收', '', '', '其他综合收益', '指定为以公允价值计量且其', '其他综合收益']"}
{"page": 131, "allrow": 3599, "type": "excel", "inside": "['项目名称', '入', '累计利得', '累计损失', '转入留存收益', '变动计入其他', '转入留存收益']"}
{"page": 131, "allrow": 3600, "type": "excel", "inside": "['', '', '', '', '的金额', '综合收益的原因', '的原因']"}
{"page": 131, "allrow": 3601, "type": "text", "inside": ""}
{"page": 131, "allrow": 3602, "type": "text", "inside": "其他说明："}
{"page": 131, "allrow": 3603, "type": "text", "inside": "19、其他非流动金融资产"}
{"page": 131, "allrow": 3604, "type": "text", "inside": "单位：元"}
{"page": 131, "allrow": 3605, "type": "excel", "inside": "['项目', '期末余额', '期初余额']"}
{"page": 131, "allrow": 3606, "type": "text", "inside": ""}
{"page": 131, "allrow": 3607, "type": "text", "inside": "其他说明："}
{"page": 131, "allrow": 3608, "type": "text", "inside": "20、投资性房地产"}
{"page": 131, "allrow": 3609, "type": "text", "inside": "（1）采用成本计量模式的投资性房地产"}
{"page": 131, "allrow": 3610, "type": "text", "inside": "□适用√不适用"}
{"page": 131, "allrow": 3611, "type": "text", "inside": "（2）采用公允价值计量模式的投资性房地产"}
{"page": 131, "allrow": 3612, "type": "text", "inside": "□适用√不适用"}
{"page": 131, "allrow": 3613, "type": "text", "inside": "（3）未办妥产权证书的投资性房地产情况"}
{"page": 131, "allrow": 3614, "type": "text", "inside": "单位：元"}
{"page": 131, "allrow": 3615, "type": "excel", "inside": "['项目', '账面价值', '未办妥产权证书原因']"}
{"page": 131, "allrow": 3616, "type": "text", "inside": ""}
{"page": 131, "allrow": 3617, "type": "text", "inside": "其他说明"}
{"page": 131, "allrow": 3618, "type": "text", "inside": "21、固定资产"}
{"page": 131, "allrow": 3619, "type": "text", "inside": "单位：元"}
{"page": 131, "allrow": 3620, "type": "excel", "inside": "['项目', '期末余额', '期初余额']"}
{"page": 131, "allrow": 3621, "type": "excel", "inside": "['固定资产', '1,898,972,408.21', '1,971,680,172.58']"}
{"page": 131, "allrow": 3622, "type": "text", "inside": ""}
{"page": 131, "allrow": 3623, "type": "页脚", "inside": "131"}
{"page": 132, "allrow": 3624, "type": "text", "inside": ""}
{"page": 132, "allrow": 3625, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 132, "allrow": 3626, "type": "excel", "inside": "['合计', '1,898,972,408.21', '1,971,680,172.58']"}
{"page": 132, "allrow": 3627, "type": "text", "inside": "（1）固定资产情况"}
{"page": 132, "allrow": 3628, "type": "text", "inside": "单位：元"}
{"page": 132, "allrow": 3629, "type": "excel", "inside": "['项目', '房屋及建筑物', '机器设备', '运输设备', '其他', '合计']"}
{"page": 132, "allrow": 3630, "type": "excel", "inside": "['一、账面原值：', '', '', '', '', '']"}
{"page": 132, "allrow": 3631, "type": "excel", "inside": "['1.期初余额', '1,447,323,408.03', '2,464,265,263.13', '20,893,633.31', '121,508,200.48', '4,053,990,504.95']"}
{"page": 132, "allrow": 3632, "type": "excel", "inside": "['2.本期增加金额', '32,566,527.68', '224,686,744.01', '1,140,336.76', '23,027,006.58', '281,420,615.03']"}
{"page": 132, "allrow": 3633, "type": "excel", "inside": "['（1）购置', '', '78,274,832.32', '1,140,336.76', '12,788,595.77', '92,203,764.85']"}
{"page": 132, "allrow": 3634, "type": "excel", "inside": "['（2）在建工程转入', '32,566,527.68', '146,411,911.69', '', '10,238,410.81', '189,216,850.18']"}
{"page": 132, "allrow": 3635, "type": "excel", "inside": "['（3）企业合并增加', '', '', '', '', '']"}
{"page": 132, "allrow": 3636, "type": "excel", "inside": "['', '14,213,813.57', '85,060,402.75', '1,126,348.32', '3,698,082.67', '104,098,647.31']"}
{"page": 132, "allrow": 3637, "type": "excel", "inside": "['3.本期减少金额', '14,213,813.57', '85,060,402.75', '1,126,348.32', '3,698,082.67', '104,098,647.31']"}
{"page": 132, "allrow": 3638, "type": "excel", "inside": "['（1）处置或报废', '', '', '', '', '']"}
{"page": 132, "allrow": 3639, "type": "excel", "inside": "['', '1,465,676,122.14', '2,603,891,604.39', '20,907,621.75', '140,837,124.39', '4,231,312,472.67']"}
{"page": 132, "allrow": 3640, "type": "excel", "inside": "['4.期末余额', '', '', '', '', '']"}
{"page": 132, "allrow": 3641, "type": "excel", "inside": "['二、累计折旧', '544,070,399.81', '1,437,776,869.83', '18,502,158.39', '81,110,728.07', '2,081,460,156.10']"}
{"page": 132, "allrow": 3642, "type": "excel", "inside": "['1.期初余额', '101,938,185.28', '219,547,577.33', '1,478,190.71', '18,634,611.05', '341,598,564.37']"}
{"page": 132, "allrow": 3643, "type": "excel", "inside": "['2.本期增加金额', '101,938,185.28', '219,547,577.33', '1,478,190.71', '18,634,611.05', '341,598,564.37']"}
{"page": 132, "allrow": 3644, "type": "excel", "inside": "['（1）计提', '', '', '', '', '']"}
{"page": 132, "allrow": 3645, "type": "excel", "inside": "['', '11,170,248.16', '75,752,587.38', '1,086,148.05', '3,245,298.50', '91,254,282.09']"}
{"page": 132, "allrow": 3646, "type": "excel", "inside": "['3.本期减少金额', '11,170,248.16', '75,752,587.38', '1,086,148.05', '3,245,298.50', '91,254,282.09']"}
{"page": 132, "allrow": 3647, "type": "excel", "inside": "['（1）处置或报废', '', '', '', '', '']"}
{"page": 132, "allrow": 3648, "type": "excel", "inside": "['', '634,838,336.93', '1,581,571,859.78', '18,894,201.05', '96,500,040.62', '2,331,804,438.38']"}
{"page": 132, "allrow": 3649, "type": "excel", "inside": "['4.期末余额', '', '', '', '', '']"}
{"page": 132, "allrow": 3650, "type": "excel", "inside": "['三、减值准备', '', '850,176.27', '', '', '850,176.27']"}
{"page": 132, "allrow": 3651, "type": "excel", "inside": "['1.期初余额', '', '', '', '', '']"}
{"page": 132, "allrow": 3652, "type": "text", "inside": ""}
{"page": 132, "allrow": 3653, "type": "页脚", "inside": "132"}
{"page": 133, "allrow": 3654, "type": "text", "inside": ""}
{"page": 133, "allrow": 3655, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 133, "allrow": 3656, "type": "excel", "inside": "['2.本期增加金额', '', '', '', '', '']"}
{"page": 133, "allrow": 3657, "type": "excel", "inside": "['（1）计提', '', '', '', '', '']"}
{"page": 133, "allrow": 3658, "type": "excel", "inside": "['', '', '314,550.19', '', '', '314,550.19']"}
{"page": 133, "allrow": 3659, "type": "excel", "inside": "['3.本期减少金额', '', '314,550.19', '', '', '314,550.19']"}
{"page": 133, "allrow": 3660, "type": "excel", "inside": "['（1）处置或报废', '', '', '', '', '']"}
{"page": 133, "allrow": 3661, "type": "excel", "inside": "['', '', '535,626.08', '', '', '535,626.08']"}
{"page": 133, "allrow": 3662, "type": "excel", "inside": "['4.期末余额', '', '', '', '', '']"}
{"page": 133, "allrow": 3663, "type": "excel", "inside": "['四、账面价值', '830,837,785.21', '1,021,784,118.53', '2,013,420.70', '44,337,083.77', '1,898,972,408.21']"}
{"page": 133, "allrow": 3664, "type": "excel", "inside": "['1.期末账面价值', '903,253,008.22', '1,025,638,217.03', '2,391,474.92', '40,397,472.41', '1,971,680,172.58']"}
{"page": 133, "allrow": 3665, "type": "excel", "inside": "['2.期初账面价值', '', '', '', '', '']"}
{"page": 133, "allrow": 3666, "type": "text", "inside": ""}
{"page": 133, "allrow": 3667, "type": "text", "inside": "（2）暂时闲置的固定资产情况"}
{"page": 133, "allrow": 3668, "type": "text", "inside": "单位：元"}
{"page": 133, "allrow": 3669, "type": "excel", "inside": "['项目', '账面原值', '累计折旧', '减值准备', '账面价值', '备注']"}
{"page": 133, "allrow": 3670, "type": "excel", "inside": "['机器设备', '', '', '', '', '']"}
{"page": 133, "allrow": 3671, "type": "text", "inside": ""}
{"page": 133, "allrow": 3672, "type": "text", "inside": "（3）通过融资租赁租入的固定资产情况"}
{"page": 133, "allrow": 3673, "type": "text", "inside": "单位：元"}
{"page": 133, "allrow": 3674, "type": "excel", "inside": "['项目', '账面原值', '累计折旧', '减值准备', '账面价值']"}
{"page": 133, "allrow": 3675, "type": "text", "inside": ""}
{"page": 133, "allrow": 3676, "type": "text", "inside": "（4）通过经营租赁租出的固定资产"}
{"page": 133, "allrow": 3677, "type": "text", "inside": "单位：元"}
{"page": 133, "allrow": 3678, "type": "excel", "inside": "['项目', '期末账面价值']"}
{"page": 133, "allrow": 3679, "type": "text", "inside": ""}
{"page": 133, "allrow": 3680, "type": "text", "inside": "（5）未办妥产权证书的固定资产情况"}
{"page": 133, "allrow": 3681, "type": "text", "inside": "单位：元"}
{"page": 133, "allrow": 3682, "type": "excel", "inside": "['项目', '账面价值', '未办妥产权证书的原因']"}
{"page": 133, "allrow": 3683, "type": "excel", "inside": "['房屋及建筑物', '215,827,114.01', '相关手续尚未办理完毕']"}
{"page": 133, "allrow": 3684, "type": "text", "inside": ""}
{"page": 133, "allrow": 3685, "type": "text", "inside": "其他说明"}
{"page": 133, "allrow": 3686, "type": "text", "inside": "期末固定资产中用于抵押的账面价值为62,782,453.27元。"}
{"page": 133, "allrow": 3687, "type": "页脚", "inside": "133"}
{"page": 134, "allrow": 3688, "type": "text", "inside": ""}
{"page": 134, "allrow": 3689, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 134, "allrow": 3690, "type": "text", "inside": "（6）固定资产清理"}
{"page": 134, "allrow": 3691, "type": "text", "inside": "单位：元"}
{"page": 134, "allrow": 3692, "type": "excel", "inside": "['项目', '期末余额', '期初余额']"}
{"page": 134, "allrow": 3693, "type": "text", "inside": ""}
{"page": 134, "allrow": 3694, "type": "text", "inside": "其他说明"}
{"page": 134, "allrow": 3695, "type": "text", "inside": "22、在建工程"}
{"page": 134, "allrow": 3696, "type": "text", "inside": "单位：元"}
{"page": 134, "allrow": 3697, "type": "excel", "inside": "['项目', '', '期末余额', '期初余额']"}
{"page": 134, "allrow": 3698, "type": "excel", "inside": "['在建工程', '', '118,847,992.45', '151,569,855.81']"}
{"page": 134, "allrow": 3699, "type": "excel", "inside": "['合计', '118,847,992.45', '', '151,569,855.81']"}
{"page": 134, "allrow": 3700, "type": "text", "inside": "（1）在建工程情况"}
{"page": 134, "allrow": 3701, "type": "text", "inside": "单位：元"}
{"page": 134, "allrow": 3702, "type": "excel", "inside": "['', '期末余额', '', '', '期初余额', '', '']"}
{"page": 134, "allrow": 3703, "type": "excel", "inside": "['项目', '账面余额', '减值准备', '账面价值', '账面余额', '减值准备', '账面价值']"}
{"page": 134, "allrow": 3704, "type": "excel", "inside": "['普洛康裕制药制剂园区工程', '9,547,905.59', '', '9,547,905.59', '', '', '']"}
{"page": 134, "allrow": 3705, "type": "excel", "inside": "['普洛康裕制药废气RTO蓄热式焚烧治理', '', '', '', '13,302,561.33', '', '13,302,561.33']"}
{"page": 134, "allrow": 3706, "type": "excel", "inside": "['普洛康裕制药氢溴酸右美沙芬技改扩产', '5,151,101.06', '', '5,151,101.06', '4,310,304.59', '', '4,310,304.59']"}
{"page": 134, "allrow": 3707, "type": "excel", "inside": "['普洛康裕制药焚烧炉改造项目', '5,095,796.35', '', '5,095,796.35', '', '', '']"}
{"page": 134, "allrow": 3708, "type": "excel", "inside": "['普洛康裕制药合成十一车间设备提升改造', '4,513,983.20', '', '4,513,983.20', '', '', '']"}
{"page": 134, "allrow": 3709, "type": "excel", "inside": "['普洛康裕制药质量部及技术部改造', '9,301,868.93', '', '9,301,868.93', '', '', '']"}
{"page": 134, "allrow": 3710, "type": "text", "inside": ""}
{"page": 134, "allrow": 3711, "type": "页脚", "inside": "134"}
{"page": 135, "allrow": 3712, "type": "text", "inside": ""}
{"page": 135, "allrow": 3713, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 135, "allrow": 3714, "type": "excel", "inside": "['普洛康裕制药有机废气预处理及收集管网改造', '4,066,373.22', '4,066,373.22', '', '']"}
{"page": 135, "allrow": 3715, "type": "excel", "inside": "['安徽普洛生物厂区工程', '', '', '2,351,458.81', '2,351,458.81']"}
{"page": 135, "allrow": 3716, "type": "excel", "inside": "['汉兴医药科技乙醛酸车间自动化及扩产改造项目', '', '', '5,970,198.95', '5,970,198.95']"}
{"page": 135, "allrow": 3717, "type": "excel", "inside": "['汉兴医药科技10吨MVR蒸馏装置项目', '', '', '5,626,652.03', '5,626,652.03']"}
{"page": 135, "allrow": 3718, "type": "excel", "inside": "['汉兴医药科技焚烧系统余热回收利用改造项目', '', '', '3,417,966.87', '3,417,966.87']"}
{"page": 135, "allrow": 3719, "type": "excel", "inside": "['汉兴医药科技RTO蓄热式焚烧废气治理项目', '', '', '27,534,601.44', '27,534,601.44']"}
{"page": 135, "allrow": 3720, "type": "excel", "inside": "['汉兴医药科技焚烧炉超低排放改造项目', '', '', '18,847,045.09', '18,847,045.09']"}
{"page": 135, "allrow": 3721, "type": "excel", "inside": "['汉兴医药科技厂区厂容厂貌提升项目', '', '', '2,508,679.03', '2,508,679.03']"}
{"page": 135, "allrow": 3722, "type": "excel", "inside": "['汉兴医药科技产能保障改造', '6,179,864.82', '6,179,864.82', '', '']"}
{"page": 135, "allrow": 3723, "type": "excel", "inside": "['汉兴医药科技羟酸甲酯扩产项目', '4,646,677.84', '4,646,677.84', '', '']"}
{"page": 135, "allrow": 3724, "type": "excel", "inside": "['普洛得邦制药二氯甲烷废气回收', '', '', '1,659,637.64', '1,659,637.64']"}
{"page": 135, "allrow": 3725, "type": "excel", "inside": "['普洛得邦制药中心化验室改造提升项目', '', '', '1,322,844.83', '1,322,844.83']"}
{"page": 135, "allrow": 3726, "type": "text", "inside": ""}
{"page": 135, "allrow": 3727, "type": "页脚", "inside": "135"}
{"page": 136, "allrow": 3728, "type": "text", "inside": ""}
{"page": 136, "allrow": 3729, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 136, "allrow": 3730, "type": "excel", "inside": "['普洛得邦医药新兴厂区RTO蓄热式焚烧废气治理项目', '', '', '5,428,127.10', '5,428,127.10']"}
{"page": 136, "allrow": 3731, "type": "excel", "inside": "['普洛得邦医药回转窑扩容改造项目', '', '', '2,006,602.07', '2,006,602.07']"}
{"page": 136, "allrow": 3732, "type": "excel", "inside": "['普洛得邦医药污水站升级改造', '3,675,486.79', '3,675,486.79', '3,291,335.07', '3,291,335.07']"}
{"page": 136, "allrow": 3733, "type": "excel", "inside": "['普洛得邦医药氨噻肟酸安全环保提升改造项目', '11,893,795.23', '11,893,795.23', '', '']"}
{"page": 136, "allrow": 3734, "type": "excel", "inside": "['浙江普洛生物重液闪蒸回收乙酸丁酯项目', '', '', '495,185.58', '495,185.58']"}
{"page": 136, "allrow": 3735, "type": "excel", "inside": "['山西优胜美特待安装设备', '', '', '2,042,538.18', '2,042,538.18']"}
{"page": 136, "allrow": 3736, "type": "excel", "inside": "['浙江巨泰药业综合仓库', '', '', '31,216,980.59', '31,216,980.59']"}
{"page": 136, "allrow": 3737, "type": "excel", "inside": "['普洛家园药业J13013生产线技改', '', '', '5,674,610.11', '5,674,610.11']"}
{"page": 136, "allrow": 3738, "type": "excel", "inside": "['普洛家园药业焚烧系统余热回收技改项目', '', '', '3,902,876.71', '3,902,876.71']"}
{"page": 136, "allrow": 3739, "type": "excel", "inside": "['普洛家园药业氟苯尼考生产线技改', '', '', '3,059,944.29', '3,059,944.29']"}
{"page": 136, "allrow": 3740, "type": "excel", "inside": "['普洛家园药业工程技术实验室', '', '', '1,019,808.43', '1,019,808.43']"}
{"page": 136, "allrow": 3741, "type": "excel", "inside": "['普洛家园药业原料药多功能车间建设项目', '26,462,950.29', '26,462,950.29', '', '']"}
{"page": 136, "allrow": 3742, "type": "excel", "inside": "['普洛家园药业生产线产品技术改造', '5,724,295.49', '5,724,295.49', '', '']"}
{"page": 136, "allrow": 3743, "type": "excel", "inside": "['待安装设备', '', '', '4,623,698.35', '4,623,698.35']"}
{"page": 136, "allrow": 3744, "type": "text", "inside": ""}
{"page": 136, "allrow": 3745, "type": "页脚", "inside": "136"}
{"page": 137, "allrow": 3746, "type": "text", "inside": ""}
{"page": 137, "allrow": 3747, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 137, "allrow": 3748, "type": "excel", "inside": "['其他项目', '22,587,893.64', '', '22,587,893.64', '1,956,198.72', '', '1,956,198.72']"}
{"page": 137, "allrow": 3749, "type": "excel", "inside": "['合计', '118,847,992.45', '118,847,992.45', '', '151,569,855.81', '151,569,855.81', '']"}
{"page": 137, "allrow": 3750, "type": "text", "inside": "（2）重要在建工程项目本期变动情况"}
{"page": 137, "allrow": 3751, "type": "text", "inside": "单位：元"}
{"page": 137, "allrow": 3752, "type": "excel", "inside": "['', '', '', '本期', '本期转入', '本期', '', '工程累计', '', '利息资本', '其中：本期', '本期', '']"}
{"page": 137, "allrow": 3753, "type": "excel", "inside": "['项目名称', '预算数', '期初余额', '增加金额', '固定资产', '其他减少', '期末余额', '投入占预', '工程进度', '化累计金', '利息资本', '利息资本', '资金来源']"}
{"page": 137, "allrow": 3754, "type": "excel", "inside": "['', '', '', '', '金额', '金额', '', '算比例', '', '额', '化金额', '化率', '']"}
{"page": 137, "allrow": 3755, "type": "excel", "inside": "['普洛康裕制药制剂园区工程', '', '2,586.21', '9,545,319.38', '', '', '9,547,905.59', '', '78%', '', '', '', '其他']"}
{"page": 137, "allrow": 3756, "type": "excel", "inside": "['普洛康裕制药焚烧炉改造项目', '', '', '5,095,796.35', '', '', '5,095,796.35', '', '80%', '', '', '', '其他']"}
{"page": 137, "allrow": 3757, "type": "excel", "inside": "['普洛康裕制药质量部及技术部改造', '', '', '9,301,868.93', '', '', '9,301,868.93', '', '75%', '', '', '', '其他']"}
{"page": 137, "allrow": 3758, "type": "excel", "inside": "['普洛康裕制药氢溴酸右美沙芬技改扩产', '', '4,310,304.59', '840,796.47', '', '', '5,151,101.06', '', '80%', '', '', '', '其他']"}
{"page": 137, "allrow": 3759, "type": "text", "inside": ""}
{"page": 137, "allrow": 3760, "type": "页脚", "inside": "137"}
{"page": 138, "allrow": 3761, "type": "text", "inside": ""}
{"page": 138, "allrow": 3762, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 138, "allrow": 3763, "type": "excel", "inside": "['汉兴医药科技RTO蓄热式焚烧废气治理项目', '27,534,601.44', '152,182.49', '27,686,783.93', '', '100%', '其他']"}
{"page": 138, "allrow": 3764, "type": "excel", "inside": "['汉兴医药科技产能保障改造', '242,808.84', '5,937,055.98', '', '6,179,864.82', '85%', '其他']"}
{"page": 138, "allrow": 3765, "type": "excel", "inside": "['浙江巨泰药业综合仓库', '31,216,980.59', '1,281,550.73', '32,498,531.32', '', '100%', '其他']"}
{"page": 138, "allrow": 3766, "type": "excel", "inside": "['汉兴医药科技乙醛酸车间自动化及扩产改造项目', '5,970,198.95', '180,208.63', '6,150,407.58', '', '100%', '其他']"}
{"page": 138, "allrow": 3767, "type": "excel", "inside": "['汉兴医药科技10吨MVR蒸馏装置项目', '5,626,652.03', '185,344.83', '5,811,996.86', '', '100%', '其他']"}
{"page": 138, "allrow": 3768, "type": "text", "inside": ""}
{"page": 138, "allrow": 3769, "type": "页脚", "inside": "138"}
{"page": 139, "allrow": 3770, "type": "text", "inside": ""}
{"page": 139, "allrow": 3771, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 139, "allrow": 3772, "type": "excel", "inside": "['普洛家园药业J13013生产线技改', '5,674,610.11', '33,241.68', '5,707,851.79', '', '', '100%', '其他']"}
{"page": 139, "allrow": 3773, "type": "excel", "inside": "['普洛家园药业原料药多功能车间建设项目', '', '26,462,950.29', '', '26,462,950.29', '', '70%', '其他']"}
{"page": 139, "allrow": 3774, "type": "excel", "inside": "['普洛家园药业生产线产品技术改造', '', '5,724,295.49', '', '5,724,295.49', '', '80%', '其他']"}
{"page": 139, "allrow": 3775, "type": "excel", "inside": "['普洛得邦医药氨噻肟酸安全环保提升改造项目', '', '11,893,795.23', '', '11,893,795.23', '', '90%', '其他']"}
{"page": 139, "allrow": 3776, "type": "excel", "inside": "['', '80,578', '76,634', '77,855', '79,357', '', '', '']"}
{"page": 139, "allrow": 3777, "type": "excel", "inside": "['合计', ',742.7', ',406.4', ',571.4', ',577.7', '--', '--', '--']"}
{"page": 139, "allrow": 3778, "type": "excel", "inside": "['', '6', '8', '8', '6', '', '', '']"}
{"page": 139, "allrow": 3779, "type": "text", "inside": ""}
{"page": 139, "allrow": 3780, "type": "text", "inside": "（3）本期计提在建工程减值准备情况"}
{"page": 139, "allrow": 3781, "type": "text", "inside": "单位：元"}
{"page": 139, "allrow": 3782, "type": "excel", "inside": "['项目', '本期计提金额', '计提原因']"}
{"page": 139, "allrow": 3783, "type": "text", "inside": ""}
{"page": 139, "allrow": 3784, "type": "页脚", "inside": "139"}
{"page": 140, "allrow": 3785, "type": "text", "inside": ""}
{"page": 140, "allrow": 3786, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 140, "allrow": 3787, "type": "text", "inside": "其他说明"}
{"page": 140, "allrow": 3788, "type": "text", "inside": "（4）工程物资"}
{"page": 140, "allrow": 3789, "type": "text", "inside": "单位：元"}
{"page": 140, "allrow": 3790, "type": "excel", "inside": "['', '期末余额', '', '', '期初余额', '', '']"}
{"page": 140, "allrow": 3791, "type": "excel", "inside": "['项目', '账面余额', '减值准备', '账面价值', '账面余额', '减值准备', '账面价值']"}
{"page": 140, "allrow": 3792, "type": "text", "inside": "其他说明："}
{"page": 140, "allrow": 3793, "type": "text", "inside": "23、生产性生物资产"}
{"page": 140, "allrow": 3794, "type": "text", "inside": "（1）采用成本计量模式的生产性生物资产"}
{"page": 140, "allrow": 3795, "type": "text", "inside": "□适用√不适用"}
{"page": 140, "allrow": 3796, "type": "text", "inside": "（2）采用公允价值计量模式的生产性生物资产"}
{"page": 140, "allrow": 3797, "type": "text", "inside": "□适用√不适用"}
{"page": 140, "allrow": 3798, "type": "text", "inside": "24、油气资产"}
{"page": 140, "allrow": 3799, "type": "text", "inside": "□适用√不适用"}
{"page": 140, "allrow": 3800, "type": "text", "inside": "25、使用权资产"}
{"page": 140, "allrow": 3801, "type": "text", "inside": "单位：元"}
{"page": 140, "allrow": 3802, "type": "excel", "inside": "['项目', '合计']"}
{"page": 140, "allrow": 3803, "type": "text", "inside": ""}
{"page": 140, "allrow": 3804, "type": "text", "inside": "其他说明："}
{"page": 140, "allrow": 3805, "type": "text", "inside": "26、无形资产"}
{"page": 140, "allrow": 3806, "type": "text", "inside": "（1）无形资产情况"}
{"page": 140, "allrow": 3807, "type": "text", "inside": "单位：元"}
{"page": 140, "allrow": 3808, "type": "excel", "inside": "['项目', '土地使用权', '专利权', '非专利技术', '合计']"}
{"page": 140, "allrow": 3809, "type": "excel", "inside": "['一、账面原值', '', '', '', '']"}
{"page": 140, "allrow": 3810, "type": "excel", "inside": "['1.期初余额', '430,606,348.54', '31,368,500.00', '2,661,114.72', '464,635,963.26']"}
{"page": 140, "allrow": 3811, "type": "excel", "inside": "['2.本期增加金额', '', '', '', '']"}
{"page": 140, "allrow": 3812, "type": "excel", "inside": "['（1）购置', '', '', '', '']"}
{"page": 140, "allrow": 3813, "type": "text", "inside": ""}
{"page": 140, "allrow": 3814, "type": "页脚", "inside": "140"}
{"page": 141, "allrow": 3815, "type": "text", "inside": ""}
{"page": 141, "allrow": 3816, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 141, "allrow": 3817, "type": "excel", "inside": "['（2）内部研发', '', '', '', '']"}
{"page": 141, "allrow": 3818, "type": "excel", "inside": "['（3）企业合并增加', '', '', '', '']"}
{"page": 141, "allrow": 3819, "type": "excel", "inside": "['3.本期减少金额', '', '', '', '']"}
{"page": 141, "allrow": 3820, "type": "excel", "inside": "['（1）处置', '', '', '', '']"}
{"page": 141, "allrow": 3821, "type": "excel", "inside": "['4.期末余额', '430,606,348.54', '31,368,500.00', '2,661,114.72', '464,635,963.26']"}
{"page": 141, "allrow": 3822, "type": "excel", "inside": "['二、累计摊销', '', '', '', '']"}
{"page": 141, "allrow": 3823, "type": "excel", "inside": "['1.期初余额', '93,913,701.73', '25,187,134.89', '2,376,061.24', '121,476,897.86']"}
{"page": 141, "allrow": 3824, "type": "excel", "inside": "['2.本期增加金额', '9,076,551.93', '2,757,560.88', '114,131.72', '11,948,244.53']"}
{"page": 141, "allrow": 3825, "type": "excel", "inside": "['（1）计提', '9,076,551.93', '2,757,560.88', '114,131.72', '11,948,244.53']"}
{"page": 141, "allrow": 3826, "type": "excel", "inside": "['3.本期减少金额', '', '', '', '']"}
{"page": 141, "allrow": 3827, "type": "excel", "inside": "['（1）处置', '', '', '', '']"}
{"page": 141, "allrow": 3828, "type": "excel", "inside": "['4.期末余额', '102,990,253.66', '27,944,695.77', '2,490,192.96', '133,425,142.39']"}
{"page": 141, "allrow": 3829, "type": "excel", "inside": "['三、减值准备', '', '', '', '']"}
{"page": 141, "allrow": 3830, "type": "excel", "inside": "['1.期初余额', '', '', '', '']"}
{"page": 141, "allrow": 3831, "type": "excel", "inside": "['2.本期增加金额', '', '', '', '']"}
{"page": 141, "allrow": 3832, "type": "excel", "inside": "['（1）计提', '', '', '', '']"}
{"page": 141, "allrow": 3833, "type": "excel", "inside": "['3.本期减少金额', '', '', '', '']"}
{"page": 141, "allrow": 3834, "type": "excel", "inside": "['（1）处置', '', '', '', '']"}
{"page": 141, "allrow": 3835, "type": "excel", "inside": "['4.期末余额', '', '', '', '']"}
{"page": 141, "allrow": 3836, "type": "excel", "inside": "['四、账面价值', '', '', '', '']"}
{"page": 141, "allrow": 3837, "type": "excel", "inside": "['1.期末账面价值', '327,616,094.88', '3,423,804.23', '170,921.76', '331,210,820.87']"}
{"page": 141, "allrow": 3838, "type": "text", "inside": ""}
{"page": 141, "allrow": 3839, "type": "页脚", "inside": "141"}
{"page": 142, "allrow": 3840, "type": "text", "inside": ""}
{"page": 142, "allrow": 3841, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 142, "allrow": 3842, "type": "excel", "inside": "['2.期初账面价值', '336,692,646.81', '6,181,365.11', '285,053.48', '343,159,065.40']"}
{"page": 142, "allrow": 3843, "type": "text", "inside": ""}
{"page": 142, "allrow": 3844, "type": "text", "inside": "本期末通过公司内部研发形成的无形资产占无形资产余额的比例。"}
{"page": 142, "allrow": 3845, "type": "text", "inside": "（2）未办妥产权证书的土地使用权情况"}
{"page": 142, "allrow": 3846, "type": "text", "inside": "单位：元"}
{"page": 142, "allrow": 3847, "type": "excel", "inside": "['项目', '账面价值', '未办妥产权证书的原因']"}
{"page": 142, "allrow": 3848, "type": "excel", "inside": "['土地', '14,696,606.80', '']"}
{"page": 142, "allrow": 3849, "type": "text", "inside": ""}
{"page": 142, "allrow": 3850, "type": "text", "inside": "其他说明："}
{"page": 142, "allrow": 3851, "type": "text", "inside": "期末用于抵押的无形资产账面价值为85,846,372.32元。"}
{"page": 142, "allrow": 3852, "type": "text", "inside": "27、开发支出"}
{"page": 142, "allrow": 3853, "type": "text", "inside": "单位：元"}
{"page": 142, "allrow": 3854, "type": "excel", "inside": "['', '', '本期增加金额', '', '本期减少金额', '', '']"}
{"page": 142, "allrow": 3855, "type": "excel", "inside": "['项目', '期初余额', '内部开发', '其他', '确认为无', '转入当期', '期末余额']"}
{"page": 142, "allrow": 3856, "type": "excel", "inside": "['', '', '支出', '', '形资产', '损益', '']"}
{"page": 142, "allrow": 3857, "type": "excel", "inside": "['', '20,066,420', '339,827,02', '', '', '359,893,44', '']"}
{"page": 142, "allrow": 3858, "type": "excel", "inside": "['生产技术', '.36', '8.46', '', '', '8.82', '0.00']"}
{"page": 142, "allrow": 3859, "type": "excel", "inside": "['', '20,066,420', '339,827,02', '', '', '359,893,44', '']"}
{"page": 142, "allrow": 3860, "type": "excel", "inside": "['合计', '.36', '8.46', '', '', '8.82', '0.00']"}
{"page": 142, "allrow": 3861, "type": "text", "inside": ""}
{"page": 142, "allrow": 3862, "type": "text", "inside": "其他说明"}
{"page": 142, "allrow": 3863, "type": "text", "inside": "28、商誉"}
{"page": 142, "allrow": 3864, "type": "text", "inside": "（1）商誉账面原值"}
{"page": 142, "allrow": 3865, "type": "text", "inside": "单位：元"}
{"page": 142, "allrow": 3866, "type": "excel", "inside": "['被投资单位名称或形成商誉的事项', '期初余额', '本期增加企业合并形成的', '本期减少处置', '期末余额']"}
{"page": 142, "allrow": 3867, "type": "excel", "inside": "['浙江巨泰药业', '20,310,091.31', '', '', '20,310,091.31']"}
{"page": 142, "allrow": 3868, "type": "excel", "inside": "['山西优胜美特', '9,194,311.26', '', '', '9,194,311.26']"}
{"page": 142, "allrow": 3869, "type": "excel", "inside": "['合计', '29,504,402.57', '', '', '29,504,402.57']"}
{"page": 142, "allrow": 3870, "type": "text", "inside": "（2）商誉减值准备"}
{"page": 142, "allrow": 3871, "type": "text", "inside": "单位：元"}
{"page": 142, "allrow": 3872, "type": "excel", "inside": "['被投资单位名', '期初余额', '本期增加', '本期减少', '期末余额']"}
{"page": 142, "allrow": 3873, "type": "text", "inside": ""}
{"page": 142, "allrow": 3874, "type": "页脚", "inside": "142"}
{"page": 143, "allrow": 3875, "type": "text", "inside": ""}
{"page": 143, "allrow": 3876, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 143, "allrow": 3877, "type": "excel", "inside": "['称或形成商誉的事项', '', '计提', '处置', '']"}
{"page": 143, "allrow": 3878, "type": "excel", "inside": "['山西优胜美特', '0.00', '9,194,311.26', '', '9,194,311.26']"}
{"page": 143, "allrow": 3879, "type": "excel", "inside": "['合计', '0.00', '9,194,311.26', '', '9,194,311.26']"}
{"page": 143, "allrow": 3880, "type": "text", "inside": "商誉所在资产组或资产组组合的相关信息"}
{"page": 143, "allrow": 3881, "type": "text", "inside": "期末对浙江巨泰药业的商誉20,310,091.31元，系本公司2010年非同一控制下企业合并取得优胜美特制药100.00%股权，公司合并成本大于购买日应享有优胜美特制药可辨认净资产公允价值的差额，2017年浙江巨泰药业吸收合并优胜美特制药，承接全部资产负债及业务，故相关商誉转到浙江巨泰药业。"}
{"page": 143, "allrow": 3882, "type": "text", "inside": "期末对山西优胜美特的商誉9,194,311.26元，系本公司2014年非同一控制下企业合并取得山西优胜美特100.00%股权，公司合并成本大于购买日应享有山西优胜美特可辨认净资产公允价值的差额。"}
{"page": 143, "allrow": 3883, "type": "text", "inside": "说明商誉减值测试过程、关键参数（如预计未来现金流量现值时的预测期增长率、稳定期增长率、利润率、折现率、预测期等）及商誉减值损失的确认方法："}
{"page": 143, "allrow": 3884, "type": "text", "inside": "公司对截止2019年12月31日存在减值迹象的商誉相关资产组进行了减值测试，相关资产组的可收回金额低于其账面价值，遵循谨慎性原则应计提商誉减值准备：2019年度，受我国仿制药一致性评价、医保控费等医药政策影响，山西优胜美特在研产品市场规模、预计收益已远低于预期，资产组业务下降较为明显。管理层判断山西优胜美特未来盈利能力较弱，经营现金流持续为负，不足以支撑商誉，故全额计提商誉减值准备。"}
{"page": 143, "allrow": 3885, "type": "text", "inside": "商誉减值测试的影响"}
{"page": 143, "allrow": 3886, "type": "text", "inside": "其他说明"}
{"page": 143, "allrow": 3887, "type": "text", "inside": "29、长期待摊费用"}
{"page": 143, "allrow": 3888, "type": "text", "inside": "单位：元"}
{"page": 143, "allrow": 3889, "type": "excel", "inside": "['项目', '期初余额', '本期增加金额', '本期摊销金额', '其他减少金额', '', '期末余额']"}
{"page": 143, "allrow": 3890, "type": "excel", "inside": "['租入固定资产改良支出', '2,025,145.05', '6,303,673.45', '2,101,283.10', '', '', '6,227,535.40']"}
{"page": 143, "allrow": 3891, "type": "excel", "inside": "['土地租赁费', '1,734,241.30', '', '45,940.20', '', '', '1,688,301.10']"}
{"page": 143, "allrow": 3892, "type": "excel", "inside": "['污水处理项目', '3,464,512.91', '', '1,165,662.34', '', '', '2,298,850.57']"}
{"page": 143, "allrow": 3893, "type": "excel", "inside": "['合计', '7,223,899.26', '6,303,673.45', '3,312,885.64', '', '10,214,687.07', '']"}
{"page": 143, "allrow": 3894, "type": "text", "inside": "其他说明"}
{"page": 143, "allrow": 3895, "type": "text", "inside": "30、递延所得税资产/递延所得税负债"}
{"page": 143, "allrow": 3896, "type": "text", "inside": "（1）未经抵销的递延所得税资产"}
{"page": 143, "allrow": 3897, "type": "text", "inside": "单位：元"}
{"page": 143, "allrow": 3898, "type": "excel", "inside": "['', '期末余额', '', '期初余额', '']"}
{"page": 143, "allrow": 3899, "type": "excel", "inside": "['项目', '可抵扣暂时性差异', '递延所得税资产', '可抵扣暂时性差异', '递延所得税资产']"}
{"page": 143, "allrow": 3900, "type": "excel", "inside": "['资产减值准备', '115,566,530.12', '20,741,873.97', '97,416,619.86', '17,632,565.40']"}
{"page": 143, "allrow": 3901, "type": "text", "inside": ""}
{"page": 143, "allrow": 3902, "type": "页脚", "inside": "143"}
{"page": 144, "allrow": 3903, "type": "text", "inside": ""}
{"page": 144, "allrow": 3904, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 144, "allrow": 3905, "type": "excel", "inside": "['内部交易未实现利润', '36,058,444.27', '5,625,120.76', '24,799,084.73', '3,972,217.53']"}
{"page": 144, "allrow": 3906, "type": "excel", "inside": "['可抵扣亏损', '80,968,857.71', '14,746,374.35', '94,985,523.38', '16,858,985.22']"}
{"page": 144, "allrow": 3907, "type": "excel", "inside": "['递延收益形成的暂时性差异对递延所得税的影响', '6,222,593.33', '933,389.00', '10,915,613.33', '1,637,342.00']"}
{"page": 144, "allrow": 3908, "type": "excel", "inside": "['流动负债形成的暂时性差异对递延所得税的影响', '19,539,335.27', '2,930,900.29', '163,926.19', '24,588.93']"}
{"page": 144, "allrow": 3909, "type": "excel", "inside": "['交易性金融负债公允价值变动形成的暂时性差异对递延所得税的影响', '16,231,031.94', '4,057,757.99', '2,486,145.90', '621,536.48']"}
{"page": 144, "allrow": 3910, "type": "excel", "inside": "['合计', '274,586,792.64', '49,035,416.36', '230,766,913.39', '40,747,235.56']"}
{"page": 144, "allrow": 3911, "type": "text", "inside": "（2）未经抵销的递延所得税负债"}
{"page": 144, "allrow": 3912, "type": "text", "inside": "单位：元"}
{"page": 144, "allrow": 3913, "type": "excel", "inside": "['', '期末余额', '', '期初余额', '']"}
{"page": 144, "allrow": 3914, "type": "excel", "inside": "['项目', '应纳税暂时性差异', '递延所得税负债', '应纳税暂时性差异', '递延所得税负债']"}
{"page": 144, "allrow": 3915, "type": "excel", "inside": "['非同一控制企业合并资产评估增值', '2,655,101.35', '663,775.33', '2,927,726.14', '731,931.53']"}
{"page": 144, "allrow": 3916, "type": "excel", "inside": "['交易性金融资产公允价值变动形成的暂时性差异对递延所得税的影响', '3,858,358.17', '578,753.43', '', '']"}
{"page": 144, "allrow": 3917, "type": "excel", "inside": "['合计', '6,513,459.52', '1,242,528.76', '2,927,726.14', '731,931.53']"}
{"page": 144, "allrow": 3918, "type": "text", "inside": "（3）以抵销后净额列示的递延所得税资产或负债"}
{"page": 144, "allrow": 3919, "type": "text", "inside": "单位：元"}
{"page": 144, "allrow": 3920, "type": "excel", "inside": "['', '递延所得税资产和负', '', '抵销后递延所得税资', '递延所得税资产和负', '抵销后递延所得税资']"}
{"page": 144, "allrow": 3921, "type": "excel", "inside": "['项目', '债期末互抵金额', '', '产或负债期末余额', '债期初互抵金额', '产或负债期初余额']"}
{"page": 144, "allrow": 3922, "type": "excel", "inside": "['递延所得税资产', '', '49,035,416.36', '', '', '40,747,235.56']"}
{"page": 144, "allrow": 3923, "type": "excel", "inside": "['递延所得税负债', '', '1,242,528.76', '', '', '731,931.53']"}
{"page": 144, "allrow": 3924, "type": "text", "inside": "（4）未确认递延所得税资产明细"}
{"page": 144, "allrow": 3925, "type": "text", "inside": "单位：元"}
{"page": 144, "allrow": 3926, "type": "excel", "inside": "['项目', '期末余额', '期初余额']"}
{"page": 144, "allrow": 3927, "type": "text", "inside": ""}
{"page": 144, "allrow": 3928, "type": "页脚", "inside": "144"}
{"page": 145, "allrow": 3929, "type": "text", "inside": ""}
{"page": 145, "allrow": 3930, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 145, "allrow": 3931, "type": "excel", "inside": "['可抵扣暂时性差异', '32,614,328.44', '55,783,622.36']"}
{"page": 145, "allrow": 3932, "type": "excel", "inside": "['可抵扣亏损', '414,285,213.06', '378,285,983.75']"}
{"page": 145, "allrow": 3933, "type": "excel", "inside": "['合计', '446,899,541.50', '434,069,606.11']"}
{"page": 145, "allrow": 3934, "type": "text", "inside": "（5）未确认递延所得税资产的可抵扣亏损将于以下年度到期"}
{"page": 145, "allrow": 3935, "type": "text", "inside": "单位：元"}
{"page": 145, "allrow": 3936, "type": "excel", "inside": "['年份', '期末金额', '期初金额', '备注']"}
{"page": 145, "allrow": 3937, "type": "excel", "inside": "['2019年', '', '1,416,095.09', '']"}
{"page": 145, "allrow": 3938, "type": "excel", "inside": "['2020年', '44,944,256.35', '44,006,216.37', '']"}
{"page": 145, "allrow": 3939, "type": "excel", "inside": "['2021年', '77,836,886.41', '70,397,775.98', '']"}
{"page": 145, "allrow": 3940, "type": "excel", "inside": "['2022年', '87,878,435.68', '84,277,181.17', '']"}
{"page": 145, "allrow": 3941, "type": "excel", "inside": "['2023年', '158,405,280.51', '178,188,715.14', '']"}
{"page": 145, "allrow": 3942, "type": "excel", "inside": "['2024年', '45,220,354.11', '', '']"}
{"page": 145, "allrow": 3943, "type": "excel", "inside": "['合计', '414,285,213.06', '378,285,983.75', '--']"}
{"page": 145, "allrow": 3944, "type": "text", "inside": ""}
{"page": 145, "allrow": 3945, "type": "text", "inside": "其他说明："}
{"page": 145, "allrow": 3946, "type": "text", "inside": "31、其他非流动资产"}
{"page": 145, "allrow": 3947, "type": "text", "inside": "是否已执行新收入准则"}
{"page": 145, "allrow": 3948, "type": "text", "inside": "□是√否"}
{"page": 145, "allrow": 3949, "type": "text", "inside": "单位：元"}
{"page": 145, "allrow": 3950, "type": "excel", "inside": "['项目', '期末余额', '期初余额']"}
{"page": 145, "allrow": 3951, "type": "excel", "inside": "['预付工程项目款', '1,631,495.13', '3,624,274.72']"}
{"page": 145, "allrow": 3952, "type": "excel", "inside": "['预付长期资产购置款', '12,175,516.55', '7,782,142.40']"}
{"page": 145, "allrow": 3953, "type": "excel", "inside": "['合计', '13,807,011.68', '11,406,417.12']"}
{"page": 145, "allrow": 3954, "type": "text", "inside": "其他说明："}
{"page": 145, "allrow": 3955, "type": "text", "inside": "32、短期借款"}
{"page": 145, "allrow": 3956, "type": "text", "inside": "（1）短期借款分类"}
{"page": 145, "allrow": 3957, "type": "text", "inside": "单位：元"}
{"page": 145, "allrow": 3958, "type": "excel", "inside": "['项目', '', '期末余额', '期初余额']"}
{"page": 145, "allrow": 3959, "type": "excel", "inside": "['抵押借款', '', '', '200,000,000.00']"}
{"page": 145, "allrow": 3960, "type": "excel", "inside": "['保证借款', '', '50,000,000.00', '280,100,000.00']"}
{"page": 145, "allrow": 3961, "type": "excel", "inside": "['保证及抵押', '', '', '134,000,000.00']"}
{"page": 145, "allrow": 3962, "type": "excel", "inside": "['合计', '50,000,000.00', '', '614,100,000.00']"}
{"page": 145, "allrow": 3963, "type": "text", "inside": ""}
{"page": 145, "allrow": 3964, "type": "页脚", "inside": "145"}
{"page": 146, "allrow": 3965, "type": "text", "inside": ""}
{"page": 146, "allrow": 3966, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 146, "allrow": 3967, "type": "text", "inside": "短期借款分类的说明："}
{"page": 146, "allrow": 3968, "type": "text", "inside": "（2）已逾期未偿还的短期借款情况"}
{"page": 146, "allrow": 3969, "type": "text", "inside": "本期末已逾期未偿还的短期借款总额为元，其中重要的已逾期未偿还的短期借款情况如下："}
{"page": 146, "allrow": 3970, "type": "text", "inside": "单位：元"}
{"page": 146, "allrow": 3971, "type": "excel", "inside": "['借款单位', '期末余额', '借款利率', '逾期时间', '逾期利率']"}
{"page": 146, "allrow": 3972, "type": "text", "inside": ""}
{"page": 146, "allrow": 3973, "type": "text", "inside": "其他说明："}
{"page": 146, "allrow": 3974, "type": "text", "inside": "33、交易性金融负债"}
{"page": 146, "allrow": 3975, "type": "text", "inside": "单位：元"}
{"page": 146, "allrow": 3976, "type": "excel", "inside": "['项目', '', '期末余额', '期初余额']"}
{"page": 146, "allrow": 3977, "type": "excel", "inside": "['交易性金融负债', '', '16,231,031.94', '2,486,145.90']"}
{"page": 146, "allrow": 3978, "type": "excel", "inside": "['其中：', '', '', '']"}
{"page": 146, "allrow": 3979, "type": "excel", "inside": "['衍生金融负债', '', '16,231,031.94', '2,486,145.90']"}
{"page": 146, "allrow": 3980, "type": "excel", "inside": "['其中：', '', '', '']"}
{"page": 146, "allrow": 3981, "type": "excel", "inside": "['合计', '16,231,031.94', '', '2,486,145.90']"}
{"page": 146, "allrow": 3982, "type": "text", "inside": "其他说明："}
{"page": 146, "allrow": 3983, "type": "text", "inside": "34、衍生金融负债"}
{"page": 146, "allrow": 3984, "type": "text", "inside": "单位：元"}
{"page": 146, "allrow": 3985, "type": "excel", "inside": "['项目', '期末余额', '期初余额']"}
{"page": 146, "allrow": 3986, "type": "text", "inside": ""}
{"page": 146, "allrow": 3987, "type": "text", "inside": "其他说明："}
{"page": 146, "allrow": 3988, "type": "text", "inside": "35、应付票据"}
{"page": 146, "allrow": 3989, "type": "text", "inside": "单位：元"}
{"page": 146, "allrow": 3990, "type": "excel", "inside": "['种类', '', '期末余额', '期初余额']"}
{"page": 146, "allrow": 3991, "type": "excel", "inside": "['银行承兑汇票', '', '923,961,227.56', '322,056,386.67']"}
{"page": 146, "allrow": 3992, "type": "excel", "inside": "['合计', '923,961,227.56', '', '322,056,386.67']"}
{"page": 146, "allrow": 3993, "type": "text", "inside": "本期末已到期未支付的应付票据总额为0.00元。"}
{"page": 146, "allrow": 3994, "type": "text", "inside": "36、应付账款"}
{"page": 146, "allrow": 3995, "type": "text", "inside": "（1）应付账款列示"}
{"page": 146, "allrow": 3996, "type": "text", "inside": "单位：元"}
{"page": 146, "allrow": 3997, "type": "excel", "inside": "['项目', '期末余额', '期初余额']"}
{"page": 146, "allrow": 3998, "type": "text", "inside": ""}
{"page": 146, "allrow": 3999, "type": "页脚", "inside": "146"}
{"page": 147, "allrow": 4000, "type": "text", "inside": ""}
{"page": 147, "allrow": 4001, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 147, "allrow": 4002, "type": "excel", "inside": "['货款及劳务采购款', '', '941,970,054.21', '619,914,368.93']"}
{"page": 147, "allrow": 4003, "type": "excel", "inside": "['工程设备款', '', '144,323,790.17', '171,378,067.99']"}
{"page": 147, "allrow": 4004, "type": "excel", "inside": "['合计', '1,086,293,844.38', '', '791,292,436.92']"}
{"page": 147, "allrow": 4005, "type": "text", "inside": "（2）账龄超过1年的重要应付账款"}
{"page": 147, "allrow": 4006, "type": "text", "inside": "单位：元"}
{"page": 147, "allrow": 4007, "type": "excel", "inside": "['项目', '期末余额', '未偿还或结转的原因']"}
{"page": 147, "allrow": 4008, "type": "text", "inside": ""}
{"page": 147, "allrow": 4009, "type": "text", "inside": "其他说明："}
{"page": 147, "allrow": 4010, "type": "text", "inside": "期末余额中无重要且超过1年的应付账款。"}
{"page": 147, "allrow": 4011, "type": "text", "inside": "37、预收款项"}
{"page": 147, "allrow": 4012, "type": "text", "inside": "是否已执行新收入准则"}
{"page": 147, "allrow": 4013, "type": "text", "inside": "□是√否"}
{"page": 147, "allrow": 4014, "type": "text", "inside": "（1）预收款项列示"}
{"page": 147, "allrow": 4015, "type": "text", "inside": "单位：元"}
{"page": 147, "allrow": 4016, "type": "excel", "inside": "['项目', '', '期末余额', '期初余额']"}
{"page": 147, "allrow": 4017, "type": "excel", "inside": "['货款', '', '140,451,754.93', '143,275,906.92']"}
{"page": 147, "allrow": 4018, "type": "excel", "inside": "['合计', '140,451,754.93', '', '143,275,906.92']"}
{"page": 147, "allrow": 4019, "type": "text", "inside": "（2）账龄超过1年的重要预收款项"}
{"page": 147, "allrow": 4020, "type": "text", "inside": "单位：元"}
{"page": 147, "allrow": 4021, "type": "excel", "inside": "['项目', '期末余额', '未偿还或结转的原因']"}
{"page": 147, "allrow": 4022, "type": "excel", "inside": "['原料药中央储备', '3,906,193.00', '按照协议执行']"}
{"page": 147, "allrow": 4023, "type": "excel", "inside": "['合计', '3,906,193.00', '--']"}
{"page": 147, "allrow": 4024, "type": "text", "inside": ""}
{"page": 147, "allrow": 4025, "type": "text", "inside": "（3）期末建造合同形成的已结算未完工项目情况"}
{"page": 147, "allrow": 4026, "type": "text", "inside": "单位：元"}
{"page": 147, "allrow": 4027, "type": "excel", "inside": "['项目', '金额']"}
{"page": 147, "allrow": 4028, "type": "text", "inside": ""}
{"page": 147, "allrow": 4029, "type": "text", "inside": "其他说明："}
{"page": 147, "allrow": 4030, "type": "text", "inside": "期末余额中预收上海现代制药股份有限公司3,906,193.00元，账龄为2-3年。2017年，普洛康裕制药与"}
{"page": 147, "allrow": 4031, "type": "text", "inside": "上海现代制药股份有限公司签订《中央原料药储备协议书》，确定普洛康裕制药为中央原料药储备责任单"}
{"page": 147, "allrow": 4032, "type": "text", "inside": "位。根据上述储备协议书，普洛康裕制药应储备治疗禽流感用盐酸金刚乙胺原料药2,200.00公斤，同时上"}
{"page": 147, "allrow": 4033, "type": "text", "inside": "海现代制药股份有限公司按照单价1,776.00元/公斤，于2017年10月向普洛康裕制药预先支付货款"}
{"page": 147, "allrow": 4034, "type": "页脚", "inside": "147"}
{"page": 148, "allrow": 4035, "type": "text", "inside": ""}
{"page": 148, "allrow": 4036, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 148, "allrow": 4037, "type": "text", "inside": "3,907,200.00元。按照上述储备协议书，普洛康裕制药应将相关储备原料药存放于公司仓库，不发生调拨时无须开具发票，储备期满后再根据国家工信部指示确定是否续签协议。"}
{"page": 148, "allrow": 4038, "type": "text", "inside": "23、应付职工薪酬"}
{"page": 148, "allrow": 4039, "type": "text", "inside": "38、合同负债"}
{"page": 148, "allrow": 4040, "type": "text", "inside": "单位：元"}
{"page": 148, "allrow": 4041, "type": "excel", "inside": "['项目', '期末余额', '期初余额']"}
{"page": 148, "allrow": 4042, "type": "text", "inside": ""}
{"page": 148, "allrow": 4043, "type": "text", "inside": "报告期内账面价值发生重大变动的金额和原因"}
{"page": 148, "allrow": 4044, "type": "text", "inside": "单位：元"}
{"page": 148, "allrow": 4045, "type": "excel", "inside": "['项目', '变动金额', '变动原因']"}
{"page": 148, "allrow": 4046, "type": "text", "inside": ""}
{"page": 148, "allrow": 4047, "type": "text", "inside": "39、应付职工薪酬"}
{"page": 148, "allrow": 4048, "type": "text", "inside": "（1）应付职工薪酬列示"}
{"page": 148, "allrow": 4049, "type": "text", "inside": "单位：元"}
{"page": 148, "allrow": 4050, "type": "excel", "inside": "['项目', '期初余额', '本期增加', '本期减少', '', '期末余额']"}
{"page": 148, "allrow": 4051, "type": "excel", "inside": "['一、短期薪酬', '94,460,282.88', '589,840,347.87', '525,435,711.56', '', '158,864,919.19']"}
{"page": 148, "allrow": 4052, "type": "excel", "inside": "['二、离职后福利-设定提存计划', '1,495,313.13', '28,572,134.05', '27,893,321.04', '', '2,174,126.14']"}
{"page": 148, "allrow": 4053, "type": "excel", "inside": "['三、辞退福利', '', '1,003,197.00', '1,003,197.00', '', '']"}
{"page": 148, "allrow": 4054, "type": "excel", "inside": "['合计', '95,955,596.01', '619,415,678.92', '554,332,229.60', '161,039,045.33', '']"}
{"page": 148, "allrow": 4055, "type": "text", "inside": "（2）短期薪酬列示"}
{"page": 148, "allrow": 4056, "type": "text", "inside": "单位：元"}
{"page": 148, "allrow": 4057, "type": "excel", "inside": "['项目', '期初余额', '本期增加', '本期减少', '期末余额']"}
{"page": 148, "allrow": 4058, "type": "excel", "inside": "['1、工资、奖金、津贴和补贴', '92,575,199.59', '525,834,349.07', '460,789,019.52', '157,620,529.14']"}
{"page": 148, "allrow": 4059, "type": "excel", "inside": "['2、职工福利费', '335,975.49', '35,824,884.54', '36,160,860.03', '']"}
{"page": 148, "allrow": 4060, "type": "excel", "inside": "['3、社会保险费', '1,218,065.64', '15,763,371.94', '16,190,202.93', '791,234.65']"}
{"page": 148, "allrow": 4061, "type": "excel", "inside": "['其中：医疗保险费', '822,119.56', '13,136,957.43', '13,303,199.44', '655,877.55']"}
{"page": 148, "allrow": 4062, "type": "excel", "inside": "['工伤保险费', '334,037.87', '1,378,174.73', '1,628,617.84', '83,594.76']"}
{"page": 148, "allrow": 4063, "type": "excel", "inside": "['生育保险费', '61,908.21', '1,248,239.78', '1,258,385.65', '51,762.34']"}
{"page": 148, "allrow": 4064, "type": "text", "inside": ""}
{"page": 148, "allrow": 4065, "type": "页脚", "inside": "148"}
{"page": 149, "allrow": 4066, "type": "text", "inside": ""}
{"page": 149, "allrow": 4067, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 149, "allrow": 4068, "type": "excel", "inside": "['4、住房公积金', '', '115,027.00', '', '8,824,057.61', '', '8,927,084.61', '', '12,000.00']"}
{"page": 149, "allrow": 4069, "type": "excel", "inside": "['5、工会经费和职工教育经费', '', '216,015.16', '', '3,593,684.71', '', '3,368,544.47', '', '441,155.40']"}
{"page": 149, "allrow": 4070, "type": "excel", "inside": "['合计', '94,460,282.88', '', '589,840,347.87', '', '525,435,711.56', '', '158,864,919.19', '']"}
{"page": 149, "allrow": 4071, "type": "text", "inside": "（3）设定提存计划列示"}
{"page": 149, "allrow": 4072, "type": "text", "inside": "单位：元"}
{"page": 149, "allrow": 4073, "type": "excel", "inside": "['项目', '', '期初余额', '', '本期增加', '', '本期减少', '', '期末余额']"}
{"page": 149, "allrow": 4074, "type": "excel", "inside": "['1、基本养老保险', '', '1,433,389.31', '', '27,526,785.99', '', '26,836,610.15', '', '2,123,565.15']"}
{"page": 149, "allrow": 4075, "type": "excel", "inside": "['2、失业保险费', '', '61,923.82', '', '1,045,348.06', '', '1,056,710.89', '', '50,560.99']"}
{"page": 149, "allrow": 4076, "type": "excel", "inside": "['合计', '1,495,313.13', '', '28,572,134.05', '', '27,893,321.04', '', '2,174,126.14', '']"}
{"page": 149, "allrow": 4077, "type": "text", "inside": "其他说明："}
{"page": 149, "allrow": 4078, "type": "text", "inside": "40、应交税费"}
{"page": 149, "allrow": 4079, "type": "text", "inside": "单位：元"}
{"page": 149, "allrow": 4080, "type": "excel", "inside": "['项目', '', '期末余额', '期初余额']"}
{"page": 149, "allrow": 4081, "type": "excel", "inside": "['增值税', '', '10,350,256.39', '13,462,714.89']"}
{"page": 149, "allrow": 4082, "type": "excel", "inside": "['企业所得税', '', '61,737,770.90', '63,575,987.32']"}
{"page": 149, "allrow": 4083, "type": "excel", "inside": "['个人所得税', '', '611,149.06', '489,236.37']"}
{"page": 149, "allrow": 4084, "type": "excel", "inside": "['城市维护建设税', '', '3,076,211.63', '5,492,064.82']"}
{"page": 149, "allrow": 4085, "type": "excel", "inside": "['房产税', '', '2,593,895.73', '1,030,105.77']"}
{"page": 149, "allrow": 4086, "type": "excel", "inside": "['土地使用税', '', '3,837,257.23', '2,243,443.33']"}
{"page": 149, "allrow": 4087, "type": "excel", "inside": "['印花税', '', '246,633.78', '214,650.14']"}
{"page": 149, "allrow": 4088, "type": "excel", "inside": "['教育费附加', '', '562,260.04', '452,194.43']"}
{"page": 149, "allrow": 4089, "type": "excel", "inside": "['水利基金', '', '15,136.92', '5,996.74']"}
{"page": 149, "allrow": 4090, "type": "excel", "inside": "['环境保护税', '', '292,640.38', '355,351.04']"}
{"page": 149, "allrow": 4091, "type": "excel", "inside": "['合计', '83,323,212.06', '', '87,321,744.85']"}
{"page": 149, "allrow": 4092, "type": "text", "inside": "其他说明："}
{"page": 149, "allrow": 4093, "type": "text", "inside": "41、其他应付款"}
{"page": 149, "allrow": 4094, "type": "text", "inside": "单位：元"}
{"page": 149, "allrow": 4095, "type": "excel", "inside": "['项目', '', '期末余额', '期初余额']"}
{"page": 149, "allrow": 4096, "type": "excel", "inside": "['应付利息', '1,890,441.90', '', '1,161,561.41']"}
{"page": 149, "allrow": 4097, "type": "excel", "inside": "['其他应付款', '', '98,364,659.79', '146,067,494.99']"}
{"page": 149, "allrow": 4098, "type": "text", "inside": ""}
{"page": 149, "allrow": 4099, "type": "页脚", "inside": "149"}
{"page": 150, "allrow": 4100, "type": "text", "inside": ""}
{"page": 150, "allrow": 4101, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 150, "allrow": 4102, "type": "excel", "inside": "['合计', '100,255,101.69', '147,229,056.40']"}
{"page": 150, "allrow": 4103, "type": "text", "inside": "（1）应付利息"}
{"page": 150, "allrow": 4104, "type": "text", "inside": "单位：元"}
{"page": 150, "allrow": 4105, "type": "excel", "inside": "['项目', '', '期末余额', '期初余额']"}
{"page": 150, "allrow": 4106, "type": "excel", "inside": "['短期借款应付利息', '', '1,890,441.90', '1,161,561.41']"}
{"page": 150, "allrow": 4107, "type": "excel", "inside": "['合计', '1,890,441.90', '', '1,161,561.41']"}
{"page": 150, "allrow": 4108, "type": "text", "inside": "重要的已逾期未支付的利息情况："}
{"page": 150, "allrow": 4109, "type": "text", "inside": "单位：元"}
{"page": 150, "allrow": 4110, "type": "excel", "inside": "['借款单位', '逾期金额', '逾期原因']"}
{"page": 150, "allrow": 4111, "type": "text", "inside": ""}
{"page": 150, "allrow": 4112, "type": "text", "inside": "其他说明："}
{"page": 150, "allrow": 4113, "type": "text", "inside": "（2）应付股利"}
{"page": 150, "allrow": 4114, "type": "text", "inside": "单位：元"}
{"page": 150, "allrow": 4115, "type": "excel", "inside": "['项目', '期末余额', '期初余额']"}
{"page": 150, "allrow": 4116, "type": "text", "inside": ""}
{"page": 150, "allrow": 4117, "type": "text", "inside": "其他说明，包括重要的超过1年未支付的应付股利，应披露未支付原因："}
{"page": 150, "allrow": 4118, "type": "text", "inside": "（3）其他应付款"}
{"page": 150, "allrow": 4119, "type": "text", "inside": "1）按款项性质列示其他应付款"}
{"page": 150, "allrow": 4120, "type": "text", "inside": "单位：元"}
{"page": 150, "allrow": 4121, "type": "excel", "inside": "['项目', '', '期末余额', '', '期初余额']"}
{"page": 150, "allrow": 4122, "type": "excel", "inside": "['往来款', '', '28,913,254.60', '', '50,781,641.17']"}
{"page": 150, "allrow": 4123, "type": "excel", "inside": "['押金、保证金及其他', '', '69,451,405.19', '', '95,285,853.82']"}
{"page": 150, "allrow": 4124, "type": "excel", "inside": "['合计', '98,364,659.79', '', '146,067,494.99', '']"}
{"page": 150, "allrow": 4125, "type": "text", "inside": "2）账龄超过1年的重要其他应付款"}
{"page": 150, "allrow": 4126, "type": "text", "inside": "单位：元"}
{"page": 150, "allrow": 4127, "type": "excel", "inside": "['项目', '期末余额', '未偿还或结转的原因']"}
{"page": 150, "allrow": 4128, "type": "text", "inside": ""}
{"page": 150, "allrow": 4129, "type": "text", "inside": "其他说明"}
{"page": 150, "allrow": 4130, "type": "text", "inside": "期末余额中无重要且超过1年的其他应付款。"}
{"page": 150, "allrow": 4131, "type": "text", "inside": "42、持有待售负债"}
{"page": 150, "allrow": 4132, "type": "text", "inside": "单位：元"}
{"page": 150, "allrow": 4133, "type": "页脚", "inside": "150"}
{"page": 151, "allrow": 4134, "type": "text", "inside": ""}
{"page": 151, "allrow": 4135, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 151, "allrow": 4136, "type": "excel", "inside": "['项目', '期末余额', '期初余额']"}
{"page": 151, "allrow": 4137, "type": "text", "inside": ""}
{"page": 151, "allrow": 4138, "type": "text", "inside": "其他说明："}
{"page": 151, "allrow": 4139, "type": "text", "inside": "43、一年内到期的非流动负债"}
{"page": 151, "allrow": 4140, "type": "text", "inside": "单位：元"}
{"page": 151, "allrow": 4141, "type": "excel", "inside": "['项目', '期末余额', '期初余额']"}
{"page": 151, "allrow": 4142, "type": "text", "inside": ""}
{"page": 151, "allrow": 4143, "type": "text", "inside": "其他说明："}
{"page": 151, "allrow": 4144, "type": "text", "inside": "44、其他流动负债"}
{"page": 151, "allrow": 4145, "type": "text", "inside": "是否已执行新收入准则"}
{"page": 151, "allrow": 4146, "type": "text", "inside": "□是√否"}
{"page": 151, "allrow": 4147, "type": "text", "inside": "单位：元"}
{"page": 151, "allrow": 4148, "type": "excel", "inside": "['项目', '期末余额', '期初余额']"}
{"page": 151, "allrow": 4149, "type": "text", "inside": ""}
{"page": 151, "allrow": 4150, "type": "text", "inside": "短期应付债券的增减变动："}
{"page": 151, "allrow": 4151, "type": "text", "inside": "单位：元"}
{"page": 151, "allrow": 4152, "type": "excel", "inside": "['', '', '', '', '', '', '', '按面值', '', '', '']"}
{"page": 151, "allrow": 4153, "type": "excel", "inside": "['债券名称', '面值', '发行日期', '债券期限', '发行金额', '期初余额', '本期发行', '计提利息', '溢折价摊销', '本期偿还', '期末余额']"}
{"page": 151, "allrow": 4154, "type": "text", "inside": ""}
{"page": 151, "allrow": 4155, "type": "text", "inside": "其他说明："}
{"page": 151, "allrow": 4156, "type": "text", "inside": "45、长期借款"}
{"page": 151, "allrow": 4157, "type": "text", "inside": "（1）长期借款分类"}
{"page": 151, "allrow": 4158, "type": "text", "inside": "单位：元"}
{"page": 151, "allrow": 4159, "type": "excel", "inside": "['项目', '期末余额', '期初余额']"}
{"page": 151, "allrow": 4160, "type": "text", "inside": ""}
{"page": 151, "allrow": 4161, "type": "text", "inside": "长期借款分类的说明："}
{"page": 151, "allrow": 4162, "type": "text", "inside": "其他说明，包括利率区间："}
{"page": 151, "allrow": 4163, "type": "text", "inside": "46、应付债券"}
{"page": 151, "allrow": 4164, "type": "text", "inside": "（1）应付债券"}
{"page": 151, "allrow": 4165, "type": "text", "inside": "单位：元"}
{"page": 151, "allrow": 4166, "type": "excel", "inside": "['项目', '期末余额', '期初余额']"}
{"page": 151, "allrow": 4167, "type": "text", "inside": ""}
{"page": 151, "allrow": 4168, "type": "text", "inside": "（2）应付债券的增减变动（不包括划分为金融负债的优先股、永续债等其他金融工具）"}
{"page": 151, "allrow": 4169, "type": "text", "inside": "单位：元"}
{"page": 151, "allrow": 4170, "type": "页脚", "inside": "151"}
{"page": 152, "allrow": 4171, "type": "text", "inside": ""}
{"page": 152, "allrow": 4172, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 152, "allrow": 4173, "type": "excel", "inside": "['', '', '', '', '', '', '', '按面值', '', '', '']"}
{"page": 152, "allrow": 4174, "type": "excel", "inside": "['债券名称', '面值', '发行日期', '债券期限', '发行金额', '期初余额', '本期发行', '计提利息', '溢折价摊销', '本期偿还', '期末余额']"}
{"page": 152, "allrow": 4175, "type": "excel", "inside": "['合计', '--', '--', '--', '', '', '', '', '', '', '']"}
{"page": 152, "allrow": 4176, "type": "text", "inside": ""}
{"page": 152, "allrow": 4177, "type": "text", "inside": "（3）可转换公司债券的转股条件、转股时间说明"}
{"page": 152, "allrow": 4178, "type": "text", "inside": "（4）划分为金融负债的其他金融工具说明"}
{"page": 152, "allrow": 4179, "type": "text", "inside": "期末发行在外的优先股、永续债等其他金融工具基本情况"}
{"page": 152, "allrow": 4180, "type": "text", "inside": "期末发行在外的优先股、永续债等金融工具变动情况表"}
{"page": 152, "allrow": 4181, "type": "text", "inside": "单位：元"}
{"page": 152, "allrow": 4182, "type": "excel", "inside": "['发行在外的金融工具', '期初数量', '账面价值', '本期增加数量', '账面价值', '本期减少数量', '账面价值', '期末数量', '账面价值']"}
{"page": 152, "allrow": 4183, "type": "text", "inside": ""}
{"page": 152, "allrow": 4184, "type": "text", "inside": "其他金融工具划分为金融负债的依据说明"}
{"page": 152, "allrow": 4185, "type": "text", "inside": "其他说明"}
{"page": 152, "allrow": 4186, "type": "text", "inside": "47、租赁负债"}
{"page": 152, "allrow": 4187, "type": "text", "inside": "单位："}
{"page": 152, "allrow": 4188, "type": "excel", "inside": "['项目', '期末余额', '期初余额']"}
{"page": 152, "allrow": 4189, "type": "text", "inside": ""}
{"page": 152, "allrow": 4190, "type": "text", "inside": "其他说明"}
{"page": 152, "allrow": 4191, "type": "text", "inside": "48、长期应付款"}
{"page": 152, "allrow": 4192, "type": "text", "inside": "单位：元"}
{"page": 152, "allrow": 4193, "type": "excel", "inside": "['项目', '', '期末余额', '期初余额']"}
{"page": 152, "allrow": 4194, "type": "excel", "inside": "['长期应付款', '', '72,000,000.00', '72,000,000.00']"}
{"page": 152, "allrow": 4195, "type": "excel", "inside": "['合计', '72,000,000.00', '', '72,000,000.00']"}
{"page": 152, "allrow": 4196, "type": "text", "inside": "（1）按款项性质列示长期应付款"}
{"page": 152, "allrow": 4197, "type": "text", "inside": "单位：元"}
{"page": 152, "allrow": 4198, "type": "excel", "inside": "['项目', '期末余额', '期初余额']"}
{"page": 152, "allrow": 4199, "type": "excel", "inside": "['农发基金投资款', '72,000,000.00', '72,000,000.00']"}
{"page": 152, "allrow": 4200, "type": "text", "inside": "其他说明："}
{"page": 152, "allrow": 4201, "type": "text", "inside": "016年6月20日，公司召开第六届董事会第二十四次会议，审议并通过了《关于与中国农发重点建设基金有限公司合作的"}
{"page": 152, "allrow": 4202, "type": "text", "inside": "议案》，同意签署《投资协议》。该基金本次以股权方式投资的建设基金总额为7,200万元，投资期限为自完成之日起10年，"}
{"page": 152, "allrow": 4203, "type": "页脚", "inside": "152"}
{"page": 153, "allrow": 4204, "type": "text", "inside": ""}
{"page": 153, "allrow": 4205, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 153, "allrow": 4206, "type": "text", "inside": "固定投资收益率为1.2%，按季度支付，本次增资对应的新增注册资本占增资后普洛康裕制药注册资本的比例9.85%。项目建设期届满后，中国农发重点建设基金有限公司有权要求本公司在2025年5月20日和2026年5月20日各支付标的股权的转让对价3,600万元，股权回购完成后，中国农发重点建设基金在普洛康裕的持股比例为零。详见公司于2016年6月21日披露于巨潮资讯网的2016-39,2016-40号公告。2016年6月30日，公司全资子公司普洛康裕制药收到中国农发重点建设基金有限公司人民币7,200万元。"}
{"page": 153, "allrow": 4207, "type": "text", "inside": "（2）专项应付款"}
{"page": 153, "allrow": 4208, "type": "text", "inside": "单位：元"}
{"page": 153, "allrow": 4209, "type": "excel", "inside": "['项目', '期初余额', '本期增加', '本期减少', '期末余额', '形成原因']"}
{"page": 153, "allrow": 4210, "type": "text", "inside": "其他说明："}
{"page": 153, "allrow": 4211, "type": "text", "inside": "49、长期应付职工薪酬"}
{"page": 153, "allrow": 4212, "type": "text", "inside": "（1）长期应付职工薪酬表"}
{"page": 153, "allrow": 4213, "type": "text", "inside": "单位：元"}
{"page": 153, "allrow": 4214, "type": "excel", "inside": "['项目', '期末余额', '期初余额']"}
{"page": 153, "allrow": 4215, "type": "text", "inside": ""}
{"page": 153, "allrow": 4216, "type": "text", "inside": "（2）设定受益计划变动情况"}
{"page": 153, "allrow": 4217, "type": "text", "inside": "设定受益计划义务现值："}
{"page": 153, "allrow": 4218, "type": "text", "inside": "单位：元"}
{"page": 153, "allrow": 4219, "type": "excel", "inside": "['项目', '本期发生额', '上期发生额']"}
{"page": 153, "allrow": 4220, "type": "text", "inside": ""}
{"page": 153, "allrow": 4221, "type": "text", "inside": "计划资产："}
{"page": 153, "allrow": 4222, "type": "text", "inside": "单位：元"}
{"page": 153, "allrow": 4223, "type": "excel", "inside": "['项目', '本期发生额', '上期发生额']"}
{"page": 153, "allrow": 4224, "type": "text", "inside": ""}
{"page": 153, "allrow": 4225, "type": "text", "inside": "设定受益计划净负债（净资产）"}
{"page": 153, "allrow": 4226, "type": "text", "inside": "单位：元"}
{"page": 153, "allrow": 4227, "type": "excel", "inside": "['项目', '本期发生额', '上期发生额']"}
{"page": 153, "allrow": 4228, "type": "text", "inside": ""}
{"page": 153, "allrow": 4229, "type": "text", "inside": "设定受益计划的内容及与之相关风险、对公司未来现金流量、时间和不确定性的影响说明："}
{"page": 153, "allrow": 4230, "type": "text", "inside": "设定受益计划重大精算假设及敏感性分析结果说明："}
{"page": 153, "allrow": 4231, "type": "text", "inside": "其他说明："}
{"page": 153, "allrow": 4232, "type": "text", "inside": "50、预计负债"}
{"page": 153, "allrow": 4233, "type": "text", "inside": "是否已执行新收入准则"}
{"page": 153, "allrow": 4234, "type": "text", "inside": "□是√否"}
{"page": 153, "allrow": 4235, "type": "text", "inside": "单位：元"}
{"page": 153, "allrow": 4236, "type": "页脚", "inside": "153"}
{"page": 154, "allrow": 4237, "type": "text", "inside": ""}
{"page": 154, "allrow": 4238, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 154, "allrow": 4239, "type": "excel", "inside": "['项目', '期末余额', '期初余额', '形成原因']"}
{"page": 154, "allrow": 4240, "type": "text", "inside": ""}
{"page": 154, "allrow": 4241, "type": "text", "inside": "其他说明，包括重要预计负债的相关重要假设、估计说明："}
{"page": 154, "allrow": 4242, "type": "text", "inside": "51、递延收益"}
{"page": 154, "allrow": 4243, "type": "text", "inside": "单位：元"}
{"page": 154, "allrow": 4244, "type": "excel", "inside": "['项目', '期初余额', '本期增加', '本期减少', '', '期末余额', '形成原因']"}
{"page": 154, "allrow": 4245, "type": "excel", "inside": "['政府补助', '130,052,096.06', '9,218,200.00', '19,468,906.57', '', '119,801,389.49', '']"}
{"page": 154, "allrow": 4246, "type": "excel", "inside": "['合计', '130,052,096.06', '9,218,200.00', '19,468,906.57', '119,801,389.49', '', '--']"}
{"page": 154, "allrow": 4247, "type": "text", "inside": ""}
{"page": 154, "allrow": 4248, "type": "text", "inside": "涉及政府补助的项目："}
{"page": 154, "allrow": 4249, "type": "text", "inside": "单位：元"}
{"page": 154, "allrow": 4250, "type": "excel", "inside": "['', '', '本期新增', '本期计入', '本期计入', '本期冲减', '', '', '与资产相']"}
{"page": 154, "allrow": 4251, "type": "excel", "inside": "['负债项目', '期初余额', '补助金额', '营业外收', '其他收益', '成本费用', '其他变动', '期末余额', '关/与收益']"}
{"page": 154, "allrow": 4252, "type": "excel", "inside": "['', '', '', '入金额', '金额', '金额', '', '', '相关']"}
{"page": 154, "allrow": 4253, "type": "excel", "inside": "['产业发展基金有限公司设备补助款', '472,000.00', '', '', '59,000.00', '', '', '413,000.00', '与资产相关']"}
{"page": 154, "allrow": 4254, "type": "excel", "inside": "['研发设备购置补助款', '3,200,000.00', '', '', '400,000.00', '', '', '2,800,000.00', '与资产相关']"}
{"page": 154, "allrow": 4255, "type": "excel", "inside": "['', '25,041,507.7', '', '', '574,427.0', '', '', '24,467,080.7', '与资产相']"}
{"page": 154, "allrow": 4256, "type": "excel", "inside": "['扶持基金', '5', '', '', '0', '', '', '5', '关']"}
{"page": 154, "allrow": 4257, "type": "excel", "inside": "['2015年度省市工业企业技术改造和技术创新项目财政奖励资金', '1,589,000.00', '', '', '227,000.00', '', '', '1,362,000.00', '与资产相关']"}
{"page": 154, "allrow": 4258, "type": "excel", "inside": "['工业企业技术改造和技术创新奖励', '742,857.15', '', '', '148,571.43', '', '', '594,285.72', '与资产相关']"}
{"page": 154, "allrow": 4259, "type": "excel", "inside": "['工业转型升级财政资金补助款', '525,000.00', '', '', '105,000.00', '', '', '420,000.00', '与资产相关']"}
{"page": 154, "allrow": 4260, "type": "text", "inside": ""}
{"page": 154, "allrow": 4261, "type": "页脚", "inside": "154"}
{"page": 155, "allrow": 4262, "type": "text", "inside": ""}
{"page": 155, "allrow": 4263, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 155, "allrow": 4264, "type": "excel", "inside": "['头孢克肟原料药技术改造项目专项资金', '200,000.00', '100,000.00', '100,000.00', '与资产相关']"}
{"page": 155, "allrow": 4265, "type": "excel", "inside": "['工业企业技术改造奖励', '656,000.00', '82,000.00', '574,000.00', '与资产相关']"}
{"page": 155, "allrow": 4266, "type": "excel", "inside": "['暗流式隔膜压滤机改造项目补助', '350,000.00', '50,000.00', '300,000.00', '与资产相关']"}
{"page": 155, "allrow": 4267, "type": "excel", "inside": "['过滤车间建设项目补助', '812,000.00', '116,000.00', '696,000.00', '与资产相关']"}
{"page": 155, "allrow": 4268, "type": "excel", "inside": "['生物制药技术改造项目', '464,000.00', '116,000.00', '348,000.00', '与资产相关']"}
{"page": 155, "allrow": 4269, "type": "excel", "inside": "['泰乐菌素专项补贴资金', '200,000.00', '100,000.00', '100,000.00', '与资产相关']"}
{"page": 155, "allrow": 4270, "type": "excel", "inside": "['吉他霉素专项补贴资金', '1,507,000.00', '753,500.00', '753,500.00', '与资产相关']"}
{"page": 155, "allrow": 4271, "type": "excel", "inside": "['生物发酵能量系统', '800,000.00', '266,666.66', '533,333.34', '与资产相关']"}
{"page": 155, "allrow": 4272, "type": "excel", "inside": "['年产20吨硫酸安普霉素、100吨马度米星胺等项目', '675,000.00', '75,000.00', '600,000.00', '与资产相关']"}
{"page": 155, "allrow": 4273, "type": "excel", "inside": "['盐酸美金刚原料药及制剂等技术改造项目', '2,200,475.00', '953,695.00', '1,246,780.00', '与资产相关']"}
{"page": 155, "allrow": 4274, "type": "excel", "inside": "['冻干粉针生产线项目专项资金', '2,000.00', '2,000.00', '', '与资产相关']"}
{"page": 155, "allrow": 4275, "type": "text", "inside": ""}
{"page": 155, "allrow": 4276, "type": "页脚", "inside": "155"}
{"page": 156, "allrow": 4277, "type": "text", "inside": ""}
{"page": 156, "allrow": 4278, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 156, "allrow": 4279, "type": "excel", "inside": "['固体制剂车间及仓储装备自动化技改项目', '1,330,000.00', '', '133,000.00', '1,197,000.00', '与资产相关']"}
{"page": 156, "allrow": 4280, "type": "excel", "inside": "['制剂国际化项目', '53,500,000.00', '', '5,350,000.00', '48,150,000.00', '与资产相关']"}
{"page": 156, "allrow": 4281, "type": "excel", "inside": "['金刚烷胺原料药产业化补贴款', '587,500.00', '', '587,500.00', '', '与资产相关']"}
{"page": 156, "allrow": 4282, "type": "excel", "inside": "['年产5亿粒盐酸左氧氟沙星胶囊生产线建设项目', '6,144,000.00', '', '768,000.00', '5,376,000.00', '与资产相关']"}
{"page": 156, "allrow": 4283, "type": "excel", "inside": "['盐酸金刚乙胺复方甲麻口服液等补贴款', '787,500.00', '', '787,500.00', '', '与资产相关']"}
{"page": 156, "allrow": 4284, "type": "excel", "inside": "['治伤软膏生产线建设项目', '175,000.00', '', '87,500.00', '87,500.00', '与资产相关']"}
{"page": 156, "allrow": 4285, "type": "excel", "inside": "['东财企(2019)53号工业企业技术改造和技术创新奖励', '', '3,460,000.00', '173,000.00', '3,287,000.00', '与资产相关']"}
{"page": 156, "allrow": 4286, "type": "excel", "inside": "['D-乙脂项目', '2,000,000.00', '', '500,000.00', '1,500,000.00', '与资产相关']"}
{"page": 156, "allrow": 4287, "type": "excel", "inside": "['青霉素口服制剂技改项目', '722,670.00', '', '127,530.00', '595,140.00', '与资产相关']"}
{"page": 156, "allrow": 4288, "type": "text", "inside": ""}
{"page": 156, "allrow": 4289, "type": "页脚", "inside": "156"}
{"page": 157, "allrow": 4290, "type": "text", "inside": ""}
{"page": 157, "allrow": 4291, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 157, "allrow": 4292, "type": "excel", "inside": "['头孢注射制剂、头孢口服制剂和青霉素口服制剂项目', '1,303,333.33', '', '230,000.00', '1,073,333.33', '与资产相关']"}
{"page": 157, "allrow": 4293, "type": "excel", "inside": "['右旋糖酐铁生产线项目', '505,714.28', '', '168,571.43', '337,142.85', '与资产相关']"}
{"page": 157, "allrow": 4294, "type": "excel", "inside": "['L-丝氨酸项目', '3,300,000.00', '', '1,100,000.00', '2,200,000.00', '与资产相关']"}
{"page": 157, "allrow": 4295, "type": "excel", "inside": "['工业企业技术改造和技术创新项目', '272,000.00', '', '136,000.00', '136,000.00', '与资产相关']"}
{"page": 157, "allrow": 4296, "type": "excel", "inside": "['能量系统优化节能技改项目', '1,435,000.00', '', '717,500.00', '717,500.00', '与资产相关']"}
{"page": 157, "allrow": 4297, "type": "excel", "inside": "['葡聚铁体技术改造项目', '1,222,857.14', '', '305,714.29', '917,142.85', '与资产相关']"}
{"page": 157, "allrow": 4298, "type": "excel", "inside": "['达诺沙星技改项目', '1,350,000.00', '', '270,000.00', '1,080,000.00', '与资产相关']"}
{"page": 157, "allrow": 4299, "type": "excel", "inside": "['美他沙酮原料项目', '714,285.72', '', '142,857.14', '571,428.58', '与资产相关']"}
{"page": 157, "allrow": 4300, "type": "excel", "inside": "['洛索洛芬原料项目', '408,000.00', '', '102,000.00', '306,000.00', '与资产相关']"}
{"page": 157, "allrow": 4301, "type": "excel", "inside": "['替卡格雷中间体技术改造项目', '662,857.12', '', '165,714.27', '497,142.85', '与资产相关']"}
{"page": 157, "allrow": 4302, "type": "excel", "inside": "['', '10,104,538.5', '4,438,200.', '2,156,126.', '12,386,612.2', '']"}
{"page": 157, "allrow": 4303, "type": "excel", "inside": "['其他项目', '7', '00', '33', '4', '']"}
{"page": 157, "allrow": 4304, "type": "excel", "inside": "['创新团队配套资金&重大新药创制', '4,090,000.00', '1,320,000.00', '1,331,533.02', '4,078,466.98', '与收益相关']"}
{"page": 157, "allrow": 4305, "type": "text", "inside": ""}
{"page": 157, "allrow": 4306, "type": "text", "inside": "其他说明："}
{"page": 157, "allrow": 4307, "type": "页脚", "inside": "157"}
{"page": 158, "allrow": 4308, "type": "text", "inside": ""}
{"page": 158, "allrow": 4309, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 158, "allrow": 4310, "type": "text", "inside": "52、其他非流动负债"}
{"page": 158, "allrow": 4311, "type": "text", "inside": "是否已执行新收入准则"}
{"page": 158, "allrow": 4312, "type": "text", "inside": "□是√否"}
{"page": 158, "allrow": 4313, "type": "text", "inside": "单位：元"}
{"page": 158, "allrow": 4314, "type": "excel", "inside": "['项目', '期末余额', '期初余额']"}
{"page": 158, "allrow": 4315, "type": "text", "inside": ""}
{"page": 158, "allrow": 4316, "type": "text", "inside": "其他说明："}
{"page": 158, "allrow": 4317, "type": "text", "inside": "53、股本"}
{"page": 158, "allrow": 4318, "type": "text", "inside": "单位：元"}
{"page": 158, "allrow": 4319, "type": "excel", "inside": "['', '', '本次变动增减（+、-）', '', '', '', '', '', '']"}
{"page": 158, "allrow": 4320, "type": "excel", "inside": "['', '期初余额', '发行新股', '送股', '公积金转股', '其他', '小计', '', '期末余额']"}
{"page": 158, "allrow": 4321, "type": "excel", "inside": "['', '1,178,523,49', '', '', '', '', '', '1,178,523,492.00', '']"}
{"page": 158, "allrow": 4322, "type": "excel", "inside": "['股份总数', '2.00', '', '', '', '', '', '', '']"}
{"page": 158, "allrow": 4323, "type": "text", "inside": "其他说明："}
{"page": 158, "allrow": 4324, "type": "text", "inside": "54、其他权益工具"}
{"page": 158, "allrow": 4325, "type": "text", "inside": "（1）期末发行在外的优先股、永续债等其他金融工具基本情况"}
{"page": 158, "allrow": 4326, "type": "text", "inside": "（2）期末发行在外的优先股、永续债等金融工具变动情况表"}
{"page": 158, "allrow": 4327, "type": "text", "inside": "单位：元"}
{"page": 158, "allrow": 4328, "type": "excel", "inside": "['发行在外的金融工具', '期初数量', '账面价值', '本期增加数量', '账面价值', '本期减少数量', '账面价值', '期末数量', '账面价值']"}
{"page": 158, "allrow": 4329, "type": "text", "inside": ""}
{"page": 158, "allrow": 4330, "type": "text", "inside": "其他权益工具本期增减变动情况、变动原因说明，以及相关会计处理的依据："}
{"page": 158, "allrow": 4331, "type": "text", "inside": "其他说明："}
{"page": 158, "allrow": 4332, "type": "text", "inside": "55、资本公积"}
{"page": 158, "allrow": 4333, "type": "text", "inside": "单位：元"}
{"page": 158, "allrow": 4334, "type": "excel", "inside": "['项目', '期初余额', '本期增加', '本期减少', '', '期末余额']"}
{"page": 158, "allrow": 4335, "type": "excel", "inside": "['资本溢价（股本溢价）', '437,054,420.13', '', '980,000.00', '', '436,074,420.13']"}
{"page": 158, "allrow": 4336, "type": "excel", "inside": "['其他资本公积', '1,931,499.88', '', '', '', '1,931,499.88']"}
{"page": 158, "allrow": 4337, "type": "excel", "inside": "['合计', '438,985,920.01', '', '980,000.00', '438,005,920.01', '']"}
{"page": 158, "allrow": 4338, "type": "text", "inside": "其他说明，包括本期增减变动情况、变动原因说明："}
{"page": 158, "allrow": 4339, "type": "页脚", "inside": "158"}
{"page": 159, "allrow": 4340, "type": "text", "inside": ""}
{"page": 159, "allrow": 4341, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 159, "allrow": 4342, "type": "text", "inside": "56、库存股"}
{"page": 159, "allrow": 4343, "type": "text", "inside": "单位：元"}
{"page": 159, "allrow": 4344, "type": "excel", "inside": "['项目', '期初余额', '本期增加', '本期减少', '期末余额']"}
{"page": 159, "allrow": 4345, "type": "text", "inside": ""}
{"page": 159, "allrow": 4346, "type": "text", "inside": "其他说明，包括本期增减变动情况、变动原因说明："}
{"page": 159, "allrow": 4347, "type": "text", "inside": "57、其他综合收益"}
{"page": 159, "allrow": 4348, "type": "text", "inside": "单位：元"}
{"page": 159, "allrow": 4349, "type": "excel", "inside": "['', '', '本期发生额本期所', '减：前期计入其他综', '减：前期计入其他综合', '', '', '税后归', '税后归', '', '期末']"}
{"page": 159, "allrow": 4350, "type": "excel", "inside": "['项目', '期初余额', '得税前', '合收益当', '收益当', '减：所得', '', '属于母', '属于少', '', '余额']"}
{"page": 159, "allrow": 4351, "type": "excel", "inside": "['', '', '发生额', '期转入损益', '期转入留存收益', '税费用', '', '公司', '数股东', '', '']"}
{"page": 159, "allrow": 4352, "type": "excel", "inside": "['二、将重分类进损益的其他综合收益', '-90,895.78', '', '', '', '', '-56,482.75', '', '', '', '-147,378.53']"}
{"page": 159, "allrow": 4353, "type": "excel", "inside": "['', '-90,895.7', '', '', '', '', '-56,482.75', '', '', '', '-147,3']"}
{"page": 159, "allrow": 4354, "type": "excel", "inside": "['外币财务报表折算差额', '8', '', '', '', '', '', '', '', '', '78.53']"}
{"page": 159, "allrow": 4355, "type": "excel", "inside": "['', '-90,895.7', '', '', '', '', '-56,482.75', '', '', '-147,378.53', '']"}
{"page": 159, "allrow": 4356, "type": "excel", "inside": "['其他综合收益合计', '8', '', '', '', '', '', '', '', '', '']"}
{"page": 159, "allrow": 4357, "type": "text", "inside": "其他说明，包括对现金流量套期损益的有效部分转为被套期项目初始确认金额调整："}
{"page": 159, "allrow": 4358, "type": "text", "inside": "58、专项储备"}
{"page": 159, "allrow": 4359, "type": "text", "inside": "单位：元"}
{"page": 159, "allrow": 4360, "type": "excel", "inside": "['项目', '期初余额', '本期增加', '本期减少', '期末余额']"}
{"page": 159, "allrow": 4361, "type": "text", "inside": ""}
{"page": 159, "allrow": 4362, "type": "text", "inside": "其他说明，包括本期增减变动情况、变动原因说明："}
{"page": 159, "allrow": 4363, "type": "text", "inside": "59、盈余公积"}
{"page": 159, "allrow": 4364, "type": "text", "inside": "单位：元"}
{"page": 159, "allrow": 4365, "type": "excel", "inside": "['项目', '期初余额', '本期增加', '本期减少', '', '期末余额']"}
{"page": 159, "allrow": 4366, "type": "excel", "inside": "['法定盈余公积', '112,256,875.56', '20,503,366.39', '', '', '132,760,241.95']"}
{"page": 159, "allrow": 4367, "type": "excel", "inside": "['合计', '112,256,875.56', '20,503,366.39', '', '132,760,241.95', '']"}
{"page": 159, "allrow": 4368, "type": "text", "inside": "盈余公积说明，包括本期增减变动情况、变动原因说明："}
{"page": 159, "allrow": 4369, "type": "页脚", "inside": "159"}
{"page": 160, "allrow": 4370, "type": "text", "inside": ""}
{"page": 160, "allrow": 4371, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 160, "allrow": 4372, "type": "text", "inside": "60、未分配利润"}
{"page": 160, "allrow": 4373, "type": "text", "inside": "单位：元"}
{"page": 160, "allrow": 4374, "type": "excel", "inside": "['项目', '', '本期', '上期']"}
{"page": 160, "allrow": 4375, "type": "excel", "inside": "['调整前上期末未分配利润', '', '1,615,584,700.94', '1,336,048,067.16']"}
{"page": 160, "allrow": 4376, "type": "excel", "inside": "['调整后期初未分配利润', '', '1,615,584,700.94', '1,336,048,067.16']"}
{"page": 160, "allrow": 4377, "type": "excel", "inside": "['加：本期归属于母公司所有者的净利润', '', '553,400,761.42', '370,561,028.28']"}
{"page": 160, "allrow": 4378, "type": "excel", "inside": "['减：提取法定盈余公积', '', '20,503,366.39', '14,420,378.00']"}
{"page": 160, "allrow": 4379, "type": "excel", "inside": "['应付普通股股利', '', '129,637,584.12', '76,604,016.50']"}
{"page": 160, "allrow": 4380, "type": "excel", "inside": "['期末未分配利润', '2,018,844,511.85', '', '1,615,584,700.94']"}
{"page": 160, "allrow": 4381, "type": "text", "inside": "调整期初未分配利润明细："}
{"page": 160, "allrow": 4382, "type": "text", "inside": "1)、由于《企业会计准则》及其相关新规定进行追溯调整，影响期初未分配利润元。"}
{"page": 160, "allrow": 4383, "type": "text", "inside": "2)、由于会计政策变更，影响期初未分配利润元。"}
{"page": 160, "allrow": 4384, "type": "text", "inside": "3)、由于重大会计差错更正，影响期初未分配利润元。"}
{"page": 160, "allrow": 4385, "type": "text", "inside": "4)、由于同一控制导致的合并范围变更，影响期初未分配利润元。"}
{"page": 160, "allrow": 4386, "type": "text", "inside": "5)、其他调整合计影响期初未分配利润元。"}
{"page": 160, "allrow": 4387, "type": "text", "inside": "61、营业收入和营业成本"}
{"page": 160, "allrow": 4388, "type": "text", "inside": "单位：元"}
{"page": 160, "allrow": 4389, "type": "excel", "inside": "['', '本期发生额', '', '上期发生额', '']"}
{"page": 160, "allrow": 4390, "type": "excel", "inside": "['项目', '收入', '成本', '收入', '成本']"}
{"page": 160, "allrow": 4391, "type": "excel", "inside": "['主营业务', '7,198,139,226.36', '4,863,626,240.99', '6,364,715,162.14', '4,331,351,812.03']"}
{"page": 160, "allrow": 4392, "type": "excel", "inside": "['其他业务', '12,572,159.78', '12,952,253.30', '11,265,336.35', '8,755,264.71']"}
{"page": 160, "allrow": 4393, "type": "excel", "inside": "['合计', '7,210,711,386.14', '4,876,578,494.29', '6,375,980,498.49', '4,340,107,076.74']"}
{"page": 160, "allrow": 4394, "type": "text", "inside": "是否已执行新收入准则"}
{"page": 160, "allrow": 4395, "type": "text", "inside": "□是√否"}
{"page": 160, "allrow": 4396, "type": "text", "inside": "其他说明"}
{"page": 160, "allrow": 4397, "type": "text", "inside": "62、税金及附加"}
{"page": 160, "allrow": 4398, "type": "text", "inside": "单位：元"}
{"page": 160, "allrow": 4399, "type": "excel", "inside": "['项目', '本期发生额', '上期发生额']"}
{"page": 160, "allrow": 4400, "type": "excel", "inside": "['城市维护建设税', '16,596,268.83', '13,934,971.85']"}
{"page": 160, "allrow": 4401, "type": "excel", "inside": "['教育费附加', '12,506,097.21', '12,779,348.50']"}
{"page": 160, "allrow": 4402, "type": "excel", "inside": "['资源税', '4,375.70', '3,586.80']"}
{"page": 160, "allrow": 4403, "type": "excel", "inside": "['房产税', '5,799,820.36', '6,470,093.44']"}
{"page": 160, "allrow": 4404, "type": "excel", "inside": "['土地使用税', '5,102,058.09', '8,591,963.54']"}
{"page": 160, "allrow": 4405, "type": "text", "inside": ""}
{"page": 160, "allrow": 4406, "type": "页脚", "inside": "160"}
{"page": 161, "allrow": 4407, "type": "text", "inside": ""}
{"page": 161, "allrow": 4408, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 161, "allrow": 4409, "type": "excel", "inside": "['车船使用税', '', '15,150.00', '', '13,278.04']"}
{"page": 161, "allrow": 4410, "type": "excel", "inside": "['印花税', '', '2,884,638.95', '', '2,849,995.46']"}
{"page": 161, "allrow": 4411, "type": "excel", "inside": "['水利基金', '', '259,513.28', '', '197,796.38']"}
{"page": 161, "allrow": 4412, "type": "excel", "inside": "['环境保护税', '', '1,247,404.56', '', '1,349,944.66']"}
{"page": 161, "allrow": 4413, "type": "excel", "inside": "['合计', '44,415,326.98', '', '46,190,978.67', '']"}
{"page": 161, "allrow": 4414, "type": "text", "inside": "其他说明："}
{"page": 161, "allrow": 4415, "type": "text", "inside": "63、销售费用"}
{"page": 161, "allrow": 4416, "type": "text", "inside": "单位：元"}
{"page": 161, "allrow": 4417, "type": "excel", "inside": "['项目', '', '本期发生额', '', '上期发生额']"}
{"page": 161, "allrow": 4418, "type": "excel", "inside": "['市场营销服务费', '', '634,636,694.95', '', '617,880,348.01']"}
{"page": 161, "allrow": 4419, "type": "excel", "inside": "['运杂费', '', '67,957,916.68', '', '55,380,466.82']"}
{"page": 161, "allrow": 4420, "type": "excel", "inside": "['差旅费', '', '12,711,093.63', '', '17,198,405.57']"}
{"page": 161, "allrow": 4421, "type": "excel", "inside": "['出口费用', '', '13,560,196.94', '', '10,095,111.97']"}
{"page": 161, "allrow": 4422, "type": "excel", "inside": "['职工薪酬', '', '83,636,862.27', '', '81,290,421.18']"}
{"page": 161, "allrow": 4423, "type": "excel", "inside": "['广告费、业务宣传费', '', '7,394,106.76', '', '10,129,437.11']"}
{"page": 161, "allrow": 4424, "type": "excel", "inside": "['业务招待费', '', '5,311,790.45', '', '8,678,469.08']"}
{"page": 161, "allrow": 4425, "type": "excel", "inside": "['其他', '', '10,129,071.66', '', '8,281,918.77']"}
{"page": 161, "allrow": 4426, "type": "excel", "inside": "['合计', '835,337,733.34', '', '808,934,578.51', '']"}
{"page": 161, "allrow": 4427, "type": "text", "inside": "其他说明："}
{"page": 161, "allrow": 4428, "type": "text", "inside": "64、管理费用"}
{"page": 161, "allrow": 4429, "type": "text", "inside": "单位：元"}
{"page": 161, "allrow": 4430, "type": "excel", "inside": "['项目', '本期发生额', '上期发生额']"}
{"page": 161, "allrow": 4431, "type": "excel", "inside": "['职工薪酬', '225,002,036.02', '212,353,416.91']"}
{"page": 161, "allrow": 4432, "type": "excel", "inside": "['水电费', '5,953,341.08', '8,432,932.33']"}
{"page": 161, "allrow": 4433, "type": "excel", "inside": "['折旧费', '45,409,864.82', '43,944,674.30']"}
{"page": 161, "allrow": 4434, "type": "excel", "inside": "['物料消耗及维修费', '30,191,862.67', '24,558,711.57']"}
{"page": 161, "allrow": 4435, "type": "excel", "inside": "['办公费', '10,397,142.01', '9,711,728.75']"}
{"page": 161, "allrow": 4436, "type": "excel", "inside": "['差旅费', '5,937,423.94', '6,018,371.41']"}
{"page": 161, "allrow": 4437, "type": "excel", "inside": "['环保排污费', '16,389,679.42', '25,595,072.63']"}
{"page": 161, "allrow": 4438, "type": "excel", "inside": "['交通费', '6,980,677.89', '6,733,706.11']"}
{"page": 161, "allrow": 4439, "type": "excel", "inside": "['无形资产摊销', '9,789,999.89', '12,162,560.01']"}
{"page": 161, "allrow": 4440, "type": "excel", "inside": "['业务招待费', '10,946,806.43', '12,988,928.94']"}
{"page": 161, "allrow": 4441, "type": "text", "inside": ""}
{"page": 161, "allrow": 4442, "type": "页脚", "inside": "161"}
{"page": 162, "allrow": 4443, "type": "text", "inside": ""}
{"page": 162, "allrow": 4444, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 162, "allrow": 4445, "type": "excel", "inside": "['中介费用、咨询费', '', '10,944,085.84', '', '12,819,574.80']"}
{"page": 162, "allrow": 4446, "type": "excel", "inside": "['租赁费', '', '4,232,713.35', '', '5,729,241.19']"}
{"page": 162, "allrow": 4447, "type": "excel", "inside": "['停工损失', '', '66,281,432.18', '', '69,294,679.23']"}
{"page": 162, "allrow": 4448, "type": "excel", "inside": "['其他费用', '', '9,659,243.06', '', '10,782,888.62']"}
{"page": 162, "allrow": 4449, "type": "excel", "inside": "['合计', '458,116,308.60', '', '461,126,486.80', '']"}
{"page": 162, "allrow": 4450, "type": "text", "inside": "其他说明："}
{"page": 162, "allrow": 4451, "type": "text", "inside": "65、研发费用"}
{"page": 162, "allrow": 4452, "type": "text", "inside": "单位：元"}
{"page": 162, "allrow": 4453, "type": "excel", "inside": "['项目', '', '本期发生额', '', '上期发生额']"}
{"page": 162, "allrow": 4454, "type": "excel", "inside": "['职工薪酬', '', '109,242,264.60', '', '76,559,763.02']"}
{"page": 162, "allrow": 4455, "type": "excel", "inside": "['折旧及摊销', '', '48,034,859.39', '', '37,191,083.21']"}
{"page": 162, "allrow": 4456, "type": "excel", "inside": "['物料消耗', '', '112,121,845.06', '', '88,934,497.50']"}
{"page": 162, "allrow": 4457, "type": "excel", "inside": "['燃料动力费用', '', '17,264,821.19', '', '12,348,274.45']"}
{"page": 162, "allrow": 4458, "type": "excel", "inside": "['委托开发费', '', '27,062,800.80', '', '24,151,374.08']"}
{"page": 162, "allrow": 4459, "type": "excel", "inside": "['中介服务费', '', '9,504,155.38', '', '4,811,946.95']"}
{"page": 162, "allrow": 4460, "type": "excel", "inside": "['检测费', '', '430,187.98', '', '1,494,374.18']"}
{"page": 162, "allrow": 4461, "type": "excel", "inside": "['设计费、新药临床试验费', '', '26,856,204.37', '', '16,711,310.36']"}
{"page": 162, "allrow": 4462, "type": "excel", "inside": "['差旅办公费', '', '5,549,053.41', '', '2,932,129.25']"}
{"page": 162, "allrow": 4463, "type": "excel", "inside": "['其他相关费用', '', '3,827,256.64', '', '4,516,023.53']"}
{"page": 162, "allrow": 4464, "type": "excel", "inside": "['合计', '359,893,448.82', '', '269,650,776.53', '']"}
{"page": 162, "allrow": 4465, "type": "text", "inside": "其他说明："}
{"page": 162, "allrow": 4466, "type": "text", "inside": "66、财务费用"}
{"page": 162, "allrow": 4467, "type": "text", "inside": "单位：元"}
{"page": 162, "allrow": 4468, "type": "excel", "inside": "['项目', '', '本期发生额', '', '上期发生额']"}
{"page": 162, "allrow": 4469, "type": "excel", "inside": "['利息支出', '', '30,151,895.95', '', '42,006,549.96']"}
{"page": 162, "allrow": 4470, "type": "excel", "inside": "['减：利息收入', '', '7,290,382.10', '', '5,366,962.74']"}
{"page": 162, "allrow": 4471, "type": "excel", "inside": "['汇兑损益', '', '-11,626,671.09', '', '-35,172,713.58']"}
{"page": 162, "allrow": 4472, "type": "excel", "inside": "['手续费', '', '1,624,332.98', '', '971,591.62']"}
{"page": 162, "allrow": 4473, "type": "excel", "inside": "['合计', '12,859,175.74', '', '2,438,465.26', '']"}
{"page": 162, "allrow": 4474, "type": "text", "inside": "其他说明："}
{"page": 162, "allrow": 4475, "type": "页脚", "inside": "162"}
{"page": 163, "allrow": 4476, "type": "text", "inside": ""}
{"page": 163, "allrow": 4477, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 163, "allrow": 4478, "type": "text", "inside": "67、其他收益"}
{"page": 163, "allrow": 4479, "type": "text", "inside": "单位：元"}
{"page": 163, "allrow": 4480, "type": "excel", "inside": "['产生其他收益的来源', '本期发生额', '上期发生额']"}
{"page": 163, "allrow": 4481, "type": "excel", "inside": "['税收返还', '', '7,593,697.87']"}
{"page": 163, "allrow": 4482, "type": "excel", "inside": "['创业团队专项补贴资金', '1,331,533.02', '910,000.00']"}
{"page": 163, "allrow": 4483, "type": "excel", "inside": "['产业发展基金设备补助', '59,000.00', '59,000.00']"}
{"page": 163, "allrow": 4484, "type": "excel", "inside": "['研发设备购置补助', '400,000.00', '400,000.00']"}
{"page": 163, "allrow": 4485, "type": "excel", "inside": "['扶持基金', '574,427.00', '574,427.00']"}
{"page": 163, "allrow": 4486, "type": "excel", "inside": "['工业强基技术改造项目设备补助', '50,000.00', '50,000.00']"}
{"page": 163, "allrow": 4487, "type": "excel", "inside": "['工业企业技术改造和技术创新财政奖励资金', '227,000.00', '227,000.00']"}
{"page": 163, "allrow": 4488, "type": "excel", "inside": "['工业企业技术改造和技术创新奖励', '148,571.43', '148,571.42']"}
{"page": 163, "allrow": 4489, "type": "excel", "inside": "['工业转型升级财政资金补助款', '105,000.00', '105,000.00']"}
{"page": 163, "allrow": 4490, "type": "excel", "inside": "['头孢克肟原料药技术改造项目专项资金', '100,000.00', '100,000.00']"}
{"page": 163, "allrow": 4491, "type": "excel", "inside": "['工业企业技术改造奖励', '82,000.00', '82,000.00']"}
{"page": 163, "allrow": 4492, "type": "excel", "inside": "['暗流式隔膜压滤机改造项目补助', '50,000.00', '50,000.00']"}
{"page": 163, "allrow": 4493, "type": "excel", "inside": "['过滤车间建设项目补助', '116,000.00', '116,000.00']"}
{"page": 163, "allrow": 4494, "type": "excel", "inside": "['生物制药技术改造项目', '116,000.00', '116,000.00']"}
{"page": 163, "allrow": 4495, "type": "excel", "inside": "['泰乐菌素专项补贴资金', '100,000.00', '100,000.00']"}
{"page": 163, "allrow": 4496, "type": "excel", "inside": "['吉他霉素专项补贴资金', '753,500.00', '753,500.00']"}
{"page": 163, "allrow": 4497, "type": "excel", "inside": "['生物发酵能量系统补助', '266,666.66', '266,666.66']"}
{"page": 163, "allrow": 4498, "type": "excel", "inside": "['盐酸美金刚原料药及制剂等技术改造项目补助', '953,695.00', '1,322,500.00']"}
{"page": 163, "allrow": 4499, "type": "excel", "inside": "['固体制剂车间及仓储装备自动化技改项目', '133,000.00', '']"}
{"page": 163, "allrow": 4500, "type": "excel", "inside": "['制剂国际化发展能力建设项目', '5,350,000.00', '']"}
{"page": 163, "allrow": 4501, "type": "excel", "inside": "['冻干粉针生产线项目专项资金', '2,000.00', '279,000.00']"}
{"page": 163, "allrow": 4502, "type": "excel", "inside": "['金刚烷胺原料药产业化补贴', '587,500.00', '587,500.00']"}
{"page": 163, "allrow": 4503, "type": "excel", "inside": "['盐酸左氧氟沙星胶囊生产线建设项目', '768,000.00', '768,000.00']"}
{"page": 163, "allrow": 4504, "type": "excel", "inside": "['盐酸金刚乙胺复方甲麻口服液等补贴款', '787,500.00', '787,500.00']"}
{"page": 163, "allrow": 4505, "type": "excel", "inside": "['治伤软膏生产线建设项目补助', '87,500.00', '87,500.00']"}
{"page": 163, "allrow": 4506, "type": "excel", "inside": "['D-乙脂项目补助', '500,000.00', '500,000.00']"}
{"page": 163, "allrow": 4507, "type": "excel", "inside": "['青霉素口服制剂技改项目补助', '127,530.00', '127,530.00']"}
{"page": 163, "allrow": 4508, "type": "text", "inside": ""}
{"page": 163, "allrow": 4509, "type": "页脚", "inside": "163"}
{"page": 164, "allrow": 4510, "type": "text", "inside": ""}
{"page": 164, "allrow": 4511, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 164, "allrow": 4512, "type": "excel", "inside": "['头孢注射、口服制剂和青霉素口服制剂项目补助', '230,000.00', '230,000.00']"}
{"page": 164, "allrow": 4513, "type": "excel", "inside": "['右旋糖酐铁生产线项目补助', '168,571.43', '168,571.43']"}
{"page": 164, "allrow": 4514, "type": "excel", "inside": "['L-丝氨酸项目补助', '1,100,000.00', '1,100,000.00']"}
{"page": 164, "allrow": 4515, "type": "excel", "inside": "['工业企业技术改造和技术创新项目', '136,000.00', '136,000.00']"}
{"page": 164, "allrow": 4516, "type": "excel", "inside": "['能量系统优化节能技改项目补助', '717,500.00', '717,500.00']"}
{"page": 164, "allrow": 4517, "type": "excel", "inside": "['葡聚铁体技术改造项目补助', '305,714.29', '305,714.28']"}
{"page": 164, "allrow": 4518, "type": "excel", "inside": "['达诺沙星技改项目补助', '270,000.00', '270,000.00']"}
{"page": 164, "allrow": 4519, "type": "excel", "inside": "['美他沙酮原料项目补助', '142,857.14', '142,857.14']"}
{"page": 164, "allrow": 4520, "type": "excel", "inside": "['洛索洛芬原料项目补助', '102,000.00', '102,000.00']"}
{"page": 164, "allrow": 4521, "type": "excel", "inside": "['替卡格雷中间体技术改造项目', '165,714.27', '165,714.30']"}
{"page": 164, "allrow": 4522, "type": "excel", "inside": "['原料药多功能车间项目', '482,857.14', '']"}
{"page": 164, "allrow": 4523, "type": "excel", "inside": "['其他与资产相关的政府补助', '1,871,269.19', '1,317,571.43']"}
{"page": 164, "allrow": 4524, "type": "excel", "inside": "['重大新药创制-索法地尔项目补助', '', '2,800,000.00']"}
{"page": 164, "allrow": 4525, "type": "excel", "inside": "['抗老年痴呆项目盐酸美金刚研发项目补助', '', '1,240,200.00']"}
{"page": 164, "allrow": 4526, "type": "excel", "inside": "['重点医药企业奖励资金', '38,835,535.35', '23,920,000.00']"}
{"page": 164, "allrow": 4527, "type": "excel", "inside": "['科技经费补助', '4,414,400.00', '1,743,000.00']"}
{"page": 164, "allrow": 4528, "type": "excel", "inside": "['中小企业扶持和科技发展专项资金', '', '1,800,000.00']"}
{"page": 164, "allrow": 4529, "type": "excel", "inside": "['省级科技型中小企业扶持和科技发展专项资金', '', '600,000.00']"}
{"page": 164, "allrow": 4530, "type": "excel", "inside": "['出口信用保险补贴', '2,334,600.00', '3,724,200.00']"}
{"page": 164, "allrow": 4531, "type": "excel", "inside": "['产品及技术出口补助', '1,274,159.79', '']"}
{"page": 164, "allrow": 4532, "type": "excel", "inside": "['出口超基数奖励', '1,885,600.00', '1,329,700.00']"}
{"page": 164, "allrow": 4533, "type": "excel", "inside": "['研发投入补助', '', '923,100.00']"}
{"page": 164, "allrow": 4534, "type": "excel", "inside": "['扶持开放型经济专项资金', '', '1,383,700.00']"}
{"page": 164, "allrow": 4535, "type": "excel", "inside": "['境外展会补贴', '1,600,500.00', '852,800.00']"}
{"page": 164, "allrow": 4536, "type": "excel", "inside": "['小微企业升级奖励资金', '', '770,000.00']"}
{"page": 164, "allrow": 4537, "type": "excel", "inside": "['院士专家工作站建设补助', '', '700,000.00']"}
{"page": 164, "allrow": 4538, "type": "excel", "inside": "['医药企业创新营销模式奖励', '3,340,000.00', '']"}
{"page": 164, "allrow": 4539, "type": "excel", "inside": "['两化融合管理奖励', '', '400,000.00']"}
{"page": 164, "allrow": 4540, "type": "excel", "inside": "['市局大气污染防治综合补贴资金', '', '260,000.00']"}
{"page": 164, "allrow": 4541, "type": "excel", "inside": "['支持开放型经济参展补助资金', '', '226,000.00']"}
{"page": 164, "allrow": 4542, "type": "excel", "inside": "['技术改造和技术创新项目财政奖励', '', '220,000.00']"}
{"page": 164, "allrow": 4543, "type": "excel", "inside": "['社保补贴', '6,076,731.13', '212,170.96']"}
{"page": 164, "allrow": 4544, "type": "text", "inside": ""}
{"page": 164, "allrow": 4545, "type": "页脚", "inside": "164"}
{"page": 165, "allrow": 4546, "type": "text", "inside": ""}
{"page": 165, "allrow": 4547, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 165, "allrow": 4548, "type": "excel", "inside": "['滨海产业领军人才（团队）资助经费', '', '200,000.00']"}
{"page": 165, "allrow": 4549, "type": "excel", "inside": "['2015-2017年科技成果转化后补助项目', '', '200,000.00']"}
{"page": 165, "allrow": 4550, "type": "excel", "inside": "['鸢都产业领军人才奖励', '', '200,000.00']"}
{"page": 165, "allrow": 4551, "type": "excel", "inside": "['2017年度节电示范和节电先进企业奖励资金', '', '200,000.00']"}
{"page": 165, "allrow": 4552, "type": "excel", "inside": "['2018年东阳市振兴实体经济财政专项激励资金', '', '120,000.00']"}
{"page": 165, "allrow": 4553, "type": "excel", "inside": "['稳岗补贴', '2,135,002.64', '513,971.01']"}
{"page": 165, "allrow": 4554, "type": "excel", "inside": "['引进海外工程师企业补助', '', '283,500.00']"}
{"page": 165, "allrow": 4555, "type": "excel", "inside": "['专利补助', '253,128.00', '330,740.00']"}
{"page": 165, "allrow": 4556, "type": "excel", "inside": "['增值税优惠减免', '302,250.00', '']"}
{"page": 165, "allrow": 4557, "type": "excel", "inside": "['2017年东阳市振兴实体经济财政专项激励', '', '160,000.00']"}
{"page": 165, "allrow": 4558, "type": "excel", "inside": "['2017年度商务促进财政专项资金', '', '541,000.00']"}
{"page": 165, "allrow": 4559, "type": "excel", "inside": "['2017年度医药产业发展奖励', '', '500,000.00']"}
{"page": 165, "allrow": 4560, "type": "excel", "inside": "['2017年度优秀工业新产品项目奖励资金', '', '200,000.00']"}
{"page": 165, "allrow": 4561, "type": "excel", "inside": "['2018年省工业和信息化发展财政专项资金', '', '150,000.00']"}
{"page": 165, "allrow": 4562, "type": "excel", "inside": "['其他与收益相关的政府补助', '7,487,982.78', '1,814,399.53']"}
{"page": 165, "allrow": 4563, "type": "excel", "inside": "['合计', '89,408,796.26', '69,285,803.03']"}
{"page": 165, "allrow": 4564, "type": "text", "inside": "68、投资收益"}
{"page": 165, "allrow": 4565, "type": "text", "inside": "单位：元"}
{"page": 165, "allrow": 4566, "type": "excel", "inside": "['项目', '', '本期发生额', '', '上期发生额']"}
{"page": 165, "allrow": 4567, "type": "excel", "inside": "['权益法核算的长期股权投资收益', '', '31,142,884.82', '', '16,007,148.92']"}
{"page": 165, "allrow": 4568, "type": "excel", "inside": "['处置长期股权投资产生的投资收益', '', '', '', '663,100.10']"}
{"page": 165, "allrow": 4569, "type": "excel", "inside": "['衍生金融工具取得的投资收益', '', '-53,534,040.29', '', '-5,185,404.44']"}
{"page": 165, "allrow": 4570, "type": "excel", "inside": "['理财产品收益', '', '1,657,997.68', '', '1,981,245.07']"}
{"page": 165, "allrow": 4571, "type": "excel", "inside": "['合计', '-20,733,157.79', '', '13,466,089.65', '']"}
{"page": 165, "allrow": 4572, "type": "text", "inside": "其他说明："}
{"page": 165, "allrow": 4573, "type": "text", "inside": "69、净敞口套期收益"}
{"page": 165, "allrow": 4574, "type": "text", "inside": "单位：元"}
{"page": 165, "allrow": 4575, "type": "excel", "inside": "['项目', '本期发生额', '上期发生额']"}
{"page": 165, "allrow": 4576, "type": "text", "inside": ""}
{"page": 165, "allrow": 4577, "type": "页脚", "inside": "165"}
{"page": 166, "allrow": 4578, "type": "text", "inside": ""}
{"page": 166, "allrow": 4579, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 166, "allrow": 4580, "type": "text", "inside": "其他说明："}
{"page": 166, "allrow": 4581, "type": "text", "inside": "70、公允价值变动收益"}
{"page": 166, "allrow": 4582, "type": "text", "inside": "单位：元"}
{"page": 166, "allrow": 4583, "type": "excel", "inside": "['产生公允价值变动收益的来源', '', '本期发生额', '', '上期发生额']"}
{"page": 166, "allrow": 4584, "type": "excel", "inside": "['交易性金融资产', '', '3,858,356.17', '', '-4,180,258.86']"}
{"page": 166, "allrow": 4585, "type": "excel", "inside": "['其中：衍生金融工具产生的公允价值变动收益', '', '', '', '']"}
{"page": 166, "allrow": 4586, "type": "excel", "inside": "['交易性金融负债', '', '-13,744,886.04', '', '-2,486,145.90']"}
{"page": 166, "allrow": 4587, "type": "excel", "inside": "['按公允价值计量的投资性房地产', '', '', '', '']"}
{"page": 166, "allrow": 4588, "type": "excel", "inside": "['合计', '-9,886,529.87', '', '-6,666,404.76', '']"}
{"page": 166, "allrow": 4589, "type": "text", "inside": "其他说明："}
{"page": 166, "allrow": 4590, "type": "text", "inside": "71、信用减值损失"}
{"page": 166, "allrow": 4591, "type": "text", "inside": "单位：元"}
{"page": 166, "allrow": 4592, "type": "excel", "inside": "['项目', '', '本期发生额', '上期发生额']"}
{"page": 166, "allrow": 4593, "type": "excel", "inside": "['坏账损失', '', '318,297.90', '']"}
{"page": 166, "allrow": 4594, "type": "excel", "inside": "['合计', '318,297.90', '', '']"}
{"page": 166, "allrow": 4595, "type": "text", "inside": ""}
{"page": 166, "allrow": 4596, "type": "text", "inside": "其他说明："}
{"page": 166, "allrow": 4597, "type": "text", "inside": "72、资产减值损失"}
{"page": 166, "allrow": 4598, "type": "text", "inside": "是否已执行新收入准则"}
{"page": 166, "allrow": 4599, "type": "text", "inside": "□是√否"}
{"page": 166, "allrow": 4600, "type": "text", "inside": "单位：元"}
{"page": 166, "allrow": 4601, "type": "excel", "inside": "['项目', '本期发生额', '上期发生额']"}
{"page": 166, "allrow": 4602, "type": "excel", "inside": "['一、坏账损失', '', '-9,346,730.98']"}
{"page": 166, "allrow": 4603, "type": "excel", "inside": "['二、存货跌价损失', '-33,504,454.56', '-27,631,630.79']"}
{"page": 166, "allrow": 4604, "type": "excel", "inside": "['十三、商誉减值损失', '-9,194,311.26', '']"}
{"page": 166, "allrow": 4605, "type": "excel", "inside": "['合计', '-42,698,765.82', '-36,978,361.77']"}
{"page": 166, "allrow": 4606, "type": "text", "inside": "其他说明："}
{"page": 166, "allrow": 4607, "type": "text", "inside": "73、资产处置收益"}
{"page": 166, "allrow": 4608, "type": "text", "inside": "单位：元"}
{"page": 166, "allrow": 4609, "type": "excel", "inside": "['资产处置收益的来源', '本期发生额', '上期发生额']"}
{"page": 166, "allrow": 4610, "type": "text", "inside": ""}
{"page": 166, "allrow": 4611, "type": "页脚", "inside": "166"}
{"page": 167, "allrow": 4612, "type": "text", "inside": ""}
{"page": 167, "allrow": 4613, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 167, "allrow": 4614, "type": "excel", "inside": "['固定资产处置损益', '4,234,859.77', '1,131,580.16']"}
{"page": 167, "allrow": 4615, "type": "excel", "inside": "['无形资产处置损益', '', '2,761,888.69']"}
{"page": 167, "allrow": 4616, "type": "excel", "inside": "['合计', '4,234,859.77', '3,893,468.85']"}
{"page": 167, "allrow": 4617, "type": "text", "inside": "74、营业外收入"}
{"page": 167, "allrow": 4618, "type": "text", "inside": "单位：元"}
{"page": 167, "allrow": 4619, "type": "excel", "inside": "['', '', '', '', '', '计入当期非经常性损益的金']"}
{"page": 167, "allrow": 4620, "type": "excel", "inside": "['项目', '', '本期发生额', '', '上期发生额', '额']"}
{"page": 167, "allrow": 4621, "type": "excel", "inside": "['政府补助', '', '400,000.00', '', '934,900.00', '400,000.00']"}
{"page": 167, "allrow": 4622, "type": "excel", "inside": "['其他', '', '1,171,992.53', '', '1,270,743.36', '1,171,992.53']"}
{"page": 167, "allrow": 4623, "type": "excel", "inside": "['合计', '1,571,992.53', '', '2,205,643.36', '', '1,571,992.53']"}
{"page": 167, "allrow": 4624, "type": "text", "inside": "计入当期损益的政府补助："}
{"page": 167, "allrow": 4625, "type": "text", "inside": "单位：元"}
{"page": 167, "allrow": 4626, "type": "excel", "inside": "['', '', '', '', '补贴是否', '是否特殊', '本期发生', '上期发生', '与资产相']"}
{"page": 167, "allrow": 4627, "type": "excel", "inside": "['补助项目', '发放主体', '发放原因', '性质类型', '影响当年', '补贴', '金额', '金额', '关/与收益']"}
{"page": 167, "allrow": 4628, "type": "excel", "inside": "['', '', '', '', '盈亏', '', '', '', '相关']"}
{"page": 167, "allrow": 4629, "type": "excel", "inside": "['2017年度资本市场奖励资金', '', '', '', '', '', '', '424,900.00', '与收益相关']"}
{"page": 167, "allrow": 4630, "type": "excel", "inside": "['2017年度税收十强政府特别奖', '', '', '', '', '', '', '400,000.00', '与收益相关']"}
{"page": 167, "allrow": 4631, "type": "excel", "inside": "['东阳市\"职工三满意\"先进单位奖励', '', '', '', '', '', '', '10,000.00', '与收益相关']"}
{"page": 167, "allrow": 4632, "type": "excel", "inside": "['浙江省AAA守合同重信用企业奖励', '', '', '', '', '', '', '100,000.00', '与收益相关']"}
{"page": 167, "allrow": 4633, "type": "excel", "inside": "['工业强市突出贡献奖励', '', '', '', '', '', '400,000.00', '', '与收益相关']"}
{"page": 167, "allrow": 4634, "type": "excel", "inside": "['合计', '', '', '', '', '', '400,000.00', '934,900.00', '']"}
{"page": 167, "allrow": 4635, "type": "text", "inside": ""}
{"page": 167, "allrow": 4636, "type": "text", "inside": "其他说明："}
{"page": 167, "allrow": 4637, "type": "页脚", "inside": "167"}
{"page": 168, "allrow": 4638, "type": "text", "inside": ""}
{"page": 168, "allrow": 4639, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 168, "allrow": 4640, "type": "text", "inside": "75、营业外支出"}
{"page": 168, "allrow": 4641, "type": "text", "inside": "单位：元"}
{"page": 168, "allrow": 4642, "type": "excel", "inside": "['', '', '', '', '', '计入当期非经常性损益的金']"}
{"page": 168, "allrow": 4643, "type": "excel", "inside": "['项目', '', '本期发生额', '', '上期发生额', '额']"}
{"page": 168, "allrow": 4644, "type": "excel", "inside": "['罚款、赔偿款支出', '', '1,767,009.83', '', '610,496.21', '1,767,009.83']"}
{"page": 168, "allrow": 4645, "type": "excel", "inside": "['非流动资产报废损失合计', '', '10,172,986.67', '', '29,868,366.27', '10,172,986.67']"}
{"page": 168, "allrow": 4646, "type": "excel", "inside": "['其中：固定资产报废损失', '', '10,172,986.67', '', '29,868,366.27', '10,172,986.67']"}
{"page": 168, "allrow": 4647, "type": "excel", "inside": "['捐赠支出', '', '35,331.98', '', '45,741.00', '35,331.98']"}
{"page": 168, "allrow": 4648, "type": "excel", "inside": "['其他', '', '24,804.39', '', '22,528.82', '24,804.39']"}
{"page": 168, "allrow": 4649, "type": "excel", "inside": "['合计', '12,000,132.87', '', '30,547,132.30', '', '12,000,132.87']"}
{"page": 168, "allrow": 4650, "type": "text", "inside": "其他说明："}
{"page": 168, "allrow": 4651, "type": "text", "inside": "76、所得税费用"}
{"page": 168, "allrow": 4652, "type": "text", "inside": "（1）所得税费用表"}
{"page": 168, "allrow": 4653, "type": "text", "inside": "单位：元"}
{"page": 168, "allrow": 4654, "type": "excel", "inside": "['项目', '', '本期发生额', '', '上期发生额']"}
{"page": 168, "allrow": 4655, "type": "excel", "inside": "['当期所得税费用', '', '88,103,080.63', '', '79,966,762.11']"}
{"page": 168, "allrow": 4656, "type": "excel", "inside": "['递延所得税费用', '', '-7,777,583.57', '', '11,663,451.65']"}
{"page": 168, "allrow": 4657, "type": "excel", "inside": "['合计', '80,325,497.06', '', '91,630,213.76', '']"}
{"page": 168, "allrow": 4658, "type": "text", "inside": "（2）会计利润与所得税费用调整过程"}
{"page": 168, "allrow": 4659, "type": "text", "inside": "单位：元"}
{"page": 168, "allrow": 4660, "type": "excel", "inside": "['项目', '', '本期发生额']"}
{"page": 168, "allrow": 4661, "type": "excel", "inside": "['利润总额', '633,726,258.48', '']"}
{"page": 168, "allrow": 4662, "type": "excel", "inside": "['按法定/适用税率计算的所得税费用', '', '158,431,564.65']"}
{"page": 168, "allrow": 4663, "type": "excel", "inside": "['子公司适用不同税率的影响', '', '-45,505,286.83']"}
{"page": 168, "allrow": 4664, "type": "excel", "inside": "['调整以前期间所得税的影响', '', '2,967,965.09']"}
{"page": 168, "allrow": 4665, "type": "excel", "inside": "['非应税收入的影响', '', '-4,675,135.58']"}
{"page": 168, "allrow": 4666, "type": "excel", "inside": "['不可抵扣的成本、费用和损失的影响', '', '1,820,027.18']"}
{"page": 168, "allrow": 4667, "type": "excel", "inside": "['使用前期未确认递延所得税资产的可抵扣亏损的影响', '', '-6,319,012.92']"}
{"page": 168, "allrow": 4668, "type": "excel", "inside": "['本期未确认递延所得税资产的可抵扣暂时性差异或可抵扣亏损的影响', '', '12,647,827.27']"}
{"page": 168, "allrow": 4669, "type": "excel", "inside": "['额外可扣除费用的影响', '', '-39,042,451.80']"}
{"page": 168, "allrow": 4670, "type": "text", "inside": ""}
{"page": 168, "allrow": 4671, "type": "页脚", "inside": "168"}
{"page": 169, "allrow": 4672, "type": "text", "inside": ""}
{"page": 169, "allrow": 4673, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 169, "allrow": 4674, "type": "excel", "inside": "['所得税费用', '80,325,497.06']"}
{"page": 169, "allrow": 4675, "type": "text", "inside": "其他说明"}
{"page": 169, "allrow": 4676, "type": "text", "inside": "77、其他综合收益"}
{"page": 169, "allrow": 4677, "type": "text", "inside": "详见附注七-合并财务报表项目注释57。"}
{"page": 169, "allrow": 4678, "type": "text", "inside": "78、现金流量表项目"}
{"page": 169, "allrow": 4679, "type": "text", "inside": "（1）收到的其他与经营活动有关的现金"}
{"page": 169, "allrow": 4680, "type": "text", "inside": "单位：元"}
{"page": 169, "allrow": 4681, "type": "excel", "inside": "['项目', '', '本期发生额', '', '上期发生额']"}
{"page": 169, "allrow": 4682, "type": "excel", "inside": "['利息收入', '', '7,290,382.10', '', '5,366,962.74']"}
{"page": 169, "allrow": 4683, "type": "excel", "inside": "['政府补助', '', '79,558,089.69', '', '62,870,791.50']"}
{"page": 169, "allrow": 4684, "type": "excel", "inside": "['押金、保证金及往来款', '', '16,012,805.74', '', '28,697,677.63']"}
{"page": 169, "allrow": 4685, "type": "excel", "inside": "['其他营业外收入', '', '1,171,992.53', '', '1,058,076.77']"}
{"page": 169, "allrow": 4686, "type": "excel", "inside": "['合计', '104,033,270.06', '', '97,993,508.64', '']"}
{"page": 169, "allrow": 4687, "type": "text", "inside": "收到的其他与经营活动有关的现金说明："}
{"page": 169, "allrow": 4688, "type": "text", "inside": "（2）支付的其他与经营活动有关的现金"}
{"page": 169, "allrow": 4689, "type": "text", "inside": "单位：元"}
{"page": 169, "allrow": 4690, "type": "excel", "inside": "['项目', '本期发生额', '上期发生额']"}
{"page": 169, "allrow": 4691, "type": "excel", "inside": "['运输费、港杂费、装卸费', '81,518,113.62', '65,475,578.79']"}
{"page": 169, "allrow": 4692, "type": "excel", "inside": "['差旅费', '18,648,517.57', '23,216,776.98']"}
{"page": 169, "allrow": 4693, "type": "excel", "inside": "['维修费', '9,492,833.99', '9,675,449.54']"}
{"page": 169, "allrow": 4694, "type": "excel", "inside": "['环保排污费', '16,389,679.42', '25,595,072.63']"}
{"page": 169, "allrow": 4695, "type": "excel", "inside": "['广告费、宣传费', '8,690,350.42', '10,749,109.95']"}
{"page": 169, "allrow": 4696, "type": "excel", "inside": "['市场营销服务费', '602,073,922.81', '525,938,367.35']"}
{"page": 169, "allrow": 4697, "type": "excel", "inside": "['技术开发费', '87,752,140.94', '80,504,230.38']"}
{"page": 169, "allrow": 4698, "type": "excel", "inside": "['办公费', '13,074,803.84', '11,367,487.94']"}
{"page": 169, "allrow": 4699, "type": "excel", "inside": "['车辆费用', '7,657,544.81', '7,626,283.17']"}
{"page": 169, "allrow": 4700, "type": "excel", "inside": "['中介机构费、咨询费', '12,030,834.75', '13,722,891.56']"}
{"page": 169, "allrow": 4701, "type": "excel", "inside": "['交际应酬费', '16,258,596.88', '21,667,398.02']"}
{"page": 169, "allrow": 4702, "type": "excel", "inside": "['房租', '4,468,962.94', '6,142,038.81']"}
{"page": 169, "allrow": 4703, "type": "excel", "inside": "['押金、保证金及往来款', '15,292,429.81', '21,992,536.56']"}
{"page": 169, "allrow": 4704, "type": "excel", "inside": "['银行手续费', '1,624,332.98', '971,591.62']"}
{"page": 169, "allrow": 4705, "type": "text", "inside": ""}
{"page": 169, "allrow": 4706, "type": "页脚", "inside": "169"}
{"page": 170, "allrow": 4707, "type": "text", "inside": ""}
{"page": 170, "allrow": 4708, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 170, "allrow": 4709, "type": "excel", "inside": "['其他费用及付现营业外支出', '', '12,974,484.73', '', '12,636,566.58']"}
{"page": 170, "allrow": 4710, "type": "excel", "inside": "['合计', '907,947,549.51', '', '837,281,379.88', '']"}
{"page": 170, "allrow": 4711, "type": "text", "inside": "支付的其他与经营活动有关的现金说明："}
{"page": 170, "allrow": 4712, "type": "text", "inside": "（3）收到的其他与投资活动有关的现金"}
{"page": 170, "allrow": 4713, "type": "text", "inside": "单位：元"}
{"page": 170, "allrow": 4714, "type": "excel", "inside": "['项目', '本期发生额', '上期发生额']"}
{"page": 170, "allrow": 4715, "type": "text", "inside": ""}
{"page": 170, "allrow": 4716, "type": "text", "inside": "收到的其他与投资活动有关的现金说明："}
{"page": 170, "allrow": 4717, "type": "text", "inside": "（4）支付的其他与投资活动有关的现金"}
{"page": 170, "allrow": 4718, "type": "text", "inside": "单位：元"}
{"page": 170, "allrow": 4719, "type": "excel", "inside": "['项目', '', '本期发生额', '', '上期发生额']"}
{"page": 170, "allrow": 4720, "type": "excel", "inside": "['人民币远期结售汇保证金', '', '13,924,899.32', '', '10,708,849.24']"}
{"page": 170, "allrow": 4721, "type": "excel", "inside": "['人民币远期结汇损失', '', '53,534,040.29', '', '5,185,404.44']"}
{"page": 170, "allrow": 4722, "type": "excel", "inside": "['合计', '67,458,939.61', '', '15,894,253.68', '']"}
{"page": 170, "allrow": 4723, "type": "text", "inside": "支付的其他与投资活动有关的现金说明："}
{"page": 170, "allrow": 4724, "type": "text", "inside": "（5）收到的其他与筹资活动有关的现金"}
{"page": 170, "allrow": 4725, "type": "text", "inside": "单位：元"}
{"page": 170, "allrow": 4726, "type": "excel", "inside": "['项目', '本期发生额', '上期发生额']"}
{"page": 170, "allrow": 4727, "type": "text", "inside": ""}
{"page": 170, "allrow": 4728, "type": "text", "inside": "收到的其他与筹资活动有关的现金说明："}
{"page": 170, "allrow": 4729, "type": "text", "inside": "（6）支付的其他与筹资活动有关的现金"}
{"page": 170, "allrow": 4730, "type": "text", "inside": "单位：元"}
{"page": 170, "allrow": 4731, "type": "excel", "inside": "['项目', '本期发生额', '上期发生额']"}
{"page": 170, "allrow": 4732, "type": "text", "inside": ""}
{"page": 170, "allrow": 4733, "type": "text", "inside": "支付的其他与筹资活动有关的现金说明："}
{"page": 170, "allrow": 4734, "type": "text", "inside": "79、现金流量表补充资料"}
{"page": 170, "allrow": 4735, "type": "text", "inside": "（1）现金流量表补充资料"}
{"page": 170, "allrow": 4736, "type": "text", "inside": "单位：元"}
{"page": 170, "allrow": 4737, "type": "excel", "inside": "['补充资料', '', '本期金额', '', '上期金额']"}
{"page": 170, "allrow": 4738, "type": "excel", "inside": "['1．将净利润调节为经营活动现金流量：', '', '--', '', '--']"}
{"page": 170, "allrow": 4739, "type": "excel", "inside": "['净利润', '553,400,761.42', '', '370,561,028.28', '']"}
{"page": 170, "allrow": 4740, "type": "text", "inside": ""}
{"page": 170, "allrow": 4741, "type": "页脚", "inside": "170"}
{"page": 171, "allrow": 4742, "type": "text", "inside": ""}
{"page": 171, "allrow": 4743, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 171, "allrow": 4744, "type": "excel", "inside": "['加：资产减值准备', '', '42,380,467.92', '', '36,978,361.77']"}
{"page": 171, "allrow": 4745, "type": "excel", "inside": "['固定资产折旧、油气资产折耗、生产性生物资产折旧', '', '341,598,564.37', '', '312,669,446.73']"}
{"page": 171, "allrow": 4746, "type": "excel", "inside": "['无形资产摊销', '', '11,948,244.53', '', '16,738,799.96']"}
{"page": 171, "allrow": 4747, "type": "excel", "inside": "['长期待摊费用摊销', '', '3,312,885.64', '', '1,096,611.12']"}
{"page": 171, "allrow": 4748, "type": "excel", "inside": "['处置固定资产、无形资产和其他长期资产的损失（收益以“－”号填列）', '', '-4,234,859.77', '', '-3,893,468.85']"}
{"page": 171, "allrow": 4749, "type": "excel", "inside": "['固定资产报废损失（收益以“－”号填列）', '', '10,172,986.67', '', '29,868,366.27']"}
{"page": 171, "allrow": 4750, "type": "excel", "inside": "['公允价值变动损失（收益以“－”号填列）', '', '9,886,529.87', '', '6,666,404.76']"}
{"page": 171, "allrow": 4751, "type": "excel", "inside": "['财务费用（收益以“－”号填列）', '', '10,154,538.81', '', '34,734,772.53']"}
{"page": 171, "allrow": 4752, "type": "excel", "inside": "['投资损失（收益以“－”号填列）', '', '20,733,157.79', '', '-13,466,089.65']"}
{"page": 171, "allrow": 4753, "type": "excel", "inside": "['递延所得税资产减少（增加以“－”号填列）', '', '-8,288,180.80', '', '12,776,672.57']"}
{"page": 171, "allrow": 4754, "type": "excel", "inside": "['递延所得税负债增加（减少以“－”号填列）', '', '510,597.23', '', '-1,113,220.92']"}
{"page": 171, "allrow": 4755, "type": "excel", "inside": "['存货的减少（增加以“－”号填列）', '', '-124,903,587.18', '', '-207,527,926.52']"}
{"page": 171, "allrow": 4756, "type": "excel", "inside": "['经营性应收项目的减少（增加以“－”号填列）', '', '-294,393,611.23', '', '-58,911,566.64']"}
{"page": 171, "allrow": 4757, "type": "excel", "inside": "['经营性应付项目的增加（减少以“－”号填列）', '', '787,787,695.09', '', '295,642,892.55']"}
{"page": 171, "allrow": 4758, "type": "excel", "inside": "['经营活动产生的现金流量净额', '', '1,360,066,190.36', '', '832,821,083.96']"}
{"page": 171, "allrow": 4759, "type": "excel", "inside": "['2．不涉及现金收支的重大投资和筹资活动：', '', '--', '', '--']"}
{"page": 171, "allrow": 4760, "type": "excel", "inside": "['3．现金及现金等价物净变动情况：', '', '--', '', '--']"}
{"page": 171, "allrow": 4761, "type": "excel", "inside": "['现金的期末余额', '', '718,073,340.03', '', '501,720,448.13']"}
{"page": 171, "allrow": 4762, "type": "excel", "inside": "['减：现金的期初余额', '', '501,720,448.13', '', '434,372,780.67']"}
{"page": 171, "allrow": 4763, "type": "excel", "inside": "['现金及现金等价物净增加额', '216,352,891.90', '', '67,347,667.46', '']"}
{"page": 171, "allrow": 4764, "type": "text", "inside": "（2）本期支付的取得子公司的现金净额"}
{"page": 171, "allrow": 4765, "type": "text", "inside": "单位：元"}
{"page": 171, "allrow": 4766, "type": "excel", "inside": "['', '金额']"}
{"page": 171, "allrow": 4767, "type": "excel", "inside": "['其中：', '--']"}
{"page": 171, "allrow": 4768, "type": "excel", "inside": "['其中：', '--']"}
{"page": 171, "allrow": 4769, "type": "excel", "inside": "['其中：', '--']"}
{"page": 171, "allrow": 4770, "type": "text", "inside": ""}
{"page": 171, "allrow": 4771, "type": "页脚", "inside": "171"}
{"page": 172, "allrow": 4772, "type": "text", "inside": ""}
{"page": 172, "allrow": 4773, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 172, "allrow": 4774, "type": "text", "inside": "其他说明："}
{"page": 172, "allrow": 4775, "type": "text", "inside": "（3）本期收到的处置子公司的现金净额"}
{"page": 172, "allrow": 4776, "type": "text", "inside": "单位：元"}
{"page": 172, "allrow": 4777, "type": "excel", "inside": "['', '金额']"}
{"page": 172, "allrow": 4778, "type": "excel", "inside": "['其中：', '--']"}
{"page": 172, "allrow": 4779, "type": "excel", "inside": "['其中：', '--']"}
{"page": 172, "allrow": 4780, "type": "excel", "inside": "['其中：', '--']"}
{"page": 172, "allrow": 4781, "type": "text", "inside": ""}
{"page": 172, "allrow": 4782, "type": "text", "inside": "其他说明："}
{"page": 172, "allrow": 4783, "type": "text", "inside": "（4）现金和现金等价物的构成"}
{"page": 172, "allrow": 4784, "type": "text", "inside": "单位：元"}
{"page": 172, "allrow": 4785, "type": "excel", "inside": "['项目', '', '期末余额', '', '期初余额']"}
{"page": 172, "allrow": 4786, "type": "excel", "inside": "['一、现金', '718,073,340.03', '', '501,720,448.13', '']"}
{"page": 172, "allrow": 4787, "type": "excel", "inside": "['其中：库存现金', '', '81,402.84', '', '216,433.61']"}
{"page": 172, "allrow": 4788, "type": "excel", "inside": "['可随时用于支付的银行存款', '', '717,991,937.19', '', '501,504,014.52']"}
{"page": 172, "allrow": 4789, "type": "excel", "inside": "['三、期末现金及现金等价物余额', '718,073,340.03', '', '501,720,448.13', '']"}
{"page": 172, "allrow": 4790, "type": "text", "inside": "其他说明："}
{"page": 172, "allrow": 4791, "type": "text", "inside": "80、所有者权益变动表项目注释"}
{"page": 172, "allrow": 4792, "type": "text", "inside": "说明对上年期末余额进行调整的“其他”项目名称及调整金额等事项："}
{"page": 172, "allrow": 4793, "type": "text", "inside": "81、所有权或使用权受到限制的资产"}
{"page": 172, "allrow": 4794, "type": "text", "inside": "单位：元"}
{"page": 172, "allrow": 4795, "type": "excel", "inside": "['项目', '期末账面价值', '受限原因']"}
{"page": 172, "allrow": 4796, "type": "excel", "inside": "['货币资金', '317,736,154.02', '保证金']"}
{"page": 172, "allrow": 4797, "type": "excel", "inside": "['固定资产', '62,782,453.27', '抵押']"}
{"page": 172, "allrow": 4798, "type": "excel", "inside": "['无形资产', '85,846,372.32', '抵押']"}
{"page": 172, "allrow": 4799, "type": "excel", "inside": "['交易性金融资产', '310,000,000.00', '质押']"}
{"page": 172, "allrow": 4800, "type": "excel", "inside": "['应收款项融资', '28,130,841.00', '质押']"}
{"page": 172, "allrow": 4801, "type": "excel", "inside": "['合计', '804,495,820.61', '--']"}
{"page": 172, "allrow": 4802, "type": "text", "inside": ""}
{"page": 172, "allrow": 4803, "type": "text", "inside": "其他说明："}
{"page": 172, "allrow": 4804, "type": "页脚", "inside": "172"}
{"page": 173, "allrow": 4805, "type": "text", "inside": ""}
{"page": 173, "allrow": 4806, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 173, "allrow": 4807, "type": "text", "inside": "82、外币货币性项目"}
{"page": 173, "allrow": 4808, "type": "text", "inside": "（1）外币货币性项目"}
{"page": 173, "allrow": 4809, "type": "text", "inside": "单位：元"}
{"page": 173, "allrow": 4810, "type": "excel", "inside": "['项目', '期末外币余额', '折算汇率', '期末折算人民币余额']"}
{"page": 173, "allrow": 4811, "type": "excel", "inside": "['货币资金', '--', '--', '']"}
{"page": 173, "allrow": 4812, "type": "excel", "inside": "['其中：美元', '39,858,571.92', '6.9762', '278,061,369.40']"}
{"page": 173, "allrow": 4813, "type": "excel", "inside": "['欧元', '4,160,927.00', '7.8155', '32,519,724.97']"}
{"page": 173, "allrow": 4814, "type": "excel", "inside": "['港币', '165,318.37', '0.8958', '148,092.20']"}
{"page": 173, "allrow": 4815, "type": "excel", "inside": "['日元', '13,006,500.02', '0.064086', '833,534.56']"}
{"page": 173, "allrow": 4816, "type": "excel", "inside": "['应收账款', '--', '--', '']"}
{"page": 173, "allrow": 4817, "type": "excel", "inside": "['其中：美元', '78,191,744.09', '6.9762', '545,481,245.12']"}
{"page": 173, "allrow": 4818, "type": "excel", "inside": "['欧元', '811,965.00', '7.8155', '6,345,912.46']"}
{"page": 173, "allrow": 4819, "type": "excel", "inside": "['港币', '', '', '']"}
{"page": 173, "allrow": 4820, "type": "excel", "inside": "['应付账款', '', '', '']"}
{"page": 173, "allrow": 4821, "type": "excel", "inside": "['其中：美元', '5,255,614.58', '6.9762', '36,664,218.42']"}
{"page": 173, "allrow": 4822, "type": "excel", "inside": "['欧元', '89,740.00', '7.8155', '701,362.97']"}
{"page": 173, "allrow": 4823, "type": "excel", "inside": "['长期借款', '--', '--', '']"}
{"page": 173, "allrow": 4824, "type": "excel", "inside": "['其中：美元', '', '', '']"}
{"page": 173, "allrow": 4825, "type": "excel", "inside": "['欧元', '', '', '']"}
{"page": 173, "allrow": 4826, "type": "excel", "inside": "['港币', '', '', '']"}
{"page": 173, "allrow": 4827, "type": "text", "inside": ""}
{"page": 173, "allrow": 4828, "type": "text", "inside": "其他说明："}
{"page": 173, "allrow": 4829, "type": "text", "inside": "（2）境外经营实体说明，包括对于重要的境外经营实体，应披露其境外主要经营地、记账本位币及选择依据，记账本位币发生变化的还应披露原因。"}
{"page": 173, "allrow": 4830, "type": "text", "inside": "□适用√不适用"}
{"page": 173, "allrow": 4831, "type": "text", "inside": "83、套期"}
{"page": 173, "allrow": 4832, "type": "text", "inside": "按照套期类别披露套期项目及相关套期工具、被套期风险的定性和定量信息："}
{"page": 173, "allrow": 4833, "type": "text", "inside": "84、政府补助"}
{"page": 173, "allrow": 4834, "type": "text", "inside": "（1）政府补助基本情况"}
{"page": 173, "allrow": 4835, "type": "text", "inside": "单位：元"}
{"page": 173, "allrow": 4836, "type": "页脚", "inside": "173"}
{"page": 174, "allrow": 4837, "type": "text", "inside": ""}
{"page": 174, "allrow": 4838, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 174, "allrow": 4839, "type": "excel", "inside": "['种类', '金额', '列报项目', '计入当期损益的金额']"}
{"page": 174, "allrow": 4840, "type": "excel", "inside": "['本期收到与资产相关', '7,898,200.00', '递延收益、其他收益', '968,534.28']"}
{"page": 174, "allrow": 4841, "type": "excel", "inside": "['本期收到与收益相关', '71,659,889.69', '其他收益、营业外收入', '71,659,889.69']"}
{"page": 174, "allrow": 4842, "type": "text", "inside": "（2）政府补助退回情况"}
{"page": 174, "allrow": 4843, "type": "text", "inside": "□适用√不适用"}
{"page": 174, "allrow": 4844, "type": "text", "inside": "其他说明："}
{"page": 174, "allrow": 4845, "type": "text", "inside": "85、其他"}
{"page": 174, "allrow": 4846, "type": "text", "inside": "八、合并范围的变更"}
{"page": 174, "allrow": 4847, "type": "text", "inside": "1、非同一控制下企业合并"}
{"page": 174, "allrow": 4848, "type": "text", "inside": "（1）本期发生的非同一控制下企业合并"}
{"page": 174, "allrow": 4849, "type": "text", "inside": "单位：元"}
{"page": 174, "allrow": 4850, "type": "excel", "inside": "['', '', '', '', '', '', '', '购买日至', '购买日至']"}
{"page": 174, "allrow": 4851, "type": "excel", "inside": "['被购买方名称', '股权取得时点', '股权取得成本', '股权取得比例', '股权取得方式', '购买日', '购买日的确定依据', '期末被购买方的收', '期末被购买方的净']"}
{"page": 174, "allrow": 4852, "type": "excel", "inside": "['', '', '', '', '', '', '', '入', '利润']"}
{"page": 174, "allrow": 4853, "type": "text", "inside": "其他说明："}
{"page": 174, "allrow": 4854, "type": "text", "inside": "（2）合并成本及商誉"}
{"page": 174, "allrow": 4855, "type": "text", "inside": "单位：元"}
{"page": 174, "allrow": 4856, "type": "excel", "inside": "['合并成本']"}
{"page": 174, "allrow": 4857, "type": "text", "inside": ""}
{"page": 174, "allrow": 4858, "type": "text", "inside": "合并成本公允价值的确定方法、或有对价及其变动的说明："}
{"page": 174, "allrow": 4859, "type": "text", "inside": "大额商誉形成的主要原因："}
{"page": 174, "allrow": 4860, "type": "text", "inside": "其他说明："}
{"page": 174, "allrow": 4861, "type": "text", "inside": "（3）被购买方于购买日可辨认资产、负债"}
{"page": 174, "allrow": 4862, "type": "text", "inside": "单位：元"}
{"page": 174, "allrow": 4863, "type": "excel", "inside": "['购买日公允价值', '购买日账面价值']"}
{"page": 174, "allrow": 4864, "type": "text", "inside": ""}
{"page": 174, "allrow": 4865, "type": "text", "inside": "可辨认资产、负债公允价值的确定方法："}
{"page": 174, "allrow": 4866, "type": "text", "inside": "企业合并中承担的被购买方的或有负债："}
{"page": 174, "allrow": 4867, "type": "text", "inside": "其他说明："}
{"page": 174, "allrow": 4868, "type": "页脚", "inside": "174"}
{"page": 175, "allrow": 4869, "type": "text", "inside": ""}
{"page": 175, "allrow": 4870, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 175, "allrow": 4871, "type": "text", "inside": "（4）购买日之前持有的股权按照公允价值重新计量产生的利得或损失"}
{"page": 175, "allrow": 4872, "type": "text", "inside": "是否存在通过多次交易分步实现企业合并且在报告期内取得控制权的交易"}
{"page": 175, "allrow": 4873, "type": "text", "inside": "□是√否"}
{"page": 175, "allrow": 4874, "type": "text", "inside": "（5）购买日或合并当期期末无法合理确定合并对价或被购买方可辨认资产、负债公允价值的相关说明（6）其他说明"}
{"page": 175, "allrow": 4875, "type": "text", "inside": "2、同一控制下企业合并"}
{"page": 175, "allrow": 4876, "type": "text", "inside": "（1）本期发生的同一控制下企业合并"}
{"page": 175, "allrow": 4877, "type": "text", "inside": "单位：元"}
{"page": 175, "allrow": 4878, "type": "excel", "inside": "['', '企业合并', '构成同一', '', '', '合并当期期初至合', '合并当期期初至合', '比较期间', '比较期间']"}
{"page": 175, "allrow": 4879, "type": "excel", "inside": "['被合并方名称', '中取得的权益比例', '控制下企业合并的', '合并日', '合并日的确定依据', '并日被合并方的收', '并日被合并方的净', '被合并方的收入', '被合并方的净利润']"}
{"page": 175, "allrow": 4880, "type": "excel", "inside": "['', '', '依据', '', '', '入', '利润', '', '']"}
{"page": 175, "allrow": 4881, "type": "excel", "inside": "['', '', '在合并前同受母公', '', '2019年4月28日，康裕保健品完成了股权的工商变更登', '', '', '', '']"}
{"page": 175, "allrow": 4882, "type": "excel", "inside": "['康裕保健品', '100.00%', '司横店集团控股有', '2019年04月28日', '记，公司已支付全部', '0.00', '0.00', '549,666.92', '-5,814.07']"}
{"page": 175, "allrow": 4883, "type": "excel", "inside": "['', '', '限公司控制', '', '对价，公司实际控制康裕保健品财务、生产经营等政策', '', '', '', '']"}
{"page": 175, "allrow": 4884, "type": "text", "inside": ""}
{"page": 175, "allrow": 4885, "type": "text", "inside": "其他说明："}
{"page": 175, "allrow": 4886, "type": "text", "inside": "（2）合并成本"}
{"page": 175, "allrow": 4887, "type": "text", "inside": "单位：元"}
{"page": 175, "allrow": 4888, "type": "excel", "inside": "['合并成本', '']"}
{"page": 175, "allrow": 4889, "type": "excel", "inside": "['--现金', '980,000.00']"}
{"page": 175, "allrow": 4890, "type": "text", "inside": ""}
{"page": 175, "allrow": 4891, "type": "text", "inside": "或有对价及其变动的说明："}
{"page": 175, "allrow": 4892, "type": "text", "inside": "其他说明："}
{"page": 175, "allrow": 4893, "type": "页脚", "inside": "175"}
{"page": 176, "allrow": 4894, "type": "text", "inside": ""}
{"page": 176, "allrow": 4895, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 176, "allrow": 4896, "type": "text", "inside": "（3）合并日被合并方资产、负债的账面价值"}
{"page": 176, "allrow": 4897, "type": "text", "inside": "单位：元"}
{"page": 176, "allrow": 4898, "type": "excel", "inside": "['', '合并日', '上期期末']"}
{"page": 176, "allrow": 4899, "type": "excel", "inside": "['应收款项', '352,639.64', '352,639.64']"}
{"page": 176, "allrow": 4900, "type": "excel", "inside": "['存货', '625,507.95', '625,507.95']"}
{"page": 176, "allrow": 4901, "type": "excel", "inside": "['其他流动资产', '16,967.39', '16,967.39']"}
{"page": 176, "allrow": 4902, "type": "excel", "inside": "['应付款项', '400.00', '400.00']"}
{"page": 176, "allrow": 4903, "type": "excel", "inside": "['其他应付款', '20,160.00', '20,160.00']"}
{"page": 176, "allrow": 4904, "type": "excel", "inside": "['净资产', '974,554.98', '974,554.98']"}
{"page": 176, "allrow": 4905, "type": "excel", "inside": "['取得的净资产', '974,554.98', '974,554.98']"}
{"page": 176, "allrow": 4906, "type": "text", "inside": "企业合并中承担的被合并方的或有负债："}
{"page": 176, "allrow": 4907, "type": "text", "inside": "其他说明："}
{"page": 176, "allrow": 4908, "type": "text", "inside": "3、反向购买"}
{"page": 176, "allrow": 4909, "type": "text", "inside": "交易基本信息、交易构成反向购买的依据、上市公司保留的资产、负债是否构成业务及其依据、合并成本的确定、按照权益性交易处理时调整权益的金额及其计算："}
{"page": 176, "allrow": 4910, "type": "text", "inside": "4、处置子公司"}
{"page": 176, "allrow": 4911, "type": "text", "inside": "是否存在单次处置对子公司投资即丧失控制权的情形"}
{"page": 176, "allrow": 4912, "type": "text", "inside": "□是√否"}
{"page": 176, "allrow": 4913, "type": "text", "inside": "是否存在通过多次交易分步处置对子公司投资且在本期丧失控制权的情形"}
{"page": 176, "allrow": 4914, "type": "text", "inside": "□是√否"}
{"page": 176, "allrow": 4915, "type": "text", "inside": "5、其他原因的合并范围变动"}
{"page": 176, "allrow": 4916, "type": "text", "inside": "说明其他原因导致的合并范围变动（如，新设子公司、清算子公司等）及其相关情况："}
{"page": 176, "allrow": 4917, "type": "text", "inside": "6、其他"}
{"page": 176, "allrow": 4918, "type": "text", "inside": "九、在其他主体中的权益"}
{"page": 176, "allrow": 4919, "type": "text", "inside": "1、在子公司中的权益"}
{"page": 176, "allrow": 4920, "type": "text", "inside": "（1）企业集团的构成"}
{"page": 176, "allrow": 4921, "type": "excel", "inside": "['', '', '', '', '持股比例', '', '']"}
{"page": 176, "allrow": 4922, "type": "excel", "inside": "['子公司名称', '主要经营地', '注册地', '业务性质', '直接', '间接', '取得方式']"}
{"page": 176, "allrow": 4923, "type": "text", "inside": ""}
{"page": 176, "allrow": 4924, "type": "页脚", "inside": "176"}
{"page": 177, "allrow": 4925, "type": "text", "inside": ""}
{"page": 177, "allrow": 4926, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 177, "allrow": 4927, "type": "excel", "inside": "['浙江普洛家园药业有限公司', '东阳市横店工业区', '东阳市横店工业区', '原料药制造', '100.00%', '', '通过设立或投资等方式取得']"}
{"page": 177, "allrow": 4928, "type": "excel", "inside": "['安徽普洛生物科技有限公司', '安徽东至香隅化工园', '安徽东至香隅化工园', '化学原料药及制剂制造等', '', '100.00%', '通过设立或投资等方式取得']"}
{"page": 177, "allrow": 4929, "type": "excel", "inside": "['', '', '', '药物专业领域', '', '', '']"}
{"page": 177, "allrow": 4930, "type": "excel", "inside": "['上海裕缘生物医药研发有限公司', '上海市浦东新区惠南镇', '上海市浦东新区惠南镇', '内的技术开发、转让、咨询、服务等', '', '100.00%', '通过设立或投资等方式取得']"}
{"page": 177, "allrow": 4931, "type": "excel", "inside": "['浙江优胜美特医药有限公司', '东阳市横店工业区', '东阳市横店工业区', '医药销售', '100.00%', '', '通过设立或投资等方式取得']"}
{"page": 177, "allrow": 4932, "type": "excel", "inside": "['普洛香港有限公司', '香港', '香港', '医药销售', '', '100.00%', '通过设立或投资等方式取得']"}
{"page": 177, "allrow": 4933, "type": "excel", "inside": "['JTPHARMACEUTICAL INC', '美国新泽西州', '美国新泽西州', '医药销售', '', '100.00%', '通过设立或投资等方式取得']"}
{"page": 177, "allrow": 4934, "type": "excel", "inside": "['', '', '', '技术开发、技', '', '', '']"}
{"page": 177, "allrow": 4935, "type": "excel", "inside": "['杭州优胜美特药物研究院有限公司', '杭州经济技术开发区', '杭州经济技术开发区', '术服务、技术咨询、成果转让:生物医药;', '', '100.00%', '通过设立或投资等方式取得']"}
{"page": 177, "allrow": 4936, "type": "excel", "inside": "['', '', '', '销售:化工产品', '', '', '']"}
{"page": 177, "allrow": 4937, "type": "excel", "inside": "['', '', '', '自营和代理各', '', '', '']"}
{"page": 177, "allrow": 4938, "type": "excel", "inside": "['宁波普洛进出口有限公司', '宁波保税区', '宁波保税区', '类及技术的进出口业务', '', '100.00%', '通过设立或投资等方式取得']"}
{"page": 177, "allrow": 4939, "type": "excel", "inside": "['', '', '', '', '', '', '通过同一控制']"}
{"page": 177, "allrow": 4940, "type": "excel", "inside": "['浙江普洛康裕制药有限公司', '东阳市横店工业区', '东阳市横店工业区', '化学原料药及制剂制造等', '100.00%', '', '下的企业合并取得']"}
{"page": 177, "allrow": 4941, "type": "excel", "inside": "['', '', '', '原料药、口服', '', '', '通过同一控制']"}
{"page": 177, "allrow": 4942, "type": "excel", "inside": "['浙江优胜美特中药有限公司', '东阳市横店工业区', '东阳市横店工业区', '液、合剂、丸剂等制造', '100.00%', '', '下的企业合并取得']"}
{"page": 177, "allrow": 4943, "type": "excel", "inside": "['', '', '', '原料药、预混', '', '', '通过同一控制']"}
{"page": 177, "allrow": 4944, "type": "excel", "inside": "['浙江普洛生物科技有限公司', '东阳市歌山镇', '东阳市歌山镇', '剂、医药中间体、粮食收购', '100.00%', '', '下的企业合并取得']"}
{"page": 177, "allrow": 4945, "type": "excel", "inside": "['', '', '', '', '', '', '通过同一控制']"}
{"page": 177, "allrow": 4946, "type": "excel", "inside": "['浙江普洛得邦制药有限公司', '东阳市横店工业区', '东阳市横店工业区', '原料药、医药中间体', '100.00%', '', '下的企业合并取得']"}
{"page": 177, "allrow": 4947, "type": "excel", "inside": "['', '', '', '', '', '', '通过同一控制']"}
{"page": 177, "allrow": 4948, "type": "excel", "inside": "['山东汉兴医药科技有限公司', '昌邑市卜庄镇', '昌邑市卜庄镇', '医药中间体制造、进出口', '100.00%', '', '下的企业合并取得']"}
{"page": 177, "allrow": 4949, "type": "text", "inside": ""}
{"page": 177, "allrow": 4950, "type": "页脚", "inside": "177"}
{"page": 178, "allrow": 4951, "type": "text", "inside": ""}
{"page": 178, "allrow": 4952, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 178, "allrow": 4953, "type": "excel", "inside": "['浙江横店普洛进出口有限公司', '东阳市横店镇万盛街', '东阳市横店镇万盛街', '自营和代理各类商品及技术进出口等', '100.00%', '', '通过同一控制下的企业合并取得']"}
{"page": 178, "allrow": 4954, "type": "excel", "inside": "['', '', '', '', '', '', '通过同一控制']"}
{"page": 178, "allrow": 4955, "type": "excel", "inside": "['浙江巨泰药业有限公司', '衢州市柯城区', '衢州市柯城区', '片剂、硬胶囊剂、原料药等', '100.00%', '', '下的企业合并取得']"}
{"page": 178, "allrow": 4956, "type": "excel", "inside": "['横店集团成都分子实验室有限公司', '成都市高新区', '成都市高新区', '药物、药物中间体研究开发', '', '100.00%', '通过同一控制下的企业合并取得']"}
{"page": 178, "allrow": 4957, "type": "excel", "inside": "['', '', '', '', '', '', '通过非同一控']"}
{"page": 178, "allrow": 4958, "type": "excel", "inside": "['山东普洛得邦医药有限公司', '潍坊市海化开发区', '潍坊市海化开发区', '医药中间体制造、销售', '', '', '制下的企业合并取得']"}
{"page": 178, "allrow": 4959, "type": "excel", "inside": "['', '', '', '', '', '', '通过非同一控']"}
{"page": 178, "allrow": 4960, "type": "excel", "inside": "['山西优胜美特药业有限公司', '山西大同市', '山西大同市', '生产注射剂', '100.00%', '', '制下的企业合并取得']"}
{"page": 178, "allrow": 4961, "type": "excel", "inside": "['', '', '', '', '', '', '通过非同一控']"}
{"page": 178, "allrow": 4962, "type": "excel", "inside": "['成都邦瑞医药科技有限公司', '成都市高新区', '成都市高新区', '药物、药物中间体研究开发', '100.00%', '', '制下的企业合并取得']"}
{"page": 178, "allrow": 4963, "type": "excel", "inside": "['', '', '', '', '', '', '通过非同一控']"}
{"page": 178, "allrow": 4964, "type": "excel", "inside": "['', '', '', '', '', '100.00%', '制下的企业合']"}
{"page": 178, "allrow": 4965, "type": "excel", "inside": "['', '', '', '', '', '', '并取得']"}
{"page": 178, "allrow": 4966, "type": "text", "inside": ""}
{"page": 178, "allrow": 4967, "type": "text", "inside": "在子公司的持股比例不同于表决权比例的说明："}
{"page": 178, "allrow": 4968, "type": "text", "inside": "①无母公司对子公司的持股比例与其在子公司表决权比例不一致的情况。"}
{"page": 178, "allrow": 4969, "type": "text", "inside": "②无母公司拥有其半数或半数以下表决权而纳入合并财务报表范围的子公司。"}
{"page": 178, "allrow": 4970, "type": "text", "inside": "③无母公司拥有半数以上表决权但未能对其形成控制的公司。"}
{"page": 178, "allrow": 4971, "type": "text", "inside": "④无子公司向母公司转移资金的能力受到严格限制的情况。"}
{"page": 178, "allrow": 4972, "type": "text", "inside": "持有半数或以下表决权但仍控制被投资单位、以及持有半数以上表决权但不控制被投资单位的依据："}
{"page": 178, "allrow": 4973, "type": "text", "inside": "对于纳入合并范围的重要的结构化主体，控制的依据："}
{"page": 178, "allrow": 4974, "type": "text", "inside": "确定公司是代理人还是委托人的依据："}
{"page": 178, "allrow": 4975, "type": "text", "inside": "其他说明："}
{"page": 178, "allrow": 4976, "type": "text", "inside": "（2）重要的非全资子公司"}
{"page": 178, "allrow": 4977, "type": "text", "inside": "单位：元"}
{"page": 178, "allrow": 4978, "type": "excel", "inside": "['', '', '本期归属于少数股东', '本期向少数股东宣告', '期末少数股东权益余']"}
{"page": 178, "allrow": 4979, "type": "excel", "inside": "['子公司名称', '少数股东持股比例', '的损益', '分派的股利', '额']"}
{"page": 178, "allrow": 4980, "type": "text", "inside": ""}
{"page": 178, "allrow": 4981, "type": "text", "inside": "子公司少数股东的持股比例不同于表决权比例的说明："}
{"page": 178, "allrow": 4982, "type": "text", "inside": "其他说明："}
{"page": 178, "allrow": 4983, "type": "页脚", "inside": "178"}
{"page": 179, "allrow": 4984, "type": "text", "inside": ""}
{"page": 179, "allrow": 4985, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 179, "allrow": 4986, "type": "text", "inside": "（3）重要非全资子公司的主要财务信息"}
{"page": 179, "allrow": 4987, "type": "text", "inside": "单位：元"}
{"page": 179, "allrow": 4988, "type": "excel", "inside": "['', '期末余额', '', '', '', '', '', '', '期初余额', '', '', '', '', '']"}
{"page": 179, "allrow": 4989, "type": "excel", "inside": "['子公司名称', '流动资产', '非流动资产', '资产合计', '流动负债', '非流动负债', '负债合计', '负债合计', '流动资产', '非流动资产', '资产合计', '流动负债', '非流动负债', '负债合计']"}
{"page": 179, "allrow": 4990, "type": "text", "inside": ""}
{"page": 179, "allrow": 4991, "type": "text", "inside": "单位：元"}
{"page": 179, "allrow": 4992, "type": "excel", "inside": "['', '本期发生额', '', '', '', '上期发生额', '', '', '']"}
{"page": 179, "allrow": 4993, "type": "excel", "inside": "['子公司名称', '营业收入', '净利润', '综合收益总额', '经营活动现金流量', '营业收入', '净利润', '综合收益总额', '经营活动现金流量']"}
{"page": 179, "allrow": 4994, "type": "text", "inside": "其他说明："}
{"page": 179, "allrow": 4995, "type": "text", "inside": "（4）使用企业集团资产和清偿企业集团债务的重大限制"}
{"page": 179, "allrow": 4996, "type": "text", "inside": "（5）向纳入合并财务报表范围的结构化主体提供的财务支持或其他支持"}
{"page": 179, "allrow": 4997, "type": "text", "inside": "其他说明："}
{"page": 179, "allrow": 4998, "type": "text", "inside": "2、在子公司的所有者权益份额发生变化且仍控制子公司的交易"}
{"page": 179, "allrow": 4999, "type": "text", "inside": "（1）在子公司所有者权益份额发生变化的情况说明"}
{"page": 179, "allrow": 5000, "type": "text", "inside": "（2）交易对于少数股东权益及归属于母公司所有者权益的影响"}
{"page": 179, "allrow": 5001, "type": "text", "inside": "单位：元"}
{"page": 179, "allrow": 5002, "type": "text", "inside": "其他说明"}
{"page": 179, "allrow": 5003, "type": "text", "inside": "3、在合营安排或联营企业中的权益"}
{"page": 179, "allrow": 5004, "type": "text", "inside": "（1）重要的合营企业或联营企业"}
{"page": 179, "allrow": 5005, "type": "excel", "inside": "['', '', '', '', '持股比例直接 间接', '持股比例', '', '对合营企业或']"}
{"page": 179, "allrow": 5006, "type": "excel", "inside": "['合营企业或联营企业名称', '主要经营地', '注册地', '业务性质', '', '直接', '间接', '联营企业投资的会计处理方']"}
{"page": 179, "allrow": 5007, "type": "excel", "inside": "['', '', '', '', '', '', '', '法']"}
{"page": 179, "allrow": 5008, "type": "text", "inside": ""}
{"page": 179, "allrow": 5009, "type": "text", "inside": "在合营企业或联营企业的持股比例不同于表决权比例的说明："}
{"page": 179, "allrow": 5010, "type": "text", "inside": "持有20%以下表决权但具有重大影响，或者持有20%或以上表决权但不具有重大影响的依据："}
{"page": 179, "allrow": 5011, "type": "页脚", "inside": "179"}
{"page": 180, "allrow": 5012, "type": "text", "inside": ""}
{"page": 180, "allrow": 5013, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 180, "allrow": 5014, "type": "text", "inside": "（2）重要合营企业的主要财务信息"}
{"page": 180, "allrow": 5015, "type": "text", "inside": "单位：元"}
{"page": 180, "allrow": 5016, "type": "excel", "inside": "['期末余额/本期发生额', '期初余额/上期发生额']"}
{"page": 180, "allrow": 5017, "type": "text", "inside": ""}
{"page": 180, "allrow": 5018, "type": "text", "inside": "其他说明"}
{"page": 180, "allrow": 5019, "type": "text", "inside": "（3）重要联营企业的主要财务信息"}
{"page": 180, "allrow": 5020, "type": "text", "inside": "单位：元"}
{"page": 180, "allrow": 5021, "type": "excel", "inside": "['期末余额/本期发生额', '期初余额/上期发生额']"}
{"page": 180, "allrow": 5022, "type": "text", "inside": ""}
{"page": 180, "allrow": 5023, "type": "text", "inside": "其他说明"}
{"page": 180, "allrow": 5024, "type": "text", "inside": "（4）不重要的合营企业和联营企业的汇总财务信息"}
{"page": 180, "allrow": 5025, "type": "text", "inside": "单位：元"}
{"page": 180, "allrow": 5026, "type": "excel", "inside": "['', '期末余额/本期发生额', '期初余额/上期发生额']"}
{"page": 180, "allrow": 5027, "type": "excel", "inside": "['合营企业：', '--', '--']"}
{"page": 180, "allrow": 5028, "type": "excel", "inside": "['下列各项按持股比例计算的合计数', '--', '--']"}
{"page": 180, "allrow": 5029, "type": "excel", "inside": "['联营企业：', '--', '--']"}
{"page": 180, "allrow": 5030, "type": "excel", "inside": "['投资账面价值合计', '122,214,608.04', '100,871,723.22']"}
{"page": 180, "allrow": 5031, "type": "excel", "inside": "['下列各项按持股比例计算的合计数', '--', '--']"}
{"page": 180, "allrow": 5032, "type": "excel", "inside": "['--净利润', '31,142,884.82', '16,007,148.92']"}
{"page": 180, "allrow": 5033, "type": "excel", "inside": "['--综合收益总额', '31,142,884.82', '16,007,148.92']"}
{"page": 180, "allrow": 5034, "type": "text", "inside": "其他说明"}
{"page": 180, "allrow": 5035, "type": "text", "inside": "（5）合营企业或联营企业向本公司转移资金的能力存在重大限制的说明"}
{"page": 180, "allrow": 5036, "type": "text", "inside": "（6）合营企业或联营企业发生的超额亏损"}
{"page": 180, "allrow": 5037, "type": "text", "inside": "单位：元"}
{"page": 180, "allrow": 5038, "type": "excel", "inside": "['', '累积未确认前期累计认的损', '本期未确认的损失（或本期', '']"}
{"page": 180, "allrow": 5039, "type": "excel", "inside": "['合营企业或联营企业名称', '失', '分享的净利润）', '本期末累积未确认的损失']"}
{"page": 180, "allrow": 5040, "type": "text", "inside": ""}
{"page": 180, "allrow": 5041, "type": "text", "inside": "其他说明"}
{"page": 180, "allrow": 5042, "type": "页脚", "inside": "180"}
{"page": 181, "allrow": 5043, "type": "text", "inside": ""}
{"page": 181, "allrow": 5044, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 181, "allrow": 5045, "type": "text", "inside": "（7）与合营企业投资相关的未确认承诺"}
{"page": 181, "allrow": 5046, "type": "text", "inside": "（8）与合营企业或联营企业投资相关的或有负债"}
{"page": 181, "allrow": 5047, "type": "text", "inside": "4、重要的共同经营"}
{"page": 181, "allrow": 5048, "type": "excel", "inside": "['', '', '', '', '持股比例/享有的份额', '']"}
{"page": 181, "allrow": 5049, "type": "excel", "inside": "['共同经营名称', '主要经营地', '注册地', '业务性质', '直接', '间接']"}
{"page": 181, "allrow": 5050, "type": "text", "inside": ""}
{"page": 181, "allrow": 5051, "type": "text", "inside": "在共同经营中的持股比例或享有的份额不同于表决权比例的说明："}
{"page": 181, "allrow": 5052, "type": "text", "inside": "共同经营为单独主体的，分类为共同经营的依据："}
{"page": 181, "allrow": 5053, "type": "text", "inside": "其他说明"}
{"page": 181, "allrow": 5054, "type": "text", "inside": "5、在未纳入合并财务报表范围的结构化主体中的权益"}
{"page": 181, "allrow": 5055, "type": "text", "inside": "未纳入合并财务报表范围的结构化主体的相关说明："}
{"page": 181, "allrow": 5056, "type": "text", "inside": "6、其他"}
{"page": 181, "allrow": 5057, "type": "text", "inside": "十、与金融工具相关的风险"}
{"page": 181, "allrow": 5058, "type": "text", "inside": "本公司的主要金融工具包括现金、银行存款、应收账款、借款、应付账款等，各项金融工具的详细情况说明见本附注五之相关项目。"}
{"page": 181, "allrow": 5059, "type": "text", "inside": "本公司从事风险管理的目标是在风险和收益之间取得平衡，将风险对本公司经营业绩的负面影响降至最低水平，使股东和其他权益投资者的利益最大化。基于该风险管理目标，本公司风险管理的基本策略是确认和分析本公司面临的各种风险，建立适当的风险承受底线和进行风险管理，并及时可靠地对各种风险进行监督，将风险控制在限定的范围内。"}
{"page": 181, "allrow": 5060, "type": "text", "inside": "本公司董事会全面负责风险管理目标和政策的确定，并对风险管理目标和政策承担最终责任，董事会已经授权相关职能部门设计和实施能确保风险管理目标和政策得以有效执行的程序。"}
{"page": 181, "allrow": 5061, "type": "text", "inside": "本公司在日常活动中面临各种与金融工具相关的风险，主要包括信用风险、流动风险及市场风险。本公司采用敏感性分析技术，对风险变量的合理、可能变化对当期损益或股东权益可能产生的影响进行分析，由于任何风险变量很少孤立地发生变化，而变量之间存在的相关性对某一风险变量的变化的最终影响金额将产生重大作用，因此下述内容是在假设每一变量的变化是在独立的情况下进行的。"}
{"page": 181, "allrow": 5062, "type": "text", "inside": "本公司管理层已审议并批准管理这些风险的政策，概括如下。"}
{"page": 181, "allrow": 5063, "type": "text", "inside": "(一)信用风险"}
{"page": 181, "allrow": 5064, "type": "text", "inside": "信用风险，是指金融工具的一方不能履行义务，造成另一方发生财务损失的风险。"}
{"page": 181, "allrow": 5065, "type": "text", "inside": "本公司面临信用风险的资产主要包括银行存款和应收款项，其信用风险主要指交易对方的违约风险，最大的风险敞口等于这些金融工具的账面价值，本公司应收款项产生的信用风险敞口的量化数据详见本附注六相关项目。为控制上述相关风险，本公司分别采取了以下措施。"}
{"page": 181, "allrow": 5066, "type": "text", "inside": "本公司将银行存款存放于信用评级较高的金融机构，故信用风险较低。"}
{"page": 181, "allrow": 5067, "type": "text", "inside": "本公司定期对采用信用方式交易的客户进行信用评估。根据信用评估结果，本公司选择与经认可的且信用良好的客户进行交易，并对其应收款项余额进行监控，以确保本公司不会面临重大坏账风险。对境外客户销售形成的应收账款，本公司通过中国出口信用保险公司对外币应收账款投保，以降低坏账风险。此外，资产负债表日，本公司详细审核应收款项的回收情"}
{"page": 181, "allrow": 5068, "type": "text", "inside": "况，以确保就无法收回的款项计提充分的坏账准备，将信用风险降低至较低水平。"}
{"page": 181, "allrow": 5069, "type": "text", "inside": "由于本公司的应收账款风险点分布于多个客户，截至2019年12月31日，本公司应收账款前五名客户的余额占应收账款总"}
{"page": 181, "allrow": 5070, "type": "text", "inside": "额的16.74%，因此不存在重大的信用集中风险。"}
{"page": 181, "allrow": 5071, "type": "页脚", "inside": "181"}
{"page": 182, "allrow": 5072, "type": "text", "inside": ""}
{"page": 182, "allrow": 5073, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 182, "allrow": 5074, "type": "text", "inside": "本公司最大风险敞口金额列示如下："}
{"page": 182, "allrow": 5075, "type": "excel", "inside": "['项目', '期末余额', '期初余额']"}
{"page": 182, "allrow": 5076, "type": "excel", "inside": "['货币资金', '1,035,809,494.05', '644,375,303.19']"}
{"page": 182, "allrow": 5077, "type": "excel", "inside": "['交易性金融资产', '463,858,356.17', '101,400,000.00']"}
{"page": 182, "allrow": 5078, "type": "excel", "inside": "['应收款项融资', '224,310,858.75', '210,813,018.23']"}
{"page": 182, "allrow": 5079, "type": "excel", "inside": "['应收账款', '1,025,138,596.19', '1,024,424,679.11']"}
{"page": 182, "allrow": 5080, "type": "excel", "inside": "['其他应收款', '7,275,197.34', '7,566,657.24']"}
{"page": 182, "allrow": 5081, "type": "excel", "inside": "['合计', '2,756,392,502.50', '1,988,579,657.77']"}
{"page": 182, "allrow": 5082, "type": "text", "inside": "(二)流动风险"}
{"page": 182, "allrow": 5083, "type": "text", "inside": "流动风险，是指本公司在履行以交付现金或其他金融资产的方式结算的义务时发生资金短缺的风险。流动风险可能源于无法尽快以公允价值售出金融资产；或者源于对方无法偿还其合同债务；或者源于提前到期的债务；或者源于无法产生预期的现金流量。本公司控制流动风险的方法是确保有足够的流动资金履行到期债务，以免造成损失或者损害公司信誉。"}
{"page": 182, "allrow": 5084, "type": "text", "inside": "为控制该项风险，本公司综合运用票据结算、银行借款等多种融资手段，优化融资结构，保持融资持续性与灵活性之间的平衡。本公司定期分析负债结构和期限，公司财务部通过监控现金余额以及对未来12个月现金流量的滚动预测，确保公司拥有充足的资金偿还到期债务。"}
{"page": 182, "allrow": 5085, "type": "text", "inside": "截至2019年12月31日，本公司金融负债列示如下："}
{"page": 182, "allrow": 5086, "type": "excel", "inside": "['项目', '期末余额', '期初余额']"}
{"page": 182, "allrow": 5087, "type": "excel", "inside": "['短期借款', '50,000,000.00', '614,100,000.00']"}
{"page": 182, "allrow": 5088, "type": "excel", "inside": "['交易性金融负债', '16,231,031.94', '2,486,145.90']"}
{"page": 182, "allrow": 5089, "type": "excel", "inside": "['应付票据', '923,961,227.56', '322,056,386.67']"}
{"page": 182, "allrow": 5090, "type": "excel", "inside": "['应付账款', '1,086,293,844.38', '791,292,436.92']"}
{"page": 182, "allrow": 5091, "type": "excel", "inside": "['其他应付款', '98,364,659.79', '146,067,494.99']"}
{"page": 182, "allrow": 5092, "type": "excel", "inside": "['合计', '2,174,850,763.67', '1,876,002,464.48']"}
{"page": 182, "allrow": 5093, "type": "text", "inside": "(三)市场风险"}
{"page": 182, "allrow": 5094, "type": "text", "inside": "市场风险，是指金融工具的公允价值或未来现金流量因市场价格变动而发生波动的风险。市场风险主要包括利率风险和外汇风险。"}
{"page": 182, "allrow": 5095, "type": "text", "inside": "1.利率风险"}
{"page": 182, "allrow": 5096, "type": "text", "inside": "利率风险，是指金融工具的公允价值或未来现金流量因市场利率变动而发生波动的风险。本公司面临的市场利率变动的风险主要与本公司以浮动利率计息的借款有关。"}
{"page": 182, "allrow": 5097, "type": "text", "inside": "截至2019年12月31日，本公司不存在以同期同档次国家基准利率上浮一定百分比的利率计息的银行借款，在其他变量不变的假设下，假定利率变动50个基准点，不会对本公司的利润总额和股东权益产生重大的影响。"}
{"page": 182, "allrow": 5098, "type": "text", "inside": "2.汇率风险"}
{"page": 182, "allrow": 5099, "type": "text", "inside": "汇率风险，是指金融工具的公允价值或未来现金流量因外汇汇率变动而发生波动的风险。本公司面临的汇率变动的风险主要与本公司外币货币性资产和负债有关。外币金融资产和金融负债折算成人民币的金额列示如下："}
{"page": 182, "allrow": 5100, "type": "excel", "inside": "['项目', '期末余额', '期初余额']"}
{"page": 182, "allrow": 5101, "type": "excel", "inside": "['货币资金', '311,562,721.13', '269,247,750.61']"}
{"page": 182, "allrow": 5102, "type": "excel", "inside": "['应收账款', '551,827,157.58', '530,753,338.65']"}
{"page": 182, "allrow": 5103, "type": "excel", "inside": "['应付账款', '37,365,581.39', '115,193,018.64']"}
{"page": 182, "allrow": 5104, "type": "text", "inside": ""}
{"page": 182, "allrow": 5105, "type": "页脚", "inside": "182"}
{"page": 183, "allrow": 5106, "type": "text", "inside": ""}
{"page": 183, "allrow": 5107, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 183, "allrow": 5108, "type": "text", "inside": "十一、公允价值的披露"}
{"page": 183, "allrow": 5109, "type": "text", "inside": "1、以公允价值计量的资产和负债的期末公允价值"}
{"page": 183, "allrow": 5110, "type": "text", "inside": "单位：元"}
{"page": 183, "allrow": 5111, "type": "excel", "inside": "['', '期末公允价值', '', '', '']"}
{"page": 183, "allrow": 5112, "type": "excel", "inside": "['项目', '第一层次公允价值计', '第二层次公允价值计', '第三层次公允价值计', '合计']"}
{"page": 183, "allrow": 5113, "type": "excel", "inside": "['', '量', '量', '量', '']"}
{"page": 183, "allrow": 5114, "type": "excel", "inside": "['一、持续的公允价值计量', '--', '--', '--', '--']"}
{"page": 183, "allrow": 5115, "type": "excel", "inside": "['二、非持续的公允价值计量', '--', '--', '--', '--']"}
{"page": 183, "allrow": 5116, "type": "text", "inside": ""}
{"page": 183, "allrow": 5117, "type": "text", "inside": "2、持续和非持续第一层次公允价值计量项目市价的确定依据"}
{"page": 183, "allrow": 5118, "type": "text", "inside": "3、持续和非持续第二层次公允价值计量项目，采用的估值技术和重要参数的定性及定量信息"}
{"page": 183, "allrow": 5119, "type": "text", "inside": "4、持续和非持续第三层次公允价值计量项目，采用的估值技术和重要参数的定性及定量信息"}
{"page": 183, "allrow": 5120, "type": "text", "inside": "5、持续的第三层次公允价值计量项目，期初与期末账面价值间的调节信息及不可观察参数敏感性分析6、持续的公允价值计量项目，本期内发生各层级之间转换的，转换的原因及确定转换时点的政策"}
{"page": 183, "allrow": 5121, "type": "text", "inside": "7、本期内发生的估值技术变更及变更原因"}
{"page": 183, "allrow": 5122, "type": "text", "inside": "8、不以公允价值计量的金融资产和金融负债的公允价值情况"}
{"page": 183, "allrow": 5123, "type": "text", "inside": "9、其他"}
{"page": 183, "allrow": 5124, "type": "text", "inside": "十二、关联方及关联交易"}
{"page": 183, "allrow": 5125, "type": "text", "inside": "1、本企业的母公司情况"}
{"page": 183, "allrow": 5126, "type": "excel", "inside": "['', '', '', '', '母公司对本企业', '母公司对本企业']"}
{"page": 183, "allrow": 5127, "type": "excel", "inside": "['母公司名称', '注册地', '业务性质', '注册资本', '的持股比例', '的表决权比例']"}
{"page": 183, "allrow": 5128, "type": "excel", "inside": "['横店集团控股有限公司', '浙江东阳', '', '200,000.00', '28.08%', '28.08%']"}
{"page": 183, "allrow": 5129, "type": "excel", "inside": "['横店集团康裕药业有限公司', '浙江东阳', '', '10,000.00', '5.05%', '5.05%']"}
{"page": 183, "allrow": 5130, "type": "excel", "inside": "['横店集团家园化工有限公司', '浙江东阳', '', '20,000.00', '3.80%', '3.80%']"}
{"page": 183, "allrow": 5131, "type": "text", "inside": ""}
{"page": 183, "allrow": 5132, "type": "页脚", "inside": "183"}
{"page": 184, "allrow": 5133, "type": "text", "inside": ""}
{"page": 184, "allrow": 5134, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 184, "allrow": 5135, "type": "excel", "inside": "['浙江横店进出口有限公司', '浙江东阳', '5,000.00', '13.28%', '13.28%']"}
{"page": 184, "allrow": 5136, "type": "text", "inside": ""}
{"page": 184, "allrow": 5137, "type": "text", "inside": "本企业的母公司情况的说明"}
{"page": 184, "allrow": 5138, "type": "text", "inside": "横店集团控股有限公司直接持有本公司28.08%股权，通过横店集团康裕药业有限公司、横店集团家园化工有限公司、浙江横店进出口有限公司间接持有本公司5.05%、3.80%、13.28%股权，通过浙江埃森化学有限公司和东阳市横店禹山运动休闲有限公司间接持有本公司0.01%和0.78%股权，故横店集团控股有限公司为本公司母公司；横店社团经济企业联合会持有横店集团控股有限公司70.00%股权，为本公司实际控制人。"}
{"page": 184, "allrow": 5139, "type": "text", "inside": "本企业最终控制方是横店社团经济企业联合会。"}
{"page": 184, "allrow": 5140, "type": "text", "inside": "其他说明："}
{"page": 184, "allrow": 5141, "type": "text", "inside": "2、本企业的子公司情况"}
{"page": 184, "allrow": 5142, "type": "text", "inside": "本企业子公司的情况详见附注。"}
{"page": 184, "allrow": 5143, "type": "text", "inside": "3、本企业合营和联营企业情况"}
{"page": 184, "allrow": 5144, "type": "text", "inside": "本企业重要的合营或联营企业详见附注。"}
{"page": 184, "allrow": 5145, "type": "text", "inside": "本期与本公司发生关联方交易，或前期与本公司发生关联方交易形成余额的其他合营或联营企业情况如下："}
{"page": 184, "allrow": 5146, "type": "excel", "inside": "['合营或联营企业名称', '与本企业关系']"}
{"page": 184, "allrow": 5147, "type": "excel", "inside": "['昌邑华普医药科技有限公司', '联营企业']"}
{"page": 184, "allrow": 5148, "type": "excel", "inside": "['亿帆优胜美特医药科技有限公司', '联营企业']"}
{"page": 184, "allrow": 5149, "type": "text", "inside": ""}
{"page": 184, "allrow": 5150, "type": "text", "inside": "其他说明"}
{"page": 184, "allrow": 5151, "type": "text", "inside": "4、其他关联方情况"}
{"page": 184, "allrow": 5152, "type": "excel", "inside": "['其他关联方名称', '其他关联方与本企业关系']"}
{"page": 184, "allrow": 5153, "type": "excel", "inside": "['浙江好乐多商贸有限公司', '同受本公司最终控制人控制']"}
{"page": 184, "allrow": 5154, "type": "excel", "inside": "['浙江新纳材料科技股份有限公司', '同受本公司最终控制人控制']"}
{"page": 184, "allrow": 5155, "type": "excel", "inside": "['东阳市横店自来水有限公司', '同受本公司最终控制人控制']"}
{"page": 184, "allrow": 5156, "type": "excel", "inside": "['浙江横店热电有限公司', '控股股东、实际控制人所施加影响的其他企业']"}
{"page": 184, "allrow": 5157, "type": "excel", "inside": "['浙江横店影视城有限公司', '同受本公司最终控制人控制']"}
{"page": 184, "allrow": 5158, "type": "excel", "inside": "['浙江横店圆明新园有限公司', '控股股东、实际控制人所施加影响的其他企业']"}
{"page": 184, "allrow": 5159, "type": "excel", "inside": "['东阳市横店污水处理有限公司', '同受本公司最终控制人控制']"}
{"page": 184, "allrow": 5160, "type": "excel", "inside": "['东阳市横店影视城国际旅行社有限公司', '同受本公司最终控制人控制']"}
{"page": 184, "allrow": 5161, "type": "excel", "inside": "['东阳市横店贵宾楼大酒店有限公司', '同受本公司最终控制人控制']"}
{"page": 184, "allrow": 5162, "type": "excel", "inside": "['东阳市横店影视城旅游大厦有限公司', '同受本公司最终控制人控制']"}
{"page": 184, "allrow": 5163, "type": "excel", "inside": "['东阳市横店影视城旅游营销有限公司', '同受本公司最终控制人控制']"}
{"page": 184, "allrow": 5164, "type": "excel", "inside": "['文荣医院', '同受本公司最终控制人控制']"}
{"page": 184, "allrow": 5165, "type": "excel", "inside": "['横店文荣医院', '同受本公司最终控制人控制']"}
{"page": 184, "allrow": 5166, "type": "text", "inside": ""}
{"page": 184, "allrow": 5167, "type": "页脚", "inside": "184"}
{"page": 185, "allrow": 5168, "type": "text", "inside": ""}
{"page": 185, "allrow": 5169, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 185, "allrow": 5170, "type": "excel", "inside": "['横店影视股份有限公司', '同受本公司最终控制人控制']"}
{"page": 185, "allrow": 5171, "type": "excel", "inside": "['横店集团东磁股份有限公司', '同受本公司最终控制人控制']"}
{"page": 185, "allrow": 5172, "type": "excel", "inside": "['杭州九里云松酒店管理有限公司', '同受本公司最终控制人控制']"}
{"page": 185, "allrow": 5173, "type": "excel", "inside": "['东阳市横店商品贸易有限公司', '同受本公司最终控制人控制']"}
{"page": 185, "allrow": 5174, "type": "excel", "inside": "['浙江微度医疗器械有限公司', '同受本公司最终控制人控制']"}
{"page": 185, "allrow": 5175, "type": "excel", "inside": "['山东埃森化学有限公司', '同受本公司最终控制人控制']"}
{"page": 185, "allrow": 5176, "type": "excel", "inside": "['浙江横店建设有限公司', '同受本公司最终控制人控制']"}
{"page": 185, "allrow": 5177, "type": "excel", "inside": "['浙江省东阳市横店园林古典建筑公司', '控股股东、实际控制人所施加影响的其他企业']"}
{"page": 185, "allrow": 5178, "type": "excel", "inside": "['横店集团房地产开发有限公司', '同受本公司最终控制人控制']"}
{"page": 185, "allrow": 5179, "type": "excel", "inside": "['浙江横店禹山生态工程有限公司', '控股股东、实际控制人所施加影响的其他企业']"}
{"page": 185, "allrow": 5180, "type": "excel", "inside": "['衢州乐泰机电设备有限公司', '同受本公司最终控制人控制']"}
{"page": 185, "allrow": 5181, "type": "excel", "inside": "['南华基金管理有限公司', '同受本公司最终控制人控制']"}
{"page": 185, "allrow": 5182, "type": "text", "inside": ""}
{"page": 185, "allrow": 5183, "type": "text", "inside": "其他说明"}
{"page": 185, "allrow": 5184, "type": "text", "inside": "5、关联交易情况"}
{"page": 185, "allrow": 5185, "type": "text", "inside": "（1）购销商品、提供和接受劳务的关联交易"}
{"page": 185, "allrow": 5186, "type": "text", "inside": "采购商品/接受劳务情况表"}
{"page": 185, "allrow": 5187, "type": "text", "inside": "单位：元"}
{"page": 185, "allrow": 5188, "type": "excel", "inside": "['关联方', '关联交易内容', '本期发生额', '获批的交易额度', '是否超过交易额度', '上期发生额']"}
{"page": 185, "allrow": 5189, "type": "excel", "inside": "['浙江好乐多商贸有限公司', '采购商品', '2,138,724.58', '', '', '2,519,675.12']"}
{"page": 185, "allrow": 5190, "type": "excel", "inside": "['浙江新纳材料科技股份有限公司', '采购商品', '1,616,478.49', '1,600,000.00', '是', '1,296,339.52']"}
{"page": 185, "allrow": 5191, "type": "excel", "inside": "['东阳市横店自来水有限公司', '水费', '9,495,570.11', '10,970,000.00', '否', '9,836,726.06']"}
{"page": 185, "allrow": 5192, "type": "excel", "inside": "['浙江横店热电有限公司', '蒸汽费、电费', '103,715,948.03', '135,720,000.00', '否', '104,886,995.58']"}
{"page": 185, "allrow": 5193, "type": "excel", "inside": "['浙江横店影视城有限公司', '门票', '614,436.00', '', '', '1,443,455.65']"}
{"page": 185, "allrow": 5194, "type": "excel", "inside": "['昌邑华普医药科技有限公司', '采购商品', '153,984,566.19', '195,000,000.00', '否', '48,022,897.49']"}
{"page": 185, "allrow": 5195, "type": "excel", "inside": "['浙江横店圆明新园有限公司', '门票', '', '', '', '403,545.66']"}
{"page": 185, "allrow": 5196, "type": "excel", "inside": "['东阳市横店污水处理有限公司', '污水处理', '4,934,820.60', '6,300,000.00', '否', '4,234,261.30']"}
{"page": 185, "allrow": 5197, "type": "excel", "inside": "['东阳市横店影视城国际旅行社有限公司', '旅游服务', '141,837.00', '', '', '2,918,643.00']"}
{"page": 185, "allrow": 5198, "type": "text", "inside": ""}
{"page": 185, "allrow": 5199, "type": "页脚", "inside": "185"}
{"page": 186, "allrow": 5200, "type": "text", "inside": ""}
{"page": 186, "allrow": 5201, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 186, "allrow": 5202, "type": "excel", "inside": "['东阳市横店贵宾楼大酒店有限公司', '餐饮住宿', '615,004.75', '', '', '477,782.24']"}
{"page": 186, "allrow": 5203, "type": "excel", "inside": "['东阳市横店影视城旅游大厦有限公司', '餐饮住宿', '142,526.01', '', '', '330,976.79']"}
{"page": 186, "allrow": 5204, "type": "excel", "inside": "['东阳市横店影视城旅游营销有限公司', '门票', '764,118.58', '', '', '316,134.00']"}
{"page": 186, "allrow": 5205, "type": "excel", "inside": "['文荣医院', '医疗服务', '', '', '', '491,806.00']"}
{"page": 186, "allrow": 5206, "type": "excel", "inside": "['横店文荣医院', '医疗服务', '2,655,030.00', '', '', '535,473.76']"}
{"page": 186, "allrow": 5207, "type": "excel", "inside": "['横店影视股份有限公司', '电影票等', '14,268.00', '', '', '20,985.00']"}
{"page": 186, "allrow": 5208, "type": "excel", "inside": "['横店集团东磁股份有限公司', '餐饮住宿', '67,971.18', '', '', '182,618.41']"}
{"page": 186, "allrow": 5209, "type": "excel", "inside": "['杭州九里云松酒店管理有限公司', '餐饮住宿', '405,070.38', '', '', '']"}
{"page": 186, "allrow": 5210, "type": "excel", "inside": "['东阳市横店商品贸易有限公司', '采购商品', '6,904,575.59', '10,000,000.00', '否', '2,414,604.09']"}
{"page": 186, "allrow": 5211, "type": "excel", "inside": "['浙江横店建设有限公司', '工程款', '10,815,701.37', '9,500,000.00', '是', '15,612,203.10']"}
{"page": 186, "allrow": 5212, "type": "excel", "inside": "['浙江横店禹山生态工程有限公司', '工程款', '816,877.06', '', '', '333,077.82']"}
{"page": 186, "allrow": 5213, "type": "excel", "inside": "['浙江省东阳市横店园林古典建筑公司', '工程款', '', '', '', '6,908,946.00']"}
{"page": 186, "allrow": 5214, "type": "excel", "inside": "['合计', '', '299,843,523.92', '', '', '203,187,146.59']"}
{"page": 186, "allrow": 5215, "type": "text", "inside": "出售商品/提供劳务情况表"}
{"page": 186, "allrow": 5216, "type": "text", "inside": "单位：元"}
{"page": 186, "allrow": 5217, "type": "excel", "inside": "['关联方', '关联交易内容', '本期发生额', '上期发生额']"}
{"page": 186, "allrow": 5218, "type": "excel", "inside": "['浙江英洛华国际贸易有限公司', '销售商品', '', '19,358,992.82']"}
{"page": 186, "allrow": 5219, "type": "excel", "inside": "['横店文荣医院', '销售商品', '', '17,465,047.71']"}
{"page": 186, "allrow": 5220, "type": "excel", "inside": "['昌邑华普医药科技有限公司', '销售商品', '8,760,723.88', '3,503,736.80']"}
{"page": 186, "allrow": 5221, "type": "excel", "inside": "['文荣医院', '销售商品', '', '20,709,609.98']"}
{"page": 186, "allrow": 5222, "type": "excel", "inside": "['浙江微度医疗器械有限公司', '销售商品', '238,152.98', '']"}
{"page": 186, "allrow": 5223, "type": "excel", "inside": "['山东埃森化学有限公司', '销售商品', '', '3,934,591.21']"}
{"page": 186, "allrow": 5224, "type": "excel", "inside": "['横店集团东磁股份有限公司', '销售商品', '', '451,700.00']"}
{"page": 186, "allrow": 5225, "type": "text", "inside": ""}
{"page": 186, "allrow": 5226, "type": "页脚", "inside": "186"}
{"page": 187, "allrow": 5227, "type": "text", "inside": ""}
{"page": 187, "allrow": 5228, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 187, "allrow": 5229, "type": "excel", "inside": "['合计', '8,998,876.86', '65,423,678.52']"}
{"page": 187, "allrow": 5230, "type": "text", "inside": "购销商品、提供和接受劳务的关联交易说明"}
{"page": 187, "allrow": 5231, "type": "text", "inside": "（2）关联受托管理/承包及委托管理/出包情况"}
{"page": 187, "allrow": 5232, "type": "text", "inside": "本公司受托管理/承包情况表："}
{"page": 187, "allrow": 5233, "type": "text", "inside": "单位：元"}
{"page": 187, "allrow": 5234, "type": "excel", "inside": "['', '', '', '', '', '', '本期确认的托']"}
{"page": 187, "allrow": 5235, "type": "excel", "inside": "['委托方/出包方名称', '受托方/承包方名称', '受托/承包资产类型', '受托/承包起始日', '受托/承包终止日', '托管收益/承包收益定价依据', '管收益/承包收益']"}
{"page": 187, "allrow": 5236, "type": "text", "inside": ""}
{"page": 187, "allrow": 5237, "type": "text", "inside": "关联托管/承包情况说明"}
{"page": 187, "allrow": 5238, "type": "text", "inside": "本公司委托管理/出包情况表："}
{"page": 187, "allrow": 5239, "type": "text", "inside": "单位：元"}
{"page": 187, "allrow": 5240, "type": "excel", "inside": "['委托方/出包方名称', '受托方/承包方名称', '委托/出包资产类型', '委托/出包起始日', '委托/出包终止日', '托管费/出包费定价依据', '本期确认的托管费/出包费']"}
{"page": 187, "allrow": 5241, "type": "text", "inside": "关联管理/出包情况说明"}
{"page": 187, "allrow": 5242, "type": "text", "inside": "（3）关联租赁情况"}
{"page": 187, "allrow": 5243, "type": "text", "inside": "本公司作为出租方："}
{"page": 187, "allrow": 5244, "type": "text", "inside": "单位：元"}
{"page": 187, "allrow": 5245, "type": "excel", "inside": "['承租方名称', '租赁资产种类', '本期确认的租赁收入', '上期确认的租赁收入']"}
{"page": 187, "allrow": 5246, "type": "excel", "inside": "['昌邑华普医药科技有限公司', '设备租赁', '514,900.00', '514,900.00']"}
{"page": 187, "allrow": 5247, "type": "text", "inside": "本公司作为承租方："}
{"page": 187, "allrow": 5248, "type": "text", "inside": "单位：元"}
{"page": 187, "allrow": 5249, "type": "excel", "inside": "['出租方名称', '租赁资产种类', '本期确认的租赁费', '上期确认的租赁费']"}
{"page": 187, "allrow": 5250, "type": "excel", "inside": "['衢州乐泰机电设备有限公司', '房屋租赁', '938,800.00', '938,800.00']"}
{"page": 187, "allrow": 5251, "type": "text", "inside": "关联租赁情况说明"}
{"page": 187, "allrow": 5252, "type": "excel", "inside": "['出租方名称', '承租方名称', '租赁资产情况', '租赁起始日', '租赁终止日', '租赁收益确定依据', '租赁收益对公司影响']"}
{"page": 187, "allrow": 5253, "type": "excel", "inside": "['衢州乐泰机电设备有限公司', '浙江巨泰药业有限公司', '衢州市柯城区新新街道彩虹路4号', '2017年1月1日', '2019年12月31日', '租赁合同', '增加公司本期成本费用93.88万元']"}
{"page": 187, "allrow": 5254, "type": "excel", "inside": "['山东汉兴医药科技有限公司', '昌邑华普医药科技有限公司', '山东省潍坊市昌邑市下营滨海经济开发区', '2019年1月1日', '2019年12月31日', '租赁合同', '增加公司本期租赁收入51.49万元']"}
{"page": 187, "allrow": 5255, "type": "text", "inside": ""}
{"page": 187, "allrow": 5256, "type": "text", "inside": "（4）关联担保情况"}
{"page": 187, "allrow": 5257, "type": "text", "inside": "本公司作为担保方"}
{"page": 187, "allrow": 5258, "type": "text", "inside": "单位：元"}
{"page": 187, "allrow": 5259, "type": "页脚", "inside": "187"}
{"page": 188, "allrow": 5260, "type": "text", "inside": ""}
{"page": 188, "allrow": 5261, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 188, "allrow": 5262, "type": "excel", "inside": "['', '', '', '', '担保是否已经履行完']"}
{"page": 188, "allrow": 5263, "type": "excel", "inside": "['被担保方', '担保金额', '担保起始日', '担保到期日', '毕']"}
{"page": 188, "allrow": 5264, "type": "text", "inside": ""}
{"page": 188, "allrow": 5265, "type": "text", "inside": "本公司作为被担保方"}
{"page": 188, "allrow": 5266, "type": "text", "inside": "单位：元"}
{"page": 188, "allrow": 5267, "type": "excel", "inside": "['', '', '', '', '担保是否已经履行完']"}
{"page": 188, "allrow": 5268, "type": "excel", "inside": "['担保方', '担保金额', '担保起始日', '担保到期日', '毕']"}
{"page": 188, "allrow": 5269, "type": "text", "inside": ""}
{"page": 188, "allrow": 5270, "type": "text", "inside": "关联担保情况说明"}
{"page": 188, "allrow": 5271, "type": "text", "inside": "截至2019年12月31日，关联方为本公司开立商业汇票提供的担保"}
{"page": 188, "allrow": 5272, "type": "excel", "inside": "['被担保方名称', '票据类别', '期末担保金额', '期初担保金额', '担保方名称']"}
{"page": 188, "allrow": 5273, "type": "excel", "inside": "['浙江横店普洛进出口有限公司', '银行承兑汇票', '340,000,000.00', '105,444,640.91', '横店集团控股有限公司']"}
{"page": 188, "allrow": 5274, "type": "excel", "inside": "['合计', '', '340,000,000.00', '105,444,640.91', '']"}
{"page": 188, "allrow": 5275, "type": "text", "inside": ""}
{"page": 188, "allrow": 5276, "type": "text", "inside": "（5）关联方资金拆借"}
{"page": 188, "allrow": 5277, "type": "text", "inside": "单位：元"}
{"page": 188, "allrow": 5278, "type": "excel", "inside": "['关联方', '拆借金额', '起始日', '到期日', '说明']"}
{"page": 188, "allrow": 5279, "type": "excel", "inside": "['拆入', '', '', '', '']"}
{"page": 188, "allrow": 5280, "type": "excel", "inside": "['', '', '', '', '该笔资金是由于历史']"}
{"page": 188, "allrow": 5281, "type": "excel", "inside": "['横店集团控股有限公司', '9,586,846.07', '', '', '原因形成的对大股东的资金占用，目前尚']"}
{"page": 188, "allrow": 5282, "type": "excel", "inside": "['', '', '', '', '未偿还。']"}
{"page": 188, "allrow": 5283, "type": "excel", "inside": "['拆出', '', '', '', '']"}
{"page": 188, "allrow": 5284, "type": "text", "inside": ""}
{"page": 188, "allrow": 5285, "type": "text", "inside": "（6）关联方资产转让、债务重组情况"}
{"page": 188, "allrow": 5286, "type": "text", "inside": "单位：元"}
{"page": 188, "allrow": 5287, "type": "excel", "inside": "['关联方', '关联交易内容', '本期发生额', '上期发生额']"}
{"page": 188, "allrow": 5288, "type": "excel", "inside": "['', '公司以98万元收购其持有的东阳普洛康裕', '', '']"}
{"page": 188, "allrow": 5289, "type": "excel", "inside": "['横店集团康裕药业有限公司', '保健食品有限公司100%股权', '980,000.00', '']"}
{"page": 188, "allrow": 5290, "type": "text", "inside": ""}
{"page": 188, "allrow": 5291, "type": "text", "inside": "（7）关键管理人员报酬"}
{"page": 188, "allrow": 5292, "type": "text", "inside": "单位：元"}
{"page": 188, "allrow": 5293, "type": "excel", "inside": "['项目', '本期发生额', '上期发生额']"}
{"page": 188, "allrow": 5294, "type": "excel", "inside": "['关键管理人员的报酬', '5,930,000.00', '5,930,000.00']"}
{"page": 188, "allrow": 5295, "type": "text", "inside": ""}
{"page": 188, "allrow": 5296, "type": "text", "inside": "（8）其他关联交易"}
{"page": 188, "allrow": 5297, "type": "text", "inside": "本期公司使用5,000万元自有闲置资金购买南华基金鑫远1号集合资产管理计划理财产品，南华基金管理有限公司"}
{"page": 188, "allrow": 5298, "type": "页脚", "inside": "188"}
{"page": 189, "allrow": 5299, "type": "text", "inside": ""}
{"page": 189, "allrow": 5300, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 189, "allrow": 5301, "type": "text", "inside": "是该产品资产管理人。"}
{"page": 189, "allrow": 5302, "type": "text", "inside": "6、关联方应收应付款项"}
{"page": 189, "allrow": 5303, "type": "text", "inside": "（1）应收项目"}
{"page": 189, "allrow": 5304, "type": "text", "inside": "单位：元"}
{"page": 189, "allrow": 5305, "type": "excel", "inside": "['', '', '期末余额', '', '期初余额', '']"}
{"page": 189, "allrow": 5306, "type": "excel", "inside": "['项目名称', '关联方', '账面余额', '坏账准备', '账面余额', '坏账准备']"}
{"page": 189, "allrow": 5307, "type": "excel", "inside": "['应收账款', '山东埃森化学有限公司', '', '', '2,584,125.80', '']"}
{"page": 189, "allrow": 5308, "type": "excel", "inside": "['其他应收款', '浙江横店影视城有限公司', '', '', '367,600.00', '']"}
{"page": 189, "allrow": 5309, "type": "text", "inside": ""}
{"page": 189, "allrow": 5310, "type": "text", "inside": "注：关联交易约定以净额结算的，应收关联方款项可以抵销后金额填列。"}
{"page": 189, "allrow": 5311, "type": "text", "inside": "（2）应付项目"}
{"page": 189, "allrow": 5312, "type": "text", "inside": "单位：元"}
{"page": 189, "allrow": 5313, "type": "excel", "inside": "['项目名称', '关联方', '期末账面余额', '期初账面余额']"}
{"page": 189, "allrow": 5314, "type": "excel", "inside": "['', '东阳市横店自来水有限公司浙江横店热电有限公司浙江好乐多商贸有限公司东阳市横店污水处理有限公司浙江横店建设有限公司', '711,238.7015,131,208.74620,297.3138,994,071.54', '775,006.9714,507,701.64170,900.00806,394.8138,178,362.75']"}
{"page": 189, "allrow": 5315, "type": "excel", "inside": "['应付账款', '昌邑华普医药科技有限公司', '22,240,649.30', '30,098,073.59']"}
{"page": 189, "allrow": 5316, "type": "excel", "inside": "['', '浙江省东阳市横店园林古典建筑公司横店文荣医院浙江新纳材料科技有限公司东阳市横店商品贸易有限公司横店集团东磁股份有限公司', '11,446,406.00258,987.0065,600.003,012,621.615,408.00', '11,446,406.002,009,151.60']"}
{"page": 189, "allrow": 5317, "type": "excel", "inside": "['其他应付款', '横店集团控股有限公司', '9,586,846.07', '9,605,846.07']"}
{"page": 189, "allrow": 5318, "type": "excel", "inside": "['其他非流动资产', '横店集团房地产开发有限公司', '480,530.50', '741,025.50']"}
{"page": 189, "allrow": 5319, "type": "text", "inside": "注：关联交易约定以净额结算的，应付关联方款项可以抵销后金额填列。"}
{"page": 189, "allrow": 5320, "type": "页脚", "inside": "189"}
{"page": 190, "allrow": 5321, "type": "text", "inside": ""}
{"page": 190, "allrow": 5322, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 190, "allrow": 5323, "type": "text", "inside": "7、关联方承诺"}
{"page": 190, "allrow": 5324, "type": "text", "inside": "8、其他"}
{"page": 190, "allrow": 5325, "type": "text", "inside": "十三、股份支付"}
{"page": 190, "allrow": 5326, "type": "text", "inside": "1、股份支付总体情况"}
{"page": 190, "allrow": 5327, "type": "text", "inside": "□适用√不适用"}
{"page": 190, "allrow": 5328, "type": "text", "inside": "2、以权益结算的股份支付情况"}
{"page": 190, "allrow": 5329, "type": "text", "inside": "□适用√不适用"}
{"page": 190, "allrow": 5330, "type": "text", "inside": "3、以现金结算的股份支付情况"}
{"page": 190, "allrow": 5331, "type": "text", "inside": "□适用√不适用"}
{"page": 190, "allrow": 5332, "type": "text", "inside": "4、股份支付的修改、终止情况"}
{"page": 190, "allrow": 5333, "type": "text", "inside": "5、其他"}
{"page": 190, "allrow": 5334, "type": "text", "inside": "十四、承诺及或有事项"}
{"page": 190, "allrow": 5335, "type": "text", "inside": "1、重要承诺事项"}
{"page": 190, "allrow": 5336, "type": "text", "inside": "资产负债表日存在的重要承诺"}
{"page": 190, "allrow": 5337, "type": "text", "inside": "为进一步推动公司建立科学、持续、稳定的分红机制，积极回报股东，引导投资者树立长期投资和理性投资的理念，保护投资者的合法权益，根据《中华人民共和国公司法》(以下简称“《公司法》”)、中国证券监督管理委员会《关于进一步落实上市公司现金分红有关事项的通知》(证监发[2012]37号)、中国证券监督管理委员会《上市公司监管指引第3号－上市公司现金分红》(证监发[2013]43号)等相关法律、法规、规范性文件，以及《普洛药业股份有限公司章程》(以下简称“《公司章程》”)的规定，制定《普洛药业股份有限公司未来三年(2017-2019年)股东回报规划》。"}
{"page": 190, "allrow": 5338, "type": "text", "inside": "公司可采用现金、股票或者现金与股票相结合的方式进行利润分配。在满足公司正常生产经营和长期发展的资金需求情况下，如无重大资金支出安排，公司将积极采取现金方式分配利润，且现金分红将优先于股票股利。如公司无重大投资计划或重大现金支出等事项发生，原则上公司每年以现金方式分配的利润应不低于当年实现的可分配利润的10%，且连续三年内以现金方式累计分配的利润不少于最近三年实现的年均可分配利润的30%。当年未分配的可分配利润可留待以后年度进行分配。具体每个年度的分红比例由董事会根据公司年度盈利状况和未来资金使用计划提出预案。在符合利润分配原则、保证公司正常经营和长远发展的前提下，在满足现金分红条件时，公司原则上每年进行一次现金分红，公司董事会可根据公司的盈利状况及资金需求状况提议公司进行中期现金分红。"}
{"page": 190, "allrow": 5339, "type": "text", "inside": "公司董事会应当综合考虑所处行业特点、发展阶段、自身经营模式、盈利水平以及是否有重大资金支出安排等因素，区分下列情形，并按照公司章程规定的程序，提出差异化的现金分红政策：公司发展阶段属成熟期且无重大资金支出安排的，进行利润分配时，现金分红在本次利润分配中所占比例最低应达到80%；公司发展阶段属成熟期且有重大资金支出安排的，进行利润分配时，现金分红在本次利润分配中所占比例最低应达到40%；公司发展阶段属成长期且有重大资金支出安排的，进行利润分配时，现金分红在本次利润分配中所占比例最低应达到20%；公司发展阶段不易区分但有重大资金支出安排的，可以按照前项规定处理。"}
{"page": 190, "allrow": 5340, "type": "页脚", "inside": "190"}
{"page": 191, "allrow": 5341, "type": "text", "inside": ""}
{"page": 191, "allrow": 5342, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 191, "allrow": 5343, "type": "text", "inside": "2、或有事项"}
{"page": 191, "allrow": 5344, "type": "text", "inside": "（1）资产负债表日存在的重要或有事项"}
{"page": 191, "allrow": 5345, "type": "text", "inside": "截至2019年12月31日，本公司不存在应披露的重大或有事项。"}
{"page": 191, "allrow": 5346, "type": "text", "inside": "（2）公司没有需要披露的重要或有事项，也应予以说明"}
{"page": 191, "allrow": 5347, "type": "text", "inside": "公司不存在需要披露的重要或有事项。"}
{"page": 191, "allrow": 5348, "type": "text", "inside": "3、其他"}
{"page": 191, "allrow": 5349, "type": "text", "inside": "十五、资产负债表日后事项"}
{"page": 191, "allrow": 5350, "type": "text", "inside": "1、重要的非调整事项"}
{"page": 191, "allrow": 5351, "type": "text", "inside": "单位：元"}
{"page": 191, "allrow": 5352, "type": "excel", "inside": "['', '', '对财务状况和经营成果的影', '']"}
{"page": 191, "allrow": 5353, "type": "excel", "inside": "['项目', '内容', '响数', '无法估计影响数的原因']"}
{"page": 191, "allrow": 5354, "type": "text", "inside": ""}
{"page": 191, "allrow": 5355, "type": "text", "inside": "2、利润分配情况"}
{"page": 191, "allrow": 5356, "type": "text", "inside": "单位：元"}
{"page": 191, "allrow": 5357, "type": "excel", "inside": "['拟分配的利润或股利', '194,456,376.18']"}
{"page": 191, "allrow": 5358, "type": "excel", "inside": "['经审议批准宣告发放的利润或股利', '194,456,376.18']"}
{"page": 191, "allrow": 5359, "type": "text", "inside": "3、销售退回"}
{"page": 191, "allrow": 5360, "type": "text", "inside": "4、其他资产负债表日后事项说明"}
{"page": 191, "allrow": 5361, "type": "text", "inside": "1、根据董事会决议，公司本年的利润分配预案为：以2019年末总股本为基数，向全体股东每10股派发现金股利1.65元（含税），上述利润分配预案尚待公司股东大会审议批准。"}
{"page": 191, "allrow": 5362, "type": "text", "inside": "2、本公司无需要披露的其他重大资产负债表日后事项。"}
{"page": 191, "allrow": 5363, "type": "页脚", "inside": "191"}
{"page": 192, "allrow": 5364, "type": "text", "inside": ""}
{"page": 192, "allrow": 5365, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 192, "allrow": 5366, "type": "text", "inside": "十六、其他重要事项"}
{"page": 192, "allrow": 5367, "type": "text", "inside": "1、前期会计差错更正"}
{"page": 192, "allrow": 5368, "type": "text", "inside": "（1）追溯重述法"}
{"page": 192, "allrow": 5369, "type": "text", "inside": "单位：元"}
{"page": 192, "allrow": 5370, "type": "excel", "inside": "['', '', '受影响的各个比较期间报表', '']"}
{"page": 192, "allrow": 5371, "type": "excel", "inside": "['会计差错更正的内容', '处理程序', '项目名称', '累积影响数']"}
{"page": 192, "allrow": 5372, "type": "text", "inside": ""}
{"page": 192, "allrow": 5373, "type": "text", "inside": "（2）未来适用法"}
{"page": 192, "allrow": 5374, "type": "excel", "inside": "['会计差错更正的内容', '批准程序', '采用未来适用法的原因']"}
{"page": 192, "allrow": 5375, "type": "text", "inside": ""}
{"page": 192, "allrow": 5376, "type": "text", "inside": "2、债务重组"}
{"page": 192, "allrow": 5377, "type": "text", "inside": "3、资产置换"}
{"page": 192, "allrow": 5378, "type": "text", "inside": "（1）非货币性资产交换"}
{"page": 192, "allrow": 5379, "type": "text", "inside": "（2）其他资产置换"}
{"page": 192, "allrow": 5380, "type": "text", "inside": "4、年金计划"}
{"page": 192, "allrow": 5381, "type": "text", "inside": "5、终止经营"}
{"page": 192, "allrow": 5382, "type": "text", "inside": "单位：元"}
{"page": 192, "allrow": 5383, "type": "excel", "inside": "['', '', '', '', '', '', '归属于母公司']"}
{"page": 192, "allrow": 5384, "type": "excel", "inside": "['项目', '收入', '费用', '利润总额', '所得税费用', '净利润', '所有者的终止']"}
{"page": 192, "allrow": 5385, "type": "excel", "inside": "['', '', '', '', '', '', '经营利润']"}
{"page": 192, "allrow": 5386, "type": "text", "inside": "其他说明"}
{"page": 192, "allrow": 5387, "type": "text", "inside": "6、分部信息"}
{"page": 192, "allrow": 5388, "type": "text", "inside": "（1）报告分部的确定依据与会计政策"}
{"page": 192, "allrow": 5389, "type": "text", "inside": "（2）报告分部的财务信息"}
{"page": 192, "allrow": 5390, "type": "text", "inside": "单位：元"}
{"page": 192, "allrow": 5391, "type": "excel", "inside": "['项目', '分部间抵销', '合计']"}
{"page": 192, "allrow": 5392, "type": "text", "inside": ""}
{"page": 192, "allrow": 5393, "type": "页脚", "inside": "192"}
{"page": 193, "allrow": 5394, "type": "text", "inside": ""}
{"page": 193, "allrow": 5395, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 193, "allrow": 5396, "type": "text", "inside": "（3）公司无报告分部的，或者不能披露各报告分部的资产总额和负债总额的，应说明原因"}
{"page": 193, "allrow": 5397, "type": "text", "inside": "（4）其他说明"}
{"page": 193, "allrow": 5398, "type": "text", "inside": "7、其他对投资者决策有影响的重要交易和事项"}
{"page": 193, "allrow": 5399, "type": "text", "inside": "8、其他"}
{"page": 193, "allrow": 5400, "type": "text", "inside": "1、截至2019年12月31日，股东对外质押本公司股份情况："}
{"page": 193, "allrow": 5401, "type": "excel", "inside": "['序号', '质押人', '质权人', '质押股数', '质押原因', '质押期限']"}
{"page": 193, "allrow": 5402, "type": "excel", "inside": "['1', '横店集团控股有限公司', '中国民生银行股份有限公司金华分行', '156,000,000.00', '贷款担保', '质权人申请解除质押为止']"}
{"page": 193, "allrow": 5403, "type": "excel", "inside": "['2', '浙江横店进出口有限公司', '中国进出口银行', '55,000,000.00', '贷款担保', '质权人申请解除质押为止']"}
{"page": 193, "allrow": 5404, "type": "excel", "inside": "['3', '横店集团家园化工有限公司', '民 生银行金华分行', '44,750,160.00', '贷款担保', '质权人申请解除质押为止']"}
{"page": 193, "allrow": 5405, "type": "text", "inside": ""}
{"page": 193, "allrow": 5406, "type": "text", "inside": "十七、母公司财务报表主要项目注释"}
{"page": 193, "allrow": 5407, "type": "text", "inside": "1、应收账款"}
{"page": 193, "allrow": 5408, "type": "text", "inside": "（1）应收账款分类披露"}
{"page": 193, "allrow": 5409, "type": "text", "inside": "单位：元"}
{"page": 193, "allrow": 5410, "type": "excel", "inside": "['', '期末余额账面余额', '', '坏账准备', '', '', '', '期初余额账面余额', '', '坏账准备', '', '']"}
{"page": 193, "allrow": 5411, "type": "excel", "inside": "['类别', '', '', '', '计提比', '', '账面价', '', '', '', '计提比', '账面价']"}
{"page": 193, "allrow": 5412, "type": "excel", "inside": "['', '金额', '比例', '金额', '例', '', '值', '金额', '比例', '金额', '例', '值']"}
{"page": 193, "allrow": 5413, "type": "excel", "inside": "['按单项计提坏账准备的应收账款', '0.00', '', '', '', '', '', '', '', '', '', '']"}
{"page": 193, "allrow": 5414, "type": "excel", "inside": "['其中：', '', '', '', '', '', '', '', '', '', '', '']"}
{"page": 193, "allrow": 5415, "type": "excel", "inside": "['按组合计提坏账准备的应收账款', '0.00', '', '', '', '', '', '', '', '', '', '']"}
{"page": 193, "allrow": 5416, "type": "excel", "inside": "['其中：', '', '', '', '', '', '', '', '', '', '', '']"}
{"page": 193, "allrow": 5417, "type": "excel", "inside": "['合计', '0.00', '', '', '', '0.00', '', '', '', '', '', '']"}
{"page": 193, "allrow": 5418, "type": "text", "inside": ""}
{"page": 193, "allrow": 5419, "type": "text", "inside": "按单项计提坏账准备："}
{"page": 193, "allrow": 5420, "type": "text", "inside": "单位：元"}
{"page": 193, "allrow": 5421, "type": "页脚", "inside": "193"}
{"page": 194, "allrow": 5422, "type": "text", "inside": ""}
{"page": 194, "allrow": 5423, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 194, "allrow": 5424, "type": "excel", "inside": "['', '期末余额', '', '', '']"}
{"page": 194, "allrow": 5425, "type": "excel", "inside": "['名称', '账面余额', '坏账准备', '计提比例', '计提理由']"}
{"page": 194, "allrow": 5426, "type": "text", "inside": ""}
{"page": 194, "allrow": 5427, "type": "text", "inside": "按组合计提坏账准备："}
{"page": 194, "allrow": 5428, "type": "text", "inside": "单位：元"}
{"page": 194, "allrow": 5429, "type": "excel", "inside": "['', '期末余额', '', '']"}
{"page": 194, "allrow": 5430, "type": "excel", "inside": "['名称', '账面余额', '坏账准备', '计提比例']"}
{"page": 194, "allrow": 5431, "type": "text", "inside": ""}
{"page": 194, "allrow": 5432, "type": "text", "inside": "确定该组合依据的说明："}
{"page": 194, "allrow": 5433, "type": "text", "inside": "如是按照预期信用损失一般模型计提应收账款坏账准备，请参照其他应收款的披露方式披露坏账准备的相关信息：□适用√不适用"}
{"page": 194, "allrow": 5434, "type": "text", "inside": "按账龄披露"}
{"page": 194, "allrow": 5435, "type": "text", "inside": "单位：元"}
{"page": 194, "allrow": 5436, "type": "excel", "inside": "['账龄', '', '账面余额']"}
{"page": 194, "allrow": 5437, "type": "excel", "inside": "['1年以内（含1年）', '', '0.00']"}
{"page": 194, "allrow": 5438, "type": "excel", "inside": "['1至2年', '', '0.00']"}
{"page": 194, "allrow": 5439, "type": "excel", "inside": "['2至3年', '', '0.00']"}
{"page": 194, "allrow": 5440, "type": "excel", "inside": "['3年以上', '', '0.00']"}
{"page": 194, "allrow": 5441, "type": "excel", "inside": "['3至4年', '', '0.00']"}
{"page": 194, "allrow": 5442, "type": "excel", "inside": "['4至5年', '', '0.00']"}
{"page": 194, "allrow": 5443, "type": "excel", "inside": "['5年以上', '', '0.00']"}
{"page": 194, "allrow": 5444, "type": "excel", "inside": "['合计', '0.00', '']"}
{"page": 194, "allrow": 5445, "type": "text", "inside": "（2）本期计提、收回或转回的坏账准备情况"}
{"page": 194, "allrow": 5446, "type": "text", "inside": "本期计提坏账准备情况："}
{"page": 194, "allrow": 5447, "type": "text", "inside": "单位：元"}
{"page": 194, "allrow": 5448, "type": "excel", "inside": "['', '', '本期变动金额', '', '', '']"}
{"page": 194, "allrow": 5449, "type": "excel", "inside": "['类别', '期初余额', '计提', '收回或转回', '核销', '期末余额']"}
{"page": 194, "allrow": 5450, "type": "text", "inside": ""}
{"page": 194, "allrow": 5451, "type": "text", "inside": "其中本期坏账准备收回或转回金额重要的："}
{"page": 194, "allrow": 5452, "type": "text", "inside": "单位：元"}
{"page": 194, "allrow": 5453, "type": "excel", "inside": "['单位名称', '收回或转回金额', '收回方式']"}
{"page": 194, "allrow": 5454, "type": "text", "inside": ""}
{"page": 194, "allrow": 5455, "type": "text", "inside": "（3）本期实际核销的应收账款情况"}
{"page": 194, "allrow": 5456, "type": "text", "inside": "单位：元"}
{"page": 194, "allrow": 5457, "type": "excel", "inside": "['项目', '核销金额']"}
{"page": 194, "allrow": 5458, "type": "text", "inside": ""}
{"page": 194, "allrow": 5459, "type": "text", "inside": "其中重要的应收账款核销情况："}
{"page": 194, "allrow": 5460, "type": "text", "inside": "单位：元"}
{"page": 194, "allrow": 5461, "type": "页脚", "inside": "194"}
{"page": 195, "allrow": 5462, "type": "text", "inside": ""}
{"page": 195, "allrow": 5463, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 195, "allrow": 5464, "type": "excel", "inside": "['', '', '', '', '', '款项是否由关联']"}
{"page": 195, "allrow": 5465, "type": "excel", "inside": "['单位名称', '应收账款性质', '核销金额', '核销原因', '履行的核销程序', '交易产生']"}
{"page": 195, "allrow": 5466, "type": "text", "inside": "应收账款核销说明："}
{"page": 195, "allrow": 5467, "type": "text", "inside": "（4）按欠款方归集的期末余额前五名的应收账款情况"}
{"page": 195, "allrow": 5468, "type": "text", "inside": "单位：元"}
{"page": 195, "allrow": 5469, "type": "excel", "inside": "['', '', '占应收账款期末余额合计数', '']"}
{"page": 195, "allrow": 5470, "type": "excel", "inside": "['单位名称', '应收账款期末余额', '的比例', '坏账准备期末余额']"}
{"page": 195, "allrow": 5471, "type": "text", "inside": ""}
{"page": 195, "allrow": 5472, "type": "text", "inside": "（5）因金融资产转移而终止确认的应收账款"}
{"page": 195, "allrow": 5473, "type": "text", "inside": "（6）转移应收账款且继续涉入形成的资产、负债金额"}
{"page": 195, "allrow": 5474, "type": "text", "inside": "其他说明："}
{"page": 195, "allrow": 5475, "type": "text", "inside": "2、其他应收款"}
{"page": 195, "allrow": 5476, "type": "text", "inside": "单位：元"}
{"page": 195, "allrow": 5477, "type": "excel", "inside": "['项目', '期末余额', '期初余额']"}
{"page": 195, "allrow": 5478, "type": "excel", "inside": "['应收股利', '200,000,000.00', '126,400,000.00']"}
{"page": 195, "allrow": 5479, "type": "excel", "inside": "['其他应收款', '357,471,512.40', '427,110,132.66']"}
{"page": 195, "allrow": 5480, "type": "excel", "inside": "['合计', '557,471,512.40', '553,510,132.66']"}
{"page": 195, "allrow": 5481, "type": "text", "inside": "（1）应收利息"}
{"page": 195, "allrow": 5482, "type": "text", "inside": "1）应收利息分类"}
{"page": 195, "allrow": 5483, "type": "text", "inside": "单位：元"}
{"page": 195, "allrow": 5484, "type": "excel", "inside": "['项目', '期末余额', '期初余额']"}
{"page": 195, "allrow": 5485, "type": "text", "inside": ""}
{"page": 195, "allrow": 5486, "type": "text", "inside": "2）重要逾期利息"}
{"page": 195, "allrow": 5487, "type": "excel", "inside": "['', '', '', '', '是否发生减值及其判']"}
{"page": 195, "allrow": 5488, "type": "excel", "inside": "['借款单位', '期末余额', '逾期时间', '逾期原因', '断依据']"}
{"page": 195, "allrow": 5489, "type": "text", "inside": ""}
{"page": 195, "allrow": 5490, "type": "text", "inside": "其他说明："}
{"page": 195, "allrow": 5491, "type": "text", "inside": "3）坏账准备计提情况"}
{"page": 195, "allrow": 5492, "type": "text", "inside": "□适用√不适用"}
{"page": 195, "allrow": 5493, "type": "页脚", "inside": "195"}
{"page": 196, "allrow": 5494, "type": "text", "inside": ""}
{"page": 196, "allrow": 5495, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 196, "allrow": 5496, "type": "text", "inside": "（2）应收股利"}
{"page": 196, "allrow": 5497, "type": "text", "inside": "1）应收股利分类"}
{"page": 196, "allrow": 5498, "type": "text", "inside": "单位：元"}
{"page": 196, "allrow": 5499, "type": "excel", "inside": "['项目(或被投资单位)', '', '期末余额', '期初余额']"}
{"page": 196, "allrow": 5500, "type": "excel", "inside": "['浙江普洛康裕制药有限公司', '', '43,400,000.00', '23,000,000.00']"}
{"page": 196, "allrow": 5501, "type": "excel", "inside": "['浙江普洛得邦制药有限公司', '', '35,110,000.00', '33,000,000.00']"}
{"page": 196, "allrow": 5502, "type": "excel", "inside": "['浙江横店普洛进出口有限公司', '', '36,970,000.00', '24,400,000.00']"}
{"page": 196, "allrow": 5503, "type": "excel", "inside": "['浙江普洛家园药业有限公司', '', '73,970,000.00', '45,000,000.00']"}
{"page": 196, "allrow": 5504, "type": "excel", "inside": "['浙江巨泰药业有限公司', '', '10,550,000.00', '1,000,000.00']"}
{"page": 196, "allrow": 5505, "type": "excel", "inside": "['合计', '200,000,000.00', '', '126,400,000.00']"}
{"page": 196, "allrow": 5506, "type": "text", "inside": "2）重要的账龄超过1年的应收股利"}
{"page": 196, "allrow": 5507, "type": "text", "inside": "单位：元"}
{"page": 196, "allrow": 5508, "type": "excel", "inside": "['', '', '', '', '是否发生减值及其判']"}
{"page": 196, "allrow": 5509, "type": "excel", "inside": "['项目(或被投资单位)', '期末余额', '账龄', '未收回的原因', '断依据']"}
{"page": 196, "allrow": 5510, "type": "text", "inside": ""}
{"page": 196, "allrow": 5511, "type": "text", "inside": "3）坏账准备计提情况"}
{"page": 196, "allrow": 5512, "type": "text", "inside": "□适用√不适用"}
{"page": 196, "allrow": 5513, "type": "text", "inside": "其他说明："}
{"page": 196, "allrow": 5514, "type": "text", "inside": "（3）其他应收款"}
{"page": 196, "allrow": 5515, "type": "text", "inside": "1）其他应收款按款项性质分类情况"}
{"page": 196, "allrow": 5516, "type": "text", "inside": "单位：元"}
{"page": 196, "allrow": 5517, "type": "excel", "inside": "['款项性质', '期末账面余额', '期初账面余额']"}
{"page": 196, "allrow": 5518, "type": "excel", "inside": "['往来款', '357,403,980.21', '427,018,314.21']"}
{"page": 196, "allrow": 5519, "type": "excel", "inside": "['其他', '71,086.52', '96,651.00']"}
{"page": 196, "allrow": 5520, "type": "excel", "inside": "['合计', '357,475,066.73', '427,114,965.21']"}
{"page": 196, "allrow": 5521, "type": "text", "inside": "2）坏账准备计提情况"}
{"page": 196, "allrow": 5522, "type": "text", "inside": "单位：元"}
{"page": 196, "allrow": 5523, "type": "excel", "inside": "['', '第一阶段', '第二阶段', '第三阶段', '']"}
{"page": 196, "allrow": 5524, "type": "excel", "inside": "['坏账准备', '未来12个月预期', '整个存续期预期信用损', '整个存续期预期信用损', '合计']"}
{"page": 196, "allrow": 5525, "type": "excel", "inside": "['', '信用损失', '失(未发生信用减值)', '失(已发生信用减值)', '']"}
{"page": 196, "allrow": 5526, "type": "text", "inside": ""}
{"page": 196, "allrow": 5527, "type": "页脚", "inside": "196"}
{"page": 197, "allrow": 5528, "type": "text", "inside": ""}
{"page": 197, "allrow": 5529, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 197, "allrow": 5530, "type": "excel", "inside": "['2019年1月1日余额', '', '4,832.55', '', '4,832.55']"}
{"page": 197, "allrow": 5531, "type": "excel", "inside": "['2019年1月1日余额在本期', '——', '——', '——', '——']"}
{"page": 197, "allrow": 5532, "type": "excel", "inside": "['本期计提', '', '-1,278.22', '', '-1,278.22']"}
{"page": 197, "allrow": 5533, "type": "excel", "inside": "['2019年12月31日余额', '', '3,554.33', '', '3,554.33']"}
{"page": 197, "allrow": 5534, "type": "text", "inside": ""}
{"page": 197, "allrow": 5535, "type": "text", "inside": "损失准备本期变动金额重大的账面余额变动情况"}
{"page": 197, "allrow": 5536, "type": "text", "inside": "□适用√不适用"}
{"page": 197, "allrow": 5537, "type": "text", "inside": "按账龄披露"}
{"page": 197, "allrow": 5538, "type": "text", "inside": "单位：元"}
{"page": 197, "allrow": 5539, "type": "excel", "inside": "['账龄', '账面余额']"}
{"page": 197, "allrow": 5540, "type": "excel", "inside": "['1年以内（含1年）', '71,086.52']"}
{"page": 197, "allrow": 5541, "type": "excel", "inside": "['合计', '71,086.52']"}
{"page": 197, "allrow": 5542, "type": "text", "inside": "3）本期计提、收回或转回的坏账准备情况"}
{"page": 197, "allrow": 5543, "type": "text", "inside": "本期计提坏账准备情况："}
{"page": 197, "allrow": 5544, "type": "text", "inside": "单位：元"}
{"page": 197, "allrow": 5545, "type": "excel", "inside": "['', '期初余额', '本期变动金额', '', '', '']"}
{"page": 197, "allrow": 5546, "type": "excel", "inside": "['类别', '', '计提', '收回或转回', '核销', '期末余额']"}
{"page": 197, "allrow": 5547, "type": "text", "inside": ""}
{"page": 197, "allrow": 5548, "type": "text", "inside": "其中本期坏账准备转回或收回金额重要的："}
{"page": 197, "allrow": 5549, "type": "text", "inside": "单位：元"}
{"page": 197, "allrow": 5550, "type": "excel", "inside": "['单位名称', '转回或收回金额', '收回方式']"}
{"page": 197, "allrow": 5551, "type": "text", "inside": ""}
{"page": 197, "allrow": 5552, "type": "text", "inside": "4）本期实际核销的其他应收款情况"}
{"page": 197, "allrow": 5553, "type": "text", "inside": "单位：元"}
{"page": 197, "allrow": 5554, "type": "excel", "inside": "['项目', '核销金额']"}
{"page": 197, "allrow": 5555, "type": "text", "inside": ""}
{"page": 197, "allrow": 5556, "type": "text", "inside": "其中重要的其他应收款核销情况："}
{"page": 197, "allrow": 5557, "type": "text", "inside": "单位：元"}
{"page": 197, "allrow": 5558, "type": "excel", "inside": "['', '', '', '', '', '款项是否由关联']"}
{"page": 197, "allrow": 5559, "type": "excel", "inside": "['单位名称', '其他应收款性质', '核销金额', '核销原因', '履行的核销程序', '交易产生']"}
{"page": 197, "allrow": 5560, "type": "text", "inside": "其他应收款核销说明："}
{"page": 197, "allrow": 5561, "type": "text", "inside": "5）按欠款方归集的期末余额前五名的其他应收款情况"}
{"page": 197, "allrow": 5562, "type": "text", "inside": "单位：元"}
{"page": 197, "allrow": 5563, "type": "页脚", "inside": "197"}
{"page": 198, "allrow": 5564, "type": "text", "inside": ""}
{"page": 198, "allrow": 5565, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 198, "allrow": 5566, "type": "excel", "inside": "['', '', '', '', '占其他应收款期', '坏账准备期末余']"}
{"page": 198, "allrow": 5567, "type": "excel", "inside": "['单位名称', '款项的性质', '期末余额', '账龄', '末余额合计数的', '额']"}
{"page": 198, "allrow": 5568, "type": "excel", "inside": "['', '', '', '', '比例', '']"}
{"page": 198, "allrow": 5569, "type": "excel", "inside": "['安徽普洛生物科技有限公司', '往来款', '255,695,116.73', '1-3年', '71.53%', '']"}
{"page": 198, "allrow": 5570, "type": "excel", "inside": "['浙江横店普洛进出口有限公司', '往来款', '39,117,795.60', '1年以内', '10.94%', '']"}
{"page": 198, "allrow": 5571, "type": "excel", "inside": "['浙江普洛生物科技有限公司', '往来款', '38,910,411.76', '1年以内', '10.88%', '']"}
{"page": 198, "allrow": 5572, "type": "excel", "inside": "['浙江普洛家园药业有限公司', '往来款', '15,303,506.62', '1年以内', '4.28%', '']"}
{"page": 198, "allrow": 5573, "type": "excel", "inside": "['浙江普洛得邦制药有限公司', '往来款', '8,377,149.50', '1年以内', '2.34%', '']"}
{"page": 198, "allrow": 5574, "type": "excel", "inside": "['合计', '--', '357,403,980.21', '--', '99.98%', '']"}
{"page": 198, "allrow": 5575, "type": "text", "inside": ""}
{"page": 198, "allrow": 5576, "type": "text", "inside": "6）涉及政府补助的应收款项"}
{"page": 198, "allrow": 5577, "type": "text", "inside": "单位：元"}
{"page": 198, "allrow": 5578, "type": "excel", "inside": "['', '', '', '', '预计收取的时间、金额']"}
{"page": 198, "allrow": 5579, "type": "excel", "inside": "['单位名称', '政府补助项目名称', '期末余额', '期末账龄', '及依据']"}
{"page": 198, "allrow": 5580, "type": "text", "inside": ""}
{"page": 198, "allrow": 5581, "type": "text", "inside": "7）因金融资产转移而终止确认的其他应收款"}
{"page": 198, "allrow": 5582, "type": "text", "inside": "8）转移其他应收款且继续涉入形成的资产、负债金额"}
{"page": 198, "allrow": 5583, "type": "text", "inside": "其他说明："}
{"page": 198, "allrow": 5584, "type": "text", "inside": "3、长期股权投资"}
{"page": 198, "allrow": 5585, "type": "text", "inside": "单位：元"}
{"page": 198, "allrow": 5586, "type": "excel", "inside": "['', '期末余额', '', '', '', '期初余额', '', '']"}
{"page": 198, "allrow": 5587, "type": "excel", "inside": "['项目', '账面余额', '减值准备', '', '账面价值', '账面余额', '减值准备', '账面价值']"}
{"page": 198, "allrow": 5588, "type": "excel", "inside": "['', '1,742,971,011.', '', '', '1,742,971,011.', '1,741,996,456.', '', '1,741,996,456.']"}
{"page": 198, "allrow": 5589, "type": "excel", "inside": "['对子公司投资', '84', '', '', '84', '86', '', '86']"}
{"page": 198, "allrow": 5590, "type": "excel", "inside": "['', '1,742,971,011.', '', '1,742,971,011.84', '', '1,741,996,456.', '', '1,741,996,456.']"}
{"page": 198, "allrow": 5591, "type": "excel", "inside": "['合计', '84', '', '', '', '86', '', '86']"}
{"page": 198, "allrow": 5592, "type": "text", "inside": "（1）对子公司投资"}
{"page": 198, "allrow": 5593, "type": "text", "inside": "单位：元"}
{"page": 198, "allrow": 5594, "type": "页脚", "inside": "198"}
{"page": 199, "allrow": 5595, "type": "text", "inside": ""}
{"page": 199, "allrow": 5596, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 199, "allrow": 5597, "type": "excel", "inside": "['', '', '期初余额', '本期增减变动', '', '', '', '', '期末余额(账', '减值准备期']"}
{"page": 199, "allrow": 5598, "type": "excel", "inside": "['被投资单位', '', '(账面价值)', '追加投资', '减少投资', '计提减值准', '其他', '', '面价值)', '末余额']"}
{"page": 199, "allrow": 5599, "type": "excel", "inside": "['', '', '', '', '', '备', '', '', '', '']"}
{"page": 199, "allrow": 5600, "type": "excel", "inside": "['浙江普洛康裕制药有限公司', '', '499,826,490.37', '', '', '', '', '', '499,826,490.37', '']"}
{"page": 199, "allrow": 5601, "type": "excel", "inside": "['浙江普洛家园药业有限公司', '', '145,514,078.32', '', '', '', '', '', '145,514,078.32', '']"}
{"page": 199, "allrow": 5602, "type": "excel", "inside": "['浙江优胜美特中药有限公司', '', '4,647,560.68', '974,554.98', '', '', '', '', '5,622,115.66', '']"}
{"page": 199, "allrow": 5603, "type": "excel", "inside": "['浙江普洛生物科技有限公司', '', '143,644,885.93', '', '', '', '', '', '143,644,885.93', '']"}
{"page": 199, "allrow": 5604, "type": "excel", "inside": "['浙江普洛得邦制药有限公司', '', '223,037,119.07', '', '', '', '', '', '223,037,119.07', '']"}
{"page": 199, "allrow": 5605, "type": "excel", "inside": "['浙江巨泰药业有限公司', '', '140,000,000.00', '', '', '', '', '', '140,000,000.00', '']"}
{"page": 199, "allrow": 5606, "type": "excel", "inside": "['山东普洛得邦医药有限公司', '', '90,000,000.00', '', '', '', '', '', '90,000,000.00', '']"}
{"page": 199, "allrow": 5607, "type": "excel", "inside": "['山东汉兴医药科技有限公司', '', '124,323,122.49', '', '', '', '', '', '124,323,122.49', '']"}
{"page": 199, "allrow": 5608, "type": "excel", "inside": "['浙江横店普洛进出口有限公司', '', '50,000,000.00', '', '', '', '', '', '50,000,000.00', '']"}
{"page": 199, "allrow": 5609, "type": "excel", "inside": "['山西优胜美特药业有限公司', '', '80,283,200.00', '', '', '', '', '', '80,283,200.00', '']"}
{"page": 199, "allrow": 5610, "type": "excel", "inside": "['浙江优胜美特医药有限公司', '', '240,720,000.00', '', '', '', '', '', '240,720,000.00', '']"}
{"page": 199, "allrow": 5611, "type": "excel", "inside": "['', '1,741,996,456.86', '', '', '', '', '', '1,742,971,011.84', '', '']"}
{"page": 199, "allrow": 5612, "type": "excel", "inside": "['合计', '', '', '974,554.98', '', '', '', '', '', '']"}
{"page": 199, "allrow": 5613, "type": "text", "inside": ""}
{"page": 199, "allrow": 5614, "type": "页脚", "inside": "199"}
{"page": 200, "allrow": 5615, "type": "text", "inside": ""}
{"page": 200, "allrow": 5616, "type": "text", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 200, "allrow": 5617, "type": "text", "inside": "（2）对联营、合营企业投资"}
{"page": 200, "allrow": 5618, "type": "text", "inside": "单位：元"}
{"page": 200, "allrow": 5619, "type": "excel", "inside": "['', '期初余', '本期增减变动', '减少投资', '', '权益法', '其他综合收益调整', '其他权益变动', '宣告发', '', '', '期末余', '减值准']"}
{"page": 200, "allrow": 5620, "type": "excel", "inside": "['投资单位', '额(账面价', '追加投资', '', '减少投资', '下确认的投资', '', '', '放现金股利或', '计提减值准备', '其他', '额(账面价', '备期末余额']"}
{"page": 200, "allrow": 5621, "type": "excel", "inside": "['', '值)', '', '', '', '损益', '', '', '利润', '', '', '值)', '']"}
{"page": 200, "allrow": 5622, "type": "excel", "inside": "['一、合营企业', '', '', '', '', '', '', '', '', '', '', '', '']"}
{"page": 200, "allrow": 5623, "type": "excel", "inside": "['二、联营企业', '', '', '', '', '', '', '', '', '', '', '', '']"}
{"page": 200, "allrow": 5624, "type": "text", "inside": ""}
{"page": 200, "allrow": 5625, "type": "text", "inside": "（3）其他说明"}
{"page": 200, "allrow": 5626, "type": "text", "inside": "4、营业收入和营业成本"}
{"page": 200, "allrow": 5627, "type": "text", "inside": "单位：元"}
{"page": 200, "allrow": 5628, "type": "excel", "inside": "['', '本期发生额', '', '上期发生额', '']"}
{"page": 200, "allrow": 5629, "type": "excel", "inside": "['项目', '收入', '成本', '收入', '成本']"}
{"page": 200, "allrow": 5630, "type": "excel", "inside": "['其他业务', '44,952,830.12', '', '35,660,377.38', '']"}
{"page": 200, "allrow": 5631, "type": "excel", "inside": "['合计', '44,952,830.12', '', '35,660,377.38', '']"}
{"page": 200, "allrow": 5632, "type": "text", "inside": ""}
{"page": 200, "allrow": 5633, "type": "text", "inside": "是否已执行新收入准则"}
{"page": 200, "allrow": 5634, "type": "text", "inside": "□是√否"}
{"page": 200, "allrow": 5635, "type": "text", "inside": "其他说明："}
{"page": 200, "allrow": 5636, "type": "text", "inside": "5、投资收益"}
{"page": 200, "allrow": 5637, "type": "text", "inside": "单位：元"}
{"page": 200, "allrow": 5638, "type": "excel", "inside": "['项目', '', '本期发生额', '', '上期发生额']"}
{"page": 200, "allrow": 5639, "type": "excel", "inside": "['成本法核算的长期股权投资收益', '', '200,000,000.00', '', '126,400,000.00']"}
{"page": 200, "allrow": 5640, "type": "excel", "inside": "['处置长期股权投资产生的投资收益', '', '', '', '160,152.33']"}
{"page": 200, "allrow": 5641, "type": "excel", "inside": "['理财收益', '', '114,711.03', '', '784,965.02']"}
{"page": 200, "allrow": 5642, "type": "excel", "inside": "['合计', '200,114,711.03', '', '127,345,117.35', '']"}
{"page": 201, "allrow": 5643, "type": "text", "inside": ""}
{"page": 201, "allrow": 5644, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 201, "allrow": 5645, "type": "text", "inside": "单位：元"}
{"page": 201, "allrow": 5646, "type": "excel", "inside": "['项目', '金额', '说明']"}
{"page": 201, "allrow": 5647, "type": "excel", "inside": "['非流动资产处置损益', '-5,938,126.90', '']"}
{"page": 201, "allrow": 5648, "type": "excel", "inside": "['计入当期损益的政府补助（与企业业务密切相关，按照国家统一标准定额或定量享受的政府补助除外）', '89,808,796.26', '本期收到的政府补助同比增加']"}
{"page": 201, "allrow": 5649, "type": "excel", "inside": "['除同公司正常经营业务相关的有效套期保值业务外，持有交易性金融资产、衍生金融资产、交易性金融负债、衍生金融负债产生的公允价值变动损益，以及处置交易性金融资产、衍生金融资产、交易性金融负债、衍生金融负债和其他债权投资取得的投资收益', '-61,762,572.48', '']"}
{"page": 201, "allrow": 5650, "type": "excel", "inside": "['除上述各项之外的其他营业外收入和支出', '-655,153.67', '']"}
{"page": 201, "allrow": 5651, "type": "excel", "inside": "['减：所得税影响额', '-2,216,995.03', '']"}
{"page": 201, "allrow": 5652, "type": "excel", "inside": "['合计', '23,669,938.24', '--']"}
{"page": 201, "allrow": 5653, "type": "text", "inside": ""}
{"page": 201, "allrow": 5654, "type": "text", "inside": "对公司根据《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》定义界定的非经常性损益项目，以及把《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。"}
{"page": 201, "allrow": 5655, "type": "text", "inside": "□适用√不适用"}
{"page": 201, "allrow": 5656, "type": "text", "inside": "2、净资产收益率及每股收益"}
{"page": 201, "allrow": 5657, "type": "excel", "inside": "['', '', '每股收益', '', '']"}
{"page": 201, "allrow": 5658, "type": "excel", "inside": "['报告期利润', '加权平均净资产收益率', '基本每股收益（元/股', '）', '稀释每股收益（元/股）']"}
{"page": 201, "allrow": 5659, "type": "excel", "inside": "['归属于公司普通股股东的净利润', '15.66%', '0.4696', '', '0.4696']"}
{"page": 201, "allrow": 5660, "type": "excel", "inside": "['扣除非经常性损益后归属于公司普通股股东的净利润', '14.99%', '0.4495', '', '0.4495']"}
{"page": 201, "allrow": 5661, "type": "text", "inside": ""}
{"page": 201, "allrow": 5662, "type": "text", "inside": "3、境内外会计准则下会计数据差异"}
{"page": 201, "allrow": 5663, "type": "text", "inside": "（1）同时按照国际会计准则与按中国会计准则披露的财务报告中净利润和净资产差异情况"}
{"page": 201, "allrow": 5664, "type": "text", "inside": "□适用√不适用"}
{"page": 201, "allrow": 5665, "type": "text", "inside": "（2）同时按照境外会计准则与按中国会计准则披露的财务报告中净利润和净资产差异情况"}
{"page": 201, "allrow": 5666, "type": "text", "inside": "□适用√不适用"}
{"page": 201, "allrow": 5667, "type": "页脚", "inside": "201"}
{"page": 202, "allrow": 5668, "type": "text", "inside": ""}
{"page": 202, "allrow": 5669, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 202, "allrow": 5670, "type": "text", "inside": "（3）境内外会计准则下会计数据差异原因说明，对已经境外审计机构审计的数据进行差异调节的，应注明该境外机构的名称"}
{"page": 202, "allrow": 5671, "type": "text", "inside": "4、其他"}
{"page": 202, "allrow": 5672, "type": "页脚", "inside": "202"}
{"page": 203, "allrow": 5673, "type": "text", "inside": ""}
{"page": 203, "allrow": 5674, "type": "页眉", "inside": "普洛药业股份有限公司2019年年度报告全文"}
{"page": 203, "allrow": 5675, "type": "text", "inside": "第十三节备查文件目录"}
{"page": 203, "allrow": 5676, "type": "text", "inside": "1、载有董事长亲笔签署的年度报告正本。"}
{"page": 203, "allrow": 5677, "type": "text", "inside": "2、载有董事长、主管会计工作负责人和会计机构负责人签名并盖章的财务报表。"}
{"page": 203, "allrow": 5678, "type": "text", "inside": "3、载有会计师事务所盖章、注册会计师签名并盖章的审计报告原件。"}
{"page": 203, "allrow": 5679, "type": "text", "inside": "4、报告期内在中国证监会指定报纸上公开披露过的所有公司文件的正本及公告原稿。"}
{"page": 203, "allrow": 5680, "type": "页脚", "inside": "203"}
